NCT Number,Title,Status,Conditions,Gender,Age,Phases,Enrollment,Study Type,Start Date,Completion Date,URL,clean_age,min_age,age_groups
NCT00006176,Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies,Completed,Familial Dementia With Neuroserpin Inclusion Bodies|Nervous System Heredodegenerative Disorder,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 4,100,Observational,"August 10, 2000","August 4, 2009",https://ClinicalTrials.gov/show/NCT00006176,10 Years and older ,10,up to 18 years old
NCT01682915,Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD,Unknown status,Attention Deficit/Hyperactivity Disorder,All,"12 Years to 20 Years   (Child, Adult)",Phase 4,240,Observational,August 2012,July 2015,https://ClinicalTrials.gov/show/NCT01682915,12 Years to 20 Years ,12,up to 18 years old
NCT03149380,Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior,Recruiting,"Alzheimer Disease|Alzheimer Disease, Late Onset|Memory Loss|Patient Education as Topic",All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,10000,Interventional,January 2017,October 2024,https://ClinicalTrials.gov/show/NCT03149380,14 Years and older ,14,up to 18 years old
NCT01699711,Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool,Completed,Down Syndrome (DS),All,"14 Years to 29 Years   (Child, Adult)",Phase 2,87,Interventional,February 2012,March 2015,https://ClinicalTrials.gov/show/NCT01699711,14 Years to 29 Years ,14,up to 18 years old
NCT01476228,EEG Objectification in Neuropsychiatry,Unknown status,Personality Disorder|Depression|Neurodegeneration|Alzheimer's Disease|Epilepsy,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Not Applicable,100,Interventional,November 2011,December 2015,https://ClinicalTrials.gov/show/NCT01476228,15 Years to 90 Years ,15,up to 18 years old
NCT00165100,Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer,Completed,Malignant Tumors|Subcutaneous Tumors|Lymph Node Tumors,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,50,Interventional,January 2000,October 2002,https://ClinicalTrials.gov/show/NCT00165100,16 Years and older ,16,up to 18 years old
NCT00978536,"A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).",Terminated,Disseminated Sclerosis,All,"17 Years to 66 Years   (Child, Adult, Older Adult)",Not Applicable,29,Interventional,February 2009,November 2011,https://ClinicalTrials.gov/show/NCT00978536,17 Years to 66 Years ,17,up to 18 years old
NCT04117178,Monitoring Anti-Dementia Drugs by Serum Levels,Not yet recruiting,Dementia|Dementia With Lewy Bodies|Dementia in Parkinsons Disease|Dementia Alzheimers|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,110,Interventional,November 2019,November 2021,https://ClinicalTrials.gov/show/NCT04117178,18 Years and older ,18,up to 18 years old
NCT03902548,Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18,Interventional,"May 17, 2018",October 2019,https://ClinicalTrials.gov/show/NCT03902548,18 Years and older ,18,up to 18 years old
NCT01095744,Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease,Completed,Alzheimer's Disease|Posterior Cortical Atrophy|Logopenic Progressive Aphasia,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,March 2009,May 2012,https://ClinicalTrials.gov/show/NCT01095744,18 Years and older ,18,up to 18 years old
NCT03602391,The Senior Companion Program Plus,Recruiting,Family|Alzheimer Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Interventional,"May 16, 2019","June 30, 2021",https://ClinicalTrials.gov/show/NCT03602391,18 Years and older ,18,up to 18 years old
NCT02291783,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment",Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,108,Interventional,November 2013,July 2014,https://ClinicalTrials.gov/show/NCT02291783,18 Years and older ,18,up to 18 years old
NCT02333942,Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia,Completed,Alzheimer Disease|Mild Cognitive Impairment|Frontotemporal Lobar Degeneration|Memory Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 4,41,Observational,May 2014,February 2015,https://ClinicalTrials.gov/show/NCT02333942,18 Years and older ,18,up to 18 years old
NCT03942341,Sleep in Adults With Down Syndrome and Alzheimer's Disease,Recruiting,Alzheimer's Disease|Obstructive Sleep Apnea|Sleep Disturbances,All,"18 Years and older   (Adult, Older Adult)",Phase 4,90,Observational,"May 8, 2019",December 2020,https://ClinicalTrials.gov/show/NCT03942341,18 Years and older ,18,up to 18 years old
NCT02134041,Amyloid Accumulation After Mild Traumatic Brain Injury,Recruiting,Traumatic Brain Injury|Dementia|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,150,Observational,October 2012,"September 18, 2019",https://ClinicalTrials.gov/show/NCT02134041,18 Years and older ,18,up to 18 years old
NCT03858283,Mindfulness for Alzheimer Caregivers,Recruiting,Alzheimer Disease|Neurodegenerative Diseases|Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,145,Interventional,"February 2, 2019","October 31, 2021",https://ClinicalTrials.gov/show/NCT03858283,18 Years and older ,18,up to 18 years old
NCT02697721,Powerful Tools for Caregivers of Dementia Patients,Completed,Caregivers|Dementia|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,February 2016,February 2019,https://ClinicalTrials.gov/show/NCT02697721,18 Years and older ,18,up to 18 years old
NCT01901263,Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,306,Observational,October 2012,October 2015,https://ClinicalTrials.gov/show/NCT01901263,18 Years and older ,18,up to 18 years old
NCT01982578,Genistein as a Possible Treatment for Alzheimer's Disease.,Recruiting,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Interventional,"September 1, 2017","December 31, 2020",https://ClinicalTrials.gov/show/NCT01982578,18 Years and older ,18,up to 18 years old
NCT01128725,"Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers",Unknown status,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,September 2010,December 2012,https://ClinicalTrials.gov/show/NCT01128725,18 Years and older ,18,up to 18 years old
NCT03687710,The Comparative Effectiveness Dementia & Alzheimer's Registry,"Active, not recruiting",Alzheimer Disease|Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000,Observational,"February 16, 2015","June 30, 2026",https://ClinicalTrials.gov/show/NCT03687710,18 Years and older ,18,up to 18 years old
NCT03444181,"ALzheimer and MUsic THerapy: Effects of Music Lessons on Brain Plasticity, Mood, and Quality of Life in Alzheimer Patients",Recruiting,Alzheimer Disease|Mild Cognitive Impairment|MCI With Increased Risk for Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,135,Interventional,"April 11, 2018","June 30, 2020",https://ClinicalTrials.gov/show/NCT03444181,18 Years and older ,18,up to 18 years old
NCT03019757,"Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease",Recruiting,Alzheimer's Disease|Lewy Body Dementia|Parkinson's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,76,Observational,"August 30, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03019757,18 Years and older ,18,up to 18 years old
NCT00291161,Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters,Completed,Dementia|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,994,Interventional,December 2006,February 2011,https://ClinicalTrials.gov/show/NCT00291161,18 Years and older ,18,up to 18 years old
NCT03288363,Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD),Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,"June 6, 2017","December 6, 2021",https://ClinicalTrials.gov/show/NCT03288363,18 Years and older ,18,up to 18 years old
NCT00585572,Wisconsin Brain Donor Program,Enrolling by invitation,Alzheimer's Disease|Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500,Observational,March 2007,October 2019,https://ClinicalTrials.gov/show/NCT00585572,18 Years and older ,18,up to 18 years old
NCT02576821,Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease,Recruiting,Patients With Cognitive Disturbances,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Interventional,"January 27, 2016",October 2020,https://ClinicalTrials.gov/show/NCT02576821,18 Years and older ,18,up to 18 years old
NCT00908492,Supporting Caregivers of Persons With Dementia: A Pilot Study,Completed,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Interventional,November 2009,September 2011,https://ClinicalTrials.gov/show/NCT00908492,18 Years and older ,18,up to 18 years old
NCT01652222,"Experimental Study to Validate the ""Therapeutic Game"" CONEM-BETA",Completed,Alzheimer's Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,101,Interventional,January 2012,August 2012,https://ClinicalTrials.gov/show/NCT01652222,18 Years and older ,18,up to 18 years old
NCT02690896,Caregiver Burden and Depression: Caring for Those Who Care for Others,Recruiting,Dementia|Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,"February 24, 2016",August 2020,https://ClinicalTrials.gov/show/NCT02690896,18 Years and older ,18,up to 18 years old
NCT02299154,Memory Problems Perceptions Among Patients and Accompaniers During Diagnosis Process :,Unknown status,Memory Disorders|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Interventional,December 2014,November 2017,https://ClinicalTrials.gov/show/NCT02299154,18 Years and older ,18,up to 18 years old
NCT04058886,Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers,Not yet recruiting,Alzheimer Dementia|Caregiver|Dementia Alzheimers,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,32,Interventional,September 2019,December 2021,https://ClinicalTrials.gov/show/NCT04058886,18 Years and older ,18,up to 18 years old
NCT01554202,Multi-modal Neuroimaging in Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,295,Interventional,January 2008,,https://ClinicalTrials.gov/show/NCT01554202,18 Years and older ,18,up to 18 years old
NCT03144921,EPIC: An Intervention for Early-stage AD Dyads,Recruiting,Dementia|Alzheimer Disease|Memory Loss,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,320,Interventional,"October 9, 2017",May 2021,https://ClinicalTrials.gov/show/NCT03144921,18 Years and older ,18,up to 18 years old
NCT03923517,RHAPSODY-plus: Online Counseling for Family Caregivers of Patients With Young Onset Dementia,Completed,Early Onset Alzheimer Disease|Frontotemporal Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"January 1, 2018","May 30, 2019",https://ClinicalTrials.gov/show/NCT03923517,18 Years and older ,18,up to 18 years old
NCT01209156,Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,11,Interventional,March 2010,June 2013,https://ClinicalTrials.gov/show/NCT01209156,18 Years and older ,18,up to 18 years old
NCT02951559,SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies,Recruiting,Encephalopathy|HIV-encephalopathy|Alzheimer Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 4,250,Interventional,March 2016,February 2021,https://ClinicalTrials.gov/show/NCT02951559,18 Years and older ,18,up to 18 years old
NCT01723553,Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD,Completed,Atypical Alzheimers Disease|Logopenic Variant of Primary Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA),All,"18 Years and older   (Adult, Older Adult)",Phase 1,27,Interventional,November 2012,March 2015,https://ClinicalTrials.gov/show/NCT01723553,18 Years and older ,18,up to 18 years old
NCT03119259,iCare-AD: A Mobile Health Application for Caregivers of Patients With Dementia.,Not yet recruiting,"Dementia, Alzheimer Type",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,448,Interventional,July 2019,"July 1, 2023",https://ClinicalTrials.gov/show/NCT03119259,18 Years and older ,18,up to 18 years old
NCT00479219,Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,17,Interventional,May 2007,October 2007,https://ClinicalTrials.gov/show/NCT00479219,18 Years and older ,18,up to 18 years old
NCT03828383,In-Home Technology for Dementia Caregivers,Recruiting,Dementia|Alzheimer's Disease|Frontotemporal Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,"February 26, 2019",February 2021,https://ClinicalTrials.gov/show/NCT03828383,18 Years and older ,18,up to 18 years old
NCT00795730,Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789,Terminated,Alzheimer Disease|Healthy Subjects,All,"18 Years and older   (Adult, Older Adult)",Phase 1,56,Interventional,January 2009,June 2009,https://ClinicalTrials.gov/show/NCT00795730,18 Years and older ,18,up to 18 years old
NCT03342326,Lexical Priming by Music in Alzheimer's Disease and Healthy Aging,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,78,Interventional,"April 3, 2018",February 2020,https://ClinicalTrials.gov/show/NCT03342326,18 Years and older ,18,up to 18 years old
NCT01926249,A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders,"Active, not recruiting",Alzheimer's Disease (AD) and Related Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2300,Observational,"April 8, 2011",October 2019,https://ClinicalTrials.gov/show/NCT01926249,18 Years and older ,18,up to 18 years old
NCT03715855,Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples,Not yet recruiting,Alzheimer Disease|Gastric Cancer|Urologic Cancer|Pneumological Cancer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Interventional,October 2018,October 2020,https://ClinicalTrials.gov/show/NCT03715855,18 Years and older ,18,up to 18 years old
NCT03721042,Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples,Not yet recruiting,Alzheimer Disease|Gastric Cancer|Urologic Cancer|Pneumological Cancer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Interventional,October 2018,October 2020,https://ClinicalTrials.gov/show/NCT03721042,18 Years and older ,18,up to 18 years old
NCT00001178,Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders,Terminated,Alzheimer's Disease|Dementia|Down's Syndrome,All,"18 Years and older   (Adult, Older Adult)",Phase 4,597,Observational,"January 19, 1981","December 17, 2012",https://ClinicalTrials.gov/show/NCT00001178,18 Years and older ,18,up to 18 years old
NCT03031184,Study of Mirtazapine for Agitation in Dementia,Recruiting,Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 3,222,Interventional,January 2017,July 2020,https://ClinicalTrials.gov/show/NCT03031184,18 Years and older ,18,up to 18 years old
NCT01028209,Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,Terminated,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12,Interventional,November 2009,"September 22, 2010",https://ClinicalTrials.gov/show/NCT01028209,18 Years and older ,18,up to 18 years old
NCT01518374,Clinical Evaluation of Florbetapir F 18 (18F-AV-45),Completed,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1768,Interventional,December 2009,"May 3, 2017",https://ClinicalTrials.gov/show/NCT01518374,18 Years and older ,18,up to 18 years old
NCT01550549,Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans,Completed,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,151,Interventional,August 2011,September 2011,https://ClinicalTrials.gov/show/NCT01550549,18 Years and older ,18,up to 18 years old
NCT02278367,Clinical Evaluation of 18F-AV-1451,Recruiting,Alzheimer's Disease|Traumatic Brain Injury|Depression,All,"18 Years and older   (Adult, Older Adult)",Phase 2,250,Interventional,December 2014,April 2019,https://ClinicalTrials.gov/show/NCT02278367,18 Years and older ,18,up to 18 years old
NCT02108769,Yogic Breathing Changes Salivary Components,Completed,Alzheimer Disease|Neurodegenerative Diseases|Cancer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,October 2013,November 2013,https://ClinicalTrials.gov/show/NCT02108769,18 Years and older ,18,up to 18 years old
NCT01190800,Capacity Assessment in Persons With Alzheimer's Disease,Completed,Alzheimer's Disease|Capacity to Consent to Treatment|Capacity to Vote|Capacity to Design a Proxy,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400,Observational,June 2010,September 2014,https://ClinicalTrials.gov/show/NCT01190800,18 Years and older ,18,up to 18 years old
NCT00970333,Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions,Completed,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,3,Interventional,August 2009,October 2010,https://ClinicalTrials.gov/show/NCT00970333,18 Years and older ,18,up to 18 years old
NCT00654563,Memory Disorders Registry,Completed,Dementia|Alzheimer's Disease|Parkinson Disease|Huntington Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,12,Observational,August 2007,March 2012,https://ClinicalTrials.gov/show/NCT00654563,18 Years and older ,18,up to 18 years old
NCT02612376,Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study,Recruiting,Alzheimer Disease|Down Syndrome|Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 4,800,Observational,February 2016,December 2030,https://ClinicalTrials.gov/show/NCT02612376,18 Years and older ,18,up to 18 years old
NCT02205424,Cognition And Neocortical Volume After Stroke,"Active, not recruiting",Ischaemic Stroke|Alzheimer's Disease|Vascular Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 4,175,Observational,May 2011,December 2020,https://ClinicalTrials.gov/show/NCT02205424,18 Years and older ,18,up to 18 years old
NCT03047694,A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Interventional,"July 15, 2019",July 2022,https://ClinicalTrials.gov/show/NCT03047694,18 Years and older ,18,up to 18 years old
NCT02063308,Oxaloacetate Pharmacokinetics and Safety,Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Interventional,February 2014,June 2014,https://ClinicalTrials.gov/show/NCT02063308,18 Years and older ,18,up to 18 years old
NCT04099823,MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics,Recruiting,Hydrocephalus|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Interventional,October 2019,October 2020,https://ClinicalTrials.gov/show/NCT04099823,18 Years and older ,18,up to 18 years old
NCT00857415,Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain,Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 3,226,Interventional,December 2008,May 2010,https://ClinicalTrials.gov/show/NCT00857415,18 Years and older ,18,up to 18 years old
NCT04077450,HRVB on Alzheimer's Disease Caregivers,Recruiting,"Burnout, Caregiver|Quality of Life",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"January 28, 2019","January 27, 2020",https://ClinicalTrials.gov/show/NCT04077450,18 Years and older ,18,up to 18 years old
NCT01819714,Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,31,Interventional,June 2013,February 2015,https://ClinicalTrials.gov/show/NCT01819714,18 Years and older ,18,up to 18 years old
NCT00362284,Comprehensive Support for Alzheimer's Disease Caregivers,Completed,Caregivers|Stress|Depression,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,161,Interventional,September 2005,January 2012,https://ClinicalTrials.gov/show/NCT00362284,18 Years and older ,18,up to 18 years old
NCT02968719,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,107,Interventional,November 2016,"July 11, 2017",https://ClinicalTrials.gov/show/NCT02968719,18 Years and older ,18,up to 18 years old
NCT02414178,F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project),Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,130,Interventional,"March 20, 2019",September 2020,https://ClinicalTrials.gov/show/NCT02414178,18 Years and older ,18,up to 18 years old
NCT00366288,Study Evaluating PAZ-417 in Healthy Young/Elderly,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,56,Observational,July 2006,March 2008,https://ClinicalTrials.gov/show/NCT00366288,18 Years and older ,18,up to 18 years old
NCT01745198,Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements,Completed,Mild Cognitive Impairment|Alzheimer's Disease|Alzheimer's Disease Related Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 4,121,Observational,December 2012,June 2014,https://ClinicalTrials.gov/show/NCT01745198,18 Years and older ,18,up to 18 years old
NCT00474552,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315",Terminated,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,56,Interventional,June 2007,October 2007,https://ClinicalTrials.gov/show/NCT00474552,18 Years and older ,18,up to 18 years old
NCT00480818,"Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects",Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80,Interventional,September 2006,July 2007,https://ClinicalTrials.gov/show/NCT00480818,18 Years and older ,18,up to 18 years old
NCT02418806,Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres,Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,231,Interventional,January 2014,September 2015,https://ClinicalTrials.gov/show/NCT02418806,18 Years and older ,18,up to 18 years old
NCT01837641,A Study of LY3002813 in Participants With Alzheimer's Disease,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,Interventional,"May 3, 2013","August 24, 2016",https://ClinicalTrials.gov/show/NCT01837641,18 Years and older ,18,up to 18 years old
NCT02563483,Yoga for Family Caregivers of Alzheimers Disease Patient,Completed,Stress|Anxiety|Compassion,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Interventional,September 2007,November 2009,https://ClinicalTrials.gov/show/NCT02563483,18 Years and older ,18,up to 18 years old
NCT01640275,Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia,Completed,General Anesthesia,All,"18 Years and older   (Adult, Older Adult)",Phase 1,105,Interventional,March 2012,March 2015,https://ClinicalTrials.gov/show/NCT01640275,18 Years and older ,18,up to 18 years old
NCT02362880,Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,February 2015,January 2019,https://ClinicalTrials.gov/show/NCT02362880,18 Years and older ,18,up to 18 years old
NCT02506374,Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads,Withdrawn,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Observational,November 2014,January 2016,https://ClinicalTrials.gov/show/NCT02506374,18 Years and older ,18,up to 18 years old
NCT00718731,Study GSI-136 in Healthy Young and Healthy Elderly Subjects,Completed,Alzheimer Disease|Healthy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80,Interventional,March 2008,August 2008,https://ClinicalTrials.gov/show/NCT00718731,18 Years and older ,18,up to 18 years old
NCT00089882,Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,360,Observational,May 2003,September 2006,https://ClinicalTrials.gov/show/NCT00089882,18 Years and older ,18,up to 18 years old
NCT01079819,"Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163",Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32,Interventional,April 2010,December 2010,https://ClinicalTrials.gov/show/NCT01079819,18 Years and older ,18,up to 18 years old
NCT01181921,The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1,Interventional,May 2011,June 2011,https://ClinicalTrials.gov/show/NCT01181921,18 Years and older ,18,up to 18 years old
NCT01447719,Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07,Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 3,110,Interventional,March 2010,July 2011,https://ClinicalTrials.gov/show/NCT01447719,18 Years and older ,18,up to 18 years old
NCT01454115,"Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163",Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,116,Interventional,June 2007,March 2009,https://ClinicalTrials.gov/show/NCT01454115,18 Years and older ,18,up to 18 years old
NCT01268020,Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,5,Interventional,December 2010,October 2012,https://ClinicalTrials.gov/show/NCT01268020,18 Years and older ,18,up to 18 years old
NCT01565369,Evaluation of Physician Training Methods to Read Florbetapir-PET Scans,Completed,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Interventional,January 2011,January 2011,https://ClinicalTrials.gov/show/NCT01565369,18 Years and older ,18,up to 18 years old
NCT00366483,Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40,Interventional,May 2006,,https://ClinicalTrials.gov/show/NCT00366483,18 Years and older ,18,up to 18 years old
NCT04111211,Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits,Not yet recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000,Observational,October 2019,October 2024,https://ClinicalTrials.gov/show/NCT04111211,18 Years and older ,18,up to 18 years old
NCT04123314,Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease,Not yet recruiting,Depressive Symptoms|Depression|Alzheimer Disease|Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,20,Interventional,"October 15, 2019","September 1, 2022",https://ClinicalTrials.gov/show/NCT04123314,18 Years and older ,18,up to 18 years old
NCT01089582,Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,628,Observational,November 2007,July 2009,https://ClinicalTrials.gov/show/NCT01089582,18 Years and older ,18,up to 18 years old
NCT03049501,Caring for the Caregiver Network,Completed,Caregivers of Alzheimer's Disease or Memory Problem Patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,244,Interventional,July 2013,"April 20, 2018",https://ClinicalTrials.gov/show/NCT03049501,18 Years and older ,18,up to 18 years old
NCT03770182,Brain Stimulation for Neurological Patients,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"January 24, 2017","January 1, 2020",https://ClinicalTrials.gov/show/NCT03770182,18 Years and older ,18,up to 18 years old
NCT03033875,"Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers",Recruiting,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,270,Interventional,"May 18, 2017","November 30, 2020",https://ClinicalTrials.gov/show/NCT03033875,18 Years and older ,18,up to 18 years old
NCT03667924,Utilizing Senior Companions to Enhance Dementia Care,Enrolling by invitation,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,25,Interventional,"May 1, 2019",October 2020,https://ClinicalTrials.gov/show/NCT03667924,18 Years and older ,18,up to 18 years old
NCT01117181,Apathy in Dementia Methylphenidate Trial (ADMET),Completed,Apathy|Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Interventional,June 2010,August 2012,https://ClinicalTrials.gov/show/NCT01117181,18 Years and older ,18,up to 18 years old
NCT03654911,Sustainable Method for Alzheimer's Prediction,Not yet recruiting,Alzheimer Disease|Amnestic-Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 4,150,Observational,"September 3, 2018","September 3, 2020",https://ClinicalTrials.gov/show/NCT03654911,18 Years and older ,18,up to 18 years old
NCT02164643,Longitudinal Study of Brain Amyloid imaGing in MEMENTO,"Active, not recruiting",Alzheimer's Disease (AD) and Related Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 3,448,Interventional,"June 10, 2014",December 2019,https://ClinicalTrials.gov/show/NCT02164643,18 Years and older ,18,up to 18 years old
NCT01978327,"GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers",Terminated,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12,Interventional,"November 22, 2013","March 3, 2014",https://ClinicalTrials.gov/show/NCT01978327,18 Years and older ,18,up to 18 years old
NCT00869817,Dominantly Inherited Alzheimer Network (DIAN),Recruiting,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,700,Observational,January 2009,July 2024,https://ClinicalTrials.gov/show/NCT00869817,18 Years and older ,18,up to 18 years old
NCT03233646,OCTA in Mild Cognitive Impairment and Alzheimer's Disease,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Retinal Vascular|Parkinson Disease|Multiple Sclerosis|Huntington Disease|Neuro-Degenerative Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000,Interventional,"July 20, 2017","April 1, 2021",https://ClinicalTrials.gov/show/NCT03233646,18 Years and older ,18,up to 18 years old
NCT03994237,Accompanying ALZHEIMER CAREGIVER,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,45,Observational,"December 12, 2018","June 7, 2019",https://ClinicalTrials.gov/show/NCT03994237,18 Years and older ,18,up to 18 years old
NCT02489110,Webnovela for Hispanic Dementia Family Caregivers,Completed,Alzheimer's Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Interventional,June 2015,September 2016,https://ClinicalTrials.gov/show/NCT02489110,18 Years and older ,18,up to 18 years old
NCT02752750,Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease,Enrolling by invitation,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Observational,May 2016,May 2020,https://ClinicalTrials.gov/show/NCT02752750,18 Years and older ,18,up to 18 years old
NCT02707978,F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD),Withdrawn,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Interventional,"September 30, 2017",December 2020,https://ClinicalTrials.gov/show/NCT02707978,18 Years and older ,18,up to 18 years old
NCT01450891,Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease,Completed,Neurodegenerative Diseases|Memory Disturbances,All,"18 Years and older   (Adult, Older Adult)",Phase 4,304,Observational,September 2009,July 2013,https://ClinicalTrials.gov/show/NCT01450891,18 Years and older ,18,up to 18 years old
NCT00192998,The Serotonergic Transmitter System in Dementia and Affective Disorders,Unknown status,Mood Disorders|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Observational,October 2003,,https://ClinicalTrials.gov/show/NCT00192998,18 Years and older ,18,up to 18 years old
NCT02319681,"Reminiscence, Anxiety and Early Alzheimer's Disease",Withdrawn,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Interventional,January 2015,June 2017,https://ClinicalTrials.gov/show/NCT02319681,18 Years and older ,18,up to 18 years old
NCT02414347,F 18 T807 Tau PET Imaging of Alzheimer's Disease,Enrolling by invitation,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Interventional,October 2014,December 2019,https://ClinicalTrials.gov/show/NCT02414347,18 Years and older ,18,up to 18 years old
NCT04100889,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease,Not yet recruiting,"Alzheimer Disease|Alzheimer Disease 1|Alzheimer Disease 2|Alzheimer Disease 3|Alzheimer Disease 4|Alzheimer Disease 5|Alzheimer Disease 6|Alzheimer Disease 7|Alzheimer Disease 8|Alzheimer Disease 9, Late-Onset|Alzheimer Disease 10|Alzheimer Disease 11|Alzheimer Disease 12|Alzheimer Disease 13|Alzheimer Disease 14|Alzheimer Disease 15|Alzheimer Disease 16|Alzheimer Disease 17|Alzheimer Disease 18|Alzheimer Disease 19|Alzheimer Disease, Early Onset|Alzheimer Disease, Late Onset|Alzheimer Disease Focal",All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Observational,September 2019,December 2020,https://ClinicalTrials.gov/show/NCT04100889,18 Years and older ,18,up to 18 years old
NCT02271685,Sound Estimation and Accuracy Task,Completed,Parkinson's|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Interventional,February 2015,May 2015,https://ClinicalTrials.gov/show/NCT02271685,18 Years and older ,18,up to 18 years old
NCT01672827,Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 3,276,Interventional,July 2012,August 2012,https://ClinicalTrials.gov/show/NCT01672827,18 Years and older ,18,up to 18 years old
NCT03938870,CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease,Recruiting,"Alzheimer's Disease|Brain Diseases|Central Nervous System Diseases|Delirium, Dementia, Amnestic, Cognitive Disorders|Dementia|Mental Disorders|Nervous System Diseases|Neurodegenerative Diseases|Tauopathies",All,"18 Years and older   (Adult, Older Adult)",Phase 4,100,Observational,August 2015,September 2021,https://ClinicalTrials.gov/show/NCT03938870,18 Years and older ,18,up to 18 years old
NCT03308032,Self-Directed Online Training for Chinese Caregivers,Unknown status,Dementia|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Interventional,"September 1, 2016","July 30, 2018",https://ClinicalTrials.gov/show/NCT03308032,18 Years and older ,18,up to 18 years old
NCT02556502,18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study,Completed,Amyloid PET Imaging,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,November 2015,November 2017,https://ClinicalTrials.gov/show/NCT02556502,18 Years and older ,18,up to 18 years old
NCT03816228,Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.,Not yet recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,"October 14, 2019",June 2025,https://ClinicalTrials.gov/show/NCT03816228,18 Years and older ,18,up to 18 years old
NCT00407576,PET Imaging of Brain Amyloid Using [11C]MeS-IMPY,Completed,Alzheimer's Disease|Healthy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30,Interventional,"December 1, 2006",,https://ClinicalTrials.gov/show/NCT00407576,18 Years and older ,18,up to 18 years old
NCT02403752,Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE),Completed,Dementia|Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,March 2015,July 2018,https://ClinicalTrials.gov/show/NCT02403752,18 Years and older ,18,up to 18 years old
NCT01434667,Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV,Completed,Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,146,Interventional,January 2010,July 2014,https://ClinicalTrials.gov/show/NCT01434667,18 Years and older ,18,up to 18 years old
NCT03786471,D-CARE - The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care,Recruiting,Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2150,Interventional,"July 8, 2019","June 30, 2023",https://ClinicalTrials.gov/show/NCT03786471,18 Years and older ,18,up to 18 years old
NCT02278354,Tau Imaging in Professional Fighters,Completed,Alzheimer's Disease,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,30,Interventional,December 2014,"February 3, 2017",https://ClinicalTrials.gov/show/NCT02278354,18 Years and older ,18,up to 18 years old
NCT03311711,Two-Phased Study of SPIRIT in Mild Dementia,Recruiting,Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,264,Interventional,"May 4, 2018","May 31, 2022",https://ClinicalTrials.gov/show/NCT03311711,18 Years and older ,18,up to 18 years old
NCT02221661,"Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center",Completed,Cognitive Impairment|Memory Complaint|Clinical Investigation in Memory Centers,All,"18 Years and older   (Adult, Older Adult)",Phase 4,606,Observational,December 2011,December 2013,https://ClinicalTrials.gov/show/NCT02221661,18 Years and older ,18,up to 18 years old
NCT01638949,Multi-modal Neuroimaging in Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,295,Interventional,May 2012,,https://ClinicalTrials.gov/show/NCT01638949,18 Years and older ,18,up to 18 years old
NCT03987464,Platform-based Mild Cognitive Impairment (MCI) Trial,Not yet recruiting,Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18,Interventional,November 2019,June 2020,https://ClinicalTrials.gov/show/NCT03987464,18 Years and older ,18,up to 18 years old
NCT02392468,"Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers",Completed,Schizophrenia|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1,61,Interventional,"April 15, 2015","August 10, 2017",https://ClinicalTrials.gov/show/NCT02392468,18 Years and older ,18,up to 18 years old
NCT03387267,Videofluoroscopic Swallowing Study (VFSS),Terminated,Stroke|Parkinson Disease|Multiple Sclerosis|Oropharyngeal Dysphagia|Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,442,Interventional,"October 24, 2017","July 23, 2018",https://ClinicalTrials.gov/show/NCT03387267,18 Years and older ,18,up to 18 years old
NCT04104659,Study of Tau Imaging With the Use of [18F]MK-6240 Tracer,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Interventional,"April 11, 2019","June 1, 2024",https://ClinicalTrials.gov/show/NCT04104659,18 Years and older ,18,up to 18 years old
NCT03076307,DAT SPECT and Procedural Motor Skills in Parkinson's Disease,Completed,Parkinson Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,9,Interventional,"October 18, 2016","July 19, 2017",https://ClinicalTrials.gov/show/NCT03076307,18 Years and older ,18,up to 18 years old
NCT01700556,A Trial to Support Caregivers of Patients With Dementia in Italy: the UP-TECH Project,Unknown status,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,900,Interventional,November 2012,January 2015,https://ClinicalTrials.gov/show/NCT01700556,18 Years and older ,18,up to 18 years old
NCT02014246,Genetic Characterization of Movement Disorders and Dementias,Recruiting,"Ataxia|Dystonia|Parkinson's Disease|Amyotrophic Lateral Sclerosis|Corticobasal Degeneration|Multiple System Atrophy|Alzheimer's Disease|Lewy Body Dementia|Parkinson Disease-Dementia|Dentatorubral-pallidoluysian Atrophy|Creutzfeldt-Jakob Disease and Fatal Familial Insomnia|Fragile X-associated Tremor/Ataxia Syndrome|Krabbe's Disease|Niemann-Pick Disease, Type C|Neuronal Ceroid Lipofuscinosis",All,"18 Years and older   (Adult, Older Adult)",Phase 4,12000,Observational,"February 12, 2003","December 31, 2019",https://ClinicalTrials.gov/show/NCT02014246,18 Years and older ,18,up to 18 years old
NCT04055532,Biomarkers in Neurodegenerative Diseases,Not yet recruiting,Mild Cognitive Impairment (MCI)|Alzheimer Disease (AD)|Dementia With Lewy Bodies (DLB)|Frontotemporal Lobar Degeneration (FTLD)|Parkinsons Disease With Dementia (PDD)|Transient Epileptic Amnesia (TEA)|Temporal Lobe Epilepsy (TLE)|Spinocerebellar Ataxias (SCA)|HIV Associated Neurocognitive Disorder (HAND)|Amyotrophic Lateral Sclerosis (ALS)|Primary Lateral Sclerosis (PLS),All,"18 Years and older   (Adult, Older Adult)",Phase 4,200,Observational,"October 1, 2019","October 1, 2025",https://ClinicalTrials.gov/show/NCT04055532,18 Years and older ,18,up to 18 years old
NCT00253227,A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,Completed,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 3,387,Interventional,July 1997,December 1998,https://ClinicalTrials.gov/show/NCT00253227,18 Years and older ,18,up to 18 years old
NCT03909347,PLAN: Dementia Literacy Education and Navigation for Korean Elders With Probable Dementia and Their Caregivers,Not yet recruiting,Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,288,Interventional,July 2020,July 2025,https://ClinicalTrials.gov/show/NCT03909347,18 Years and older ,18,up to 18 years old
NCT04048759,The Promotion of Physical Activity for the Prevention of Alzheimer's Disease in Adults With Down Syndrome,Not yet recruiting,Down Syndrome|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,"January 1, 2020","January 1, 2024",https://ClinicalTrials.gov/show/NCT04048759,18 Years and older ,18,up to 18 years old
NCT03945968,The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.,Recruiting,Coronary Heart Disease|Anemia|Bronchial Asthma|Stroke|Epilepsy|Parkinson's Disease|Heart Rhythm Disorders|Alzheimer's Disease|Neuromuscular Diseases|Diabetes|Chronic Heart Failure|Chronic Obstructive Pulmonary Disease|Chronic Kidney Diseases,All,"18 Years and older   (Adult, Older Adult)",Phase 4,16000,Observational,"July 1, 2019","January 30, 2021",https://ClinicalTrials.gov/show/NCT03945968,18 Years and older ,18,up to 18 years old
NCT02522091,"Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI",Unknown status,Alzheimer's Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,178,Interventional,November 2010,,https://ClinicalTrials.gov/show/NCT02522091,18 Years and older ,18,up to 18 years old
NCT03724136,Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study,Recruiting,"Alzheimer Disease|Alzheimer Dementia|Vascular Dementia|Lewy Body Disease|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia, Mixed|Parkinson-Dementia Syndrome|Chronic Traumatic Encephalopathy|Huntington's Dementia|Wernicke Korsakoff Syndrome|Traumatic Brain Injury|Dementia, Multi-Infarct|Autism|Autism Spectrum Disorder|Autistic Behavior|Autistic Disorder, Current or Active State|Cadasil|LATE Limbic-predominant Age-related TDP-43 Encephalopathy",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,"October 24, 2018","October 24, 2022",https://ClinicalTrials.gov/show/NCT03724136,18 Years and older ,18,up to 18 years old
NCT03899298,Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions,Not yet recruiting,Orthopedic Disorder|Neurologic Disorder|Urologic Diseases|Erectile Dysfunction|Autoimmune Diseases|Renal Failure|Renal Insufficiency|Kidney Diseases|Cardiac Event|Cardiomyopathies|CHF|Pulmonary Disease|COPD|Alzheimer Disease|Stroke|Neuropathy;Peripheral|Arthritis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5000,Interventional,"September 1, 2019","March 20, 2029",https://ClinicalTrials.gov/show/NCT03899298,18 Years and older ,18,up to 18 years old
NCT02750982,"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",Completed,Alzheimer's Disease|Amyotrophic Lateral Sclerosis|Brain Injury|Huntington's Disease|Multiple Sclerosis|Parkinson's Disease|Stroke|Spinal Cord Injury,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Interventional,July 2016,August 2018,https://ClinicalTrials.gov/show/NCT02750982,18 Years and older ,18,up to 18 years old
NCT00253188,A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,Completed,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 3,653,Interventional,February 1997,December 1998,https://ClinicalTrials.gov/show/NCT00253188,18 Years and older ,18,up to 18 years old
NCT04037501,Effectiveness of a Care Management System to Reduce Unmet Needs of Informal Caregivers of People With Dementia,Not yet recruiting,"Dementia|Caregiver Burnout|Carer Stress Syndrome|Relatives|Partner, Domestic",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,504,Interventional,November 2019,March 2022,https://ClinicalTrials.gov/show/NCT04037501,18 Years and older ,18,up to 18 years old
NCT01565434,Erythrocyte Complement Receptor 1 and Alzheimer Disease,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,February 2012,April 2015,https://ClinicalTrials.gov/show/NCT01565434,18 Years and older ,18,up to 18 years old
NCT00253201,A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,Completed,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 3,636,Interventional,,October 1997,https://ClinicalTrials.gov/show/NCT00253201,18 Years and older ,18,up to 18 years old
NCT01366027,PRISM Registry: Pseudobulbar Affect Registry Series,Completed,Alzheimer's Disease|Amyotrophic Lateral Sclerosis (ALS)|Multiple Sclerosis (MS)|Parkinson's Disease|Stroke|Traumatic Brain Injury,All,"18 Years and older   (Adult, Older Adult)",Phase 4,5290,Observational,May 2011,September 2012,https://ClinicalTrials.gov/show/NCT01366027,18 Years and older ,18,up to 18 years old
NCT03734289,Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People With AD and TBI,Recruiting,Dementia|Traumatic Brain Injury,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Interventional,"February 1, 2017","December 31, 2019",https://ClinicalTrials.gov/show/NCT03734289,18 Years and older ,18,up to 18 years old
NCT02494531,Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging,Recruiting,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,May 2015,January 2020,https://ClinicalTrials.gov/show/NCT02494531,18 Years and older ,18,up to 18 years old
NCT03592563,CUHK Brain Health Longitudinal Study,Recruiting,"Stroke, Ischemic|Stroke Syndrome|Stroke|Stroke, Acute|Dementia|Brain Ischemia|Brain Diseases|Alzheimer Disease|Health Attitude|Health Knowledge, Attitudes, Practice|Health Personnel Attitude|Healthy Aging",All,"18 Years and older   (Adult, Older Adult)",Phase 4,5000,Observational,"July 1, 2019","December 31, 2048",https://ClinicalTrials.gov/show/NCT03592563,18 Years and older ,18,up to 18 years old
NCT00145132,Beta-CIT-SPECT and Neurophysiology in Depression,Completed,Depression,All,"18 Years and older   (Adult, Older Adult)",Phase 4,30,Interventional,June 2005,December 2009,https://ClinicalTrials.gov/show/NCT00145132,18 Years and older ,18,up to 18 years old
NCT03506672,Assessing the Effectiveness of an Approach for Vocal Behaviors in Older People Living in Nursing Homes,Recruiting,Behavioral Symptoms,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,324,Interventional,"November 30, 2018",September 2021,https://ClinicalTrials.gov/show/NCT03506672,18 Years and older ,18,up to 18 years old
NCT03907748,Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia,Not yet recruiting,"Dementia|Dementia, Vascular|Dementia With Lewy Bodies|Dementia, Mixed|Dementia Alzheimers|Behavioural and Psychiatric Symptoms of Dementia|Depression|Quality of Life",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,990,Interventional,"September 1, 2019","April 1, 2022",https://ClinicalTrials.gov/show/NCT03907748,18 Years and older ,18,up to 18 years old
NCT03623542,Adverse Drug Reactions in Older Subjects,Completed,Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 4,293,Observational,"May 1, 2010","November 1, 2011",https://ClinicalTrials.gov/show/NCT03623542,18 Years and older ,18,up to 18 years old
NCT01867359,The Genetic Characterization of Dementia,Completed,Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 4,87,Observational,"March 14, 2003","September 20, 2016",https://ClinicalTrials.gov/show/NCT01867359,18 Years and older ,18,up to 18 years old
NCT03657732,The Chinese Familial Alzheimer's Network,Recruiting,Alzheimer Disease|Familial Alzheimer Disease (FAD),All,"18 Years and older   (Adult, Older Adult)",Phase 4,10000,Observational,"January 10, 2008","January 1, 2028",https://ClinicalTrials.gov/show/NCT03657732,18 Years and older ,18,up to 18 years old
NCT00321971,Prevention of Depression in Spouses of People With Cognitive Impairment,Completed,Depression,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,73,Interventional,February 2007,December 2011,https://ClinicalTrials.gov/show/NCT00321971,18 Years and older ,18,up to 18 years old
NCT03628404,Defining the Genetic Etiology of Alzheimer's Disease in the Faroe Islands,Recruiting,Alzheimer Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000,Observational,"September 1, 2015","January 1, 2020",https://ClinicalTrials.gov/show/NCT03628404,18 Years and older ,18,up to 18 years old
NCT00874783,Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases,Recruiting,Neurodegenerative Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120,Observational,April 2009,December 2025,https://ClinicalTrials.gov/show/NCT00874783,18 Years and older ,18,up to 18 years old
NCT00878059,Alzheimer's Family Research,Completed,Decision Making,All,"18 Years and older   (Adult, Older Adult)",Phase 4,165,Observational,July 2008,December 2011,https://ClinicalTrials.gov/show/NCT00878059,18 Years and older ,18,up to 18 years old
NCT00249080,Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease,Completed,Neurodegenerative Diseases|Mild Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 4,182,Observational,June 2005,August 2007,https://ClinicalTrials.gov/show/NCT00249080,18 Years and older ,18,up to 18 years old
NCT03650816,Cerebrovascular Reactivity in Alzheimer's Disease,Not yet recruiting,Alzheimer Disease|Subjective Cognitive Impairment,All,"18 Years and older   (Adult, Older Adult)",Phase 4,48,Observational,September 2019,"August 2, 2021",https://ClinicalTrials.gov/show/NCT03650816,18 Years and older ,18,up to 18 years old
NCT03098459,Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study,Recruiting,Delirium|Cognitive Impairment|Alzheimer; Early Onset|Trauma|Polytrauma|Traumatic Brain Injury|ICU|Critical Illness,Male,"18 Years and older   (Adult, Older Adult)",Phase 4,900,Observational,"November 2, 2017",November 2021,https://ClinicalTrials.gov/show/NCT03098459,18 Years and older ,18,up to 18 years old
NCT01807026,A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease,Completed,Alzheimer Disease|Healthy Volunteers,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36,Interventional,March 2013,May 2013,https://ClinicalTrials.gov/show/NCT01807026,18 Years and older ,18,up to 18 years old
NCT01334749,Observational Study on Determinants of Dementia After Stroke,"Active, not recruiting",Ischemic Stroke|Hemorrhagic Stroke,All,"18 Years and older   (Adult, Older Adult)",Phase 4,736,Observational,April 2011,January 2029,https://ClinicalTrials.gov/show/NCT01334749,18 Years and older ,18,up to 18 years old
NCT01078168,Alzheimer`s Disease Acitretin Medication,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,22,Interventional,March 2010,May 2013,https://ClinicalTrials.gov/show/NCT01078168,18 Years and older ,18,up to 18 years old
NCT00086138,Depression in Alzheimer's Disease-2,Completed,Alzheimer's Disease|Depression,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,131,Interventional,July 2004,July 2009,https://ClinicalTrials.gov/show/NCT00086138,18 Years and older ,18,up to 18 years old
NCT01550718,Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial,Completed,Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,152,Interventional,February 2012,February 2015,https://ClinicalTrials.gov/show/NCT01550718,18 Years and older ,18,up to 18 years old
NCT04113577,COgilus Remediation in Alzheimer Patients (CORA),Not yet recruiting,Patient Satisfaction|Neurocognitive Disorders,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120,Observational,"October 30, 2019","October 30, 2020",https://ClinicalTrials.gov/show/NCT04113577,18 Years and older ,18,up to 18 years old
NCT01639586,Comparison for the Patient With Alzheimer Disease the Impact of Three Different Groups of Patient Care,Unknown status,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,360,Interventional,August 2011,April 2013,https://ClinicalTrials.gov/show/NCT01639586,18 Years and older ,18,up to 18 years old
NCT01353430,Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD),Recruiting,Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia|Paget Disease of Bone|Frontotemporal Dementia|Myopathy,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Observational,January 2000,December 2026,https://ClinicalTrials.gov/show/NCT01353430,18 Years and older ,18,up to 18 years old
NCT03417219,Mobile Tablet Education to Advance Caregiver Health,Completed,Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Interventional,"January 1, 2015","June 30, 2018",https://ClinicalTrials.gov/show/NCT03417219,18 Years and older ,18,up to 18 years old
NCT03894254,Predictive Factors of Autonomy Loss in Real-life Cohort,Not yet recruiting,Memory Disorders,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5250,Interventional,"April 1, 2019","March 1, 2032",https://ClinicalTrials.gov/show/NCT03894254,18 Years and older ,18,up to 18 years old
NCT03610698,Life Enhancing Activities for Family Caregivers (LEAF 2.0),Not yet recruiting,Caregivers,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Interventional,"August 31, 2019","March 31, 2023",https://ClinicalTrials.gov/show/NCT03610698,18 Years and older ,18,up to 18 years old
NCT04044131,Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients,Not yet recruiting,Alzheimer Disease|Parkinson Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Interventional,"September 1, 2019",September 2020,https://ClinicalTrials.gov/show/NCT04044131,18 Years and older ,18,up to 18 years old
NCT01430286,Web-based Psycho-Educational Program to Support Carers of Alzheimer's Patients,Completed,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,49,Interventional,October 2011,July 2014,https://ClinicalTrials.gov/show/NCT01430286,18 Years and older ,18,up to 18 years old
NCT02428387,"Evaluation of ""My Tools 4 Care"" for Family Caregivers of Persons With Dementia",Completed,Family|Dementia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,199,Interventional,April 2015,"April 12, 2017",https://ClinicalTrials.gov/show/NCT02428387,18 Years and older ,18,up to 18 years old
NCT01513967,A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,Completed,Moderate to Severe Alzheimer|Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,Interventional,January 2012,June 2015,https://ClinicalTrials.gov/show/NCT01513967,18 Years and older ,18,up to 18 years old
NCT00459355,Home Safety Clinical Trial for Alzheimer's Disease,Completed,Alzheimer's Disease|Dementia,All,"18 Years and older   (Adult, Older Adult)",Phase 1,254,Interventional,July 2007,December 2011,https://ClinicalTrials.gov/show/NCT00459355,18 Years and older ,18,up to 18 years old
NCT02868905,Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women,Unknown status,Obesity|Alzheimer's Disease,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,160,Interventional,September 2016,September 2018,https://ClinicalTrials.gov/show/NCT02868905,18 Years and older ,18,up to 18 years old
NCT01638884,Prospective Memory Imaging,Unknown status,Alzheimer Disease,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,118,Interventional,September 2010,June 2015,https://ClinicalTrials.gov/show/NCT01638884,18 Years and older ,18,up to 18 years old
NCT03185182,Diagnostic Imaging for Clear Cell Renal Cell Carcinoma,Terminated,Clear Cell Renal Cell Carcinoma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5,Interventional,"July 14, 2017","September 12, 2018",https://ClinicalTrials.gov/show/NCT03185182,18 Years and older ,18,up to 18 years old
NCT03864965,Advance Care Planning in Cognitive Disorders Clinic,Recruiting,Advance Care Planning,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,240,Interventional,"July 1, 2019",August 2020,https://ClinicalTrials.gov/show/NCT03864965,18 Years to 100 Years ,18,up to 18 years old
NCT02309723,Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,315,Interventional,September 2013,November 2013,https://ClinicalTrials.gov/show/NCT02309723,18 Years to 100 Years ,18,up to 18 years old
NCT02650843,Non-motor Symptoms and Brain Dopamine Transporter Binding,Enrolling by invitation,Parkinson Disease|Parkinsonism,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,1000,Observational,January 2015,December 2024,https://ClinicalTrials.gov/show/NCT02650843,18 Years to 100 Years ,18,up to 18 years old
NCT01592552,"A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery",Completed,Alzheimer's Disease|Multiple Sclerosis|Parkinson's Disease|Huntington's Disease|Amyotrophic Lateral Sclerosis (ALS),All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,20,Observational,November 2011,March 2015,https://ClinicalTrials.gov/show/NCT01592552,18 Years to 100 Years ,18,up to 18 years old
NCT03448601,Alzheimer's Disease and Precision Medicine Research With American Indian and Alaska Native People,Not yet recruiting,Alzheimer Disease,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,3000,Interventional,"August 1, 2019","August 31, 2022",https://ClinicalTrials.gov/show/NCT03448601,18 Years to 100 Years ,18,up to 18 years old
NCT02685787,Early Counseling and Support for Alzheimer's Disease Caregivers,Unknown status,Alzheimer's Disease,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,230,Interventional,April 2012,December 2017,https://ClinicalTrials.gov/show/NCT02685787,18 Years to 100 Years ,18,up to 18 years old
NCT03134963,Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study,Completed,Mild Cognitive Impairment|Alzheimer Disease|Vascular Dementia|Healthy Controls,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,51,Observational,"May 5, 2017","December 1, 2017",https://ClinicalTrials.gov/show/NCT03134963,18 Years to 100 Years ,18,up to 18 years old
NCT03282916,Anti-viral Therapy in Alzheimer's Disease,Recruiting,Alzheimer Disease|Herpes Simplex 1|Herpes Simplex 2,All,"18 Years to 105 Years   (Adult, Older Adult)",Phase 2,130,Interventional,"February 12, 2018",August 2022,https://ClinicalTrials.gov/show/NCT03282916,18 Years to 105 Years ,18,up to 18 years old
NCT03108846,Escitalopram for Agitation in Alzheimer's Disease,Recruiting,Dementia,All,"18 Years to 109 Years   (Adult, Older Adult)",Phase 3,392,Interventional,"January 3, 2018",August 2022,https://ClinicalTrials.gov/show/NCT03108846,18 Years to 109 Years ,18,up to 18 years old
NCT03932812,Building a Bridge (BAB) Between Clinical and Community Care,Not yet recruiting,Caregiver Burden,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,106,Interventional,May 2019,January 2021,https://ClinicalTrials.gov/show/NCT03932812,18 Years to 110 Years ,18,up to 18 years old
NCT03682185,The Healthy Patterns Study,Recruiting,Dementia|Alzheimer Disease|Circadian Rhythm Disorders|Circadian Rhythm Sleep Disorder|Insomnia|Hypersomnia|Cognitive Impairment|Cognitive Decline|Mild Cognitive Impairment|Frontotemporal Dementia|Neurocognitive Disorders|Vascular Dementia|Sleep Disorder|Memory Impairment,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 3,200,Interventional,"May 1, 2016","May 31, 2021",https://ClinicalTrials.gov/show/NCT03682185,18 Years to 110 Years ,18,up to 18 years old
NCT03896711,MEMORI Corps: Activity-based Companion Care for Dementia,Not yet recruiting,Alzheimer Disease|Dementia,All,"18 Years to 115 Years   (Adult, Older Adult)",Not Applicable,560,Interventional,"December 15, 2019","September 29, 2024",https://ClinicalTrials.gov/show/NCT03896711,18 Years to 115 Years ,18,up to 18 years old
NCT03653871,Caregiver Study Dr. Phillips,Recruiting,Alzheimer Disease|Dementia,All,"18 Years to 115 Years   (Adult, Older Adult)",Not Applicable,210,Interventional,"September 11, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03653871,18 Years to 115 Years ,18,up to 18 years old
NCT01498263,"Inherited Diseases, Caregiving, and Social Networks",Recruiting,Alzheimer Disease and Related Dementias|Inherited Neurodegenerative Disorders|Inherited Metabolic Disorders (Inborn Errors of Metabolism)|Undiagnosed Diseases|Healthy Volunteer,All,"18 Years to 118 Years   (Adult, Older Adult)",Phase 4,3300,Observational,"January 9, 2012",,https://ClinicalTrials.gov/show/NCT01498263,18 Years to 118 Years ,18,up to 18 years old
NCT02681822,Multi-center Imaging Genetics Studies in China,Recruiting,Alzheimer Disease|Schizophrenia|Major Depressive Disorders,All,18 Years to 30 Years   (Adult),Phase 4,10000,Observational,November 2015,December 2020,https://ClinicalTrials.gov/show/NCT02681822,18 Years to 30 Years ,18,up to 18 years old
NCT02899403,Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003,Recruiting,Alzheimer Disease|ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder),Male,18 Years to 30 Years   (Adult),Not Applicable,20,Interventional,"May 19, 2017",December 2020,https://ClinicalTrials.gov/show/NCT02899403,18 Years to 30 Years ,18,up to 18 years old
NCT02288000,Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases,Recruiting,Alzheimer Disease|Battery,Male,18 Years to 30 Years   (Adult),Phase 1,30,Interventional,"September 14, 2016",September 2020,https://ClinicalTrials.gov/show/NCT02288000,18 Years to 30 Years ,18,up to 18 years old
NCT02891343,Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers,Recruiting,Alteration of Cognitive Function|Hypoxia,Male,18 Years to 30 Years   (Adult),Not Applicable,20,Interventional,November 2015,February 2020,https://ClinicalTrials.gov/show/NCT02891343,18 Years to 30 Years ,18,up to 18 years old
NCT02453763,In Vivo Imaging of Therapeutic Electric Current Flow,Completed,Parkinson Disease|Epilepsy|Alzheimer's Disease|Stroke|Autism|Depression|Schizophrenia,All,18 Years to 30 Years   (Adult),Phase 4,17,Observational,June 2015,"July 6, 2017",https://ClinicalTrials.gov/show/NCT02453763,18 Years to 30 Years ,18,up to 18 years old
NCT01487395,Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development,Completed,Alzheimer Disease|Battery,Male,18 Years to 30 Years   (Adult),Phase 1,30,Interventional,December 2011,December 2013,https://ClinicalTrials.gov/show/NCT01487395,18 Years to 30 Years ,18,up to 18 years old
NCT00592943,PET Study Examining the Dopaminergic Activity of Armodafinil in Adults,Completed,Healthy,All,18 Years to 35 Years   (Adult),Phase 1|Phase 2,12,Interventional,October 2007,May 2010,https://ClinicalTrials.gov/show/NCT00592943,18 Years to 35 Years ,18,up to 18 years old
NCT03711825,Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults,Completed,Alzheimer Disease|Gastric Retention|Healthy,All,18 Years to 40 Years   (Adult),Early Phase 1,8,Interventional,"September 10, 2018","November 13, 2018",https://ClinicalTrials.gov/show/NCT03711825,18 Years to 40 Years ,18,up to 18 years old
NCT04023994,"A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants",Recruiting,Alzheimers Disease,Male,18 Years to 40 Years   (Adult),Phase 1,60,Interventional,"August 3, 2019","April 24, 2020",https://ClinicalTrials.gov/show/NCT04023994,18 Years to 40 Years ,18,up to 18 years old
NCT01325662,A Study to Evaluate the Use of an Indwelling Catheter to Obtain Cerebrospinal Fluid (CSF) by Low-rate Continuous Sampling (MK-0000-211),Completed,Alzheimer's Disease,All,18 Years to 40 Years   (Adult),Phase 4,11,Observational,March 2011,September 2011,https://ClinicalTrials.gov/show/NCT01325662,18 Years to 40 Years ,18,up to 18 years old
NCT03698695,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","Active, not recruiting",Cognitive Impairment|Alzheimer Disease,Male,18 Years to 40 Years   (Adult),Phase 1,152,Interventional,"September 27, 2018","December 20, 2019",https://ClinicalTrials.gov/show/NCT03698695,18 Years to 40 Years ,18,up to 18 years old
NCT01258452,Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects,Completed,Alzheimer's Disease,Male,18 Years to 45 Years   (Adult),Phase 1,12,Interventional,February 2011,March 2011,https://ClinicalTrials.gov/show/NCT01258452,18 Years to 45 Years ,18,up to 18 years old
NCT00954252,"Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects",Completed,Alzheimer's Disease,Male,18 Years to 45 Years   (Adult),Phase 1,84,Interventional,October 2009,May 2010,https://ClinicalTrials.gov/show/NCT00954252,18 Years to 45 Years ,18,up to 18 years old
NCT00479700,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects",Completed,Alzheimer Disease,All,18 Years to 45 Years   (Adult),Phase 1,80,Interventional,May 2006,July 2006,https://ClinicalTrials.gov/show/NCT00479700,18 Years to 45 Years ,18,up to 18 years old
NCT01203384,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,Alzheimer's Disease,Male,18 Years to 45 Years   (Adult),Phase 1,48,Interventional,September 2010,December 2010,https://ClinicalTrials.gov/show/NCT01203384,18 Years to 45 Years ,18,up to 18 years old
NCT00726726,Drug Interaction Study With a Potential Alzheimer's Disease Compound,Completed,Alzheimer Disease,Male,18 Years to 45 Years   (Adult),Phase 1,22,Interventional,August 2008,October 2008,https://ClinicalTrials.gov/show/NCT00726726,18 Years to 45 Years ,18,up to 18 years old
NCT00689637,Drug Interaction Study Between AZD3480 and Warfarin,Completed,Alzheimer's Disease,Male,18 Years to 45 Years   (Adult),Phase 1,26,Interventional,September 2007,February 2009,https://ClinicalTrials.gov/show/NCT00689637,18 Years to 45 Years ,18,up to 18 years old
NCT00901498,Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease,Completed,Alzheimer's Disease|Healthy,Male,18 Years to 45 Years   (Adult),Phase 1,36,Interventional,May 2009,July 2009,https://ClinicalTrials.gov/show/NCT00901498,18 Years to 45 Years ,18,up to 18 years old
NCT00689559,Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects,Completed,Alzheimer's Disease,Male,18 Years to 45 Years   (Adult),Phase 1,52,Interventional,March 2008,April 2009,https://ClinicalTrials.gov/show/NCT00689559,18 Years to 45 Years ,18,up to 18 years old
NCT02051335,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,Completed,Memory Impairment|Alzheimer's Disease,Male,18 Years to 45 Years   (Adult),Phase 1,27,Interventional,January 2014,May 2014,https://ClinicalTrials.gov/show/NCT02051335,18 Years to 45 Years ,18,up to 18 years old
NCT00884533,QTc Study of Rosi XR in Healthy Volunteers,Withdrawn,Alzheimer's Disease,All,18 Years to 45 Years   (Adult),Phase 1,0,Interventional,June 2009,August 2009,https://ClinicalTrials.gov/show/NCT00884533,18 Years to 45 Years ,18,up to 18 years old
NCT03944460,SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate,Completed,Alzheimer Dementia|Alzheimer Disease,Male,18 Years to 45 Years   (Adult),Phase 1,40,Interventional,"April 9, 2018","July 27, 2018",https://ClinicalTrials.gov/show/NCT03944460,18 Years to 45 Years ,18,up to 18 years old
NCT03955380,MAD Phase I Study to Investigate Contraloid Acetate,Completed,Alzheimer Dementia|Alzheimer Disease,All,18 Years to 45 Years   (Adult),Phase 1,24,Interventional,"December 12, 2018","April 3, 2019",https://ClinicalTrials.gov/show/NCT03955380,18 Years to 45 Years ,18,up to 18 years old
NCT00479440,"Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults",Completed,Alzheimer Disease,All,18 Years to 45 Years   (Adult),Phase 1,56,Interventional,August 2006,March 2007,https://ClinicalTrials.gov/show/NCT00479440,18 Years to 45 Years ,18,up to 18 years old
NCT00906191,Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects,Completed,Alzheimer Disease,Male,18 Years to 50 Years   (Adult),Phase 1,6,Interventional,May 2009,August 2009,https://ClinicalTrials.gov/show/NCT00906191,18 Years to 50 Years ,18,up to 18 years old
NCT03971123,Study to Compare the Pharmacokinetics of Two Formulations of Tricaprilin and a Placebo on Ketone Body Production,Recruiting,Alzheimer Disease,Male,18 Years to 50 Years   (Adult),Phase 1,12,Interventional,"August 30, 2019","March 31, 2020",https://ClinicalTrials.gov/show/NCT03971123,18 Years to 50 Years ,18,up to 18 years old
NCT00452504,Single Ascending Dose Study of SRA-444 in Healthy Subjects,Completed,Alzheimer Disease,Male,18 Years to 50 Years   (Adult),Phase 1,64,Interventional,February 2007,June 2007,https://ClinicalTrials.gov/show/NCT00452504,18 Years to 50 Years ,18,up to 18 years old
NCT00519298,Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects,Completed,Healthy|Adult,All,18 Years to 50 Years   (Adult),Phase 1,25,Interventional,October 2007,March 2008,https://ClinicalTrials.gov/show/NCT00519298,18 Years to 50 Years ,18,up to 18 years old
NCT00959881,Study Evaluating The Coadministration of Begacestat And Donepezil,Completed,Healthy Subjects,All,18 Years to 50 Years   (Adult),Phase 1,47,Interventional,August 2009,November 2009,https://ClinicalTrials.gov/show/NCT00959881,18 Years to 50 Years ,18,up to 18 years old
NCT00459693,PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD),Terminated,HIV-Dementia|HIV-Associated Cognitive Motor Complex|AIDS Encephalopathy|AIDS Dementia Complex|AIDS-Related Dementia Complex|HIV Infections|Healthy,All,18 Years to 50 Years   (Adult),Not Applicable,40,Interventional,"April 9, 2007","April 6, 2014",https://ClinicalTrials.gov/show/NCT00459693,18 Years to 50 Years ,18,up to 18 years old
NCT00494962,Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects,Completed,Alzheimer Disease,All,18 Years to 50 Years   (Adult),Phase 1,40,Interventional,June 2007,June 2007,https://ClinicalTrials.gov/show/NCT00494962,18 Years to 50 Years ,18,up to 18 years old
NCT02126514,"A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293",Completed,Healthy Volunteers|Mass Balance Study,Male,18 Years to 55 Years   (Adult),Phase 1,12,Interventional,May 2014,May 2014,https://ClinicalTrials.gov/show/NCT02126514,18 Years to 55 Years ,18,up to 18 years old
NCT03030105,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,38,Interventional,January 2017,June 2017,https://ClinicalTrials.gov/show/NCT03030105,18 Years to 55 Years ,18,up to 18 years old
NCT02197884,A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants,Completed,Healthy,Male,18 Years to 55 Years   (Adult),Phase 1,13,Interventional,July 2014,September 2014,https://ClinicalTrials.gov/show/NCT02197884,18 Years to 55 Years ,18,up to 18 years old
NCT03587649,Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss,Recruiting,Alzheimer Disease|Parkinson Disease|Healthy Volunteers,All,18 Years to 55 Years   (Adult),Phase 1,15,Interventional,"May 7, 2018","May 7, 2020",https://ClinicalTrials.gov/show/NCT03587649,18 Years to 55 Years ,18,up to 18 years old
NCT03551769,Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production,Completed,Alzheimer Disease,Male,18 Years to 55 Years   (Adult),Phase 1,20,Interventional,"August 5, 2018","August 27, 2018",https://ClinicalTrials.gov/show/NCT03551769,18 Years to 55 Years ,18,up to 18 years old
NCT00692510,Drug Interaction Study Between AZD3480 and Cytochrome P450,Completed,Metabolism|Alzheimer's Disease,Male,18 Years to 55 Years   (Adult),Phase 1,18,Interventional,November 2007,September 2008,https://ClinicalTrials.gov/show/NCT00692510,18 Years to 55 Years ,18,up to 18 years old
NCT00745576,Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered,Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,14,Interventional,October 2008,December 2008,https://ClinicalTrials.gov/show/NCT00745576,18 Years to 55 Years ,18,up to 18 years old
NCT00733785,"PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers",Completed,Alzheimer's Disease,All,18 Years to 55 Years   (Adult),Phase 1,60,Interventional,"August 13, 2008","November 28, 2008",https://ClinicalTrials.gov/show/NCT00733785,18 Years to 55 Years ,18,up to 18 years old
NCT00987220,"Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid",Completed,Alzheimer's Disease|Dementia,All,18 Years to 55 Years   (Adult),Phase 4,12,Observational,October 2009,February 2010,https://ClinicalTrials.gov/show/NCT00987220,18 Years to 55 Years ,18,up to 18 years old
NCT03635879,Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides,Withdrawn,Alzheimer Disease,Male,18 Years to 55 Years   (Adult),Phase 1,0,Interventional,"February 13, 2019","April 16, 2019",https://ClinicalTrials.gov/show/NCT03635879,18 Years to 55 Years ,18,up to 18 years old
NCT00468897,A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.,Completed,Alzheimer's Disease,All,18 Years to 55 Years   (Adult),Phase 1,50,Interventional,"March 21, 2007","May 2, 2007",https://ClinicalTrials.gov/show/NCT00468897,18 Years to 55 Years ,18,up to 18 years old
NCT00831506,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,Completed,Alzheimer Disease|Huntington Disease,All,18 Years to 55 Years   (Adult),Phase 1,12,Interventional,February 2009,May 2009,https://ClinicalTrials.gov/show/NCT00831506,18 Years to 55 Years ,18,up to 18 years old
NCT02005991,A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377,Completed,Healthy,All,18 Years to 55 Years   (Adult),Phase 1,4,Interventional,November 2013,January 2014,https://ClinicalTrials.gov/show/NCT02005991,18 Years to 55 Years ,18,up to 18 years old
NCT02211079,"A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates",Completed,Healthy,Male,18 Years to 55 Years   (Adult),Phase 1,16,Interventional,September 2014,November 2014,https://ClinicalTrials.gov/show/NCT02211079,18 Years to 55 Years ,18,up to 18 years old
NCT02534480,Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose),Completed,Alzheimer's Disease,All,18 Years to 55 Years   (Adult),Phase 1,40,Interventional,March 2015,November 2015,https://ClinicalTrials.gov/show/NCT02534480,18 Years to 55 Years ,18,up to 18 years old
NCT02648672,BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects,Completed,Alzheimer's Disease,All,18 Years to 55 Years   (Adult),Phase 1,32,Interventional,December 2015,July 2016,https://ClinicalTrials.gov/show/NCT02648672,18 Years to 55 Years ,18,up to 18 years old
NCT03545789,Phase 1 Test-retest Evaluation of [18F]MNI-958 PET,Recruiting,Healthy Volunteers|Alzheimer Disease|Progressive Supranuclear Palsy,All,18 Years to 55 Years   (Adult),Phase 1,14,Interventional,"March 12, 2018","March 12, 2020",https://ClinicalTrials.gov/show/NCT03545789,18 Years to 55 Years ,18,up to 18 years old
NCT00988624,A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine),Completed,Alzheimer's Disease|Huntington Disease,All,18 Years to 55 Years   (Adult),Phase 1,20,Interventional,October 2009,December 2009,https://ClinicalTrials.gov/show/NCT00988624,18 Years to 55 Years ,18,up to 18 years old
NCT02782975,"Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants",Completed,Alzheimer's Disease,All,18 Years to 55 Years   (Adult),Phase 1,28,Interventional,May 2016,November 2016,https://ClinicalTrials.gov/show/NCT02782975,18 Years to 55 Years ,18,up to 18 years old
NCT01221259,"A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",Completed,Alzheimer's Disease,All,18 Years to 55 Years   (Adult),Phase 1,60,Interventional,January 2010,November 2012,https://ClinicalTrials.gov/show/NCT01221259,18 Years to 55 Years ,18,up to 18 years old
NCT01042314,Drug-Drug Interaction Study With Aricept® (Donepezil),Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,18,Interventional,January 2010,April 2010,https://ClinicalTrials.gov/show/NCT01042314,18 Years to 55 Years ,18,up to 18 years old
NCT01039194,Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER),Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,18,Interventional,January 2010,April 2010,https://ClinicalTrials.gov/show/NCT01039194,18 Years to 55 Years ,18,up to 18 years old
NCT00966966,Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered,Completed,Healthy,All,18 Years to 55 Years   (Adult),Phase 1,17,Interventional,September 2009,December 2009,https://ClinicalTrials.gov/show/NCT00966966,18 Years to 55 Years ,18,up to 18 years old
NCT01002079,Drug-Drug Interaction Study With Rifampin,Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,20,Interventional,August 2010,October 2010,https://ClinicalTrials.gov/show/NCT01002079,18 Years to 55 Years ,18,up to 18 years old
NCT01137799,The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients,Terminated,Schizophrenia|Alzheimer's Disease|Cognition Disorders,Male,18 Years to 55 Years   (Adult),Phase 1,47,Interventional,August 2009,March 2011,https://ClinicalTrials.gov/show/NCT01137799,18 Years to 55 Years ,18,up to 18 years old
NCT00979316,Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects,Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,62,Interventional,September 2009,February 2010,https://ClinicalTrials.gov/show/NCT00979316,18 Years to 55 Years ,18,up to 18 years old
NCT00788047,A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan,Completed,Huntington Disease|Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,14,Interventional,November 2008,January 2009,https://ClinicalTrials.gov/show/NCT00788047,18 Years to 55 Years ,18,up to 18 years old
NCT01348737,"Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers",Completed,Alzheimer's Disease|Safety|Tolerability|Blood Concentration|Healthy Volunteers,All,18 Years to 55 Years   (Adult),Phase 1,72,Interventional,June 2011,November 2011,https://ClinicalTrials.gov/show/NCT01348737,18 Years to 55 Years ,18,up to 18 years old
NCT00860275,Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole,Completed,Alzheimer Disease,All,18 Years to 55 Years   (Adult),Phase 1,30,Interventional,April 2009,June 2009,https://ClinicalTrials.gov/show/NCT00860275,18 Years to 55 Years ,18,up to 18 years old
NCT00593138,Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate,Completed,Drug Binding to DAT Receptors,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,23,Interventional,December 2006,December 2009,https://ClinicalTrials.gov/show/NCT00593138,18 Years to 55 Years ,18,up to 18 years old
NCT00825084,"A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects",Completed,Alzheimer's Disease|Huntington's Disease,All,18 Years to 55 Years   (Adult),Phase 1,45,Interventional,February 2009,May 2009,https://ClinicalTrials.gov/show/NCT00825084,18 Years to 55 Years ,18,up to 18 years old
NCT00827034,"A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",Completed,Alzheimer's Disease|Huntington's Disease,All,18 Years to 55 Years   (Adult),Phase 1,14,Interventional,February 2009,April 2009,https://ClinicalTrials.gov/show/NCT00827034,18 Years to 55 Years ,18,up to 18 years old
NCT00931073,A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers,Completed,Alzheimer's Disease|Huntington's Disease,All,18 Years to 55 Years   (Adult),Phase 1,24,Interventional,July 2009,October 2009,https://ClinicalTrials.gov/show/NCT00931073,18 Years to 55 Years ,18,up to 18 years old
NCT00975481,A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users,Completed,Alzheimer's Disease|Huntington's Disease,All,18 Years to 55 Years   (Adult),Phase 1,36,Interventional,October 2009,February 2010,https://ClinicalTrials.gov/show/NCT00975481,18 Years to 55 Years ,18,up to 18 years old
NCT02040987,AZD3293 Thorough QT Study in Healthy Male Volunteers,Completed,Alzheimer's Disease,Male,18 Years to 55 Years   (Adult),Phase 1,52,Interventional,January 2014,May 2014,https://ClinicalTrials.gov/show/NCT02040987,18 Years to 55 Years ,18,up to 18 years old
NCT01702467,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",Completed,Alzheimer's Disease,Male,18 Years to 55 Years   (Adult),Phase 1,27,Interventional,"October 19, 2012","May 15, 2013",https://ClinicalTrials.gov/show/NCT01702467,18 Years to 55 Years ,18,up to 18 years old
NCT02968875,"Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise Training",Completed,Alzheimer's Disease,All,18 Years to 60 Years   (Adult),Not Applicable,54,Interventional,July 2015,February 2018,https://ClinicalTrials.gov/show/NCT02968875,18 Years to 60 Years ,18,up to 18 years old
NCT02303158,Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression,Terminated,Alzheimer's Disease,All,18 Years to 60 Years   (Adult),Phase 4,50,Observational,January 2014,October 2018,https://ClinicalTrials.gov/show/NCT02303158,18 Years to 60 Years ,18,up to 18 years old
NCT01492322,SPECT Imaging of DAT Genotype,Terminated,Nicotine Withdrawal,All,18 Years to 60 Years   (Adult),Phase 4,14,Observational,November 2011,October 2014,https://ClinicalTrials.gov/show/NCT01492322,18 Years to 60 Years ,18,up to 18 years old
NCT00701532,Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction,Completed,Cocaine Addiction|Cocaine Dependence,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,29,Interventional,April 2009,January 2013,https://ClinicalTrials.gov/show/NCT00701532,18 Years to 65 Years ,18,up to 18 years old
NCT02710188,Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation,Completed,Alzheimer's Disease,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,14,Interventional,February 2016,August 2016,https://ClinicalTrials.gov/show/NCT02710188,18 Years to 65 Years ,18,up to 18 years old
NCT03641768,Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics,Withdrawn,Alzheimer Dementia|Posttraumatic Stress Disorder|Traumatic Brain Injury,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,"January 1, 2019","January 1, 2021",https://ClinicalTrials.gov/show/NCT03641768,18 Years to 65 Years ,18,up to 18 years old
NCT02439099,Retinoic Acid Homeostasis in Neuropsychiatric Diseases,Recruiting,Major Depression|Alzheimer's Disease|Alcoholism|Schizophrenia,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,200,Observational,March 2015,December 2019,https://ClinicalTrials.gov/show/NCT02439099,18 Years to 65 Years ,18,up to 18 years old
NCT00870311,"Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients",Completed,Bipolar Disorder,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,28,Interventional,March 1996,April 2004,https://ClinicalTrials.gov/show/NCT00870311,18 Years to 65 Years ,18,up to 18 years old
NCT00726115,"Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531",Completed,Alzheimer Disease,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,56,Interventional,August 2008,February 2009,https://ClinicalTrials.gov/show/NCT00726115,18 Years to 65 Years ,18,up to 18 years old
NCT03217396,Biomarkers of Synaptic Damage in Multiple Sclerosis,Recruiting,Multiple Sclerosis|Parkinson Disease|Amyotrophic Lateral Sclerosis|Alzheimer Disease,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,150,Observational,"November 22, 2017","September 30, 2020",https://ClinicalTrials.gov/show/NCT03217396,18 Years to 65 Years ,18,up to 18 years old
NCT02130661,Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers,Withdrawn,Alzheimer's Disease,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Interventional,October 2017,January 2018,https://ClinicalTrials.gov/show/NCT02130661,18 Years to 65 Years ,18,up to 18 years old
NCT02649985,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,Recruiting,Multiple Sclerosis|Alzheimer's Disease,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Interventional,January 2016,"June 30, 2019",https://ClinicalTrials.gov/show/NCT02649985,18 Years to 70 Years ,18,up to 18 years old
NCT02859207,A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects,Completed,Early Alzheimer's Disease,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,32,Interventional,August 2016,"January 25, 2017",https://ClinicalTrials.gov/show/NCT02859207,18 Years to 70 Years ,18,up to 18 years old
NCT01622894,Genetics of Mendelian Forms of Young Onset Alzheimer Disease,Unknown status,Autosomal Dominant Cases of Alzheimer 's Disease,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,150,Observational,November 2009,December 2018,https://ClinicalTrials.gov/show/NCT01622894,18 Years to 75 Years ,18,up to 18 years old
NCT03840083,Sleep-dependent Learning in Aging,Recruiting,Sleep,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,584,Interventional,"July 15, 2018","July 15, 2024",https://ClinicalTrials.gov/show/NCT03840083,18 Years to 75 Years ,18,up to 18 years old
NCT03935568,A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects,Recruiting,Alzheimer's Disease,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,40,Interventional,"June 24, 2019","December 31, 2019",https://ClinicalTrials.gov/show/NCT03935568,18 Years to 75 Years ,18,up to 18 years old
NCT01827982,"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo",Completed,Healthy,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,56,Interventional,March 2013,July 2013,https://ClinicalTrials.gov/show/NCT01827982,18 Years to 75 Years ,18,up to 18 years old
NCT00691340,Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease,Withdrawn,Alzheimer's Disease|Glaucoma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,0,Observational,June 2008,August 2011,https://ClinicalTrials.gov/show/NCT00691340,18 Years to 75 Years ,18,up to 18 years old
NCT02570997,Ascending Dose Study of CT1812 in Healthy Volunteers,Completed,Cognitive Impairment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,80,Interventional,September 2015,,https://ClinicalTrials.gov/show/NCT02570997,18 Years to 75 Years ,18,up to 18 years old
NCT00824590,"A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function",Completed,Alzheimer's Disease|Huntington's Disease,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Interventional,February 2009,October 2009,https://ClinicalTrials.gov/show/NCT00824590,18 Years to 75 Years ,18,up to 18 years old
NCT01421056,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),Completed,Alzheimer's Disease,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,74,Interventional,July 2011,November 2012,https://ClinicalTrials.gov/show/NCT01421056,18 Years to 79 Years ,18,up to 18 years old
NCT01303744,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,Completed,Alzheimer's Disease,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,96,Interventional,March 2011,April 2012,https://ClinicalTrials.gov/show/NCT01303744,18 Years to 79 Years ,18,up to 18 years old
NCT01602393,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase,Completed,Alzheimer's Disease,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,51,Interventional,May 2012,October 2013,https://ClinicalTrials.gov/show/NCT01602393,18 Years to 79 Years ,18,up to 18 years old
NCT03071224,Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein,Recruiting,Alzheimer Disease|Healthy Volunteers,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,15,Interventional,June 2016,June 2020,https://ClinicalTrials.gov/show/NCT03071224,18 Years to 80 Years ,18,up to 18 years old
NCT02761707,Biomarkers in Neural Disorders,Completed,Parkinson's Disease|Alzheimer's Disease|Progressive Supranuclear Palsy|Essential Tremor|Multiple System Atrophy|Drug Induced Parkinson's Disease|Diffuse Lewy Body Disease|Myasthenia Gravis|Spinal Cord Injuries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,54,Observational,June 2016,"July 16, 2019",https://ClinicalTrials.gov/show/NCT02761707,18 Years to 80 Years ,18,up to 18 years old
NCT03859245,Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention,Recruiting,Diabetic Retinopathy (DR)|Age-related Macular Degeneration (AMD)|Mid-peripheral Drusen Formation|Diabetic Macular Edema (DME),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"February 23, 2019","September 30, 2020",https://ClinicalTrials.gov/show/NCT03859245,18 Years to 80 Years ,18,up to 18 years old
NCT02820896,A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,74,Interventional,"June 29, 2016","June 26, 2017",https://ClinicalTrials.gov/show/NCT02820896,18 Years to 80 Years ,18,up to 18 years old
NCT01826110,PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers,Completed,Alzheimer's Disease,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,21,Interventional,September 2013,July 2018,https://ClinicalTrials.gov/show/NCT01826110,18 Years to 80 Years ,18,up to 18 years old
NCT01760005,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,Recruiting,"Alzheimers Disease|Dementia|Alzheimers Disease, Familial",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,490,Interventional,December 2012,March 2021,https://ClinicalTrials.gov/show/NCT01760005,18 Years to 80 Years ,18,up to 18 years old
NCT00991419,To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden,Completed,Alzheimer's Disease,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,25,Interventional,February 2010,August 2011,https://ClinicalTrials.gov/show/NCT00991419,18 Years to 80 Years ,18,up to 18 years old
NCT02789800,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,"Active, not recruiting",Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1956,Interventional,"April 22, 2016","March 1, 2020",https://ClinicalTrials.gov/show/NCT02789800,18 Years to 80 Years ,18,up to 18 years old
NCT02742597,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,"Active, not recruiting",Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV|Multimorbidity,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1980,Interventional,"January 12, 2016","March 1, 2020",https://ClinicalTrials.gov/show/NCT02742597,18 Years to 80 Years ,18,up to 18 years old
NCT03088956,"Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)","Active, not recruiting",Frontotemporal Dementia|Behavioral Variant Frontotemporal Dementia,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,40,Observational,"January 29, 2018","October 28, 2019",https://ClinicalTrials.gov/show/NCT03088956,18 Years to 80 Years ,18,up to 18 years old
NCT00056524,Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter),Completed,Alzheimer's Disease|Stroke|Parkinson's Disease|Traumatic Brain Injury,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,600,Interventional,February 2003,June 2007,https://ClinicalTrials.gov/show/NCT00056524,18 Years to 80 Years ,18,up to 18 years old
NCT03352258,Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Interventional,"November 17, 2017","December 30, 2020",https://ClinicalTrials.gov/show/NCT03352258,18 Years to 80 Years ,18,up to 18 years old
NCT03089918,A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,Completed,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,11,Interventional,"May 17, 2017","August 24, 2018",https://ClinicalTrials.gov/show/NCT03089918,18 Years to 85 Years ,18,up to 18 years old
NCT02638519,HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,120,Interventional,June 2016,June 2019,https://ClinicalTrials.gov/show/NCT02638519,18 Years to 85 Years ,18,up to 18 years old
NCT00959803,Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.,Completed,Healthy,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,17,Interventional,August 2009,November 2009,https://ClinicalTrials.gov/show/NCT00959803,18 Years to 85 Years ,18,up to 18 years old
NCT01339130,Assessment of Social-emotional Functioning in Neurological Diseases,Completed,Alzheimer Disease|Stroke|Parkinson's Disease|Lewy Body Dementia|Huntington Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,177,Interventional,June 2009,June 2013,https://ClinicalTrials.gov/show/NCT01339130,18 Years to 85 Years ,18,up to 18 years old
NCT02621606,[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001),Completed,Alzheimer's Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Interventional,"January 8, 2016","December 28, 2017",https://ClinicalTrials.gov/show/NCT02621606,18 Years to 85 Years ,18,up to 18 years old
NCT01564706,A Study of 18F-AV-45 in Healthy Volunteers,Completed,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,9,Interventional,October 2007,January 2008,https://ClinicalTrials.gov/show/NCT01564706,18 Years to 85 Years ,18,up to 18 years old
NCT00462917,REVEAL III: Risk Evaluation and Education for Alzheimer's Disease,Completed,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,290,Interventional,March 2007,October 2009,https://ClinicalTrials.gov/show/NCT00462917,18 Years to 85 Years ,18,up to 18 years old
NCT01385033,[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002),Terminated,Alzheimer's Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Interventional,"August 19, 2011","May 15, 2012",https://ClinicalTrials.gov/show/NCT01385033,18 Years to 85 Years ,18,up to 18 years old
NCT03123224,The COACH Project: Combined Online Assistance for Caregiver Health,Recruiting,"Traumas, Brain|Alzheimer Disease|Dementia|Head Injury|Concussion, Brain|TBI",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,August 2015,July 2018,https://ClinicalTrials.gov/show/NCT03123224,18 Years to 85 Years ,18,up to 18 years old
NCT03298672,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017",Completed,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,88,Interventional,"October 9, 2017","September 5, 2019",https://ClinicalTrials.gov/show/NCT03298672,18 Years to 85 Years ,18,up to 18 years old
NCT02129452,Olfactory Neuroepithelial Tissue of Alzheimer Disease,Completed,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,40,Observational,January 2013,February 2015,https://ClinicalTrials.gov/show/NCT02129452,18 Years to 85 Years ,18,up to 18 years old
NCT03635047,A Phase I Study for Safety and Tolerability of AL002.,Recruiting,Healthy|Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,67,Interventional,"November 12, 2018",March 2020,https://ClinicalTrials.gov/show/NCT03635047,18 Years to 85 Years ,18,up to 18 years old
NCT01659398,Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients,Completed,Mild Cognitive Impairment,All,"18 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,8,Interventional,June 2012,October 2014,https://ClinicalTrials.gov/show/NCT01659398,18 Years to 85 Years ,18,up to 18 years old
NCT03822208,First in Human Study for Safety and Tolerability of AL003.,Recruiting,Healthy|Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,54,Interventional,"March 29, 2019",July 2020,https://ClinicalTrials.gov/show/NCT03822208,18 Years to 85 Years ,18,up to 18 years old
NCT01680588,Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,70,Interventional,August 2012,December 2018,https://ClinicalTrials.gov/show/NCT01680588,18 Years to 85 Years ,18,up to 18 years old
NCT02793232,"Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.",Completed,Healthy Subjects,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,46,Interventional,"June 13, 2016","January 5, 2017",https://ClinicalTrials.gov/show/NCT02793232,18 Years to 85 Years ,18,up to 18 years old
NCT00571025,Risk Evaluation and Education for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,301,Interventional,August 2000,April 2004,https://ClinicalTrials.gov/show/NCT00571025,18 Years to 85 Years ,18,up to 18 years old
NCT02103894,Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects,Completed,Alzheimer's Disease (AD)|Parkinson's Disease (PD)|Chronic Traumatic Encephalopathy (CTE)|Progressive Supranuclear Palsy (PSP)|Frontal Temporal Dementia (FTD)|Pick's Disease|Tauopathies,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Interventional,February 2014,September 2016,https://ClinicalTrials.gov/show/NCT02103894,18 Years to 85 Years ,18,up to 18 years old
NCT02509117,First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979,Completed,Healthy Subjects,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,55,Interventional,July 2015,July 2016,https://ClinicalTrials.gov/show/NCT02509117,18 Years to 85 Years ,18,up to 18 years old
NCT03720548,A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD),Completed,Alzheimer Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,36,Interventional,"November 5, 2018","May 14, 2019",https://ClinicalTrials.gov/show/NCT03720548,18 Years to 85 Years ,18,up to 18 years old
NCT02562989,[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001),Completed,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,13,Interventional,"October 19, 2015","December 27, 2016",https://ClinicalTrials.gov/show/NCT02562989,18 Years to 85 Years ,18,up to 18 years old
NCT00870974,A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions,Completed,Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,48,Interventional,March 2009,November 2016,https://ClinicalTrials.gov/show/NCT00870974,18 Years to 85 Years ,18,up to 18 years old
NCT03838185,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147",Recruiting,Alzheimer's Disease,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,64,Interventional,"January 22, 2019",January 2020,https://ClinicalTrials.gov/show/NCT03838185,18 Years to 85 Years ,18,up to 18 years old
NCT00714571,Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI),Completed,Mild Cognitive Impairment|Alzheimer's Disease|Traumatic Brain Injury,All,"18 Years to 88 Years   (Adult, Older Adult)",Phase 1,82,Interventional,July 2008,September 2014,https://ClinicalTrials.gov/show/NCT00714571,18 Years to 88 Years ,18,up to 18 years old
NCT01148498,A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's,Completed,Alzheimer's Disease,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,55,Interventional,August 2010,August 2012,https://ClinicalTrials.gov/show/NCT01148498,18 Years to 90 Years ,18,up to 18 years old
NCT03435861,Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients,Recruiting,Alzheimer Disease,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,40,Interventional,"October 8, 2018","January 30, 2021",https://ClinicalTrials.gov/show/NCT03435861,18 Years to 90 Years ,18,up to 18 years old
NCT03297177,Autologous Stem/Stromal Cells in Neurological Disorders and Disease,Not yet recruiting,"Dementia|Parkinson|Altered Behavior in Alzheimer Disease|Demyelinating Autoimmune Diseases, CNS|Demyelinating Sensorimotor Neuropathy|Corticobasal Degeneration",All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,300,Interventional,"January 1, 2020","January 1, 2023",https://ClinicalTrials.gov/show/NCT03297177,18 Years to 90 Years ,18,up to 18 years old
NCT00149175,Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment,Unknown status,Alzheimer's Disease|Dementia|Neurodegenerative Disorders,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,4000,Observational,December 2002,October 2007,https://ClinicalTrials.gov/show/NCT00149175,18 Years to 90 Years ,18,up to 18 years old
NCT03397667,The Aging Brain ANSWERS Program,Recruiting,Traumatic Brain Injury|Alzheimer Disease|Veterans|Family Caregivers|Caregiver Burden|Quality of Life,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,400,Interventional,"August 1, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03397667,18 Years to 90 Years ,18,up to 18 years old
NCT02681172,Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD,Completed,Alzheimer's Disease (AD),All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,218,Interventional,October 2015,November 2016,https://ClinicalTrials.gov/show/NCT02681172,18 Years to 90 Years ,18,up to 18 years old
NCT00306124,Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment,Unknown status,Alzheimer's Disease|Mild Cognitive Impairment|Healthy,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,120,Interventional,January 2006,March 2008,https://ClinicalTrials.gov/show/NCT00306124,18 Years to 90 Years ,18,up to 18 years old
NCT00029120,Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder,Completed,Alzheimer Disease|Dementia|Memory Disorder|Healthy,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,450,Observational,"December 18, 2001","April 21, 2008",https://ClinicalTrials.gov/show/NCT00029120,18 Years to 90 Years ,18,up to 18 years old
NCT00666445,Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test,Completed,Alzheimer's Disease,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,150,Observational,April 2008,December 2009,https://ClinicalTrials.gov/show/NCT00666445,18 Years to 90 Years ,18,up to 18 years old
NCT01461109,"Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls",Completed,Parkinson Disease|Alzheimer Disease,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,4,Interventional,August 2011,May 2014,https://ClinicalTrials.gov/show/NCT01461109,18 Years to 90 Years ,18,up to 18 years old
NCT04045990,Network Modulation in Alzheimer's Disease,Recruiting,Alzheimer Disease|Primary Progressive Aphasia|Mild Cognitive Impairment,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,"September 1, 2018",December 2021,https://ClinicalTrials.gov/show/NCT04045990,18 Years to 90 Years ,18,up to 18 years old
NCT03080051,Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain,Completed,Progressive Supranuclear Palsy|Alzheimer Disease|Healthy Volunteers,All,"18 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,6,Interventional,August 2016,"March 6, 2017",https://ClinicalTrials.gov/show/NCT03080051,18 Years to 90 Years ,18,up to 18 years old
NCT02767609,Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging,Completed,Traumatic Brain Injury|Multiple Sclerosis|Alzheimer's Disease|Tumor,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1,Interventional,May 2014,"March 3, 2017",https://ClinicalTrials.gov/show/NCT02767609,18 Years to 90 Years ,18,up to 18 years old
NCT00001480,The Evaluation and Follow-up of Individuals With Memory Disorder,Completed,Alzheimer's Disease|Dementia|Healthy|Memory Disorder,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,750,Observational,"March 21, 1995","March 31, 2007",https://ClinicalTrials.gov/show/NCT00001480,18 Years to 90 Years ,18,up to 18 years old
NCT02051361,Antiplatelet Therapy Following Stent Implantation,Completed,"Acute Myocardial Infarction|Coronary Syndrome|Angina, Unstable",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,900,Observational,April 2014,May 2016,https://ClinicalTrials.gov/show/NCT02051361,18 Years to 90 Years ,18,up to 18 years old
NCT00303277,Do HMG CoA Reductase Inhibitors Affect Abeta Levels?,Completed,Alzheimer's Disease|Aging,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,35,Interventional,August 2002,April 2005,https://ClinicalTrials.gov/show/NCT00303277,18 Years to 90 Years ,18,up to 18 years old
NCT02769065,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,Terminated,Alzheimer Disease|Healthy Volunteers,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,179,Interventional,"May 5, 2016","June 8, 2017",https://ClinicalTrials.gov/show/NCT02769065,18 Years to 90 Years ,18,up to 18 years old
NCT01762618,Experimental Study of the Impact of a Group Therapy Psychological Intervention for Caregivers of Alzheimer's Disease Patients,Completed,Psychological Support to Caregivers of Azlheimer's Patients,All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,83,Interventional,January 2012,July 2013,https://ClinicalTrials.gov/show/NCT01762618,18 Years to 95 Years ,18,up to 18 years old
NCT00735046,Cognitive Behavioural Therapy of Early Dementia,Completed,Dementia,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 4,200,Observational,April 2008,April 2010,https://ClinicalTrials.gov/show/NCT00735046,18 Years to 95 Years ,18,up to 18 years old
NCT03971994,Emotion and Attention in Alzheimer's Disease (ATEMMA),Recruiting,Alzheimer Disease,All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,75,Interventional,"May 31, 2019","July 27, 2021",https://ClinicalTrials.gov/show/NCT03971994,18 Years to 95 Years ,18,up to 18 years old
NCT00416078,Online Caregiver Psychoeducation and Support for Alzheimer's,Completed,Alzheimer's Disease,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2|Phase 3,53,Interventional,August 2007,December 2012,https://ClinicalTrials.gov/show/NCT00416078,18 Years to 95 Years ,18,up to 18 years old
NCT03682081,Interventions for Patients With Alzheimer's Disease and Dysphagia,Not yet recruiting,Dementia|Dysphagia,All,"18 Years to 99 Years   (Adult, Older Adult)",Early Phase 1,76,Interventional,"November 1, 2019","February 1, 2023",https://ClinicalTrials.gov/show/NCT03682081,18 Years to 99 Years ,18,up to 18 years old
NCT02585232,Optimizing Dementia Care,Recruiting,"Alzheimer's Disease|Dementia|Dementia, Vascular|Caregivers|Veterans",All,"19 Years and older   (Adult, Older Adult)",Not Applicable,68,Interventional,"October 1, 2016","October 31, 2020",https://ClinicalTrials.gov/show/NCT02585232,19 Years and older ,19,18 to 40 years old
NCT02695004,"Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).",Unknown status,Alzheimer's Disease,Male,19 Years to 50 Years   (Adult),Phase 1,45,Interventional,February 2016,December 2017,https://ClinicalTrials.gov/show/NCT02695004,19 Years to 50 Years ,19,18 to 40 years old
NCT03802162,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355",Not yet recruiting,Alzheimer's Disease (AD),All,19 Years to 55 Years   (Adult),Phase 1,60,Interventional,"February 13, 2019","July 31, 2019",https://ClinicalTrials.gov/show/NCT03802162,19 Years to 55 Years ,19,18 to 40 years old
NCT03299062,"Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders",Recruiting,Alzheimer Disease|Neurodegenerative Diseases,All,"19 Years to 89 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"November 14, 2017","August 1, 2020",https://ClinicalTrials.gov/show/NCT03299062,19 Years to 89 Years ,19,18 to 40 years old
NCT00927108,Rajavtihi Neuronal Adult Stem Cells Project,Unknown status,Alzheimer's Disease|Parkinson's Disease|Multiple Sclerosis,All,"20 Years and older   (Adult, Older Adult)",Phase 2,10,Interventional,July 2009,,https://ClinicalTrials.gov/show/NCT00927108,20 Years and older ,20,18 to 40 years old
NCT03969732,Multimodal Biomarkers for Diagnosis and Prognosis in CAA,Recruiting,Cerebral Amyloid Angiopathy|Intracranial Hemorrhages|Alzheimer Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 3,240,Interventional,"September 27, 2018","July 31, 2022",https://ClinicalTrials.gov/show/NCT03969732,20 Years and older ,20,18 to 40 years old
NCT00719394,Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males,Completed,Alzheimer Disease|Healthy,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,72,Interventional,March 2008,August 2008,https://ClinicalTrials.gov/show/NCT00719394,20 Years and older ,20,18 to 40 years old
NCT03542656,Application of Amyloid PET in Cerebral Amyloid Angiopathy,Completed,Cerebral Amyloid Angiopathy|Intracranial Hemorrhages|Alzheimer Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 3,160,Interventional,"September 11, 2014","March 22, 2018",https://ClinicalTrials.gov/show/NCT03542656,20 Years and older ,20,18 to 40 years old
NCT00684710,"Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects",Completed,Alzheimer Disease|Healthy,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,56,Interventional,April 2008,August 2008,https://ClinicalTrials.gov/show/NCT00684710,20 Years and older ,20,18 to 40 years old
NCT02614131,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),Terminated,Healthy|Alzheimer's Disease|Mild Cognitive Impairment,All,"20 Years and older   (Adult, Older Adult)",Phase 1,50,Interventional,December 2015,December 2016,https://ClinicalTrials.gov/show/NCT02614131,20 Years and older ,20,18 to 40 years old
NCT02323334,A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease,Completed,Healthy Volunteers|Alzheimer Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 1,136,Interventional,December 2014,February 2016,https://ClinicalTrials.gov/show/NCT02323334,20 Years and older ,20,18 to 40 years old
NCT03378037,The Effects of Acupuncture on the Risk of AD After TBI,Recruiting,"Brain Injuries, Traumatic",All,"20 Years and older   (Adult, Older Adult)",Not Applicable,76,Interventional,"December 25, 2017",June 2020,https://ClinicalTrials.gov/show/NCT03378037,20 Years and older ,20,18 to 40 years old
NCT02016560,"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects",Completed,Alzheimer's Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,383,Interventional,December 2013,"July 28, 2017",https://ClinicalTrials.gov/show/NCT02016560,20 Years and older ,20,18 to 40 years old
NCT01859767,Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.,Completed,Alzheimer's Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6,Interventional,April 2013,April 2015,https://ClinicalTrials.gov/show/NCT01859767,20 Years and older ,20,18 to 40 years old
NCT01867372,Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes,Terminated,Alzheimer's Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 4,213,Observational,"March 10, 2003","September 22, 2014",https://ClinicalTrials.gov/show/NCT01867372,20 Years and older ,20,18 to 40 years old
NCT01227252,A Safety Study of LY2886721 Multiple Doses in Healthy Subjects,Completed,Alzheimer's Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 1,42,Interventional,December 2010,April 2011,https://ClinicalTrials.gov/show/NCT01227252,20 Years and older ,20,18 to 40 years old
NCT00479349,"Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531",Completed,Alzheimer Disease,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,32,Interventional,May 2007,January 2008,https://ClinicalTrials.gov/show/NCT00479349,20 Years and older ,20,18 to 40 years old
NCT00441987,Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953,Completed,Alzheimer Disease|Healthy,Male,"20 Years and older   (Adult, Older Adult)",Phase 1,96,Interventional,February 2007,July 2009,https://ClinicalTrials.gov/show/NCT00441987,20 Years and older ,20,18 to 40 years old
NCT01133405,A Safety Study of LY2886721 Single Doses in Healthy Subjects,Completed,Alzheimer's Disease,All,"20 Years and older   (Adult, Older Adult)",Phase 1,40,Interventional,June 2010,October 2010,https://ClinicalTrials.gov/show/NCT01133405,20 Years and older ,20,18 to 40 years old
NCT03174938,The Swedish BioFINDER 2 Study,Recruiting,Dementia|Alzheimer Disease|Parkinson Disease|Lewy Body Disease|Parkinson-Dementia Syndrome|Frontotemporal Degeneration|Semantic Dementia|Progressive Nonfluent Aphasia|Progressive Supranuclear Palsy|Corticobasal Degeneration|Multiple System Atrophy|Mild Cognitive Impairment,All,"20 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1505,Interventional,"May 15, 2017","December 31, 2028",https://ClinicalTrials.gov/show/NCT03174938,20 Years to 100 Years ,20,18 to 40 years old
NCT03283449,Tau PET Imaging in Atypical Dementias,Recruiting,Primary Progressive Aphasia With Suspected Alzheimer's Disease,All,"20 Years to 100 Years   (Adult, Older Adult)",Phase 1,70,Interventional,February 2016,"February 1, 2023",https://ClinicalTrials.gov/show/NCT03283449,20 Years to 100 Years ,20,18 to 40 years old
NCT04025801,Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals,Not yet recruiting,Healthy Individuals|Diabetes|Hypertension|Fabry Disease|Metabolic Disease|Alzheimer Disease|Dementia|Limbal Insufficiency|Phlyctenulosis|Ocular Rosacea|Graft Versus Host Disease in Eye|Dry Eye Syndrome,All,20 Years to 40 Years   (Adult),Phase 4,400,Observational,"July 31, 2019",June 2020,https://ClinicalTrials.gov/show/NCT04025801,20 Years to 40 Years ,20,18 to 40 years old
NCT01057030,Multiple Dose Japanese Bridging Study,Completed,Alzheimer Disease,Male,20 Years to 45 Years   (Adult),Phase 1,22,Interventional,March 2010,June 2010,https://ClinicalTrials.gov/show/NCT01057030,20 Years to 45 Years ,20,18 to 40 years old
NCT00479297,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males",Completed,Alzheimer Disease,Male,20 Years to 45 Years   (Adult),Phase 1,72,Interventional,May 2006,February 2007,https://ClinicalTrials.gov/show/NCT00479297,20 Years to 45 Years ,20,18 to 40 years old
NCT02820155,Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects,Unknown status,Healthy,Male,20 Years to 45 Years   (Adult),Phase 1,80,Interventional,June 2016,February 2017,https://ClinicalTrials.gov/show/NCT02820155,20 Years to 45 Years ,20,18 to 40 years old
NCT01860625,"A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects",Completed,Alzheimer Disease,Male,20 Years to 45 Years   (Adult),Phase 1,36,Interventional,April 2013,February 2014,https://ClinicalTrials.gov/show/NCT01860625,20 Years to 45 Years ,20,18 to 40 years old
NCT00480467,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males",Completed,Alzheimer Disease,Male,20 Years to 45 Years   (Adult),Phase 1,32,Interventional,September 2006,August 2007,https://ClinicalTrials.gov/show/NCT00480467,20 Years to 45 Years ,20,18 to 40 years old
NCT02178124,"A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.",Completed,Alzheimer Disease,Male,20 Years to 45 Years   (Adult),Phase 1,24,Interventional,July 2014,December 2014,https://ClinicalTrials.gov/show/NCT02178124,20 Years to 45 Years ,20,18 to 40 years old
NCT01297036,Pharmacokinetic Comparisons of Two Donepezil Formulations,Completed,Alzheimer Disease,Male,20 Years to 45 Years   (Adult),Phase 1,22,Interventional,January 2008,May 2008,https://ClinicalTrials.gov/show/NCT01297036,20 Years to 45 Years ,20,18 to 40 years old
NCT03584568,Reappraising Intergeneration Relationships in Dementia Caregiving,Recruiting,Alzheimer Dementia,All,20 Years to 60 Years   (Adult),Not Applicable,154,Interventional,"November 11, 2018","July 8, 2021",https://ClinicalTrials.gov/show/NCT03584568,20 Years to 60 Years ,20,18 to 40 years old
NCT03212599,Disulfiram as a Modulator of Amyloid Precursor Protein-processing,Completed,Alcohol Addiction,All,20 Years to 60 Years   (Adult),Phase 4,17,Observational,May 2013,July 2017,https://ClinicalTrials.gov/show/NCT03212599,20 Years to 60 Years ,20,18 to 40 years old
NCT00713765,Pharmacokinetic Interaction Between AZD3480 and Donepezil,Terminated,Alzheimer's Disease,All,20 Years to 60 Years   (Adult),Phase 1,33,Interventional,December 2008,December 2008,https://ClinicalTrials.gov/show/NCT00713765,20 Years to 60 Years ,20,18 to 40 years old
NCT00838084,A Safety Study of LY2811376 Single Doses in Healthy Subjects,Completed,Alzheimer's Disease,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1,61,Interventional,December 2008,June 2009,https://ClinicalTrials.gov/show/NCT00838084,20 Years to 65 Years ,20,18 to 40 years old
NCT01297114,"Imaging of Cognition, Learning, and Memory in Aging",Completed,Alzheimer's Disease,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,294,Observational,March 2011,"October 1, 2017",https://ClinicalTrials.gov/show/NCT01297114,20 Years to 70 Years ,20,18 to 40 years old
NCT03052712,Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies,Recruiting,Alzheimer Disease|Parkinson Disease|Frontal Dementia|Huntington Disease|Traumatic Brain Injury|Stroke,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1170,Interventional,"September 9, 2016","September 9, 2019",https://ClinicalTrials.gov/show/NCT03052712,20 Years to 80 Years ,20,18 to 40 years old
NCT03112096,A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1,20,Interventional,"May 17, 2017","August 30, 2018",https://ClinicalTrials.gov/show/NCT03112096,20 Years to 80 Years ,20,18 to 40 years old
NCT02149017,Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F),Terminated,Alzheimer Disease,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Interventional,December 2010,December 2012,https://ClinicalTrials.gov/show/NCT02149017,20 Years to 80 Years ,20,18 to 40 years old
NCT00548145,The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer Disease|Hypercholesterolemia,All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,38,Interventional,November 2007,March 2012,https://ClinicalTrials.gov/show/NCT00548145,20 Years to 85 Years ,20,18 to 40 years old
NCT03389698,Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD,Recruiting,Alzheimer Disease,All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"December 18, 2018",February 2021,https://ClinicalTrials.gov/show/NCT03389698,20 Years to 85 Years ,20,18 to 40 years old
NCT03227185,Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients,Recruiting,Healthy|Mild Cognitive Impairment|Alzheimer Disease,All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Interventional,"October 1, 2017","February 29, 2020",https://ClinicalTrials.gov/show/NCT03227185,20 Years to 85 Years ,20,18 to 40 years old
NCT00692705,"Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid",Completed,Alzheimer´s Disease,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 1,13,Interventional,January 2008,December 2008,https://ClinicalTrials.gov/show/NCT00692705,20 Years to 85 Years ,20,18 to 40 years old
NCT02370524,Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease (AD),All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 1,16,Interventional,January 2015,January 2016,https://ClinicalTrials.gov/show/NCT02370524,20 Years to 90 Years ,20,18 to 40 years old
NCT03625128,"18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls",Completed,Alzheimer's Disease|Cortical Basal Syndrome|Frontotemporal Dementia|Progressive Supranuclear Palsy|Vascular Cognitive Impairment,All,"20 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,36,Interventional,"January 2, 2018","December 3, 2018",https://ClinicalTrials.gov/show/NCT03625128,20 Years to 90 Years ,20,18 to 40 years old
NCT02686216,"Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )",Completed,Alzheimer's Disease,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 1,24,Interventional,December 2015,November 2016,https://ClinicalTrials.gov/show/NCT02686216,20 Years to 90 Years ,20,18 to 40 years old
NCT02137460,Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease|Mild Cognitive Impairment,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 4,920,Observational,May 2014,February 2020,https://ClinicalTrials.gov/show/NCT02137460,20 Years to 90 Years ,20,18 to 40 years old
NCT00094913,PET Changes in Alzheimer's Disease (AD),Unknown status,Alzheimer Disease,All,"20 Years to 90 Years   (Adult, Older Adult)",Phase 4,105,Observational,May 2004,April 2005,https://ClinicalTrials.gov/show/NCT00094913,20 Years to 90 Years ,20,18 to 40 years old
NCT01322373,A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test,Unknown status,Alzheimer's Disease,All,"20 Years to 92 Years   (Adult, Older Adult)",Phase 4,120,Observational,March 2011,August 2011,https://ClinicalTrials.gov/show/NCT01322373,20 Years to 92 Years ,20,18 to 40 years old
NCT03587012,Brain Fitness APP for Cognitive Enhancement,Enrolling by invitation,Mild Cognitive Impairment|Alzheimer Dementia,All,"20 Years to 95 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"June 20, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03587012,20 Years to 95 Years ,20,18 to 40 years old
NCT02343757,Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid,Unknown status,Dementia|Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,October 2013,December 2016,https://ClinicalTrials.gov/show/NCT02343757,21 Years and older ,21,18 to 40 years old
NCT01020838,Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology,Completed,Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 3,218,Interventional,November 2009,December 2013,https://ClinicalTrials.gov/show/NCT01020838,21 Years and older ,21,18 to 40 years old
NCT00965835,Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome,Unknown status,Down Syndrome|Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 4,40,Observational,August 2009,May 2011,https://ClinicalTrials.gov/show/NCT00965835,21 Years and older ,21,18 to 40 years old
NCT00467766,Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease,Completed,Alzheimer Disease|Caregivers,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300,Interventional,July 1999,June 2003,https://ClinicalTrials.gov/show/NCT00467766,21 Years and older ,21,18 to 40 years old
NCT00759863,LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia,Completed,Alzheimer's Disease|Dementia,All,"21 Years and older   (Adult, Older Adult)",Phase 2,242,Interventional,August 2006,April 2009,https://ClinicalTrials.gov/show/NCT00759863,21 Years and older ,21,18 to 40 years old
NCT00178165,Coordinating Center for Enhancing ADRD Caregiving,Completed,Dementia|Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,1200,Interventional,September 1996,November 2001,https://ClinicalTrials.gov/show/NCT00178165,21 Years and older ,21,18 to 40 years old
NCT01886820,A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology,Unknown status,Dementia|Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 3,290,Interventional,June 2013,September 2018,https://ClinicalTrials.gov/show/NCT01886820,21 Years and older ,21,18 to 40 years old
NCT01378195,iCare Stress Management e-Training for Dementia Family Caregivers,Completed,Alzheimer's Disease|Dementia,All,"21 Years and older   (Adult, Older Adult)",Phase 2,150,Interventional,May 2011,July 2012,https://ClinicalTrials.gov/show/NCT01378195,21 Years and older ,21,18 to 40 years old
NCT02915939,The Residential Care Transition Module,Recruiting,Alzheimer Disease|Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,240,Interventional,December 2016,May 2021,https://ClinicalTrials.gov/show/NCT02915939,21 Years and older ,21,18 to 40 years old
NCT03665909,A Proactive Health Monitoring Intervention for Dementia Caregivers,"Active, not recruiting",Dementia|Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 3,170,Interventional,"April 1, 2014","March 3, 2020",https://ClinicalTrials.gov/show/NCT03665909,21 Years and older ,21,18 to 40 years old
NCT03333252,A Non-pharmacological Intervention for Patients With Alzheimer's Disease and Family Caregivers (Care Partners Program),Recruiting,Caregiver,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,246,Interventional,"January 29, 2018","April 30, 2021",https://ClinicalTrials.gov/show/NCT03333252,21 Years and older ,21,18 to 40 years old
NCT00593372,Treatment of Language and Memory in Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 1,11,Interventional,August 2003,April 2010,https://ClinicalTrials.gov/show/NCT00593372,21 Years and older ,21,18 to 40 years old
NCT02300584,"Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program",Completed,Dementia|Alzheimer's Disease|Depression,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,42,Interventional,November 2014,October 2015,https://ClinicalTrials.gov/show/NCT02300584,21 Years and older ,21,18 to 40 years old
NCT00259467,Project TAP: Tailored Activities Project,Completed,Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 1,60,Interventional,February 2004,January 2007,https://ClinicalTrials.gov/show/NCT00259467,21 Years and older ,21,18 to 40 years old
NCT00259480,Project ACT: Advancing Caregiving Techniques,Completed,Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 3,272,Interventional,August 2001,March 2015,https://ClinicalTrials.gov/show/NCT00259480,21 Years and older ,21,18 to 40 years old
NCT03218982,Vietnamese Caregiver Intervention Study,Recruiting,Alzheimer's Disease (Incl Subtypes)|Cognitive Impairment,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,24,Interventional,"May 22, 2017","June 30, 2020",https://ClinicalTrials.gov/show/NCT03218982,21 Years and older ,21,18 to 40 years old
NCT00259454,Project COPE:Managing Dementia at Home,Completed,"Dementia, Alzheimer Type",All,"21 Years and older   (Adult, Older Adult)",Phase 3,278,Interventional,June 2005,July 2009,https://ClinicalTrials.gov/show/NCT00259454,21 Years and older ,21,18 to 40 years old
NCT01465360,"Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center",Completed,Alzheimer's Disease|Mild Cognitive Impairment|Vascular Dementia|Fronto-temporal Dementia|Primary Progressive Aphasia|Parkinson' Disease Dementia|Mixed Dementia,All,"21 Years and older   (Adult, Older Adult)",Phase 4,160,Observational,November 2011,,https://ClinicalTrials.gov/show/NCT01465360,21 Years and older ,21,18 to 40 years old
NCT02120664,Florbetapir Calibration to the Centiloid Scale,Completed,Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 1,35,Interventional,April 2014,September 2015,https://ClinicalTrials.gov/show/NCT02120664,21 Years and older ,21,18 to 40 years old
NCT03244917,Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias,Recruiting,"Dementia|Infection, Bacterial",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,410,Interventional,"October 15, 2017",March 2021,https://ClinicalTrials.gov/show/NCT03244917,21 Years and older ,21,18 to 40 years old
NCT03100617,Alzheimer's Family Caregiver Intervention in Vietnam,Recruiting,Dementia Alzheimers,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,8,Interventional,"August 26, 2017","June 18, 2019",https://ClinicalTrials.gov/show/NCT03100617,21 Years and older ,21,18 to 40 years old
NCT00255866,Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers,Completed,Dementia|Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,90,Interventional,January 2004,December 2006,https://ClinicalTrials.gov/show/NCT00255866,21 Years and older ,21,18 to 40 years old
NCT02759887,Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD),Unknown status,Down Syndrome|Alzheimer's Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,November 2016,June 2019,https://ClinicalTrials.gov/show/NCT02759887,21 Years and older ,21,18 to 40 years old
NCT03282877,iCST Web-application for People With Dementia,"Active, not recruiting",Mild Dementia|Moderate Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,43,Interventional,"May 1, 2018",August 2019,https://ClinicalTrials.gov/show/NCT03282877,21 Years and older ,21,18 to 40 years old
NCT02440646,Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography,Enrolling by invitation,Coronary Atherosclerosis|Coronary Artery Disease|Radiocontrast-induced Thyroid Dysfunction|Contrast-induced Nephropathy|Cerebrovascular Disease|Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 4,1080,Observational,May 2015,February 2020,https://ClinicalTrials.gov/show/NCT02440646,21 Years and older ,21,18 to 40 years old
NCT01005862,Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers,Completed,Alzheimer's Disease,All,"21 Years and older   (Adult, Older Adult)",Phase 1,17,Interventional,March 2010,September 2012,https://ClinicalTrials.gov/show/NCT01005862,21 Years and older ,21,18 to 40 years old
NCT01145482,Mechanisms of Insulin Facilitation of Memory,Completed,Memory Disorders,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,12,Interventional,July 2010,April 2014,https://ClinicalTrials.gov/show/NCT01145482,21 Years and older ,21,18 to 40 years old
NCT01892579,Reducing Agitation in People With Dementia: the Customized Activity Trial,Completed,Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,250,Interventional,November 2013,"November 23, 2017",https://ClinicalTrials.gov/show/NCT01892579,21 Years and older ,21,18 to 40 years old
NCT02420535,An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia,Completed,Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,114,Interventional,May 2015,October 2016,https://ClinicalTrials.gov/show/NCT02420535,21 Years and older ,21,18 to 40 years old
NCT00182897,PACT: Providers and Alzheimer's Caregivers Together,Completed,Alzheimer's Disease|Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,120,Interventional,October 2000,November 2005,https://ClinicalTrials.gov/show/NCT00182897,21 Years and older ,21,18 to 40 years old
NCT01550172,Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers,Completed,Caregivers of Persons With Dementia,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,April 2012,July 2016,https://ClinicalTrials.gov/show/NCT01550172,21 Years and older ,21,18 to 40 years old
NCT01188070,Caregiver Stress: Interventions to Promote Health and Wellbeing,Completed,Health Promotion,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,354,Interventional,January 2010,May 2014,https://ClinicalTrials.gov/show/NCT01188070,21 Years and older ,21,18 to 40 years old
NCT00119561,Testing the Effectiveness of Telephone Support for Dementia Caregivers,Completed,Dementia|Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,154,Interventional,February 2005,January 2014,https://ClinicalTrials.gov/show/NCT00119561,21 Years and older ,21,18 to 40 years old
NCT00177489,Coordinating Center for Caregiver Intervention Trial,Completed,Dementia|Alzheimer Disease,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,613,Interventional,June 2002,September 2005,https://ClinicalTrials.gov/show/NCT00177489,21 Years and older ,21,18 to 40 years old
NCT01772537,The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.,Terminated,Thoracic Aneurysm|Aneurysm Stent|Cardiopulmonary Bypass|Abdominal Aneurysm,All,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,14,Interventional,May 2012,February 2014,https://ClinicalTrials.gov/show/NCT01772537,21 Years to 100 Years ,21,18 to 40 years old
NCT02347202,Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention,Recruiting,Alzheimer's Disease|Dementia,All,"21 Years to 125 Years   (Adult, Older Adult)",Not Applicable,240,Interventional,October 2015,September 2019,https://ClinicalTrials.gov/show/NCT02347202,21 Years to 125 Years ,21,18 to 40 years old
NCT02741505,Brain Sleep Deprivation MRI Effects (BEDTIME),Not yet recruiting,Alzheimer's Disease,All,21 Years to 30 Years   (Adult),Not Applicable,20,Interventional,June 2019,December 2019,https://ClinicalTrials.gov/show/NCT02741505,21 Years to 30 Years ,21,18 to 40 years old
NCT02061878,A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects,Completed,Alzheimer's Disease,All,21 Years to 50 Years   (Adult),Phase 1,12,Interventional,August 2014,November 2014,https://ClinicalTrials.gov/show/NCT02061878,21 Years to 50 Years ,21,18 to 40 years old
NCT00765115,A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.,Completed,Alzheimer Disease,Male,21 Years to 50 Years   (Adult),Phase 1,27,Interventional,July 2006,September 2007,https://ClinicalTrials.gov/show/NCT00765115,21 Years to 50 Years ,21,18 to 40 years old
NCT02740634,Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study,Recruiting,Atypical Alzheimer's Disease|Logopenic Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA),All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,May 2016,March 2021,https://ClinicalTrials.gov/show/NCT02740634,21 Years to 80 Years ,21,18 to 40 years old
NCT03360019,Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:,Not yet recruiting,"Dementia, Vascular|Alzheimer Dementia|Lewy Body Dementia With Behavioral Disturbance",All,"21 Years to 85 Years   (Adult, Older Adult)",Not Applicable,187,Interventional,September 2019,January 2021,https://ClinicalTrials.gov/show/NCT03360019,21 Years to 85 Years ,21,18 to 40 years old
NCT03393546,Auricular Point Acupressure to Manage Pain in Patients With Alzheimer's Disease and Related Disorders,Recruiting,Pain|Alzheimer Disease,All,"21 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,"August 1, 2018","December 30, 2019",https://ClinicalTrials.gov/show/NCT03393546,21 Years to 85 Years ,21,18 to 40 years old
NCT00438724,Couples Coping With Alzheimer's Disease,Unknown status,Aging|Alzheimer Disease|Dementia,All,"21 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,November 2004,November 2007,https://ClinicalTrials.gov/show/NCT00438724,21 Years to 90 Years ,21,18 to 40 years old
NCT03371420,PET Imaging of Subjects Using 124I-PU-AD,Completed,Lymphoma|Solid Malignancy|Alzheimer Disease|Myeloma,All,"21 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,5,Interventional,April 2016,"June 10, 2019",https://ClinicalTrials.gov/show/NCT03371420,21 Years to 90 Years ,21,18 to 40 years old
NCT00409279,An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"21 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Interventional,September 2003,April 2008,https://ClinicalTrials.gov/show/NCT00409279,21 Years to 90 Years ,21,18 to 40 years old
NCT00621010,Safety Study of CTS21166 to Treat Alzheimer Disease,Completed,Alzheimer's Disease,Male,"22 Years and older   (Adult, Older Adult)",Phase 1,56,Interventional,June 2007,February 2008,https://ClinicalTrials.gov/show/NCT00621010,22 Years and older ,22,18 to 40 years old
NCT01778946,Nicotine Treatment of Cognitive Decline in Down Syndrome,Recruiting,Down Syndrome|Mild Cognitive Impairment,All,"25 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Interventional,April 2013,December 2019,https://ClinicalTrials.gov/show/NCT01778946,25 Years and older ,25,18 to 40 years old
NCT02187627,"Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants",Completed,"Alzheimer's Disease, Healthy Volunteer",All,"25 Years and older   (Adult, Older Adult)",Phase 1,52,Interventional,"August 31, 2014","February 29, 2016",https://ClinicalTrials.gov/show/NCT02187627,25 Years and older ,25,18 to 40 years old
NCT02813070,Comparison of PET Amyloid Imaging in Japanese and Western Subjects,Completed,Mild Cognitive Impairment|Alzheimer's Disease|Healthy,All,"25 Years and older   (Adult, Older Adult)",Phase 2,70,Interventional,October 2012,May 2013,https://ClinicalTrials.gov/show/NCT02813070,25 Years and older ,25,18 to 40 years old
NCT00785759,"Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers",Completed,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,All,"25 Years and older   (Adult, Older Adult)",Phase 2,78,Interventional,September 2008,December 2009,https://ClinicalTrials.gov/show/NCT00785759,25 Years and older ,25,18 to 40 years old
NCT02792179,Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants,Completed,Alzheimer's Disease,All,"25 Years and older   (Adult, Older Adult)",Phase 1,4,Interventional,"July 19, 2016","September 28, 2016",https://ClinicalTrials.gov/show/NCT02792179,25 Years and older ,25,18 to 40 years old
NCT00315575,Memory Imaging of Normal Aging,Completed,Alzheimer's Disease,All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 4,90,Observational,August 2005,July 2008,https://ClinicalTrials.gov/show/NCT00315575,25 Years to 65 Years ,25,18 to 40 years old
NCT02492529,Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"25 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Interventional,"July 21, 2015","December 31, 2017",https://ClinicalTrials.gov/show/NCT02492529,25 Years to 75 Years ,25,18 to 40 years old
NCT02928211,Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations,Recruiting,Mild Cognitive Impairment|Alzheimer's Disease,All,"25 Years to 90 Years   (Adult, Older Adult)",Phase 1,105,Interventional,July 2016,January 2019,https://ClinicalTrials.gov/show/NCT02928211,25 Years to 90 Years ,25,18 to 40 years old
NCT02840279,A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects,Completed,Alzheimer's Disease,All,"25 Years to 90 Years   (Adult, Older Adult)",Phase 1,77,Interventional,June 2016,December 2016,https://ClinicalTrials.gov/show/NCT02840279,25 Years to 90 Years ,25,18 to 40 years old
NCT01775696,Central and Systemic Inflammation in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 4,125,Observational,"December 8, 2011","April 4, 2017",https://ClinicalTrials.gov/show/NCT01775696,30 Years and older ,30,18 to 40 years old
NCT02471833,Health Evaluation in African Americans Using RAS Therapy,Recruiting,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 1,66,Interventional,April 2015,"June 30, 2020",https://ClinicalTrials.gov/show/NCT02471833,30 Years and older ,30,18 to 40 years old
NCT00355498,Amyloid Plaque and Tangle Imaging in Aging and Dementia,Completed,Memory Disorders|Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 4,194,Observational,September 2005,May 2010,https://ClinicalTrials.gov/show/NCT00355498,30 Years and older ,30,18 to 40 years old
NCT03432195,A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations,Completed,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 1,66,Interventional,"January 31, 2018","June 28, 2018",https://ClinicalTrials.gov/show/NCT03432195,30 Years and older ,30,18 to 40 years old
NCT03259958,A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®,Completed,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 1,86,Interventional,"October 30, 2017","March 14, 2018",https://ClinicalTrials.gov/show/NCT03259958,30 Years and older ,30,18 to 40 years old
NCT01303133,Natural History of Amyloid Deposition in Adults With Down Syndrome,Completed,Down Syndrome,All,"30 Years and older   (Adult, Older Adult)",Phase 4,81,Observational,August 2009,"March 31, 2018",https://ClinicalTrials.gov/show/NCT01303133,30 Years and older ,30,18 to 40 years old
NCT02754830,A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 1,110,Interventional,"April 25, 2016","July 10, 2018",https://ClinicalTrials.gov/show/NCT02754830,30 Years and older ,30,18 to 40 years old
NCT01871610,Amyloid Accumulation After Mild Traumatic Brain Injury,Unknown status,Traumatic Brain Injury,All,"30 Years and older   (Adult, Older Adult)",Phase 2,40,Interventional,November 2012,October 2013,https://ClinicalTrials.gov/show/NCT01871610,30 Years and older ,30,18 to 40 years old
NCT01607476,Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET),Completed,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 2,89,Interventional,July 2012,March 2016,https://ClinicalTrials.gov/show/NCT01607476,30 Years and older ,30,18 to 40 years old
NCT03451591,LACunar Intervention (LACI-2) Trial-2,Recruiting,"Cerebral Small Vessel Diseases|Stroke, Lacunar",All,"30 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400,Interventional,"January 8, 2018",November 2020,https://ClinicalTrials.gov/show/NCT03451591,30 Years and older ,30,18 to 40 years old
NCT03438604,A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS),Completed,Alzheimer's Disease,All,"30 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,"February 13, 2018","June 30, 2018",https://ClinicalTrials.gov/show/NCT03438604,30 Years and older ,30,18 to 40 years old
NCT03618186,Tau PET Imaging in African Americans,Enrolling by invitation,Cognitive Impairment,All,"30 Years and older   (Adult, Older Adult)",Phase 2,90,Interventional,"November 26, 2018",May 2024,https://ClinicalTrials.gov/show/NCT03618186,30 Years and older ,30,18 to 40 years old
NCT00950430,Imaging of Brain Amyloid Plaques in the Aging Population,Enrolling by invitation,Alzheimer's Disease|Dementia With Lewy Bodies|Frontotemporal Dementia|Vascular Dementia,All,"30 Years to 100 Years   (Adult, Older Adult)",Phase 4,2500,Interventional,April 2008,April 2023,https://ClinicalTrials.gov/show/NCT00950430,30 Years to 100 Years ,30,18 to 40 years old
NCT03371706,Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia,Recruiting,Primary Progressive Aphasia,All,"30 Years to 100 Years   (Adult, Older Adult)",Not Applicable,90,Interventional,"April 3, 2018","February 1, 2024",https://ClinicalTrials.gov/show/NCT03371706,30 Years to 100 Years ,30,18 to 40 years old
NCT01609335,Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults,Completed,Alzheimer's Disease,All,30 Years to 49 Years   (Adult),Phase 1,41,Interventional,July 2012,August 2013,https://ClinicalTrials.gov/show/NCT01609335,30 Years to 49 Years ,30,18 to 40 years old
NCT00612872,Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects,Terminated,Parkinson Disease|Alzheimer Disease|Healthy Controls|Multiple Sclerosis,All,30 Years to 50 Years   (Adult),Phase 1,46,Interventional,January 2008,"November 1, 2009",https://ClinicalTrials.gov/show/NCT00612872,30 Years to 50 Years ,30,18 to 40 years old
NCT01924858,A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.,Terminated,Alzheimer's Disease,Male,30 Years to 55 Years   (Adult),Phase 1,4,Interventional,"August 19, 2013","March 3, 2014",https://ClinicalTrials.gov/show/NCT01924858,30 Years to 55 Years ,30,18 to 40 years old
NCT01716897,An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption,Completed,Alzheimer's Disease,Male,30 Years to 55 Years   (Adult),Phase 1,18,Interventional,October 2012,February 2013,https://ClinicalTrials.gov/show/NCT01716897,30 Years to 55 Years ,30,18 to 40 years old
NCT02141971,Down Syndrome Biomarker Initiative (DSBI),Completed,Down Syndrome|Alzheimer's Disease,All,30 Years to 60 Years   (Adult),Phase 4,12,Observational,"June 1, 2013","April 15, 2017",https://ClinicalTrials.gov/show/NCT02141971,30 Years to 60 Years ,30,18 to 40 years old
NCT01998841,"A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort","Active, not recruiting",Alzheimer's Disease,All,30 Years to 60 Years   (Adult),Phase 2,252,Interventional,"December 20, 2013","February 25, 2022",https://ClinicalTrials.gov/show/NCT01998841,30 Years to 60 Years ,30,18 to 40 years old
NCT03977584,Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease,Not yet recruiting,Alzheimer Disease,All,30 Years to 60 Years   (Adult),Phase 2,150,Interventional,"June 10, 2019","February 25, 2022",https://ClinicalTrials.gov/show/NCT03977584,30 Years to 60 Years ,30,18 to 40 years old
NCT03901456,Care to Plan: a Tailored Resource for Family Members of Persons With Dementia,Recruiting,Dementia|Alzheimer Disease|Memory Loss,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120,Interventional,"September 1, 2019","August 1, 2021",https://ClinicalTrials.gov/show/NCT03901456,30 Years to 70 Years ,30,18 to 40 years old
NCT02474251,Brain Sleep Clearance of Amyloid-Beta Peptides,"Active, not recruiting",Obstructive Sleep Apnea|Alzheimer's Disease,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,38,Interventional,"October 1, 2015","July 31, 2019",https://ClinicalTrials.gov/show/NCT02474251,30 Years to 75 Years ,30,18 to 40 years old
NCT02612805,The Diabetes and Aquatic Training Study (DATS),Completed,"Diabetes Mellitus, Type 2",All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,November 2015,May 2016,https://ClinicalTrials.gov/show/NCT02612805,30 Years to 75 Years ,30,18 to 40 years old
NCT01089270,Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives,Unknown status,Parkinson Disease,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,80,Observational,March 2010,,https://ClinicalTrials.gov/show/NCT01089270,30 Years to 80 Years ,30,18 to 40 years old
NCT02397980,Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia,Unknown status,Alzheimer's Disease|Dementia,All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,March 2015,December 2016,https://ClinicalTrials.gov/show/NCT02397980,30 Years to 80 Years ,30,18 to 40 years old
NCT03388242,Protein and microRNA Markers for Early Detection of Alzheimer's Disease,Recruiting,Mild Cognitive Impairment,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,120,Observational,"December 7, 2017","March 30, 2020",https://ClinicalTrials.gov/show/NCT03388242,30 Years to 80 Years ,30,18 to 40 years old
NCT01294540,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort",Completed,Alzheimer's Disease,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 1,73,Interventional,December 2010,December 2011,https://ClinicalTrials.gov/show/NCT01294540,30 Years to 85 Years ,30,18 to 40 years old
NCT03778151,Repetitive TMS of the Default Mode Network in AD,Recruiting,Alzheimer Disease,All,"30 Years to 85 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,"February 1, 2018","February 1, 2020",https://ClinicalTrials.gov/show/NCT03778151,30 Years to 85 Years ,30,18 to 40 years old
NCT04124029,Contributions of mTBI to Neurodegeneration Due to CTE and Alzheimer's Disease,Not yet recruiting,Mild Traumatic Brain Injury|Moderate Traumatic Brain Injury|Mild Cognitive Impairment,All,"30 Years to 90 Years   (Adult, Older Adult)",Phase 4,800,Observational,"March 31, 2020","March 31, 2025",https://ClinicalTrials.gov/show/NCT04124029,30 Years to 90 Years ,30,18 to 40 years old
NCT00811122,"Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly",Unknown status,Alzheimer's Disease,All,"30 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,30,Interventional,November 2009,April 2018,https://ClinicalTrials.gov/show/NCT00811122,30 Years to 90 Years ,30,18 to 40 years old
NCT01322568,Research on Aging Project in Iceland: Second Stage,Completed,Atherosclerosis|Osteoporosis|Obesity|Glucose Abnormalities|Alzheimer's Disease|Vascular Dimentia,All,32 Years to 60 Years   (Adult),Phase 4,5764,Observational,"January 31, 2003","February 11, 2014",https://ClinicalTrials.gov/show/NCT01322568,32 Years to 60 Years ,32,18 to 40 years old
NCT01378026,Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation,Unknown status,Amyotrophic Lateral Sclerosis|Alzheimer Disease|Parkinson's Disease,All,"32 Years to 87 Years   (Adult, Older Adult)",Phase 4,120,Observational,January 2012,,https://ClinicalTrials.gov/show/NCT01378026,32 Years to 87 Years ,32,18 to 40 years old
NCT00677885,P-glycoprotein Function in Brain Diseases,Completed,Alzheimer Disease|Parkinson Disease|Frontotemporal Lobar Degeneration,All,"35 Years and older   (Adult, Older Adult)",Phase 4,20,Observational,"May 9, 2008","August 25, 2014",https://ClinicalTrials.gov/show/NCT00677885,35 Years and older ,35,18 to 40 years old
NCT01565330,A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers,Completed,Alzheimer Disease,All,"35 Years and older   (Adult, Older Adult)",Phase 1,20,Interventional,March 2008,August 2008,https://ClinicalTrials.gov/show/NCT01565330,35 Years and older ,35,18 to 40 years old
NCT01565343,A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers,Completed,Alzheimer's Disease,All,"35 Years and older   (Adult, Older Adult)",Phase 1,25,Interventional,April 2008,April 2009,https://ClinicalTrials.gov/show/NCT01565343,35 Years and older ,35,18 to 40 years old
NCT01565356,Evaluation of PET Scan Timing Relative to AV-45 Injection Time,Completed,Alzheimer's Disease,All,"35 Years and older   (Adult, Older Adult)",Not Applicable,41,Interventional,March 2010,May 2010,https://ClinicalTrials.gov/show/NCT01565356,35 Years and older ,35,18 to 40 years old
NCT03901261,Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21),Recruiting,Down Syndrome|Alzheimer Disease,All,"35 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,"April 26, 2019","March 31, 2023",https://ClinicalTrials.gov/show/NCT03901261,35 Years and older ,35,18 to 40 years old
NCT00937846,Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study,Completed,Cognitive Disorders,Male,35 Years to 55 Years   (Adult),Phase 1,4,Interventional,"July 15, 2009","August 28, 2009",https://ClinicalTrials.gov/show/NCT00937846,35 Years to 55 Years ,35,18 to 40 years old
NCT01153802,"An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands",Completed,Depressive Disorder,Male,35 Years to 55 Years   (Adult),Phase 1,12,Interventional,"April 3, 2009","October 12, 2009",https://ClinicalTrials.gov/show/NCT01153802,35 Years to 55 Years ,35,18 to 40 years old
NCT00777361,"Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers",Terminated,Alzheimer's Disease,Male,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1,9,Interventional,October 2008,October 2009,https://ClinicalTrials.gov/show/NCT00777361,35 Years to 65 Years ,35,18 to 40 years old
NCT00486044,Evaluating Simvastatin's Potential Role in Therapy,Completed,Alzheimer Disease,All,"35 Years to 69 Years   (Adult, Older Adult)",Phase 2,103,Interventional,February 2005,June 2009,https://ClinicalTrials.gov/show/NCT00486044,35 Years to 69 Years ,35,18 to 40 years old
NCT04080544,Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study,Not yet recruiting,Alzheimer Disease|Cognitive Decline,All,"38 Years to 96 Years   (Adult, Older Adult)",Phase 2,125,Interventional,"September 15, 2019","June 30, 2022",https://ClinicalTrials.gov/show/NCT04080544,38 Years to 96 Years ,38,18 to 40 years old
NCT01608217,Delta-THC in Dementia,Completed,Behavioural Disturbances|Pain|Dementia|Alzheimer's Dementia|Vascular Dementia,All,"40 Years and older   (Adult, Older Adult)",Phase 2,50,Interventional,June 2012,June 2014,https://ClinicalTrials.gov/show/NCT01608217,40 Years and older ,40,18 to 40 years old
NCT02249403,Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type,Completed,Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 2,362,Interventional,January 1999,,https://ClinicalTrials.gov/show/NCT02249403,40 Years and older ,40,18 to 40 years old
NCT02675270,Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia,Recruiting,"Aphasia, Primary Progressive|Anomia|Alzheimer Disease",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,85,Interventional,November 2011,June 2022,https://ClinicalTrials.gov/show/NCT02675270,40 Years and older ,40,18 to 40 years old
NCT00253214,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation,Completed,Alzheimer Disease|Dementia,All,"40 Years and older   (Adult, Older Adult)",Phase 3,973,Interventional,March 2001,July 2002,https://ClinicalTrials.gov/show/NCT00253214,40 Years and older ,40,18 to 40 years old
NCT02249351,Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type,Terminated,Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 2,54,Interventional,December 1999,,https://ClinicalTrials.gov/show/NCT02249351,40 Years and older ,40,18 to 40 years old
NCT00880347,Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia,Completed,Alzheimer's Disease|Dementia,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,550,Interventional,February 2008,February 2011,https://ClinicalTrials.gov/show/NCT00880347,40 Years and older ,40,18 to 40 years old
NCT00216593,Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study,Completed,Dementia|Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 3,415,Interventional,December 2003,March 2008,https://ClinicalTrials.gov/show/NCT00216593,40 Years and older ,40,18 to 40 years old
NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Completed,Alzheimer's Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 3,613,Interventional,August 2007,October 2012,https://ClinicalTrials.gov/show/NCT00235716,40 Years and older ,40,18 to 40 years old
NCT03279523,F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected,Recruiting,Alzheimer Disease|HIV,All,"40 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,May 2016,November 2021,https://ClinicalTrials.gov/show/NCT03279523,40 Years and older ,40,18 to 40 years old
NCT03136679,Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease,Recruiting,Mild Cognitive Impairment|Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 4,220,Observational,"March 22, 2017","December 31, 2022",https://ClinicalTrials.gov/show/NCT03136679,40 Years and older ,40,18 to 40 years old
NCT01320527,A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"40 Years and older   (Adult, Older Adult)",Phase 2,135,Interventional,August 2008,April 2012,https://ClinicalTrials.gov/show/NCT01320527,40 Years and older ,40,18 to 40 years old
NCT04073225,"Optimizing Cognitive, Environmental, and Neuromotor Stimulation in Traumatic Brain Injury",Not yet recruiting,Traumatic Brain Injury|Dementia Alzheimers,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,66,Interventional,October 2019,June 2022,https://ClinicalTrials.gov/show/NCT04073225,40 Years and older ,40,18 to 40 years old
NCT00645190,"A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease",Completed,Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 3,215,Interventional,March 2004,February 2005,https://ClinicalTrials.gov/show/NCT00645190,40 Years and older ,40,18 to 40 years old
NCT02708485,Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,15,Interventional,April 2009,July 2017,https://ClinicalTrials.gov/show/NCT02708485,40 Years and older ,40,18 to 40 years old
NCT00245206,Side Effects of Newer Antipsychotics in Older Adults,Completed,Schizophrenia|Alzheimer's Disease|Dementia,All,"40 Years and older   (Adult, Older Adult)",Phase 4,406,Interventional,August 2005,October 2010,https://ClinicalTrials.gov/show/NCT00245206,40 Years and older ,40,18 to 40 years old
NCT00721383,Telephone Resources and Assistance for Caregivers (TRAC),Completed,Alzheimer's Disease,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,211,Interventional,May 2007,February 2013,https://ClinicalTrials.gov/show/NCT00721383,40 Years and older ,40,18 to 40 years old
NCT00142324,CALM-AD,Unknown status,Alzheimer's Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 4,190,Interventional,November 2003,December 2005,https://ClinicalTrials.gov/show/NCT00142324,40 Years and older ,40,18 to 40 years old
NCT02886494,A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia,Completed,Alzheimer's Disease or Vascular Dementia,All,"40 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,December 2016,"November 1, 2018",https://ClinicalTrials.gov/show/NCT02886494,40 Years and older ,40,18 to 40 years old
NCT02946710,"P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid",Completed,Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 4,120,Observational,December 2014,December 2017,https://ClinicalTrials.gov/show/NCT02946710,40 Years and older ,40,18 to 40 years old
NCT03811184,Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen,Recruiting,Cognitive Impairment|Alzheimer Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 4,400,Observational,"January 17, 2019",June 2020,https://ClinicalTrials.gov/show/NCT03811184,40 Years and older ,40,18 to 40 years old
NCT00261573,A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia,Completed,Alzheimer Disease|Vascular Dementia,All,"40 Years and older   (Adult, Older Adult)",Phase 3,593,Interventional,December 1998,December 2000,https://ClinicalTrials.gov/show/NCT00261573,40 Years and older ,40,18 to 40 years old
NCT01478633,Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil,Completed,Alzheimer's Disease,All,"40 Years and older   (Adult, Older Adult)",Phase 4,102,Interventional,September 2011,June 2013,https://ClinicalTrials.gov/show/NCT01478633,40 Years and older ,40,18 to 40 years old
NCT02467413,BAC in Patient With Alzheimer's Disease or Vascular Dementia,Withdrawn,Alzheimer's Disease|Vascular Dementia,All,"40 Years and older   (Adult, Older Adult)",Phase 2,0,Interventional,"December 1, 2019",December 2021,https://ClinicalTrials.gov/show/NCT02467413,40 Years and older ,40,18 to 40 years old
NCT01194713,Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics,Completed,Alzheimer Disease,Male,40 Years to 60 Years   (Adult),Not Applicable,26,Interventional,March 2011,September 2013,https://ClinicalTrials.gov/show/NCT01194713,40 Years to 60 Years ,40,18 to 40 years old
NCT03794141,Genetic Information as a Life Style Change Motivator,"Active, not recruiting","Health Behavior|Alzheimer Disease, Protection Against",All,40 Years to 60 Years   (Adult),Not Applicable,333,Interventional,"January 2, 2017","July 31, 2019",https://ClinicalTrials.gov/show/NCT03794141,40 Years to 60 Years ,40,18 to 40 years old
NCT03507257,Longitudinal Early-onset Alzheimer's Disease Study Protocol,Recruiting,Early Onset Alzheimer Disease|Alzheimer Disease|Mild Cognitive Impairment,All,40 Years to 64 Years   (Adult),Phase 4,600,Observational,"April 30, 2018","August 31, 2023",https://ClinicalTrials.gov/show/NCT03507257,40 Years to 64 Years ,40,18 to 40 years old
NCT04002583,48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease,Not yet recruiting,Early Onset Alzheimer Disease,All,40 Years to 64 Years   (Adult),Not Applicable,20,Interventional,"January 1, 2020",January 2021,https://ClinicalTrials.gov/show/NCT04002583,40 Years to 64 Years ,40,18 to 40 years old
NCT02290912,Gray Matters Alzheimer's Disease Prevention Intervention,Completed,Alzheimer's Disease,All,40 Years to 64 Years   (Adult),Not Applicable,146,Interventional,April 2014,December 2014,https://ClinicalTrials.gov/show/NCT02290912,40 Years to 64 Years ,40,18 to 40 years old
NCT02323217,I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers,Completed,Healthy Volunteers|Alzheimer Disease|Molecular Imaging,Male,"40 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,20,Interventional,January 2015,July 2016,https://ClinicalTrials.gov/show/NCT02323217,40 Years to 65 Years ,40,18 to 40 years old
NCT00751907,Cerebral and Peripheral Perfusion Pilot Study,Completed,Alzheimer's Disease,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,16,Interventional,June 2006,April 2007,https://ClinicalTrials.gov/show/NCT00751907,40 Years to 65 Years ,40,18 to 40 years old
NCT03746366,[C-11]PiB PET Imaging in Alcohol Use Disorders,Recruiting,Alcohol Use Disorder,All,"40 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,40,Interventional,"December 1, 2018","December 31, 2022",https://ClinicalTrials.gov/show/NCT03746366,40 Years to 65 Years ,40,18 to 40 years old
NCT00980785,Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's,Completed,Alzheimer's Disease|Hypertension,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,14,Interventional,April 2009,July 2011,https://ClinicalTrials.gov/show/NCT00980785,40 Years to 65 Years ,40,18 to 40 years old
NCT03240406,Multicultural Healthy Diet to Reduce Cognitive Decline,Recruiting,Diet Modification|Cognitive Decline|Cognitive Change,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,326,Interventional,"October 2, 2018","September 14, 2022",https://ClinicalTrials.gov/show/NCT03240406,40 Years to 65 Years ,40,18 to 40 years old
NCT02537938,Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose),Completed,Alzheimer's Disease,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Interventional,January 2016,December 2016,https://ClinicalTrials.gov/show/NCT02537938,40 Years to 65 Years ,40,18 to 40 years old
NCT03645993,Early Onset Alzheimer's Disease Genomic Study,Recruiting,Alzheimer Disease,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,2,Observational,"June 16, 2017","June 16, 2022",https://ClinicalTrials.gov/show/NCT03645993,40 Years to 65 Years ,40,18 to 40 years old
NCT02832921,Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk,Recruiting,Alzheimer's Disease (AD),All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,July 2016,August 2019,https://ClinicalTrials.gov/show/NCT02832921,40 Years to 65 Years ,40,18 to 40 years old
NCT02109705,Porphyromonas Gingivalis and Alzheimer`s Disease,Unknown status,Alzheimer`s Disease|Dementia|Periodontitis,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 4,90,Observational,March 2014,,https://ClinicalTrials.gov/show/NCT02109705,40 Years to 70 Years ,40,18 to 40 years old
NCT00939822,Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"40 Years to 72 Years   (Adult, Older Adult)",Phase 2,88,Interventional,March 2009,September 2013,https://ClinicalTrials.gov/show/NCT00939822,40 Years to 72 Years ,40,18 to 40 years old
NCT03865017,A Safety and Tolerability Study of GB301,Not yet recruiting,Alzheimer Disease,All,"40 Years to 72 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Interventional,"December 1, 2019","December 1, 2021",https://ClinicalTrials.gov/show/NCT03865017,40 Years to 72 Years ,40,18 to 40 years old
NCT01553929,Physical Training and Cognitive Activity on the Mild Cognitive Impairment (MCI) Patient,Terminated,Mild Cognitive Impairment|Alzheimer's Disease,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,5,Interventional,March 2012,January 2015,https://ClinicalTrials.gov/show/NCT01553929,40 Years to 75 Years ,40,18 to 40 years old
NCT01147679,"Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls",Unknown status,Frontotemporal Dementia|Frontotemporal Degeneration|Alzheimer's Disease|Social Behavior,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 4,99,Observational,January 2010,July 2014,https://ClinicalTrials.gov/show/NCT01147679,40 Years to 75 Years ,40,18 to 40 years old
NCT02667496,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,Dementia Alzheimer's Type,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,0,Interventional,November 2016,"March 31, 2017",https://ClinicalTrials.gov/show/NCT02667496,40 Years to 80 Years ,40,18 to 40 years old
NCT01339195,Post-stroke Cognitive Impairment and Dementia,Completed,Stroke|Cognitive Disorders|Behavioral Disorders,All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1635,Interventional,August 2010,December 2016,https://ClinicalTrials.gov/show/NCT01339195,40 Years to 80 Years ,40,18 to 40 years old
NCT00545974,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,Completed,Frontal Lobe Dementia|Frontotemporal Lobe Dementia|Semantic Dementia,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,81,Interventional,October 2007,December 2012,https://ClinicalTrials.gov/show/NCT00545974,40 Years to 80 Years ,40,18 to 40 years old
NCT02656498,"[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease",Recruiting,Alzheimer's Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,180,Interventional,January 2016,December 2019,https://ClinicalTrials.gov/show/NCT02656498,40 Years to 80 Years ,40,18 to 40 years old
NCT03510572,Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain,Recruiting,Healthy Volunteer|Alzheimer Disease|Frontotemporal Dementia|Parkinson Disease,All,"40 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,20,Interventional,"June 4, 2018",July 2019,https://ClinicalTrials.gov/show/NCT03510572,40 Years to 80 Years ,40,18 to 40 years old
NCT03115814,Deep Brain Stimulation for Treatment of Severe Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,6,Observational,"April 17, 2017",June 2019,https://ClinicalTrials.gov/show/NCT03115814,40 Years to 80 Years ,40,18 to 40 years old
NCT02253043,The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,10,Interventional,May 2014,December 2018,https://ClinicalTrials.gov/show/NCT02253043,40 Years to 80 Years ,40,18 to 40 years old
NCT00658125,Deep Brain Stimulation (DBS) for Alzheimer's Disease,Completed,Alzheimer Disease,All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,6,Interventional,"March 1, 2007","June 30, 2010",https://ClinicalTrials.gov/show/NCT00658125,40 Years to 80 Years ,40,18 to 40 years old
NCT01089283,Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics,Unknown status,Parkinson Disease,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,80,Observational,March 2010,,https://ClinicalTrials.gov/show/NCT01089283,40 Years to 80 Years ,40,18 to 40 years old
NCT02811653,Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Not Applicable,155,Interventional,December 2015,December 2019,https://ClinicalTrials.gov/show/NCT02811653,40 Years to 85 Years ,40,18 to 40 years old
NCT03381482,"Ectosomes, New Biomarkers of Tau Pathology?",Recruiting,Alzheimer Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,100,Observational,"December 20, 2017",December 2019,https://ClinicalTrials.gov/show/NCT03381482,40 Years to 85 Years ,40,18 to 40 years old
NCT00478491,fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease,Completed,Magnetic Resonance Imaging|Alzheimer's Disease|Dementia|Adult Children|Risk,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,390,Observational,January 2003,July 2011,https://ClinicalTrials.gov/show/NCT00478491,40 Years to 85 Years ,40,18 to 40 years old
NCT03153371,Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks,Recruiting,"Alzheimer Disease, Early Onset|Alzheimer Disease|Alzheimer Disease, Late Onset|Dementia, Alzheimer Type|Logopenic Progressive Aphasia|Primary Progressive Aphasia|Visuospatial/Perceptual Abilities|Posterior Cortical Atrophy|Executive Dysfunction|Corticobasal Degeneration|Ideomotor Apraxia",All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,180,Observational,"April 4, 2016","March 31, 2022",https://ClinicalTrials.gov/show/NCT03153371,40 Years to 85 Years ,40,18 to 40 years old
NCT03663387,PET Measures of CSF Clearance in Preclinical Alzheimer's Disease,Recruiting,Mild Cognitive Impairment,All,"40 Years to 85 Years   (Adult, Older Adult)",Not Applicable,136,Interventional,"July 30, 2018",June 2022,https://ClinicalTrials.gov/show/NCT03663387,40 Years to 85 Years ,40,18 to 40 years old
NCT00408525,Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease,Completed,Alzheimer's Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 1,41,Interventional,December 2006,"August 24, 2012",https://ClinicalTrials.gov/show/NCT00408525,40 Years to 85 Years ,40,18 to 40 years old
NCT01823666,Predicting the Conversion From Mild Cognitive Impairment to Dementia,Completed,"Mild Cognitive Impairment|Alzheimer Disease|Dementia, Vascular",All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,250,Observational,September 2012,September 2014,https://ClinicalTrials.gov/show/NCT01823666,40 Years to 85 Years ,40,18 to 40 years old
NCT03030586,ADDIA Proof-of-Performance Clinical Study,Recruiting,Alzheimer Disease (AD)|Frontotemporal Lobar Degeneration|Dementia With Lewy Bodies (DLB)|Parkinson Disease Dementia (PDD)|Progressive Supranuclear Palsy (PSP)|Corticobasal Degeneration (CBD),All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,800,Observational,January 2017,March 2019,https://ClinicalTrials.gov/show/NCT03030586,40 Years to 85 Years ,40,18 to 40 years old
NCT03903211,"Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease",Recruiting,Cognitively Normal|Mild Cognitive Impairment|Alzheimer Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,72,Interventional,"April 9, 2019","February 28, 2021",https://ClinicalTrials.gov/show/NCT03903211,40 Years to 85 Years ,40,18 to 40 years old
NCT00153010,An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type,Completed,Alzheimer Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,430,Interventional,February 2003,,https://ClinicalTrials.gov/show/NCT00153010,40 Years to 85 Years ,40,18 to 40 years old
NCT02819700,Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI),Unknown status,"Frontotemporal Dementia|Huntington Disease|Alzheimer Disease|Semantic Dementia|Dementia, Vascular",All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 4,285,Observational,January 2013,December 2017,https://ClinicalTrials.gov/show/NCT02819700,40 Years to 85 Years ,40,18 to 40 years old
NCT00733863,Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.,Completed,Alzheimer Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,27,Interventional,July 2008,,https://ClinicalTrials.gov/show/NCT00733863,40 Years to 85 Years ,40,18 to 40 years old
NCT00956410,To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients,Completed,Alzheimer Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,21,Interventional,September 2009,June 2011,https://ClinicalTrials.gov/show/NCT00956410,40 Years to 85 Years ,40,18 to 40 years old
NCT00795418,Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients,Completed,Alzheimer's Disease,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,31,Interventional,October 2008,,https://ClinicalTrials.gov/show/NCT00795418,40 Years to 85 Years ,40,18 to 40 years old
NCT03305809,A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),Recruiting,Lewy Body Dementia,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,340,Interventional,"November 9, 2017","June 22, 2020",https://ClinicalTrials.gov/show/NCT03305809,40 Years to 85 Years ,40,18 to 40 years old
NCT00432081,Effect of Indomethacin on the Progression of Alzheimer's Disease,Completed,Alzheimer Disease,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 3,160,Interventional,May 2000,August 2005,https://ClinicalTrials.gov/show/NCT00432081,40 Years to 90 Years ,40,18 to 40 years old
NCT00165724,Alzheimer's Disease Long-term Follow-up Study (ALF Study),Completed,Alzheimer's Disease,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,114,Interventional,June 2004,December 2006,https://ClinicalTrials.gov/show/NCT00165724,40 Years to 90 Years ,40,18 to 40 years old
NCT02860338,COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE,Completed,Mild Cognitive Impairment|Dementia|Hypoxia|Hyperhomocysteinemia|Vitamin B 12 Deficiency|Iron Deficiency|Anemia|TBI|Neurodegenerative Disorders|Alzheimer's Disease|Vascular Dementia|Brain Injuries|Tauopathies|Parkinson's Disease|Lewy Body Dementia|Frontotemporal Dementia|TDP-43 Proteinopathies,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,900,Observational,January 2009,December 2015,https://ClinicalTrials.gov/show/NCT02860338,40 Years to 90 Years ,40,18 to 40 years old
NCT00065169,Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs,Completed,Alzheimer Disease|Dementia,All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,138,Interventional,November 2000,November 2005,https://ClinicalTrials.gov/show/NCT00065169,40 Years to 90 Years ,40,18 to 40 years old
NCT00369603,Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients,Terminated,Alzheimer's Disease,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,4,Interventional,October 2006,November 2007,https://ClinicalTrials.gov/show/NCT00369603,40 Years to 90 Years ,40,18 to 40 years old
NCT00702780,Progression Delaying Effect of Escitalopram in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,74,Interventional,November 2008,September 2011,https://ClinicalTrials.gov/show/NCT00702780,40 Years to 90 Years ,40,18 to 40 years old
NCT00267163,Brain Imaging and Mental Disorders of Aging Intervention,Completed,Cognition Disorders,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,64,Interventional,September 2000,July 2007,https://ClinicalTrials.gov/show/NCT00267163,40 Years to 90 Years ,40,18 to 40 years old
NCT03732053,The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients,Completed,Alzheimer's Type Dementia|Cognitive Decline|Postural; Strain,All,"40 Years to 95 Years   (Adult, Older Adult)",Not Applicable,135,Interventional,"December 5, 2016","July 3, 2017",https://ClinicalTrials.gov/show/NCT03732053,40 Years to 95 Years ,40,18 to 40 years old
NCT01330160,Study of Factors Influencing Post-stroke Dementia,Recruiting,Cerebrovascular Disorders|Dementia,All,"40 Years to 95 Years   (Adult, Older Adult)",Phase 4,1100,Observational,"February 27, 2010",December 2023,https://ClinicalTrials.gov/show/NCT01330160,40 Years to 95 Years ,40,18 to 40 years old
NCT01928420,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",Completed,Alzheimer's Disease|Dementia,All,"40 Years to 95 Years   (Adult, Older Adult)",Phase 2,30,Interventional,April 2007,June 2014,https://ClinicalTrials.gov/show/NCT01928420,40 Years to 95 Years ,40,18 to 40 years old
NCT03116126,Noradrenergic Add-on Therapy With Guanfacine,Recruiting,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 3,160,Interventional,"January 4, 2019","March 31, 2021",https://ClinicalTrials.gov/show/NCT03116126,45 Years and older ,45,40 to 65 years old
NCT03011723,Tailored Music Therapy for Dementia,"Active, not recruiting","Alzheimer Dementia|Dementia, Vascular|Dementia, Lewy Body|Dementia Parkinson's Disease",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,10,Interventional,January 2017,April 2021,https://ClinicalTrials.gov/show/NCT03011723,45 Years and older ,45,40 to 65 years old
NCT00814801,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 3,580,Interventional,February 2007,September 2008,https://ClinicalTrials.gov/show/NCT00814801,45 Years and older ,45,40 to 65 years old
NCT03412604,Effect of Modulating Gamma Oscillations Using tACS,Recruiting,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,10,Interventional,"August 2, 2018","May 15, 2019",https://ClinicalTrials.gov/show/NCT03412604,45 Years and older ,45,40 to 65 years old
NCT01724151,Effects of Exercise Training in Patients With Mild Cognitive Impairment,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,April 2009,April 2012,https://ClinicalTrials.gov/show/NCT01724151,45 Years and older ,45,40 to 65 years old
NCT01993628,Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)),Unknown status,Alzheimer's Disease|Lewy Body's Dementia,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,October 2013,November 2016,https://ClinicalTrials.gov/show/NCT01993628,45 Years and older ,45,40 to 65 years old
NCT02414282,"F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)",Enrolling by invitation,Alzheimer Disease|Progressive Posterior Cortical Dysfunction (PPCD),All,"45 Years and older   (Adult, Older Adult)",Phase 2,25,Interventional,March 2015,September 2020,https://ClinicalTrials.gov/show/NCT02414282,45 Years and older ,45,40 to 65 years old
NCT00966017,"Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia",Unknown status,Down Syndrome|Alzheimer's Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 4,108,Observational,July 2009,February 2014,https://ClinicalTrials.gov/show/NCT00966017,45 Years and older ,45,40 to 65 years old
NCT01890343,"Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.",Completed,Alzheimer's Disease|Frontotemporal Dementia,All,"45 Years and older   (Adult, Older Adult)",Phase 2,34,Interventional,September 2009,April 2013,https://ClinicalTrials.gov/show/NCT01890343,45 Years and older ,45,40 to 65 years old
NCT01660815,A Study of Florbetapir (18F) in Japanese Healthy Volunteers,Completed,Alzheimer's Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 1,7,Interventional,August 2012,January 2013,https://ClinicalTrials.gov/show/NCT01660815,45 Years and older ,45,40 to 65 years old
NCT01779310,Clinical Pathway for Alzheimer's Disease in China (CPAD),Completed,Mild Cognitive Impairment|Alzheimer's Disease|Dementia,All,"45 Years and older   (Adult, Older Adult)",Phase 4,1024,Observational,November 2012,April 2013,https://ClinicalTrials.gov/show/NCT01779310,45 Years and older ,45,40 to 65 years old
NCT03702907,DC Longitudinal Study on Aging and Specimen Bank,Recruiting,Alzheimer Disease|Dementia|Mild Cognitive Impairment|Aging|Aging Disorder,All,"45 Years and older   (Adult, Older Adult)",Phase 4,1000,Observational,"January 1, 2007",January 2027,https://ClinicalTrials.gov/show/NCT03702907,45 Years and older ,45,40 to 65 years old
NCT00338117,"Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease",Completed,Alzheimer's Disease|Dementia,All,"45 Years and older   (Adult, Older Adult)",Phase 3,554,Interventional,August 1995,May 1997,https://ClinicalTrials.gov/show/NCT00338117,45 Years and older ,45,40 to 65 years old
NCT01315639,New Biomarker for Alzheimer's Disease Diagnostic,"Active, not recruiting",Alzheimer's Disease|Mild Cognitive Impairment,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,1067,Interventional,"September 3, 2010",February 2019,https://ClinicalTrials.gov/show/NCT01315639,45 Years and older ,45,40 to 65 years old
NCT02226835,Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198,Terminated,Age-Related Macular Degeneration|Alzheiner's Disease|AMD,All,"45 Years and older   (Adult, Older Adult)",Phase 4,33,Observational,"August 13, 2014","January 24, 2017",https://ClinicalTrials.gov/show/NCT02226835,45 Years and older ,45,40 to 65 years old
NCT03851523,Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Subjective Cognitive Decline,All,"45 Years and older   (Adult, Older Adult)",Phase 4,400,Observational,"February 12, 2018","December 31, 2021",https://ClinicalTrials.gov/show/NCT03851523,45 Years and older ,45,40 to 65 years old
NCT01876459,Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.,Unknown status,"""Alzheimer's Disease"" and ""Lewy Body Disease""",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,265,Interventional,April 2013,April 2015,https://ClinicalTrials.gov/show/NCT01876459,45 Years and older ,45,40 to 65 years old
NCT02213458,Care Ecosystem: Navigating Patients and Families Through Stages of Care,Completed,"Dementia|Alzheimer Disease|Dementia, Vascular|Lewy Body Disease|Frontotemporal Lobar Degeneration|Memory Disorders",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,780,Interventional,"March 20, 2015","March 8, 2018",https://ClinicalTrials.gov/show/NCT02213458,45 Years and older ,45,40 to 65 years old
NCT03880240,Gamma Induction for Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,55,Interventional,"August 5, 2019",November 2023,https://ClinicalTrials.gov/show/NCT03880240,45 Years and older ,45,40 to 65 years old
NCT00301574,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.,Completed,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 3,398,Interventional,April 2001,February 2004,https://ClinicalTrials.gov/show/NCT00301574,45 Years and older ,45,40 to 65 years old
NCT03290326,tACS for Amyloid-β Reduction in Alzheimer's Disease,Completed,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,17,Interventional,"November 27, 2017","May 14, 2019",https://ClinicalTrials.gov/show/NCT03290326,45 Years and older ,45,40 to 65 years old
NCT00955422,Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 4,197,Observational,"July 31, 2009","July 6, 2017",https://ClinicalTrials.gov/show/NCT00955422,45 Years and older ,45,40 to 65 years old
NCT00304629,Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease,Completed,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 3,241,Interventional,March 2000,March 2002,https://ClinicalTrials.gov/show/NCT00304629,45 Years and older ,45,40 to 65 years old
NCT01314950,Alzheimer's Disease Multiple Intervention Trial,Completed,Alzheimer's Disease,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,180,Interventional,July 2010,December 2015,https://ClinicalTrials.gov/show/NCT01314950,45 Years and older ,45,40 to 65 years old
NCT03998423,Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"45 Years and older   (Adult, Older Adult)",Phase 1,30,Interventional,October 2019,"May 31, 2022",https://ClinicalTrials.gov/show/NCT03998423,45 Years and older ,45,40 to 65 years old
NCT01142336,Effects of Simvastatin on Biomarkers,Completed,Alzheimer's Disease,All,45 Years to 64 Years   (Adult),Phase 4,49,Interventional,June 2010,October 2015,https://ClinicalTrials.gov/show/NCT01142336,45 Years to 64 Years ,45,40 to 65 years old
NCT02485730,Early Identification of Markers in Alzheimer's Families / ALFA,Recruiting,Alzheimer's Disease,All,45 Years to 64 Years   (Adult),Phase 4,400,Observational,"October 25, 2016",January 2024,https://ClinicalTrials.gov/show/NCT02485730,45 Years to 64 Years ,45,40 to 65 years old
NCT01723670,Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment,Withdrawn,Alzheimer's Disease,All,45 Years to 64 Years   (Adult),Phase 2,0,Interventional,December 2012,March 2016,https://ClinicalTrials.gov/show/NCT01723670,45 Years to 64 Years ,45,40 to 65 years old
NCT03411291,Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study,Completed,Alzheimer's Disease,All,"45 Years to 65 Years   (Adult, Older Adult)",Phase 4,18,Observational,April 2007,September 2010,https://ClinicalTrials.gov/show/NCT03411291,45 Years to 65 Years ,45,40 to 65 years old
NCT01777789,The Role of Mid-Life Adiposity in Functional Brain Connectivity,Terminated,Alzheimer's Disease,All,"45 Years to 65 Years   (Adult, Older Adult)",Phase 4,60,Observational,December 2012,February 2016,https://ClinicalTrials.gov/show/NCT01777789,45 Years to 65 Years ,45,40 to 65 years old
NCT03117829,Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial,Completed,PreDiabetes,All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"March 15, 2017","June 17, 2019",https://ClinicalTrials.gov/show/NCT03117829,45 Years to 65 Years ,45,40 to 65 years old
NCT02463084,Macronutrient Effects on Alzheimer's Disease (MEAL-2),Completed,Prediabetic State|Insulin Resistance|Middle Age|Prehypertension|Mild Cognitive Impairment,All,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,March 2013,June 2016,https://ClinicalTrials.gov/show/NCT02463084,45 Years to 65 Years ,45,40 to 65 years old
NCT03269149,Tango for Alzheimer's Disease Patients' Caregivers,Recruiting,Alzheimer's Disease,Female,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"September 19, 2017",July 2021,https://ClinicalTrials.gov/show/NCT03269149,45 Years to 65 Years ,45,40 to 65 years old
NCT02289118,Tau Imaging in Young Onset Dementia,Completed,"Alzheimer's Disease, Early Onset|Logopenic Progressive Aphasia|Posterior Cortical Atrophy (PCA)",All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 4,16,Observational,November 2014,"January 31, 2019",https://ClinicalTrials.gov/show/NCT02289118,45 Years to 70 Years ,45,40 to 65 years old
NCT03920826,Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease (TRANSFORM-AD),Recruiting,Alzheimer Disease,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,"September 11, 2019",December 2021,https://ClinicalTrials.gov/show/NCT03920826,45 Years to 75 Years ,45,40 to 65 years old
NCT03352739,Fornix and NbM as Targets of Stimulation In Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"December 1, 2017","December 1, 2020",https://ClinicalTrials.gov/show/NCT03352739,45 Years to 75 Years ,45,40 to 65 years old
NCT02393027,"Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999",Terminated,Idiopathic Parkinson Disease,All,"45 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,16,Interventional,March 2015,May 2017,https://ClinicalTrials.gov/show/NCT02393027,45 Years to 75 Years ,45,40 to 65 years old
NCT01835717,Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population,"Active, not recruiting",Healthy Individuals,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 4,2743,Observational,April 2013,December 2020,https://ClinicalTrials.gov/show/NCT01835717,45 Years to 75 Years ,45,40 to 65 years old
NCT02198586,"Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old",Completed,Alzheimer's Disease,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 4,575,Observational,April 2014,September 2015,https://ClinicalTrials.gov/show/NCT02198586,45 Years to 75 Years ,45,40 to 65 years old
NCT04088643,4Hz Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease,Not yet recruiting,Alzheimer Disease,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,October 2019,December 2021,https://ClinicalTrials.gov/show/NCT04088643,45 Years to 75 Years ,45,40 to 65 years old
NCT02685969,Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants,Recruiting,Alzheimer's Disease,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 4,440,Observational,"March 1, 2017","March 1, 2020",https://ClinicalTrials.gov/show/NCT02685969,45 Years to 75 Years ,45,40 to 65 years old
NCT02903862,Health-eBrain Study,Withdrawn,Depression and Burden in Caregivers,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,July 2016,July 2017,https://ClinicalTrials.gov/show/NCT02903862,45 Years to 75 Years ,45,40 to 65 years old
NCT03883633,Reversal of Cognitive Decline (ReCODE) Study,Recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"45 Years to 76 Years   (Adult, Older Adult)",Phase 4,30,Observational,"June 30, 2019","November 30, 2020",https://ClinicalTrials.gov/show/NCT03883633,45 Years to 76 Years ,45,40 to 65 years old
NCT02772523,Control and Intervention Programme on Alzheimer's Disease Risk Factors,"Active, not recruiting",Alzheimer's Disease,All,"45 Years to 78 Years   (Adult, Older Adult)",Not Applicable,409,Interventional,May 2016,May 2019,https://ClinicalTrials.gov/show/NCT02772523,45 Years to 78 Years ,45,40 to 65 years old
NCT01746498,Therapeutic Effect of Direct Current Stimulation on Cognitive Function of Mild to Moderate Alzheimer Patients,Completed,Alzheimer Disease,All,"45 Years to 79 Years   (Adult, Older Adult)",Not Applicable,33,Interventional,June 2011,November 2012,https://ClinicalTrials.gov/show/NCT01746498,45 Years to 79 Years ,45,40 to 65 years old
NCT03173846,Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease (NPAD),"Active, not recruiting",Alzheimer Disease,All,"45 Years to 79 Years   (Adult, Older Adult)",Phase 4,90,Observational,"May 5, 2017","October 31, 2019",https://ClinicalTrials.gov/show/NCT03173846,45 Years to 79 Years ,45,40 to 65 years old
NCT02002819,Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability,Recruiting,Alzheimer's Disease,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,36,Interventional,June 2014,December 2019,https://ClinicalTrials.gov/show/NCT02002819,45 Years to 80 Years ,45,40 to 65 years old
NCT02384993,aeRobic Exercise and Cognitive Health,Completed,Alzheimer's Disease|Aging,All,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,24,Interventional,January 2015,August 2016,https://ClinicalTrials.gov/show/NCT02384993,45 Years to 80 Years ,45,40 to 65 years old
NCT03699644,Multimodal Ocular Imaging in Neurodegeneration,Recruiting,Alzheimer Disease|Alzheimer Dementia|Frontotemporal Dementia,All,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Interventional,"January 4, 2019",December 2020,https://ClinicalTrials.gov/show/NCT03699644,45 Years to 80 Years ,45,40 to 65 years old
NCT03887481,Effects of tDCS on Verbal Short-term Memory in Neurodegenerative Disorders,Recruiting,Primary Progressive Aphasia|Mild Cognitive Impairment|Frontotemporal Dementia|Alzheimer Disease,All,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Interventional,"August 28, 2019",January 2026,https://ClinicalTrials.gov/show/NCT03887481,45 Years to 80 Years ,45,40 to 65 years old
NCT01403519,Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized,Unknown status,Alzheimer's Disease,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 4,70,Observational,July 2011,January 2014,https://ClinicalTrials.gov/show/NCT01403519,45 Years to 80 Years ,45,40 to 65 years old
NCT02227953,A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease,Unknown status,Alzheimer's Disease,All,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Interventional,August 2014,December 2014,https://ClinicalTrials.gov/show/NCT02227953,45 Years to 80 Years ,45,40 to 65 years old
NCT03918616,"P2X7 Receptor, Inflammation and Neurodegenerative Diseases",Completed,Neuro-Degenerative Disease,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 4,50,Observational,"February 20, 2017","March 30, 2019",https://ClinicalTrials.gov/show/NCT03918616,45 Years to 80 Years ,45,40 to 65 years old
NCT02119546,Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease,Completed,Mild CognitIve Impairment|Alzheimer's Disease,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,19,Interventional,May 2010,December 2012,https://ClinicalTrials.gov/show/NCT02119546,45 Years to 85 Years ,45,40 to 65 years old
NCT01608061,ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,50,Interventional,May 2012,September 2018,https://ClinicalTrials.gov/show/NCT01608061,45 Years to 85 Years ,45,40 to 65 years old
NCT01661673,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,52,Interventional,November 2012,,https://ClinicalTrials.gov/show/NCT01661673,45 Years to 85 Years ,45,40 to 65 years old
NCT01782248,Self-consciousness in Dementia,Recruiting,Alzheimer Disease|Fronto-temporal Lobar Dementia,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,65,Interventional,"March 13, 2013","March 12, 2020",https://ClinicalTrials.gov/show/NCT01782248,45 Years to 85 Years ,45,40 to 65 years old
NCT02910739,An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016),Completed,Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Interventional,"October 11, 2016","April 12, 2017",https://ClinicalTrials.gov/show/NCT02910739,45 Years to 85 Years ,45,40 to 65 years old
NCT04052737,PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease,Recruiting,Alzheimer Disease|Dementia,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,80,Interventional,"March 23, 2018",July 2020,https://ClinicalTrials.gov/show/NCT04052737,45 Years to 85 Years ,45,40 to 65 years old
NCT00006399,Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease,Completed,Alzheimer Disease,Female,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,45,Interventional,September 1999,March 2004,https://ClinicalTrials.gov/show/NCT00006399,45 Years to 85 Years ,45,40 to 65 years old
NCT01559220,Deep Brain Stimulation for the Treatment of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,3,Interventional,March 2012,January 2016,https://ClinicalTrials.gov/show/NCT01559220,45 Years to 85 Years ,45,40 to 65 years old
NCT03967535,Connectomics in Psychiatric Classification,Recruiting,Dementia|Dementia Alzheimers|Frontotemporal Dementia|Pick's Disease With Dementia,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 4,30,Observational,"December 1, 2018",January 2021,https://ClinicalTrials.gov/show/NCT03967535,45 Years to 85 Years ,45,40 to 65 years old
NCT02380573,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,Mild Cognitive Impairment|MCI|Aging|Alzheimer's Disease|AD,All,"45 Years to 89 Years   (Adult, Older Adult)",Phase 2,117,Interventional,July 2015,July 2023,https://ClinicalTrials.gov/show/NCT02380573,45 Years to 89 Years ,45,40 to 65 years old
NCT00679627,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 3,2051,Interventional,June 2008,May 2012,https://ClinicalTrials.gov/show/NCT00679627,45 Years to 90 Years ,45,40 to 65 years old
NCT00987090,Early-onset and Late-onset Sporadic Alzheimer's Disease (AD),Unknown status,Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Not Applicable,240,Interventional,October 2009,,https://ClinicalTrials.gov/show/NCT00987090,45 Years to 90 Years ,45,40 to 65 years old
NCT02778971,Implications for Management of PET Amyloid Classification Technology,Recruiting,Mild Cognitive Impairment|Dementia|Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 4,50,Observational,June 2016,June 2019,https://ClinicalTrials.gov/show/NCT02778971,45 Years to 90 Years ,45,40 to 65 years old
NCT02097056,Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 4,171,Interventional,February 2014,May 2015,https://ClinicalTrials.gov/show/NCT02097056,45 Years to 90 Years ,45,40 to 65 years old
NCT00890890,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 2,263,Interventional,May 2009,July 2013,https://ClinicalTrials.gov/show/NCT00890890,45 Years to 90 Years ,45,40 to 65 years old
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 3,1467,Interventional,June 2007,,https://ClinicalTrials.gov/show/NCT00478205,45 Years to 90 Years ,45,40 to 65 years old
NCT00104273,Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD),Completed,Dementia|Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 2,376,Interventional,August 2004,,https://ClinicalTrials.gov/show/NCT00104273,45 Years to 90 Years ,45,40 to 65 years old
NCT02550665,Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg,Completed,Alzheimer's Disease,All,"45 Years to 90 Years   (Adult, Older Adult)",Phase 3,176,Interventional,December 2014,October 2016,https://ClinicalTrials.gov/show/NCT02550665,45 Years to 90 Years ,45,40 to 65 years old
NCT00566501,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,"45 Years to 91 Years   (Adult, Older Adult)",Phase 3,915,Interventional,December 2007,August 2010,https://ClinicalTrials.gov/show/NCT00566501,45 Years to 91 Years ,45,40 to 65 years old
NCT00088751,Treatment Study of Frontotemporal Dementia,Completed,Frontotemporal Lobar Degeneration,All,"45 Years to 95 Years   (Adult, Older Adult)",Phase 4,20,Observational,"July 23, 2004","June 1, 2009",https://ClinicalTrials.gov/show/NCT00088751,45 Years to 95 Years ,45,40 to 65 years old
NCT03538574,Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers,Recruiting,Insomnia Chronic,All,"45 Years to 95 Years   (Adult, Older Adult)",Not Applicable,150,Interventional,"July 1, 2018","May 30, 2024",https://ClinicalTrials.gov/show/NCT03538574,45 Years to 95 Years ,45,40 to 65 years old
NCT01047579,"A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,51,Interventional,April 2010,January 2012,https://ClinicalTrials.gov/show/NCT01047579,50 Years and older ,50,40 to 65 years old
NCT03038334,Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease,Not yet recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,"February 20, 2017","October 20, 2019",https://ClinicalTrials.gov/show/NCT03038334,50 Years and older ,50,40 to 65 years old
NCT00556660,Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,20,Interventional,September 2007,July 2008,https://ClinicalTrials.gov/show/NCT00556660,50 Years and older ,50,40 to 65 years old
NCT01152216,An Extension of the CONCERT Protocol (DIM18),Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,672,Interventional,April 2010,,https://ClinicalTrials.gov/show/NCT01152216,50 Years and older ,50,40 to 65 years old
NCT00217763,European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients,Unknown status,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,930,Interventional,September 2005,December 2007,https://ClinicalTrials.gov/show/NCT00217763,50 Years and older ,50,40 to 65 years old
NCT01255046,Study of STA-1 as an Add-on Treatment to Donepezil,Unknown status,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,136,Interventional,December 2015,,https://ClinicalTrials.gov/show/NCT01255046,50 Years and older ,50,40 to 65 years old
NCT00857649,Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,369,Interventional,December 2003,September 2010,https://ClinicalTrials.gov/show/NCT00857649,50 Years and older ,50,40 to 65 years old
NCT01504854,Resveratrol for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,119,Interventional,May 2012,March 2014,https://ClinicalTrials.gov/show/NCT01504854,50 Years and older ,50,40 to 65 years old
NCT01594346,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Completed,Alzheimer's Disease|Down Syndrome,All,"50 Years and older   (Adult, Older Adult)",Phase 3,349,Interventional,September 2000,April 2010,https://ClinicalTrials.gov/show/NCT01594346,50 Years and older ,50,40 to 65 years old
NCT01707719,Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Alzheimer's Disease,Recruiting,Alzheimer Disease|Oxidative Stress|Adrenocortical Hyperfunction,All,"50 Years and older   (Adult, Older Adult)",Phase 4,50,Observational,June 2015,September 2018,https://ClinicalTrials.gov/show/NCT01707719,50 Years and older ,50,40 to 65 years old
NCT00480701,Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease,Completed,Alzheimer Disease|Parkinson Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,26,Interventional,February 2007,October 2011,https://ClinicalTrials.gov/show/NCT00480701,50 Years and older ,50,40 to 65 years old
NCT00606164,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease",Unknown status,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,9,Interventional,April 2008,December 2008,https://ClinicalTrials.gov/show/NCT00606164,50 Years and older ,50,40 to 65 years old
NCT00104013,Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1455,Interventional,November 2003,November 2007,https://ClinicalTrials.gov/show/NCT00104013,50 Years and older ,50,40 to 65 years old
NCT00056329,Vitamin E in Aging Persons With Down Syndrome,Unknown status,Down Syndrome|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,350,Interventional,April 2002,May 2012,https://ClinicalTrials.gov/show/NCT00056329,50 Years and older ,50,40 to 65 years old
NCT00103649,18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1306,Interventional,November 2003,October 2007,https://ClinicalTrials.gov/show/NCT00103649,50 Years and older ,50,40 to 65 years old
NCT03019536,A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,"January 31, 2017","June 5, 2019",https://ClinicalTrials.gov/show/NCT03019536,50 Years and older ,50,40 to 65 years old
NCT02017340,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,511,Interventional,"April 24, 2013","December 16, 2016",https://ClinicalTrials.gov/show/NCT02017340,50 Years and older ,50,40 to 65 years old
NCT00702143,"A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Phase 2,184,Interventional,June 2008,December 2008,https://ClinicalTrials.gov/show/NCT00702143,50 Years and older ,50,40 to 65 years old
NCT01297140,"The PACO Study (""Personnalité Alzheimer COmportement"")",Unknown status,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,252,Interventional,January 2009,November 2015,https://ClinicalTrials.gov/show/NCT01297140,50 Years and older ,50,40 to 65 years old
NCT00322153,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,Completed,Dementia of the Alzheimer's Type,All,"50 Years and older   (Adult, Older Adult)",Phase 3,677,Interventional,June 2005,January 2008,https://ClinicalTrials.gov/show/NCT00322153,50 Years and older ,50,40 to 65 years old
NCT00216502,A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease,Completed,Alzheimer Disease|Dementia|Mental Disorders|Brain Diseases,All,"50 Years and older   (Adult, Older Adult)",Phase 3,254,Interventional,August 2001,November 2005,https://ClinicalTrials.gov/show/NCT00216502,50 Years and older ,50,40 to 65 years old
NCT03672201,Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia,Recruiting,Alzheimer's Disease|Alzheimer Dementia (AD)|Aggression,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,220,Interventional,"November 1, 2018",April 2020,https://ClinicalTrials.gov/show/NCT03672201,50 Years and older ,50,40 to 65 years old
NCT01539031,Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease,Completed,Alzheimer's Type Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 3,351,Interventional,March 2012,March 2015,https://ClinicalTrials.gov/show/NCT01539031,50 Years and older ,50,40 to 65 years old
NCT00857233,Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,297,Interventional,June 2004,October 2010,https://ClinicalTrials.gov/show/NCT00857233,50 Years and older ,50,40 to 65 years old
NCT00711139,Long-term Safety and Tolerability of AFFITOPE AD01,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,22,Observational,June 2008,November 2009,https://ClinicalTrials.gov/show/NCT00711139,50 Years and older ,50,40 to 65 years old
NCT00096473,Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease,Completed,Alzheimer's Disease|Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 3,229,Interventional,January 2001,September 2005,https://ClinicalTrials.gov/show/NCT00096473,50 Years and older ,50,40 to 65 years old
NCT01841125,Escitalopram for the Treatment of Depression in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,84,Interventional,November 2011,July 2014,https://ClinicalTrials.gov/show/NCT01841125,50 Years and older ,50,40 to 65 years old
NCT00829816,"Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,46,Interventional,December 2008,August 2010,https://ClinicalTrials.gov/show/NCT00829816,50 Years and older ,50,40 to 65 years old
NCT01696123,Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,125,Interventional,January 2011,August 2012,https://ClinicalTrials.gov/show/NCT01696123,50 Years and older ,50,40 to 65 years old
NCT03846492,Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS,Recruiting,"Alzheimer Disease|Dementia, Mixed|Dementia|Behavior Problem|Dementia, Alzheimer Type",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,90,Interventional,"April 24, 2019",June 2022,https://ClinicalTrials.gov/show/NCT03846492,50 Years and older ,50,40 to 65 years old
NCT03399591,Gait Disorders in Patients With Cognitive Decline,Recruiting,"Gait Disorders, Neurologic",All,"50 Years and older   (Adult, Older Adult)",Phase 4,100,Observational,"May 2, 2017",March 2019,https://ClinicalTrials.gov/show/NCT03399591,50 Years and older ,50,40 to 65 years old
NCT00287248,Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,38,Interventional,February 2006,March 2008,https://ClinicalTrials.gov/show/NCT00287248,50 Years and older ,50,40 to 65 years old
NCT02080364,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,880,Interventional,April 2015,"June 1, 2018",https://ClinicalTrials.gov/show/NCT02080364,50 Years and older ,50,40 to 65 years old
NCT03656107,The Cognition and Flow Study,Recruiting,Dementia|Alzheimer Disease|Mild Cognitive Impairment|Aging|Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"January 14, 2019","April 2, 2020",https://ClinicalTrials.gov/show/NCT03656107,50 Years and older ,50,40 to 65 years old
NCT01066546,An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,5,Interventional,April 2010,July 2010,https://ClinicalTrials.gov/show/NCT01066546,50 Years and older ,50,40 to 65 years old
NCT02992132,Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE),Terminated,Agitation and Aggression in Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,111,Interventional,November 2016,"February 16, 2018",https://ClinicalTrials.gov/show/NCT02992132,50 Years and older ,50,40 to 65 years old
NCT04118764,Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound,Not yet recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,6,Interventional,October 2019,July 2020,https://ClinicalTrials.gov/show/NCT04118764,50 Years and older ,50,40 to 65 years old
NCT00120874,"Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,20,Interventional,August 2006,November 2011,https://ClinicalTrials.gov/show/NCT00120874,50 Years and older ,50,40 to 65 years old
NCT03661034,"Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)",Recruiting,"Alzheimer Disease, Early Onset|Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Memory Disorders|Memory Loss|Memory Impairment|Memory Disorders, Age Related|Alzheimer Disease, Late Onset|Cognitive Impairment|Dementia, Mild|Dementia, Alzheimer Type|Cognitive Decline",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"May 31, 2018","November 1, 2019",https://ClinicalTrials.gov/show/NCT03661034,50 Years and older ,50,40 to 65 years old
NCT00216515,The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,102,Interventional,March 2004,November 2005,https://ClinicalTrials.gov/show/NCT00216515,50 Years and older ,50,40 to 65 years old
NCT03118947,A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease,Completed,Agitation and Aggression in Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,79,Interventional,"February 23, 2017","February 25, 2019",https://ClinicalTrials.gov/show/NCT03118947,50 Years and older ,50,40 to 65 years old
NCT00088673,Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease,Unknown status,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,950,Interventional,June 2004,,https://ClinicalTrials.gov/show/NCT00088673,50 Years and older ,50,40 to 65 years old
NCT00488670,Escitalopram and Depression in Elderly Alzheimer's Patients,Terminated,Depressive Disorder,All,"50 Years and older   (Adult, Older Adult)",Phase 3,50,Interventional,December 2010,June 2011,https://ClinicalTrials.gov/show/NCT00488670,50 Years and older ,50,40 to 65 years old
NCT02958670,Imaging Tau Deposition in the Brain of Elderly Subjects,Enrolling by invitation,Mild Cognitive Impairment|Healthy|Alzheimer Disease|Neurocognitive Disorders,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,November 2016,November 2023,https://ClinicalTrials.gov/show/NCT02958670,50 Years and older ,50,40 to 65 years old
NCT01962779,"Sleep, Aging and Risk for Alzheimer's Disease","Active, not recruiting",Sleep Disordered Breathing|Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,224,Interventional,"July 31, 2013","December 30, 2019",https://ClinicalTrials.gov/show/NCT01962779,50 Years and older ,50,40 to 65 years old
NCT02249468,An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population,Terminated,Mild and Moderate Alzheimer's Disease|Cognitively Healthy People,All,"50 Years and older   (Adult, Older Adult)",Phase 4,191,Observational,October 2014,November 2016,https://ClinicalTrials.gov/show/NCT02249468,50 Years and older ,50,40 to 65 years old
NCT00626210,Modafinil Treatment for Sleep/Wake Disturbances in Older Adults,Terminated,Insomnia|Sleep Initiation and Maintenance Disorders|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,2,Interventional,February 2008,October 2012,https://ClinicalTrials.gov/show/NCT00626210,50 Years and older ,50,40 to 65 years old
NCT03328195,Vielight Neuro RX Gamma - Feasibility Pilot,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"December 4, 2017",November 2019,https://ClinicalTrials.gov/show/NCT03328195,50 Years and older ,50,40 to 65 years old
NCT01019421,Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,278,Interventional,December 2009,,https://ClinicalTrials.gov/show/NCT01019421,50 Years and older ,50,40 to 65 years old
NCT02727699,"A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)",Completed,"Dementia, Alzheimer Type",All,"50 Years and older   (Adult, Older Adult)",Phase 2,186,Interventional,"March 23, 2017","March 15, 2019",https://ClinicalTrials.gov/show/NCT02727699,50 Years and older ,50,40 to 65 years old
NCT00051909,Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,200,Interventional,November 2002,June 2003,https://ClinicalTrials.gov/show/NCT00051909,50 Years and older ,50,40 to 65 years old
NCT01662882,"A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,48,Interventional,October 2012,February 2013,https://ClinicalTrials.gov/show/NCT01662882,50 Years and older ,50,40 to 65 years old
NCT00829374,Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1003,Interventional,March 2009,December 2011,https://ClinicalTrials.gov/show/NCT00829374,50 Years and older ,50,40 to 65 years old
NCT01503944,A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET),Completed,Dementia With Lewy Bodies|Alzheimer's Disease|Parkinson's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30,Interventional,March 2010,July 2011,https://ClinicalTrials.gov/show/NCT01503944,50 Years and older ,50,40 to 65 years old
NCT02663531,Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease,Recruiting,Mild Cognitive Impairment|Alzheimer Disease|Healthy,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150,Interventional,"September 27, 2016",September 2019,https://ClinicalTrials.gov/show/NCT02663531,50 Years and older ,50,40 to 65 years old
NCT00675623,A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,598,Interventional,May 2008,,https://ClinicalTrials.gov/show/NCT00675623,50 Years and older ,50,40 to 65 years old
NCT03405662,Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,16,Interventional,"August 16, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03405662,50 Years and older ,50,40 to 65 years old
NCT02884492,Imaging Tau in Alzheimer's Disease and Normal Aging,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,17,Interventional,July 2016,"June 30, 2017",https://ClinicalTrials.gov/show/NCT02884492,50 Years and older ,50,40 to 65 years old
NCT00749216,Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,33,Interventional,September 2008,July 2009,https://ClinicalTrials.gov/show/NCT00749216,50 Years and older ,50,40 to 65 years old
NCT00230568,EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,100,Interventional,December 2005,December 2007,https://ClinicalTrials.gov/show/NCT00230568,50 Years and older ,50,40 to 65 years old
NCT00804271,Memantine and Validation of a New Alzheimer's Disease Scale,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,487,Interventional,December 2008,November 2009,https://ClinicalTrials.gov/show/NCT00804271,50 Years and older ,50,40 to 65 years old
NCT00377715,"Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,183,Interventional,September 2005,,https://ClinicalTrials.gov/show/NCT00377715,50 Years and older ,50,40 to 65 years old
NCT00380302,Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,162,Interventional,September 2006,July 2007,https://ClinicalTrials.gov/show/NCT00380302,50 Years and older ,50,40 to 65 years old
NCT01565382,Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI),Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,February 2011,February 2011,https://ClinicalTrials.gov/show/NCT01565382,50 Years and older ,50,40 to 65 years old
NCT03926702,Tau Imaging With JNJ067,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Progressive Supranuclear Palsy,All,"50 Years and older   (Adult, Older Adult)",Early Phase 1,18,Interventional,"June 18, 2019",January 2021,https://ClinicalTrials.gov/show/NCT03926702,50 Years and older ,50,40 to 65 years old
NCT03424200,Coaching for Cognition in Alzheimer's (COCOA),Recruiting,Alzheimer Disease|Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,"November 1, 2017","November 1, 2022",https://ClinicalTrials.gov/show/NCT03424200,50 Years and older ,50,40 to 65 years old
NCT00605046,Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects,Terminated,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,1,Interventional,August 2007,June 2008,https://ClinicalTrials.gov/show/NCT00605046,50 Years and older ,50,40 to 65 years old
NCT02624778,A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,61,Interventional,"December 22, 2015","August 28, 2019",https://ClinicalTrials.gov/show/NCT02624778,50 Years and older ,50,40 to 65 years old
NCT00954538,"Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,19,Interventional,August 2009,May 2011,https://ClinicalTrials.gov/show/NCT00954538,50 Years and older ,50,40 to 65 years old
NCT00024531,Lipitor as a Treatment for Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,98,Interventional,October 2000,August 2004,https://ClinicalTrials.gov/show/NCT00024531,50 Years and older ,50,40 to 65 years old
NCT00285025,Study of the Effect of SR57667B in Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,500,Interventional,March 2005,September 2005,https://ClinicalTrials.gov/show/NCT00285025,50 Years and older ,50,40 to 65 years old
NCT00842673,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,168,Interventional,February 2009,September 2010,https://ClinicalTrials.gov/show/NCT00842673,50 Years and older ,50,40 to 65 years old
NCT00453544,Enhancing Consent for Alzheimer's Research,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,252,Interventional,April 2006,September 2012,https://ClinicalTrials.gov/show/NCT00453544,50 Years and older ,50,40 to 65 years old
NCT01565291,A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Early Phase 1,32,Interventional,June 2007,January 2008,https://ClinicalTrials.gov/show/NCT01565291,50 Years and older ,50,40 to 65 years old
NCT00711321,Long-term Safety and Tolerability of AFFITOPE AD02,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,23,Observational,November 2008,April 2010,https://ClinicalTrials.gov/show/NCT00711321,50 Years and older ,50,40 to 65 years old
NCT01843075,Evaluating Liraglutide in Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,204,Interventional,January 2014,December 2019,https://ClinicalTrials.gov/show/NCT01843075,50 Years and older ,50,40 to 65 years old
NCT00715858,A Pilot Study of Inflammatory Markers in Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,21,Interventional,May 2008,October 2009,https://ClinicalTrials.gov/show/NCT00715858,50 Years and older ,50,40 to 65 years old
NCT00692588,MRI to Measure Treatment With Antibiotics in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,58,Observational,June 2008,June 2010,https://ClinicalTrials.gov/show/NCT00692588,50 Years and older ,50,40 to 65 years old
NCT01723826,A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,360,Interventional,"December 7, 2012","February 8, 2017",https://ClinicalTrials.gov/show/NCT01723826,50 Years and older ,50,40 to 65 years old
NCT00285077,Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,390,Interventional,March 2004,November 2006,https://ClinicalTrials.gov/show/NCT00285077,50 Years and older ,50,40 to 65 years old
NCT00236431,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,Completed,Dementia|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1063,Interventional,May 2001,December 2003,https://ClinicalTrials.gov/show/NCT00236431,50 Years and older ,50,40 to 65 years old
NCT00622713,"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,228,Interventional,January 2008,January 2009,https://ClinicalTrials.gov/show/NCT00622713,50 Years and older ,50,40 to 65 years old
NCT00889603,Non-Interventional Study With Aricept® Evess,Completed,Alzheimer's Disease|Vascular Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 4,370,Observational,May 2009,March 2010,https://ClinicalTrials.gov/show/NCT00889603,50 Years and older ,50,40 to 65 years old
NCT00867828,Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE),Completed,Early Onset Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,175,Interventional,May 2009,January 2011,https://ClinicalTrials.gov/show/NCT00867828,50 Years and older ,50,40 to 65 years old
NCT00154635,Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease,Unknown status,"Dementia, Alzheimer Type",All,"50 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,September 2005,,https://ClinicalTrials.gov/show/NCT00154635,50 Years and older ,50,40 to 65 years old
NCT00982202,Pioglitazone in Alzheimer Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,25,Interventional,January 2002,January 2005,https://ClinicalTrials.gov/show/NCT00982202,50 Years and older ,50,40 to 65 years old
NCT01009255,Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,196,Interventional,"November 2, 2009","November 10, 2010",https://ClinicalTrials.gov/show/NCT01009255,50 Years and older ,50,40 to 65 years old
NCT03447613,Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,86,Observational,"August 1, 2013","December 31, 2014",https://ClinicalTrials.gov/show/NCT03447613,50 Years and older ,50,40 to 65 years old
NCT01420315,The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,502,Observational,August 2011,August 2012,https://ClinicalTrials.gov/show/NCT01420315,50 Years and older ,50,40 to 65 years old
NCT03744312,Imaging Inflammation in Alzheimer's Disease With 11C-ER176,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50,Interventional,"September 10, 2018","July 20, 2021",https://ClinicalTrials.gov/show/NCT03744312,50 Years and older ,50,40 to 65 years old
NCT01992380,A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,November 2013,May 2014,https://ClinicalTrials.gov/show/NCT01992380,50 Years and older ,50,40 to 65 years old
NCT00053599,Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,400,Interventional,December 2002,October 2007,https://ClinicalTrials.gov/show/NCT00053599,50 Years and older ,50,40 to 65 years old
NCT01009476,Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine,Completed,"Dementia|Alzheimer Disease|Dementia, Vascular",All,"50 Years and older   (Adult, Older Adult)",Phase 4,1134,Observational,March 2006,August 2008,https://ClinicalTrials.gov/show/NCT01009476,50 Years and older ,50,40 to 65 years old
NCT03657745,Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Dementia|Cognition Disorders in Old Age|Cognitive Decline|Cognitive Deterioration,All,"50 Years and older   (Adult, Older Adult)",Phase 4,2000,Observational,"January 1, 2018","December 31, 2023",https://ClinicalTrials.gov/show/NCT03657745,50 Years and older ,50,40 to 65 years old
NCT01230853,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,80,Interventional,August 2010,February 2013,https://ClinicalTrials.gov/show/NCT01230853,50 Years and older ,50,40 to 65 years old
NCT02264899,MEMENTO-VAScular COmponents of Dementia,"Active, not recruiting",Alzheimer's Disease (AD)|Alzheimer's Disease (AD) Related Disorders,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,350,Interventional,"November 4, 2014",December 2020,https://ClinicalTrials.gov/show/NCT02264899,50 Years and older ,50,40 to 65 years old
NCT00857506,Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45),Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Phase 2,152,Interventional,January 2009,December 2011,https://ClinicalTrials.gov/show/NCT00857506,50 Years and older ,50,40 to 65 years old
NCT00277810,"Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease",Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,250,Interventional,March 2006,June 2008,https://ClinicalTrials.gov/show/NCT00277810,50 Years and older ,50,40 to 65 years old
NCT01872598,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,721,Interventional,January 2012,December 2019,https://ClinicalTrials.gov/show/NCT01872598,50 Years and older ,50,40 to 65 years old
NCT02646982,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Recruiting,Mild Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Phase 2,72,Interventional,June 2016,September 2021,https://ClinicalTrials.gov/show/NCT02646982,50 Years and older ,50,40 to 65 years old
NCT02516046,18F-AV-1451 Autopsy Study,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,156,Interventional,September 2015,"July 15, 2018",https://ClinicalTrials.gov/show/NCT02516046,50 Years and older ,50,40 to 65 years old
NCT00842816,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,210,Interventional,February 2009,May 2011,https://ClinicalTrials.gov/show/NCT00842816,50 Years and older ,50,40 to 65 years old
NCT02795780,Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,79,Interventional,August 2016,"August 28, 2017",https://ClinicalTrials.gov/show/NCT02795780,50 Years and older ,50,40 to 65 years old
NCT00838110,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,742,Interventional,February 2009,January 2010,https://ClinicalTrials.gov/show/NCT00838110,50 Years and older ,50,40 to 65 years old
NCT01238458,"Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers",Unknown status,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,150,Interventional,November 2009,June 2013,https://ClinicalTrials.gov/show/NCT01238458,50 Years and older ,50,40 to 65 years old
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,933,Interventional,October 2013,July 2016,https://ClinicalTrials.gov/show/NCT01955161,50 Years and older ,50,40 to 65 years old
NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,734,Interventional,March 2014,January 2017,https://ClinicalTrials.gov/show/NCT02006654,50 Years and older ,50,40 to 65 years old
NCT01082965,Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,18,Interventional,July 2010,July 2012,https://ClinicalTrials.gov/show/NCT01082965,50 Years and older ,50,40 to 65 years old
NCT02079246,Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1463,Interventional,"April 7, 2014","July 6, 2017",https://ClinicalTrials.gov/show/NCT02079246,50 Years and older ,50,40 to 65 years old
NCT01921972,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,232,Interventional,November 2004,May 2009,https://ClinicalTrials.gov/show/NCT01921972,50 Years and older ,50,40 to 65 years old
NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,858,Interventional,February 2014,December 2016,https://ClinicalTrials.gov/show/NCT02006641,50 Years and older ,50,40 to 65 years old
NCT01734395,A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,1882,Observational,March 2007,January 2008,https://ClinicalTrials.gov/show/NCT01734395,50 Years and older ,50,40 to 65 years old
NCT00236574,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,Completed,Dementia|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,974,Interventional,May 2001,November 2003,https://ClinicalTrials.gov/show/NCT00236574,50 Years and older ,50,40 to 65 years old
NCT00469456,Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,265,Interventional,April 2007,November 2008,https://ClinicalTrials.gov/show/NCT00469456,50 Years and older ,50,40 to 65 years old
NCT00843115,Observational Study Of Donepezil In Routine Clinical Practice,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,370,Observational,February 2007,April 2008,https://ClinicalTrials.gov/show/NCT00843115,50 Years and older ,50,40 to 65 years old
NCT00141661,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,67,Interventional,October 2005,June 2006,https://ClinicalTrials.gov/show/NCT00141661,50 Years and older ,50,40 to 65 years old
NCT03239561,Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Early Phase 1,15,Interventional,"September 6, 2017","April 30, 2018",https://ClinicalTrials.gov/show/NCT03239561,50 Years and older ,50,40 to 65 years old
NCT03670615,Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia,Recruiting,Mild Cognitive Impairment|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,"November 28, 2018",August 2021,https://ClinicalTrials.gov/show/NCT03670615,50 Years and older ,50,40 to 65 years old
NCT00722046,Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,198,Interventional,December 2008,August 2011,https://ClinicalTrials.gov/show/NCT00722046,50 Years and older ,50,40 to 65 years old
NCT00551161,Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,12,Interventional,August 2007,December 2011,https://ClinicalTrials.gov/show/NCT00551161,50 Years and older ,50,40 to 65 years old
NCT03402503,"Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,70,Interventional,"November 26, 2018","October 19, 2020",https://ClinicalTrials.gov/show/NCT03402503,50 Years and older ,50,40 to 65 years old
NCT01421420,Alzheimer's Disease Core Center,Recruiting,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Memory Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 4,900,Observational,July 2001,July 2025,https://ClinicalTrials.gov/show/NCT01421420,50 Years and older ,50,40 to 65 years old
NCT00097916,An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,34,Interventional,September 2004,April 2006,https://ClinicalTrials.gov/show/NCT00097916,50 Years and older ,50,40 to 65 years old
NCT03634007,Gene Therapy for APOE4 Homozygote of Alzheimer's Disease,Recruiting,Alzheimer Disease|Early Onset Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,15,Interventional,September 2019,December 2021,https://ClinicalTrials.gov/show/NCT03634007,50 Years and older ,50,40 to 65 years old
NCT03295110,Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases,Unknown status,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"February 13, 2018",September 2019,https://ClinicalTrials.gov/show/NCT03295110,50 Years and older ,50,40 to 65 years old
NCT00479843,Nutritional Programme for Dementia Elderly Patient,Completed,Alzheimer's Disease|Dementia,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,946,Interventional,July 2005,July 2007,https://ClinicalTrials.gov/show/NCT00479843,50 Years and older ,50,40 to 65 years old
NCT01481558,Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease,Completed,Apathy|Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,40,Interventional,January 2012,May 2012,https://ClinicalTrials.gov/show/NCT01481558,50 Years and older ,50,40 to 65 years old
NCT03666624,Socially Isolated Older Adults Living With Dementia,Not yet recruiting,Alzheimer Disease|Dementia,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,"May 30, 2019","September 1, 2019",https://ClinicalTrials.gov/show/NCT03666624,50 Years and older ,50,40 to 65 years old
NCT00239759,MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,2000,Observational,September 2002,June 2008,https://ClinicalTrials.gov/show/NCT00239759,50 Years and older ,50,40 to 65 years old
NCT04118985,Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease,Enrolling by invitation,Cognitive Symptom|Pre Senile Dementia|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,"October 10, 2019","October 30, 2020",https://ClinicalTrials.gov/show/NCT04118985,50 Years and older ,50,40 to 65 years old
NCT03550131,Innovations in Dementia Empowerment and Action,Recruiting,Alzheimer Disease|Dementia,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,225,Interventional,"December 5, 2018","May 31, 2022",https://ClinicalTrials.gov/show/NCT03550131,50 Years and older ,50,40 to 65 years old
NCT03307993,Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,3,Interventional,"September 22, 2017","February 19, 2018",https://ClinicalTrials.gov/show/NCT03307993,50 Years and older ,50,40 to 65 years old
NCT00657813,Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition,Terminated,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,3,Interventional,March 2008,"September 30, 2008",https://ClinicalTrials.gov/show/NCT00657813,50 Years and older ,50,40 to 65 years old
NCT02955706,Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,328,Interventional,April 2016,February 2019,https://ClinicalTrials.gov/show/NCT02955706,50 Years and older ,50,40 to 65 years old
NCT02804789,European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS),Recruiting,Alzheimer's Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 4,6000,Observational,May 2016,"June 30, 2020",https://ClinicalTrials.gov/show/NCT02804789,50 Years and older ,50,40 to 65 years old
NCT03117738,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,"Active, not recruiting",Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21,Interventional,"April 3, 2017",September 2019,https://ClinicalTrials.gov/show/NCT03117738,50 Years and older ,50,40 to 65 years old
NCT03454646,Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL),Not yet recruiting,Alzheimer Disease|Cholinesterase Inhibitors,All,"50 Years and older   (Adult, Older Adult)",Phase 4,1205,Interventional,"March 15, 2018","September 15, 2021",https://ClinicalTrials.gov/show/NCT03454646,50 Years and older ,50,40 to 65 years old
NCT03384069,CBT for African Americans With Cognitive Impairment,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"January 10, 2018","March 31, 2020",https://ClinicalTrials.gov/show/NCT03384069,50 Years and older ,50,40 to 65 years old
NCT03430648,Is Tau Protein Linked to Mobility Function?,Enrolling by invitation,Alzheimer Disease|Physical Activity,All,"50 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,"September 7, 2017",June 2020,https://ClinicalTrials.gov/show/NCT03430648,50 Years and older ,50,40 to 65 years old
NCT01153607,Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers,Completed,Diagnostic Imaging,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,June 2010,October 2011,https://ClinicalTrials.gov/show/NCT01153607,50 Years and older ,50,40 to 65 years old
NCT01009359,"Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",Completed,Diagnostic Imaging,All,"50 Years and older   (Adult, Older Adult)",Phase 1,22,Interventional,October 2009,October 2010,https://ClinicalTrials.gov/show/NCT01009359,50 Years and older ,50,40 to 65 years old
NCT02854917,"Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome",Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,20,Observational,July 2016,"January 5, 2018",https://ClinicalTrials.gov/show/NCT02854917,50 Years and older ,50,40 to 65 years old
NCT02987842,Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease,Unknown status,Mild Cognitive Impairment|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,December 2016,December 2017,https://ClinicalTrials.gov/show/NCT02987842,50 Years and older ,50,40 to 65 years old
NCT03709238,Pain Processing and Pain Reporting in Patients With Alzheimer's Disease,Recruiting,Pain,All,"50 Years and older   (Adult, Older Adult)",Phase 4,50,Observational,"January 3, 2019","August 31, 2021",https://ClinicalTrials.gov/show/NCT03709238,50 Years and older ,50,40 to 65 years old
NCT02654574,"Comparison of Two Modes of Administration of the IADL Questionnaire, Assessing the Level of Functional Autonomy of Patients to Carry Out the Tasks of Daily Living: Randomized Controlled Trial Among Patients of a Memory Clinic",Completed,Alzheimer's Disease|Dementia Disorders,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,299,Interventional,June 2014,April 2016,https://ClinicalTrials.gov/show/NCT02654574,50 Years and older ,50,40 to 65 years old
NCT00711204,Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease,Withdrawn,Severe Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,0,Interventional,January 2008,,https://ClinicalTrials.gov/show/NCT00711204,50 Years and older ,50,40 to 65 years old
NCT01125631,Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,8,Interventional,May 2010,August 2011,https://ClinicalTrials.gov/show/NCT01125631,50 Years and older ,50,40 to 65 years old
NCT00561392,Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,208,Interventional,November 2007,November 2008,https://ClinicalTrials.gov/show/NCT00561392,50 Years and older ,50,40 to 65 years old
NCT01066481,A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease,Withdrawn,Alzheimer's Disease|Dementia|Dimebon|Investigational Drug,All,"50 Years and older   (Adult, Older Adult)",Phase 2,0,Interventional,April 2010,April 2012,https://ClinicalTrials.gov/show/NCT01066481,50 Years and older ,50,40 to 65 years old
NCT00954590,A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease,Terminated,Moderate to Severe Alzheimer,All,"50 Years and older   (Adult, Older Adult)",Phase 3,89,Interventional,October 2009,,https://ClinicalTrials.gov/show/NCT00954590,50 Years and older ,50,40 to 65 years old
NCT00838942,Life From Vision in Alzheimer Disease,Completed,Alzheimer Disease|Cataract,All,"50 Years and older   (Adult, Older Adult)",Phase 4,80,Observational,December 2004,April 2011,https://ClinicalTrials.gov/show/NCT00838942,50 Years and older ,50,40 to 65 years old
NCT02553928,Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer,Completed,Alzheimer Dementia (AD),All,"50 Years and older   (Adult, Older Adult)",Phase 4,62,Interventional,October 2015,July 2016,https://ClinicalTrials.gov/show/NCT02553928,50 Years and older ,50,40 to 65 years old
NCT03138018,Aging Stereotypes and Prodromal Alzheimer's Disease,Recruiting,Mild Cognitive Impairment (MCI),All,"50 Years and older   (Adult, Older Adult)",Not Applicable,260,Interventional,"July 6, 2018","July 1, 2023",https://ClinicalTrials.gov/show/NCT03138018,50 Years and older ,50,40 to 65 years old
NCT03095417,Improving the Recovery and Outcome Every Day After the ICU,Recruiting,Delirium|Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,344,Interventional,"September 25, 2017","June 1, 2023",https://ClinicalTrials.gov/show/NCT03095417,50 Years and older ,50,40 to 65 years old
NCT00703430,Memantine on Aggression and Agitation of Alzheimer's Disease (AD),Unknown status,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,50,Interventional,March 2008,June 2014,https://ClinicalTrials.gov/show/NCT00703430,50 Years and older ,50,40 to 65 years old
NCT00403520,Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,240,Interventional,November 2006,August 2010,https://ClinicalTrials.gov/show/NCT00403520,50 Years and older ,50,40 to 65 years old
NCT01276353,A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia,Completed,Alzheimer's Type Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 2,45,Interventional,January 2011,April 2012,https://ClinicalTrials.gov/show/NCT01276353,50 Years and older ,50,40 to 65 years old
NCT01822951,Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT),Withdrawn,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,0,Interventional,,December 2016,https://ClinicalTrials.gov/show/NCT01822951,50 Years and older ,50,40 to 65 years old
NCT00544453,Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC,Terminated,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,2,Interventional,October 2007,July 2008,https://ClinicalTrials.gov/show/NCT00544453,50 Years and older ,50,40 to 65 years old
NCT02051764,Imaging Characteristics of a Follow-up 18F-AV-1451 Scan,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,38,Interventional,May 2014,December 2016,https://ClinicalTrials.gov/show/NCT02051764,50 Years and older ,50,40 to 65 years old
NCT03081533,Circle Dance for Family Caregivers of the Elderly With Alzheimer.,Recruiting,Family Caregiver,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,"September 6, 2017",July 2019,https://ClinicalTrials.gov/show/NCT03081533,50 Years and older ,50,40 to 65 years old
NCT00855686,Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies,Completed,Parkinson's Disease Dementia|Dementia With Lewy Bodies,All,"50 Years and older   (Adult, Older Adult)",Phase 4,199,Interventional,January 2007,January 2009,https://ClinicalTrials.gov/show/NCT00855686,50 Years and older ,50,40 to 65 years old
NCT00596284,Cognitive Behavior Therapy for Treating Anxiety in People With Dementia,Completed,Anxiety Disorders|Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 1,34,Interventional,January 2008,June 2010,https://ClinicalTrials.gov/show/NCT00596284,50 Years and older ,50,40 to 65 years old
NCT00884507,A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,389,Interventional,May 2009,November 2010,https://ClinicalTrials.gov/show/NCT00884507,50 Years and older ,50,40 to 65 years old
NCT03022968,Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD),"Active, not recruiting",Alzheimer Disease|Benson's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,17,Interventional,"January 10, 2017","November 25, 2019",https://ClinicalTrials.gov/show/NCT03022968,50 Years and older ,50,40 to 65 years old
NCT00870519,Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,2,Interventional,January 2009,December 2010,https://ClinicalTrials.gov/show/NCT00870519,50 Years and older ,50,40 to 65 years old
NCT00704782,Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,50,Interventional,April 2008,August 2010,https://ClinicalTrials.gov/show/NCT00704782,50 Years and older ,50,40 to 65 years old
NCT00976118,Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,34,Interventional,February 2006,February 2009,https://ClinicalTrials.gov/show/NCT00976118,50 Years and older ,50,40 to 65 years old
NCT01555827,Retinal Neurodegenerative Signs in Alzheimer's Diseases,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,"March 12, 2012","June 7, 2014",https://ClinicalTrials.gov/show/NCT01555827,50 Years and older ,50,40 to 65 years old
NCT01554683,Seizure Activity in Alzheimer's Disease,Completed,Alzheimer's Disease|Seizures,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,February 2012,"July 1, 2017",https://ClinicalTrials.gov/show/NCT01554683,50 Years and older ,50,40 to 65 years old
NCT02916056,2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension),Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,298,Interventional,December 2016,"June 1, 2018",https://ClinicalTrials.gov/show/NCT02916056,50 Years and older ,50,40 to 65 years old
NCT03991988,Montelukast Therapy on Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,150,Interventional,"September 25, 2019",August 2021,https://ClinicalTrials.gov/show/NCT03991988,50 Years and older ,50,40 to 65 years old
NCT00130429,Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,250,Interventional,January 2004,September 2005,https://ClinicalTrials.gov/show/NCT00130429,50 Years and older ,50,40 to 65 years old
NCT04114994,Longitudinal Cognitive Assessment by BoCA,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia|Frontotemporal Dementia|Parkinson Disease|Multiple Sclerosis|TBI,All,"50 Years and older   (Adult, Older Adult)",Phase 4,10000,Observational,"October 1, 2019","October 1, 2029",https://ClinicalTrials.gov/show/NCT04114994,50 Years and older ,50,40 to 65 years old
NCT00571064,The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility,Completed,Mild to Severe Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,97,Interventional,January 2008,"April 22, 2009",https://ClinicalTrials.gov/show/NCT00571064,50 Years and older ,50,40 to 65 years old
NCT03806478,Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease,Not yet recruiting,Dementia|Alzheimer Disease 1|Alzheimer Disease 2|Alzheimer Disease 3,All,"50 Years and older   (Adult, Older Adult)",Phase 2,60,Interventional,June 2021,December 2022,https://ClinicalTrials.gov/show/NCT03806478,50 Years and older ,50,40 to 65 years old
NCT00675090,Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,28,Interventional,"February 21, 2008","June 16, 2009",https://ClinicalTrials.gov/show/NCT00675090,50 Years and older ,50,40 to 65 years old
NCT02035553,A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis,Completed,Alzheimer's Disease Psychosis,All,"50 Years and older   (Adult, Older Adult)",Phase 2,181,Interventional,November 2013,"October 27, 2016",https://ClinicalTrials.gov/show/NCT02035553,50 Years and older ,50,40 to 65 years old
NCT00945672,A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,36,Interventional,August 2009,June 2011,https://ClinicalTrials.gov/show/NCT00945672,50 Years and older ,50,40 to 65 years old
NCT01406145,A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,60,Interventional,"June 16, 2011","November 4, 2011",https://ClinicalTrials.gov/show/NCT01406145,50 Years and older ,50,40 to 65 years old
NCT00912288,A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease,Terminated,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,86,Interventional,September 2009,August 2010,https://ClinicalTrials.gov/show/NCT00912288,50 Years and older ,50,40 to 65 years old
NCT04081285,Epigenetic Biomarkers for Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,250,Observational,"September 1, 2019","December 31, 2023",https://ClinicalTrials.gov/show/NCT04081285,50 Years and older ,50,40 to 65 years old
NCT03809351,UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy,Not yet recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,160,Interventional,"June 1, 2020","June 1, 2024",https://ClinicalTrials.gov/show/NCT03809351,50 Years and older ,50,40 to 65 years old
NCT03061474,Nicotinamide as an Early Alzheimer's Disease Treatment,Recruiting,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years and older   (Adult, Older Adult)",Phase 2,48,Interventional,"July 12, 2017","June 30, 2020",https://ClinicalTrials.gov/show/NCT03061474,50 Years and older ,50,40 to 65 years old
NCT00477659,Neural Correlates In Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,14,Interventional,July 2007,August 2008,https://ClinicalTrials.gov/show/NCT00477659,50 Years and older ,50,40 to 65 years old
NCT00733642,Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,15,Interventional,August 2008,July 2009,https://ClinicalTrials.gov/show/NCT00733642,50 Years and older ,50,40 to 65 years old
NCT00886951,Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,2,Interventional,March 2009,March 2009,https://ClinicalTrials.gov/show/NCT00886951,50 Years and older ,50,40 to 65 years old
NCT03044249,A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression,Recruiting,Psychosis|Dementia|Aggression|Agitation|Alzheimer Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100,Interventional,"May 4, 2017",August 2020,https://ClinicalTrials.gov/show/NCT03044249,50 Years and older ,50,40 to 65 years old
NCT00948766,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,716,Interventional,July 2009,June 2012,https://ClinicalTrials.gov/show/NCT00948766,50 Years and older ,50,40 to 65 years old
NCT00939783,An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,649,Interventional,September 2009,August 2010,https://ClinicalTrials.gov/show/NCT00939783,50 Years and older ,50,40 to 65 years old
NCT01035164,Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers,Completed,Positron-Emission Tomography|Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,25,Interventional,June 2007,January 2010,https://ClinicalTrials.gov/show/NCT01035164,50 Years and older ,50,40 to 65 years old
NCT00174382,Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia,Terminated,"Dementia, Vascular|Dementia, Mixed",All,"50 Years and older   (Adult, Older Adult)",Phase 3,149,Interventional,June 2005,April 2008,https://ClinicalTrials.gov/show/NCT00174382,50 Years and older ,50,40 to 65 years old
NCT00013923,Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,40,Interventional,,June 2005,https://ClinicalTrials.gov/show/NCT00013923,50 Years and older ,50,40 to 65 years old
NCT00017940,Gene Therapy for Alzheimer's Disease Clinical Trial,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,8,Interventional,,November 2003,https://ClinicalTrials.gov/show/NCT00017940,50 Years and older ,50,40 to 65 years old
NCT00074529,Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED),Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,512,Interventional,October 2003,January 2006,https://ClinicalTrials.gov/show/NCT00074529,50 Years and older ,50,40 to 65 years old
NCT00605059,Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects,Terminated,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,3,Interventional,August 2007,June 2008,https://ClinicalTrials.gov/show/NCT00605059,50 Years and older ,50,40 to 65 years old
NCT03168997,Memantine Treatment in Alzheimer's Disease Patients,Unknown status,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,222,Interventional,"July 15, 2017","December 31, 2018",https://ClinicalTrials.gov/show/NCT03168997,50 Years and older ,50,40 to 65 years old
NCT00423228,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,Completed,Moderate Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,228,Interventional,February 2007,April 2009,https://ClinicalTrials.gov/show/NCT00423228,50 Years and older ,50,40 to 65 years old
NCT00334906,Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease),Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,75,Interventional,July 2005,,https://ClinicalTrials.gov/show/NCT00334906,50 Years and older ,50,40 to 65 years old
NCT00240695,A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment,Completed,Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases,All,"50 Years and older   (Adult, Older Adult)",Phase 3,724,Interventional,May 2003,May 2004,https://ClinicalTrials.gov/show/NCT00240695,50 Years and older ,50,40 to 65 years old
NCT00630851,A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes,Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,249,Interventional,October 2002,October 2004,https://ClinicalTrials.gov/show/NCT00630851,50 Years and older ,50,40 to 65 years old
NCT00439166,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,100,Interventional,February 2007,December 2010,https://ClinicalTrials.gov/show/NCT00439166,50 Years and older ,50,40 to 65 years old
NCT00448799,Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls,Completed,Alzheimers Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,30,Interventional,March 2007,March 2008,https://ClinicalTrials.gov/show/NCT00448799,50 Years and older ,50,40 to 65 years old
NCT03340571,Blood Biomarker of Alzheimer's Disease (AD),Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,"March 12, 2018",July 2019,https://ClinicalTrials.gov/show/NCT03340571,50 Years and older ,50,40 to 65 years old
NCT00456417,Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects,Completed,Alzheimers Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,30,Interventional,April 2007,December 2007,https://ClinicalTrials.gov/show/NCT00456417,50 Years and older ,50,40 to 65 years old
NCT00566397,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,402,Interventional,December 2007,December 2010,https://ClinicalTrials.gov/show/NCT00566397,50 Years and older ,50,40 to 65 years old
NCT03090854,Cholinergic Markers Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,100,Observational,"November 6, 2017","May 5, 2020",https://ClinicalTrials.gov/show/NCT03090854,50 Years and older ,50,40 to 65 years old
NCT00164749,A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,Interventional,October 2004,July 2006,https://ClinicalTrials.gov/show/NCT00164749,50 Years and older ,50,40 to 65 years old
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,402,Interventional,February 2007,May 2009,https://ClinicalTrials.gov/show/NCT00440050,50 Years and older ,50,40 to 65 years old
NCT00439010,Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects,Completed,Alzheimers Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,30,Interventional,February 2007,January 2008,https://ClinicalTrials.gov/show/NCT00439010,50 Years and older ,50,40 to 65 years old
NCT00142805,Ketasyn in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100,Interventional,October 2004,March 2006,https://ClinicalTrials.gov/show/NCT00142805,50 Years and older ,50,40 to 65 years old
NCT02899091,Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24,Interventional,September 2016,December 2021,https://ClinicalTrials.gov/show/NCT02899091,50 Years and older ,50,40 to 65 years old
NCT00090116,The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,400,Interventional,March 2003,March 2005,https://ClinicalTrials.gov/show/NCT00090116,50 Years and older ,50,40 to 65 years old
NCT03484143,Neuro RX Gamma - Pivotal Phase,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,228,Interventional,"June 26, 2019",May 2021,https://ClinicalTrials.gov/show/NCT03484143,50 Years and older ,50,40 to 65 years old
NCT00244322,Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,45,Interventional,October 2005,December 2006,https://ClinicalTrials.gov/show/NCT00244322,50 Years and older ,50,40 to 65 years old
NCT00329082,Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,25,Interventional,May 2006,May 2008,https://ClinicalTrials.gov/show/NCT00329082,50 Years and older ,50,40 to 65 years old
NCT00495417,Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,July 2007,August 2009,https://ClinicalTrials.gov/show/NCT00495417,50 Years and older ,50,40 to 65 years old
NCT00099710,Curcumin in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,33,Interventional,July 2003,December 2007,https://ClinicalTrials.gov/show/NCT00099710,50 Years and older ,50,40 to 65 years old
NCT03503331,UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy,Recruiting,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,160,Interventional,"April 20, 2018","April 1, 2024",https://ClinicalTrials.gov/show/NCT03503331,50 Years and older ,50,40 to 65 years old
NCT00073658,Treating Behavioral Disturbances in Individuals With Dementia,Completed,Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 2,137,Interventional,January 2000,June 2005,https://ClinicalTrials.gov/show/NCT00073658,50 Years and older ,50,40 to 65 years old
NCT00151398,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),Completed,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,229,Interventional,September 2005,March 2008,https://ClinicalTrials.gov/show/NCT00151398,50 Years and older ,50,40 to 65 years old
NCT02708186,Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD),Completed,Dementia With Lewy Bodies|REM Sleep Behavior Disorder|Parkinson's Disease Dementia,All,"50 Years and older   (Adult, Older Adult)",Phase 2,29,Interventional,March 2016,May 2018,https://ClinicalTrials.gov/show/NCT02708186,50 Years and older ,50,40 to 65 years old
NCT00314912,Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,650,Interventional,May 2006,,https://ClinicalTrials.gov/show/NCT00314912,50 Years and older ,50,40 to 65 years old
NCT00428389,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,262,Interventional,January 2007,February 2008,https://ClinicalTrials.gov/show/NCT00428389,50 Years and older ,50,40 to 65 years old
NCT00299988,Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,24,Interventional,February 2006,April 2010,https://ClinicalTrials.gov/show/NCT00299988,50 Years and older ,50,40 to 65 years old
NCT02871427,Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder,Terminated,Lewy Body Dementia|Dementia With Lewy Bodies|Parkinson's Disease Dementia|Visual Hallucinations|REM Sleep Behavior Disorder,All,"50 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,"October 20, 2016","January 17, 2019",https://ClinicalTrials.gov/show/NCT02871427,50 Years and older ,50,40 to 65 years old
NCT02265757,Behavioral Interventions to Prevent or Delay Dementia,Completed,Mild Cognitive Impairment|Memory Disorders|Mild Dementia|Impaired Cognition|Mild Cognitive Disorder|Amnestic Disorder|Dementia and Amnestic Conditions|Poor Short-term Memory|Memory Impairment,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,272,Interventional,June 2014,"March 31, 2018",https://ClinicalTrials.gov/show/NCT02265757,50 Years and older ,50,40 to 65 years old
NCT02085265,Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients,Recruiting,Alzheimer's Disease|Hypertension,All,"50 Years and older   (Adult, Older Adult)",Phase 2,240,Interventional,March 2014,March 2021,https://ClinicalTrials.gov/show/NCT02085265,50 Years and older ,50,40 to 65 years old
NCT00862940,A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,277,Interventional,September 2005,April 2009,https://ClinicalTrials.gov/show/NCT00862940,50 Years and older ,50,40 to 65 years old
NCT00895895,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,Terminated,Alzheimer Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 2,526,Interventional,May 2009,May 2011,https://ClinicalTrials.gov/show/NCT00895895,50 Years and older ,50,40 to 65 years old
NCT01538212,Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,55,Observational,January 2012,October 2012,https://ClinicalTrials.gov/show/NCT01538212,50 Years and older ,50,40 to 65 years old
NCT02918539,Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials,Completed,Alzheimer Disease|Cognition Disorders,All,"50 Years and older   (Adult, Older Adult)",Phase 4,317,Observational,October 2016,"October 18, 2017",https://ClinicalTrials.gov/show/NCT02918539,50 Years and older ,50,40 to 65 years old
NCT01926691,Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO),Unknown status,Stroke|Dementia|Cerebrovascular Disorders|Alzheimer's Disease|Brain Ischemia,All,"50 Years and older   (Adult, Older Adult)",Phase 4,534,Observational,April 2008,,https://ClinicalTrials.gov/show/NCT01926691,50 Years and older ,50,40 to 65 years old
NCT00646269,Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Interventional,March 2008,December 2012,https://ClinicalTrials.gov/show/NCT00646269,50 Years and older ,50,40 to 65 years old
NCT00968097,Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition,Terminated,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 1,12,Interventional,April 2008,July 2008,https://ClinicalTrials.gov/show/NCT00968097,50 Years and older ,50,40 to 65 years old
NCT00731224,Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,380,Interventional,July 2008,October 2011,https://ClinicalTrials.gov/show/NCT00731224,50 Years and older ,50,40 to 65 years old
NCT00234637,Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment,Completed,Alzheimer's Disease,All,"50 Years and older   (Adult, Older Adult)",Phase 4,204,Interventional,November 2003,June 2005,https://ClinicalTrials.gov/show/NCT00234637,50 Years and older ,50,40 to 65 years old
NCT03297268,Behavioral and Environmental Sensing and Intervention,Unknown status,Behavioral and Psychiatric Symptoms of Dementia|Dementia|Caregivers,All,"50 Years and older   (Adult, Older Adult)",Phase 4,24,Observational,May 2016,August 2019,https://ClinicalTrials.gov/show/NCT03297268,50 Years and older ,50,40 to 65 years old
NCT03160027,Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia),Completed,"Dementia, Alzheimer Type",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"May 15, 2017","March 29, 2019",https://ClinicalTrials.gov/show/NCT03160027,50 Years and older ,50,40 to 65 years old
NCT03489044,An Investigation of Levetiracetam in Alzheimer's Disease,Enrolling by invitation,Alzheimer Disease|Epilepsy,All,"50 Years and older   (Adult, Older Adult)",Phase 2,30,Interventional,November 2018,January 2020,https://ClinicalTrials.gov/show/NCT03489044,50 Years and older ,50,40 to 65 years old
NCT03069391,The Interactive Physical and Cognitive Exercise System,"Active, not recruiting","Alzheimer Disease, Early Onset|MCI|Aging|Mild Cognitive Impairment|Neurocognitive Disorder|Cognitive Impairment|Cognitive Change",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,31,Interventional,"March 4, 2017","June 30, 2020",https://ClinicalTrials.gov/show/NCT03069391,50 Years and older ,50,40 to 65 years old
NCT04055376,Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease,Recruiting,Alzheimer Disease|Alzheimer Dementia,All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,12,Interventional,"August 14, 2019","April 30, 2021",https://ClinicalTrials.gov/show/NCT04055376,50 Years to 100 Years ,50,40 to 65 years old
NCT03939780,Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients,Not yet recruiting,Healthy|Alzheimer Disease,All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,24,Interventional,October 2019,January 2023,https://ClinicalTrials.gov/show/NCT03939780,50 Years to 100 Years ,50,40 to 65 years old
NCT03752463,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 2,160,Interventional,"May 22, 2015","December 31, 2019",https://ClinicalTrials.gov/show/NCT03752463,50 Years to 100 Years ,50,40 to 65 years old
NCT03373604,Imaging Tau in Alzheimer's Disease and Normal Aging,Enrolling by invitation,Alzheimer Disease,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 2,175,Interventional,"December 11, 2017","August 20, 2021",https://ClinicalTrials.gov/show/NCT03373604,50 Years to 100 Years ,50,40 to 65 years old
NCT01796314,Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life,Completed,Alzheimer Disease,All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,170,Interventional,January 2013,February 2017,https://ClinicalTrials.gov/show/NCT01796314,50 Years to 100 Years ,50,40 to 65 years old
NCT02103673,DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia,Completed,Behavioral and Psychological Symptoms in Alzheimer's Disease|Behavioral and Psychological Symptoms in Vascular Dementia,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 2,90,Interventional,February 2014,November 2017,https://ClinicalTrials.gov/show/NCT02103673,50 Years to 100 Years ,50,40 to 65 years old
NCT04042922,High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,"April 19, 2019","April 30, 2021",https://ClinicalTrials.gov/show/NCT04042922,50 Years to 100 Years ,50,40 to 65 years old
NCT02825732,MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint,Completed,Neurocognitive Disorders,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 4,1300,Observational,November 2011,January 2016,https://ClinicalTrials.gov/show/NCT02825732,50 Years to 100 Years ,50,40 to 65 years old
NCT02957227,Diagnosis of Alzheimer's Disease Using Event Related Potentials,Recruiting,Mild Cognitive Impairment,All,"50 Years to 100 Years   (Adult, Older Adult)",Phase 4,170,Observational,July 2016,January 2019,https://ClinicalTrials.gov/show/NCT02957227,50 Years to 100 Years ,50,40 to 65 years old
NCT03038035,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,Unknown status,Alzheimer Disease,All,"50 Years to 120 Years   (Adult, Older Adult)",Phase 2,150,Interventional,December 2016,June 2019,https://ClinicalTrials.gov/show/NCT03038035,50 Years to 120 Years ,50,40 to 65 years old
NCT00706186,Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients,Terminated,Mild Alzheimer's Disease,All,"50 Years to 65 Years   (Adult, Older Adult)",Phase 4,4,Interventional,,,https://ClinicalTrials.gov/show/NCT00706186,50 Years to 65 Years ,50,40 to 65 years old
NCT00586430,The Impact of Lorazepam on Cognition in APOE e4 Carriers,Completed,Alzheimer's Disease,All,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,36,Interventional,December 2005,July 2007,https://ClinicalTrials.gov/show/NCT00586430,50 Years to 65 Years ,50,40 to 65 years old
NCT00888056,Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,5,Interventional,June 2009,,https://ClinicalTrials.gov/show/NCT00888056,50 Years to 65 Years ,50,40 to 65 years old
NCT00947934,Study of the Brain Stimulation Effect on Memory Impairment in Alzheimer Disease,Unknown status,Memory Disorders,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,5,Interventional,August 2009,August 2012,https://ClinicalTrials.gov/show/NCT00947934,50 Years to 70 Years ,50,40 to 65 years old
NCT02530255,Telomerase Activator and Retinal Amyloid,Completed,Alzheimer Disease,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,48,Interventional,"December 1, 2016","December 31, 2018",https://ClinicalTrials.gov/show/NCT02530255,50 Years to 70 Years ,50,40 to 65 years old
NCT04074837,"Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers",Recruiting,Alzheimer Disease,All,"50 Years to 72 Years   (Adult, Older Adult)",Phase 1,56,Interventional,"August 1, 2019","April 1, 2020",https://ClinicalTrials.gov/show/NCT04074837,50 Years to 72 Years ,50,40 to 65 years old
NCT03186989,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",Recruiting,Mild Alzheimer's Disease,All,"50 Years to 74 Years   (Adult, Older Adult)",Phase 1|Phase 2,44,Interventional,"June 5, 2017","February 29, 2020",https://ClinicalTrials.gov/show/NCT03186989,50 Years to 74 Years ,50,40 to 65 years old
NCT02719327,Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid,Recruiting,Alzheimer's Disease,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,150,Interventional,"June 8, 2017","November 30, 2021",https://ClinicalTrials.gov/show/NCT02719327,50 Years to 75 Years ,50,40 to 65 years old
NCT01297218,The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease,Completed,Dementia of the Alzheimer's Type,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,9,Interventional,February 2011,December 2011,https://ClinicalTrials.gov/show/NCT01297218,50 Years to 75 Years ,50,40 to 65 years old
NCT03923569,Epileptiform Activity During REM Sleep in Alzheimer's Disease,Not yet recruiting,"Alzheimer Disease, Early Onset",All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,April 2019,April 2022,https://ClinicalTrials.gov/show/NCT03923569,50 Years to 75 Years ,50,40 to 65 years old
NCT03790982,Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,240,Interventional,"December 1, 2018","July 30, 2021",https://ClinicalTrials.gov/show/NCT03790982,50 Years to 75 Years ,50,40 to 65 years old
NCT01696591,The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD,Unknown status,"Alzheimer Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Tauopathies|Neurodegenerative Diseases|Delirium, Dementia, Amnestic, Cognitive Disorders|Mental Disorders",All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 4,14,Observational,March 2012,September 2013,https://ClinicalTrials.gov/show/NCT01696591,50 Years to 75 Years ,50,40 to 65 years old
NCT02835716,Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO,Recruiting,Alzheimer Disease,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 4,150,Observational,September 2016,September 2020,https://ClinicalTrials.gov/show/NCT02835716,50 Years to 75 Years ,50,40 to 65 years old
NCT04122001,Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease,Not yet recruiting,"Alzheimer Disease, Early Onset|Atypical Alzheimer's Disease|Logopenic Progressive Aphasia",All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"August 1, 2020","July 31, 2025",https://ClinicalTrials.gov/show/NCT04122001,50 Years to 75 Years ,50,40 to 65 years old
NCT04042532,Theta-burst Stimulation on Cognitive Function in the Patients With Young-onset Alzheimer's Disease Dementia,Not yet recruiting,"Alzheimer Disease, Early Onset",All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,70,Interventional,"August 1, 2019","July 31, 2022",https://ClinicalTrials.gov/show/NCT04042532,50 Years to 75 Years ,50,40 to 65 years old
NCT01075763,A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,42,Interventional,November 2004,May 2008,https://ClinicalTrials.gov/show/NCT01075763,50 Years to 75 Years ,50,40 to 65 years old
NCT02340195,Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function,Completed,Alzheimer Disease,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 1,16,Interventional,January 2015,,https://ClinicalTrials.gov/show/NCT02340195,50 Years to 75 Years ,50,40 to 65 years old
NCT03030365,Orientation in AD Patients: PET-MR Study,Not yet recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 4,30,Observational,"February 15, 2017","February 15, 2020",https://ClinicalTrials.gov/show/NCT03030365,50 Years to 79 Years ,50,40 to 65 years old
NCT02860065,CPC-201 Alzheimer's Disease Type Dementia: PET Study,Withdrawn,Alzheimer's Disease,All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2,0,Interventional,"September 30, 2016","June 30, 2017",https://ClinicalTrials.gov/show/NCT02860065,50 Years to 79 Years ,50,40 to 65 years old
NCT02185053,A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia,Completed,Alzheimer's Disease,All,"50 Years to 79 Years   (Adult, Older Adult)",Phase 2,41,Interventional,July 2014,July 2016,https://ClinicalTrials.gov/show/NCT02185053,50 Years to 79 Years ,50,40 to 65 years old
NCT01163825,Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients,Unknown status,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,6,Interventional,January 2008,,https://ClinicalTrials.gov/show/NCT01163825,50 Years to 80 Years ,50,40 to 65 years old
NCT01001637,Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,26,Interventional,October 2009,November 2010,https://ClinicalTrials.gov/show/NCT01001637,50 Years to 80 Years ,50,40 to 65 years old
NCT01245530,An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia,Completed,Alzheimer Type Dementia,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 3,280,Interventional,June 2008,March 2011,https://ClinicalTrials.gov/show/NCT01245530,50 Years to 80 Years ,50,40 to 65 years old
NCT03472183,Exploration of the Enteric Nervous System in Alzheimer Disease,Recruiting,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"April 26, 2018","August 25, 2020",https://ClinicalTrials.gov/show/NCT03472183,50 Years to 80 Years ,50,40 to 65 years old
NCT01334450,Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients,Unknown status,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,42,Interventional,June 2011,June 2013,https://ClinicalTrials.gov/show/NCT01334450,50 Years to 80 Years ,50,40 to 65 years old
NCT01309763,Safety and Tolerability of AFFITOPE AD03,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,28,Interventional,October 2010,November 2011,https://ClinicalTrials.gov/show/NCT01309763,50 Years to 80 Years ,50,40 to 65 years old
NCT00608946,Treatment With Copper in Patients With Mild Alzheimer´s Dementia,Completed,Alzheimer´s Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,68,Interventional,March 2004,,https://ClinicalTrials.gov/show/NCT00608946,50 Years to 80 Years ,50,40 to 65 years old
NCT03875638,Treating Hyperexcitability in AD With Levetiracetam,Recruiting,"Alzheimer Disease, Early Onset",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,85,Interventional,"August 22, 2019",November 2023,https://ClinicalTrials.gov/show/NCT03875638,50 Years to 80 Years ,50,40 to 65 years old
NCT01469351,Identifying Potential Effects of Liraglutide on Degenerative Changes,Completed,Alzheimers Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,34,Interventional,January 2012,April 2013,https://ClinicalTrials.gov/show/NCT01469351,50 Years to 80 Years ,50,40 to 65 years old
NCT01397578,A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,91,Interventional,"August 31, 2011","April 30, 2014",https://ClinicalTrials.gov/show/NCT01397578,50 Years to 80 Years ,50,40 to 65 years old
NCT03070821,Therapy of Alzheimer's Disease With Neurofeedback,Completed,Alzheimer Dementia (AD)|Elderly,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"January 30, 2013","June 30, 2016",https://ClinicalTrials.gov/show/NCT03070821,50 Years to 80 Years ,50,40 to 65 years old
NCT00965588,"Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,19,Interventional,February 2009,April 2011,https://ClinicalTrials.gov/show/NCT00965588,50 Years to 80 Years ,50,40 to 65 years old
NCT00414622,GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease,Completed,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Interventional,November 2006,April 2007,https://ClinicalTrials.gov/show/NCT00414622,50 Years to 80 Years ,50,40 to 65 years old
NCT01343966,A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY),Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,448,Interventional,"April 30, 2011","February 28, 2014",https://ClinicalTrials.gov/show/NCT01343966,50 Years to 80 Years ,50,40 to 65 years old
NCT01428453,A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,124,Interventional,"October 1, 2011","February 18, 2013",https://ClinicalTrials.gov/show/NCT01428453,50 Years to 80 Years ,50,40 to 65 years old
NCT01370954,NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support),Completed,Early Memory Loss|Mild Cognitive Impairment|Alzheimer's Disease|Vascular Dementia,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,204,Observational,May 2011,December 2012,https://ClinicalTrials.gov/show/NCT01370954,50 Years to 80 Years ,50,40 to 65 years old
NCT01656525,A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,28,Interventional,June 2012,June 2014,https://ClinicalTrials.gov/show/NCT01656525,50 Years to 80 Years ,50,40 to 65 years old
NCT00637442,Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD),Unknown status,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,February 2008,,https://ClinicalTrials.gov/show/NCT00637442,50 Years to 80 Years ,50,40 to 65 years old
NCT01568086,Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A,Terminated,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,16,Observational,December 2011,October 2013,https://ClinicalTrials.gov/show/NCT01568086,50 Years to 80 Years ,50,40 to 65 years old
NCT03522129,Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,18,Interventional,"May 16, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03522129,50 Years to 80 Years ,50,40 to 65 years old
NCT02204969,LIWA for Treatment of Alzheimer Patients,Unknown status,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,100,Interventional,January 2015,December 2015,https://ClinicalTrials.gov/show/NCT02204969,50 Years to 80 Years ,50,40 to 65 years old
NCT02600130,Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,30,Interventional,August 2016,March 2020,https://ClinicalTrials.gov/show/NCT02600130,50 Years to 80 Years ,50,40 to 65 years old
NCT02841605,Enteric Nervous System in Alzheimer Disease,Unknown status,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,55,Interventional,October 2016,May 2019,https://ClinicalTrials.gov/show/NCT02841605,50 Years to 80 Years ,50,40 to 65 years old
NCT03352557,Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,654,Interventional,"May 3, 2018","June 30, 2024",https://ClinicalTrials.gov/show/NCT03352557,50 Years to 80 Years ,50,40 to 65 years old
NCT00454870,Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Interventional,February 2007,October 2007,https://ClinicalTrials.gov/show/NCT00454870,50 Years to 80 Years ,50,40 to 65 years old
NCT03939286,Multimodal Imaging Study on Physical Activity in Patients With Alzheimer`s Disease,Recruiting,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Interventional,"April 8, 2019",October 2021,https://ClinicalTrials.gov/show/NCT03939286,50 Years to 80 Years ,50,40 to 65 years old
NCT02409030,Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,700,Observational,January 2014,"October 18, 2017",https://ClinicalTrials.gov/show/NCT02409030,50 Years to 80 Years ,50,40 to 65 years old
NCT00087789,CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,10,Interventional,June 2004,May 2010,https://ClinicalTrials.gov/show/NCT00087789,50 Years to 80 Years ,50,40 to 65 years old
NCT04029623,Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease,Not yet recruiting,Prodromal Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,66,Interventional,December 2019,March 2024,https://ClinicalTrials.gov/show/NCT04029623,50 Years to 80 Years ,50,40 to 65 years old
NCT00633841,Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,24,Interventional,February 2008,September 2009,https://ClinicalTrials.gov/show/NCT00633841,50 Years to 80 Years ,50,40 to 65 years old
NCT01887899,Influence of tDCS on Cortical Plasticity in Patients With Dementia of the Alzheimer Type,Unknown status,Dementia of Type Alzheimer,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,15,Interventional,May 2013,December 2017,https://ClinicalTrials.gov/show/NCT01887899,50 Years to 80 Years ,50,40 to 65 years old
NCT00100334,Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Interventional,December 2004,August 2005,https://ClinicalTrials.gov/show/NCT00100334,50 Years to 80 Years ,50,40 to 65 years old
NCT01780519,The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms,Completed,Alzheimer's Disease (AD),All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,57,Interventional,January 2013,September 2016,https://ClinicalTrials.gov/show/NCT01780519,50 Years to 80 Years ,50,40 to 65 years old
NCT02907567,Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,19,Interventional,September 2016,September 2017,https://ClinicalTrials.gov/show/NCT02907567,50 Years to 80 Years ,50,40 to 65 years old
NCT04082611,The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition,Recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"July 12, 2019",May 2022,https://ClinicalTrials.gov/show/NCT04082611,50 Years to 80 Years ,50,40 to 65 years old
NCT01701089,A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers,Completed,"Healthy Volunteer, Alzheimer's Disease",All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,17,Interventional,September 2012,May 2013,https://ClinicalTrials.gov/show/NCT01701089,50 Years to 80 Years ,50,40 to 65 years old
NCT00753662,Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,45,Interventional,November 2008,November 2012,https://ClinicalTrials.gov/show/NCT00753662,50 Years to 80 Years ,50,40 to 65 years old
NCT03290274,Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease,Recruiting,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,6,Interventional,"March 1, 2017","December 1, 2019",https://ClinicalTrials.gov/show/NCT03290274,50 Years to 80 Years ,50,40 to 65 years old
NCT03056729,Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease,Recruiting,Alzheimer's Disease|Healthy Volunteer,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,48,Interventional,"February 17, 2017","February 14, 2020",https://ClinicalTrials.gov/show/NCT03056729,50 Years to 80 Years ,50,40 to 65 years old
NCT01979419,Korea Alzheimer's Disease Neuroimaging Initiative,"Active, not recruiting",Mild Cognitive Impairment|Alzheimer's Disease|Subcortical Vascular Dementia,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,500,Observational,November 2012,October 2020,https://ClinicalTrials.gov/show/NCT01979419,50 Years to 80 Years ,50,40 to 65 years old
NCT02874820,I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD,Completed,Alzheimer Disease,Male,"50 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,2,Interventional,July 2016,July 2017,https://ClinicalTrials.gov/show/NCT02874820,50 Years to 80 Years ,50,40 to 65 years old
NCT01189084,Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,14,Observational,April 2010,July 2011,https://ClinicalTrials.gov/show/NCT01189084,50 Years to 80 Years ,50,40 to 65 years old
NCT03943264,A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's,Recruiting,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,18,Interventional,June 2019,December 2020,https://ClinicalTrials.gov/show/NCT03943264,50 Years to 80 Years ,50,40 to 65 years old
NCT00100282,Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,125,Interventional,May 2003,June 2005,https://ClinicalTrials.gov/show/NCT00100282,50 Years to 80 Years ,50,40 to 65 years old
NCT03703856,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,88,Interventional,"January 31, 2019",August 2023,https://ClinicalTrials.gov/show/NCT03703856,50 Years to 80 Years ,50,40 to 65 years old
NCT01227564,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,63,Interventional,February 2011,February 2014,https://ClinicalTrials.gov/show/NCT01227564,50 Years to 80 Years ,50,40 to 65 years old
NCT00411580,Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,58,Interventional,June 2005,December 2008,https://ClinicalTrials.gov/show/NCT00411580,50 Years to 80 Years ,50,40 to 65 years old
NCT03035851,Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias,Recruiting,Alzheimer Disease|Dementia,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,264,Interventional,January 2017,January 2025,https://ClinicalTrials.gov/show/NCT03035851,50 Years to 80 Years ,50,40 to 65 years old
NCT01117818,"Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,335,Interventional,September 2010,December 2013,https://ClinicalTrials.gov/show/NCT01117818,50 Years to 80 Years ,50,40 to 65 years old
NCT03289143,A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 2,457,Interventional,"October 4, 2017","September 20, 2022",https://ClinicalTrials.gov/show/NCT03289143,50 Years to 80 Years ,50,40 to 65 years old
NCT01966666,"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease","Active, not recruiting",Alzheimer's Disease,All,"50 Years to 82 Years   (Adult, Older Adult)",Phase 1,33,Interventional,November 2013,November 2019,https://ClinicalTrials.gov/show/NCT01966666,50 Years to 82 Years ,50,40 to 65 years old
NCT03319810,Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease,Completed,Mild Cognitive Impairment,All,"50 Years to 84 Years   (Adult, Older Adult)",Phase 2,5,Interventional,"January 4, 2018","July 19, 2018",https://ClinicalTrials.gov/show/NCT03319810,50 Years to 84 Years ,50,40 to 65 years old
NCT01300728,Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment,"Active, not recruiting",Mild Cognitive Impairment,All,"50 Years to 84 Years   (Adult, Older Adult)",Phase 2,52,Interventional,January 2011,December 2019,https://ClinicalTrials.gov/show/NCT01300728,50 Years to 84 Years ,50,40 to 65 years old
NCT00134953,Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment,Terminated,Cognitive Symptoms,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,24,Interventional,January 2003,May 2004,https://ClinicalTrials.gov/show/NCT00134953,50 Years to 85 Years ,50,40 to 65 years old
NCT00099242,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,Completed,"Alzheimer's Disease|Dementia, Alzheimer Type",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1040,Interventional,November 2003,January 2006,https://ClinicalTrials.gov/show/NCT00099242,50 Years to 85 Years ,50,40 to 65 years old
NCT02759159,The Study of Mechanism of Alzheimer's Disease Using Acupuncture Based on fMRI,Unknown status,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,120,Interventional,June 2016,December 2018,https://ClinicalTrials.gov/show/NCT02759159,50 Years to 85 Years ,50,40 to 65 years old
NCT01117948,Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.,Terminated,Alzheimer´s Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,219,Interventional,September 2009,April 2011,https://ClinicalTrials.gov/show/NCT01117948,50 Years to 85 Years ,50,40 to 65 years old
NCT01325402,An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease,Completed,Maximum Diagnostic Mass of [18Fluor]AZD4694,Male,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Interventional,August 2011,November 2012,https://ClinicalTrials.gov/show/NCT01325402,50 Years to 85 Years ,50,40 to 65 years old
NCT00305903,Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,150,Interventional,March 2006,August 2007,https://ClinicalTrials.gov/show/NCT00305903,50 Years to 85 Years ,50,40 to 65 years old
NCT02537626,An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease,Not yet recruiting,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"February 15, 2018","December 15, 2018",https://ClinicalTrials.gov/show/NCT02537626,50 Years to 85 Years ,50,40 to 65 years old
NCT03090516,Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease,Recruiting,Alzheimer's,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,240,Interventional,"August 10, 2016","March 10, 2020",https://ClinicalTrials.gov/show/NCT03090516,50 Years to 85 Years ,50,40 to 65 years old
NCT01537757,"A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Interventional,March 2012,May 2012,https://ClinicalTrials.gov/show/NCT01537757,50 Years to 85 Years ,50,40 to 65 years old
NCT00151333,Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Interventional,February 2005,April 2005,https://ClinicalTrials.gov/show/NCT00151333,50 Years to 85 Years ,50,40 to 65 years old
NCT03113812,Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,24,Interventional,"January 1, 2014","July 30, 2015",https://ClinicalTrials.gov/show/NCT03113812,50 Years to 85 Years ,50,40 to 65 years old
NCT00710684,"A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,682,Interventional,"July 1, 2008","November 16, 2010",https://ClinicalTrials.gov/show/NCT00710684,50 Years to 85 Years ,50,40 to 65 years old
NCT00568776,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,353,Interventional,December 2007,May 2010,https://ClinicalTrials.gov/show/NCT00568776,50 Years to 85 Years ,50,40 to 65 years old
NCT03819699,Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD,Terminated,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,3,Interventional,"December 12, 2018","June 27, 2019",https://ClinicalTrials.gov/show/NCT03819699,50 Years to 85 Years ,50,40 to 65 years old
NCT03656042,To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,21,Interventional,March 2009,August 2014,https://ClinicalTrials.gov/show/NCT03656042,50 Years to 85 Years ,50,40 to 65 years old
NCT00224497,A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,380,Interventional,September 2005,,https://ClinicalTrials.gov/show/NCT00224497,50 Years to 85 Years ,50,40 to 65 years old
NCT03659643,"Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker",Recruiting,Mild Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,300,Observational,"January 1, 2018","October 1, 2020",https://ClinicalTrials.gov/show/NCT03659643,50 Years to 85 Years ,50,40 to 65 years old
NCT02054208,Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,45,Interventional,February 2014,July 2019,https://ClinicalTrials.gov/show/NCT02054208,50 Years to 85 Years ,50,40 to 65 years old
NCT01547689,Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Interventional,March 2012,December 2016,https://ClinicalTrials.gov/show/NCT01547689,50 Years to 85 Years ,50,40 to 65 years old
NCT02984540,Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease,Completed,Mild Cognitive Impairment|Insulin Resistance,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,25,Interventional,February 2015,"April 3, 2017",https://ClinicalTrials.gov/show/NCT02984540,50 Years to 85 Years ,50,40 to 65 years old
NCT03283059,Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,600,Interventional,"August 16, 2017","February 16, 2020",https://ClinicalTrials.gov/show/NCT03283059,50 Years to 85 Years ,50,40 to 65 years old
NCT03069014,Study of LM11A-31-BHS in Mild-moderate AD Patients,Recruiting,Mild to Moderate Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,190,Interventional,"February 15, 2017","October 31, 2019",https://ClinicalTrials.gov/show/NCT03069014,50 Years to 85 Years ,50,40 to 65 years old
NCT00558402,Meditation or Education for Alzheimer Caregivers,Completed,Caregivers|Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,72,Interventional,November 2007,July 2011,https://ClinicalTrials.gov/show/NCT00558402,50 Years to 85 Years ,50,40 to 65 years old
NCT01496170,"A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,32,Interventional,December 2011,June 2012,https://ClinicalTrials.gov/show/NCT01496170,50 Years to 85 Years ,50,40 to 65 years old
NCT00219232,An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,868,Interventional,February 2003,July 2006,https://ClinicalTrials.gov/show/NCT00219232,50 Years to 85 Years ,50,40 to 65 years old
NCT03325205,MR Guided tDCS in Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"August 22, 2017","December 30, 2020",https://ClinicalTrials.gov/show/NCT03325205,50 Years to 85 Years ,50,40 to 65 years old
NCT00069849,A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,64,Interventional,July 2003,,https://ClinicalTrials.gov/show/NCT00069849,50 Years to 85 Years ,50,40 to 65 years old
NCT00649220,Memantine and Antipsychotics Use,Terminated,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,19,Interventional,July 2008,June 2009,https://ClinicalTrials.gov/show/NCT00649220,50 Years to 85 Years ,50,40 to 65 years old
NCT00940589,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,Completed,Alzheimer's Disease|Sleep Disorder,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,73,Interventional,September 2009,May 2013,https://ClinicalTrials.gov/show/NCT00940589,50 Years to 85 Years ,50,40 to 65 years old
NCT03466177,Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease,Recruiting,Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Dementia,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,90,Observational,"April 1, 2018","December 31, 2020",https://ClinicalTrials.gov/show/NCT03466177,50 Years to 85 Years ,50,40 to 65 years old
NCT04004767,TRC-PAD Program: In-Clinic Trial-Ready Cohort,Enrolling by invitation,Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer Disease|Dementia,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,2000,Observational,"June 4, 2019","April 30, 2023",https://ClinicalTrials.gov/show/NCT04004767,50 Years to 85 Years ,50,40 to 65 years old
NCT01179373,Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,45,Interventional,August 2010,June 2015,https://ClinicalTrials.gov/show/NCT01179373,50 Years to 85 Years ,50,40 to 65 years old
NCT03008161,Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,83,Interventional,December 2016,"February 6, 2019",https://ClinicalTrials.gov/show/NCT03008161,50 Years to 85 Years ,50,40 to 65 years old
NCT01059877,Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia,Completed,Dementia,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,11,Interventional,January 2010,February 2012,https://ClinicalTrials.gov/show/NCT01059877,50 Years to 85 Years ,50,40 to 65 years old
NCT02787746,Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,241,Interventional,April 2016,March 2019,https://ClinicalTrials.gov/show/NCT02787746,50 Years to 85 Years ,50,40 to 65 years old
NCT03625401,Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease,Recruiting,"Alzheimer Disease, Early Onset",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,88,Interventional,"October 4, 2018","July 31, 2020",https://ClinicalTrials.gov/show/NCT03625401,50 Years to 85 Years ,50,40 to 65 years old
NCT03671889,ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,10,Interventional,"September 28, 2018",December 2024,https://ClinicalTrials.gov/show/NCT03671889,50 Years to 85 Years ,50,40 to 65 years old
NCT03507790,A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.,Recruiting,Mild to Moderate Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,120,Interventional,"October 2, 2018","July 31, 2020",https://ClinicalTrials.gov/show/NCT03507790,50 Years to 85 Years ,50,40 to 65 years old
NCT02050464,Computational Tools for Early Diagnosis of Memory Disorders,Completed,"Alzheimer Disease|Frontotemporal Dementia|Dementia, Vascular|Mild Cognitive Impairment",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,126,Observational,December 2013,April 2017,https://ClinicalTrials.gov/show/NCT02050464,50 Years to 85 Years ,50,40 to 65 years old
NCT00838877,"Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,26,Interventional,January 2009,October 2009,https://ClinicalTrials.gov/show/NCT00838877,50 Years to 85 Years ,50,40 to 65 years old
NCT03114657,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,806,Interventional,"March 29, 2017","June 11, 2019",https://ClinicalTrials.gov/show/NCT03114657,50 Years to 85 Years ,50,40 to 65 years old
NCT03834402,INTERCEPTOR Project: From MCI to Dementia,Recruiting,Mild Cognitive Impairment|Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,500,Observational,"May 1, 2019","December 31, 2023",https://ClinicalTrials.gov/show/NCT03834402,50 Years to 85 Years ,50,40 to 65 years old
NCT02703636,"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.",Completed,Mild to Moderate Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,118,Interventional,"May 9, 2016","May 7, 2018",https://ClinicalTrials.gov/show/NCT02703636,50 Years to 85 Years ,50,40 to 65 years old
NCT01548430,A Safety Study of TTP4000 in Subjects With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,8,Interventional,October 2011,February 2013,https://ClinicalTrials.gov/show/NCT01548430,50 Years to 85 Years ,50,40 to 65 years old
NCT03197740,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,346,Interventional,"October 12, 2017","November 30, 2019",https://ClinicalTrials.gov/show/NCT03197740,50 Years to 85 Years ,50,40 to 65 years old
NCT02956486,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,950,Interventional,"October 20, 2016","November 21, 2023",https://ClinicalTrials.gov/show/NCT02956486,50 Years to 85 Years ,50,40 to 65 years old
NCT03204604,The Brain Ketone Body Challenge Imaging Study,Withdrawn,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,"August 8, 2016",March 2019,https://ClinicalTrials.gov/show/NCT03204604,50 Years to 85 Years ,50,40 to 65 years old
NCT00498602,Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,160,Interventional,November 2007,February 2013,https://ClinicalTrials.gov/show/NCT00498602,50 Years to 85 Years ,50,40 to 65 years old
NCT00960531,A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,160,Interventional,July 2009,December 2013,https://ClinicalTrials.gov/show/NCT00960531,50 Years to 85 Years ,50,40 to 65 years old
NCT00752232,Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Interventional,December 2008,July 2012,https://ClinicalTrials.gov/show/NCT00752232,50 Years to 85 Years ,50,40 to 65 years old
NCT02670083,CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,813,Interventional,"March 22, 2016","May 31, 2019",https://ClinicalTrials.gov/show/NCT02670083,50 Years to 85 Years ,50,40 to 65 years old
NCT02947893,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,42,Interventional,January 2017,February 2020,https://ClinicalTrials.gov/show/NCT02947893,50 Years to 85 Years ,50,40 to 65 years old
NCT02875496,Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain,Recruiting,Early Onset Alzheimer Disease|Mild Cognitive Impairment|Depression|Aging,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,2000,Observational,August 2016,December 2022,https://ClinicalTrials.gov/show/NCT02875496,50 Years to 85 Years ,50,40 to 65 years old
NCT00104442,Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,80,Interventional,October 2003,April 2006,https://ClinicalTrials.gov/show/NCT00104442,50 Years to 85 Years ,50,40 to 65 years old
NCT01453569,"Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",Completed,Alzheimer Disease|Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,255,Interventional,October 2011,August 2013,https://ClinicalTrials.gov/show/NCT01453569,50 Years to 85 Years ,50,40 to 65 years old
NCT01850238,"Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease",Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,30,Interventional,May 2013,March 2015,https://ClinicalTrials.gov/show/NCT01850238,50 Years to 85 Years ,50,40 to 65 years old
NCT04040348,Alzheimer's Disease Stem Cells Multiple Infusions,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,10,Interventional,"September 16, 2019","September 1, 2021",https://ClinicalTrials.gov/show/NCT04040348,50 Years to 85 Years ,50,40 to 65 years old
NCT01093664,"Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Interventional,October 2009,July 2010,https://ClinicalTrials.gov/show/NCT01093664,50 Years to 85 Years ,50,40 to 65 years old
NCT00348192,SB-742457 And Donepezil In Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,200,Interventional,May 2006,,https://ClinicalTrials.gov/show/NCT00348192,50 Years to 85 Years ,50,40 to 65 years old
NCT01764243,Safety and Efficacy of MT-4666,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,450,Interventional,November 2012,July 2015,https://ClinicalTrials.gov/show/NCT01764243,50 Years to 85 Years ,50,40 to 65 years old
NCT02640092,Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,72,Interventional,"December 23, 2015","June 11, 2019",https://ClinicalTrials.gov/show/NCT02640092,50 Years to 85 Years ,50,40 to 65 years old
NCT01054976,The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,99,Interventional,October 2006,February 2009,https://ClinicalTrials.gov/show/NCT01054976,50 Years to 85 Years ,50,40 to 65 years old
NCT03748706,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,12,Interventional,"March 7, 2019","May 8, 2019",https://ClinicalTrials.gov/show/NCT03748706,50 Years to 85 Years ,50,40 to 65 years old
NCT02221947,"Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,9,Interventional,June 2014,December 2014,https://ClinicalTrials.gov/show/NCT02221947,50 Years to 85 Years ,50,40 to 65 years old
NCT02322021,Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease,"Active, not recruiting","Alzheimer Disease|Dementia, Alzheimer Type",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,71,Interventional,"November 26, 2014","July 31, 2022",https://ClinicalTrials.gov/show/NCT02322021,50 Years to 85 Years ,50,40 to 65 years old
NCT02500784,Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease,Suspended,Alzheimer's Disease|Cognitive Dysfunction,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,60,Interventional,January 2023,July 2025,https://ClinicalTrials.gov/show/NCT02500784,50 Years to 85 Years ,50,40 to 65 years old
NCT01044758,Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI),Completed,Mild Cognitive Impairment (MCI),All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,96,Interventional,December 2009,July 2012,https://ClinicalTrials.gov/show/NCT01044758,50 Years to 85 Years ,50,40 to 65 years old
NCT03978338,A Study to Evaluate the Efficacy and Safety of Brain Polypeptide Solution in Mild Alzheimer's Disease,Not yet recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,July 2019,September 2020,https://ClinicalTrials.gov/show/NCT03978338,50 Years to 85 Years ,50,40 to 65 years old
NCT00112073,AAB-001 in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,234,Interventional,April 2005,December 2008,https://ClinicalTrials.gov/show/NCT00112073,50 Years to 85 Years ,50,40 to 65 years old
NCT04079803,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,60,Interventional,"August 15, 2019","April 15, 2020",https://ClinicalTrials.gov/show/NCT04079803,50 Years to 85 Years ,50,40 to 65 years old
NCT03587376,Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat),Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,9,Interventional,"May 30, 2018","August 23, 2018",https://ClinicalTrials.gov/show/NCT03587376,50 Years to 85 Years ,50,40 to 65 years old
NCT00334568,Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease,Terminated,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,12,Interventional,December 2004,July 2007,https://ClinicalTrials.gov/show/NCT00334568,50 Years to 85 Years ,50,40 to 65 years old
NCT01548287,A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment,Completed,Mild Cognitive Impairment|Mild Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,164,Interventional,April 2012,January 2013,https://ClinicalTrials.gov/show/NCT01548287,50 Years to 85 Years ,50,40 to 65 years old
NCT03828747,A Study of RO7105705 in Patients With Moderate Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,260,Interventional,"January 30, 2019","September 24, 2021",https://ClinicalTrials.gov/show/NCT03828747,50 Years to 85 Years ,50,40 to 65 years old
NCT03919669,A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking,Enrolling by invitation,Alzheimer Disease|Mild Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,42,Interventional,"April 1, 2019",September 2022,https://ClinicalTrials.gov/show/NCT03919669,50 Years to 85 Years ,50,40 to 65 years old
NCT02672306,Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,16,Interventional,"October 20, 2017",October 2019,https://ClinicalTrials.gov/show/NCT02672306,50 Years to 85 Years ,50,40 to 65 years old
NCT00500500,Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Interventional,July 2005,April 2008,https://ClinicalTrials.gov/show/NCT00500500,50 Years to 85 Years ,50,40 to 65 years old
NCT01715350,Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,151,Interventional,May 2012,June 2015,https://ClinicalTrials.gov/show/NCT01715350,50 Years to 85 Years ,50,40 to 65 years old
NCT03514875,Effects of Mitochondrial-targeted Antioxidant on Alzheimer's Disease,Not yet recruiting,"Alzheimer Disease|Alzheimer Disease, Early Onset",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,12,Interventional,"July 1, 2019","October 1, 2020",https://ClinicalTrials.gov/show/NCT03514875,50 Years to 85 Years ,50,40 to 65 years old
NCT00455000,"A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,37,Interventional,March 2007,September 2009,https://ClinicalTrials.gov/show/NCT00455000,50 Years to 85 Years ,50,40 to 65 years old
NCT03130036,Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning,Completed,Alzheimer Disease|Mild Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,34,Interventional,"June 9, 2015",June 2017,https://ClinicalTrials.gov/show/NCT03130036,50 Years to 85 Years ,50,40 to 65 years old
NCT02477800,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1605,Interventional,"August 31, 2015","April 30, 2022",https://ClinicalTrials.gov/show/NCT02477800,50 Years to 85 Years ,50,40 to 65 years old
NCT00397891,Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,80,Interventional,October 2006,February 2010,https://ClinicalTrials.gov/show/NCT00397891,50 Years to 85 Years ,50,40 to 65 years old
NCT02008513,Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006,Terminated,Alzheimer´s Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,194,Interventional,June 2013,September 2014,https://ClinicalTrials.gov/show/NCT02008513,50 Years to 85 Years ,50,40 to 65 years old
NCT00607308,"A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,20,Interventional,February 2008,October 2010,https://ClinicalTrials.gov/show/NCT00607308,50 Years to 85 Years ,50,40 to 65 years old
NCT02444637,Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD,Unknown status,Alzheimer Disease|CVA (Cerebrovascular Accident),All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,100,Interventional,April 2015,,https://ClinicalTrials.gov/show/NCT02444637,50 Years to 85 Years ,50,40 to 65 years old
NCT02593318,Trial of Oxaloacetate in Alzheimer's Disease (TOAD),Completed,Alzheimer's Disease (AD),All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,30,Interventional,October 2015,September 2018,https://ClinicalTrials.gov/show/NCT02593318,50 Years to 85 Years ,50,40 to 65 years old
NCT03980730,Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,300,Interventional,"June 27, 2019",July 2023,https://ClinicalTrials.gov/show/NCT03980730,50 Years to 85 Years ,50,40 to 65 years old
NCT02579252,24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,208,Interventional,March 2016,June 2019,https://ClinicalTrials.gov/show/NCT02579252,50 Years to 85 Years ,50,40 to 65 years old
NCT01348061,"Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls",Completed,Alzheimer Disease|Progressive Supranuclear Palsy,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,16,Observational,July 2011,July 2013,https://ClinicalTrials.gov/show/NCT01348061,50 Years to 85 Years ,50,40 to 65 years old
NCT00423085,Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,859,Interventional,January 2007,April 2010,https://ClinicalTrials.gov/show/NCT00423085,50 Years to 85 Years ,50,40 to 65 years old
NCT03036280,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,950,Interventional,"December 29, 2016","November 21, 2023",https://ClinicalTrials.gov/show/NCT03036280,50 Years to 85 Years ,50,40 to 65 years old
NCT02484547,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1605,Interventional,"September 30, 2015","April 30, 2022",https://ClinicalTrials.gov/show/NCT02484547,50 Years to 85 Years ,50,40 to 65 years old
NCT02711683,DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil,Recruiting,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,120,Observational,March 2016,March 2020,https://ClinicalTrials.gov/show/NCT02711683,50 Years to 85 Years ,50,40 to 65 years old
NCT03867253,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,Recruiting,Mild to Moderate Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,33,Interventional,"May 16, 2019","November 15, 2020",https://ClinicalTrials.gov/show/NCT03867253,50 Years to 85 Years ,50,40 to 65 years old
NCT03739905,ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"December 6, 2018",December 2019,https://ClinicalTrials.gov/show/NCT03739905,50 Years to 85 Years ,50,40 to 65 years old
NCT01569516,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,288,Interventional,June 2011,October 2012,https://ClinicalTrials.gov/show/NCT01569516,50 Years to 85 Years ,50,40 to 65 years old
NCT01529619,"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,52,Interventional,March 2012,December 2013,https://ClinicalTrials.gov/show/NCT01529619,50 Years to 85 Years ,50,40 to 65 years old
NCT01399125,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,501,Interventional,July 2011,May 2013,https://ClinicalTrials.gov/show/NCT01399125,50 Years to 85 Years ,50,40 to 65 years old
NCT02293915,An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease,Completed,Mild to Moderate Alzheimer Disease|Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,818,Interventional,"April 1, 2014","September 28, 2018",https://ClinicalTrials.gov/show/NCT02293915,50 Years to 85 Years ,50,40 to 65 years old
NCT01953601,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Terminated,Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1454,Interventional,"November 5, 2013","April 17, 2018",https://ClinicalTrials.gov/show/NCT01953601,50 Years to 85 Years ,50,40 to 65 years old
NCT03422250,Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia,Completed,"Alzheimer Disease|Frontotemporal Dementia, Behavioral Variant",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,66,Interventional,"June 8, 2015","November 3, 2018",https://ClinicalTrials.gov/show/NCT03422250,50 Years to 85 Years ,50,40 to 65 years old
NCT01585272,Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia,Completed,Alzheimer's Dementia,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,121,Interventional,August 2012,June 2015,https://ClinicalTrials.gov/show/NCT01585272,50 Years to 85 Years ,50,40 to 65 years old
NCT01282619,Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,390,Interventional,May 2010,June 2012,https://ClinicalTrials.gov/show/NCT01282619,50 Years to 85 Years ,50,40 to 65 years old
NCT01485302,Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,48,Interventional,January 2012,February 2015,https://ClinicalTrials.gov/show/NCT01485302,50 Years to 85 Years ,50,40 to 65 years old
NCT02778438,A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,30,Observational,February 2016,August 2016,https://ClinicalTrials.gov/show/NCT02778438,50 Years to 85 Years ,50,40 to 65 years old
NCT01482013,Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease,Terminated,Mild Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,7,Interventional,October 2011,March 2012,https://ClinicalTrials.gov/show/NCT01482013,50 Years to 85 Years ,50,40 to 65 years old
NCT03801642,Dapagliflozin In Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,48,Interventional,"January 29, 2019",October 2020,https://ClinicalTrials.gov/show/NCT03801642,50 Years to 85 Years ,50,40 to 65 years old
NCT02406027,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,Terminated,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,90,Interventional,"July 2, 2015","June 28, 2018",https://ClinicalTrials.gov/show/NCT02406027,50 Years to 85 Years ,50,40 to 65 years old
NCT03221894,A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,90,Observational,"July 15, 2017",September 2017,https://ClinicalTrials.gov/show/NCT03221894,50 Years to 85 Years ,50,40 to 65 years old
NCT00265148,Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,80,Interventional,May 2004,July 2008,https://ClinicalTrials.gov/show/NCT00265148,50 Years to 85 Years ,50,40 to 65 years old
NCT03119961,Blood Brain Barrier Opening in Alzheimer' Disease,Unknown status,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Interventional,"June 26, 2017","July 1, 2019",https://ClinicalTrials.gov/show/NCT03119961,50 Years to 85 Years ,50,40 to 65 years old
NCT02260674,A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,114,Interventional,November 2014,June 2016,https://ClinicalTrials.gov/show/NCT02260674,50 Years to 85 Years ,50,40 to 65 years old
NCT00021723,"Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,375,Interventional,September 2001,September 2003,https://ClinicalTrials.gov/show/NCT00021723,50 Years to 85 Years ,50,40 to 65 years old
NCT01614886,"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,216,Interventional,July 2012,May 2014,https://ClinicalTrials.gov/show/NCT01614886,50 Years to 85 Years ,50,40 to 65 years old
NCT03507192,Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.,Recruiting,Mild Cognitive Impairment|Alzheimer Dementia,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"September 25, 2017","December 31, 2019",https://ClinicalTrials.gov/show/NCT03507192,50 Years to 85 Years ,50,40 to 65 years old
NCT01073228,Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease|Central Nervous System Diseases|Cognition,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,409,Interventional,April 2010,February 2012,https://ClinicalTrials.gov/show/NCT01073228,50 Years to 85 Years ,50,40 to 65 years old
NCT03605667,Study of BHV-4157 in Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,292,Interventional,"July 31, 2018","December 20, 2020",https://ClinicalTrials.gov/show/NCT03605667,50 Years to 85 Years ,50,40 to 65 years old
NCT00959192,"Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,32,Interventional,August 2009,January 2013,https://ClinicalTrials.gov/show/NCT00959192,50 Years to 85 Years ,50,40 to 65 years old
NCT00479557,"Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,86,Interventional,May 2007,January 2013,https://ClinicalTrials.gov/show/NCT00479557,50 Years to 85 Years ,50,40 to 65 years old
NCT03612622,Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Early Alzheimer's Disease,Recruiting,Transcranial Magnetic Stimulation|Magnetic Resonance Imaging|Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,"May 1, 2018","December 30, 2020",https://ClinicalTrials.gov/show/NCT03612622,50 Years to 85 Years ,50,40 to 65 years old
NCT01224106,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,799,Interventional,"November 30, 2010","August 28, 2020",https://ClinicalTrials.gov/show/NCT01224106,50 Years to 85 Years ,50,40 to 65 years old
NCT00812565,Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,58,Interventional,February 2009,September 2010,https://ClinicalTrials.gov/show/NCT00812565,50 Years to 85 Years ,50,40 to 65 years old
NCT00990613,A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin,Completed,Alzheimer's Disease|Huntington's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,19,Interventional,October 2009,January 2010,https://ClinicalTrials.gov/show/NCT00990613,50 Years to 85 Years ,50,40 to 65 years old
NCT00708552,Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,576,Interventional,"July 4, 2008","March 9, 2010",https://ClinicalTrials.gov/show/NCT00708552,50 Years to 85 Years ,50,40 to 65 years old
NCT03752294,A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.,Not yet recruiting,Mild Cognitive Impairment|Mild Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,40,Interventional,November 2018,December 2021,https://ClinicalTrials.gov/show/NCT03752294,50 Years to 85 Years ,50,40 to 65 years old
NCT01350362,"Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients",Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,306,Interventional,April 2011,October 2012,https://ClinicalTrials.gov/show/NCT01350362,50 Years to 85 Years ,50,40 to 65 years old
NCT00506415,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1584,Interventional,June 2007,May 2011,https://ClinicalTrials.gov/show/NCT00506415,50 Years to 85 Years ,50,40 to 65 years old
NCT03250741,Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,94,Interventional,June 2016,November 2018,https://ClinicalTrials.gov/show/NCT03250741,50 Years to 85 Years ,50,40 to 65 years old
NCT03277573,Salsalate in Patients Mild to Moderate Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,40,Interventional,"July 21, 2017","October 21, 2019",https://ClinicalTrials.gov/show/NCT03277573,50 Years to 85 Years ,50,40 to 65 years old
NCT03493282,Effect of CT1812 Treatment on Brain Synaptic Density,Recruiting,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,21,Interventional,"April 20, 2018","July 30, 2020",https://ClinicalTrials.gov/show/NCT03493282,50 Years to 85 Years ,50,40 to 65 years old
NCT00381238,Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,33,Interventional,"June 20, 2006","February 3, 2009",https://ClinicalTrials.gov/show/NCT00381238,50 Years to 85 Years ,50,40 to 65 years old
NCT01600859,Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02),Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,65,Interventional,July 2012,October 2013,https://ClinicalTrials.gov/show/NCT01600859,50 Years to 85 Years ,50,40 to 65 years old
NCT03810794,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease,Recruiting,Alzheimer Disease|Cognitive Impairment,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,180,Interventional,"March 1, 2019","September 30, 2021",https://ClinicalTrials.gov/show/NCT03810794,50 Years to 85 Years ,50,40 to 65 years old
NCT02518412,Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease,Unknown status,Alzheimer Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,May 2013,February 2016,https://ClinicalTrials.gov/show/NCT02518412,50 Years to 85 Years ,50,40 to 65 years old
NCT01948791,16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 4,222,Interventional,August 2014,September 2015,https://ClinicalTrials.gov/show/NCT01948791,50 Years to 85 Years ,50,40 to 65 years old
NCT02580305,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,563,Interventional,September 2015,October 2019,https://ClinicalTrials.gov/show/NCT02580305,50 Years to 85 Years ,50,40 to 65 years old
NCT03639987,A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities,"Active, not recruiting",Cognitive Dysfunction|Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,500,Interventional,"December 20, 2018","November 13, 2023",https://ClinicalTrials.gov/show/NCT03639987,50 Years to 85 Years ,50,40 to 65 years old
NCT02585934,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,Completed,Alzheimer's Disease,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1315,Interventional,October 2015,September 2017,https://ClinicalTrials.gov/show/NCT02585934,50 Years to 85 Years ,50,40 to 65 years old
NCT03172117,Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.,Recruiting,Alzheimer's Disease,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 1|Phase 2,45,Interventional,"May 19, 2017","December 31, 2021",https://ClinicalTrials.gov/show/NCT03172117,50 Years to 86 Years ,50,40 to 65 years old
NCT00736775,"A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 1,56,Interventional,August 2008,,https://ClinicalTrials.gov/show/NCT00736775,50 Years to 86 Years ,50,40 to 65 years old
NCT02586909,12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension,Terminated,Alzheimer's Disease,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 3,1100,Interventional,April 2016,March 2018,https://ClinicalTrials.gov/show/NCT02586909,50 Years to 86 Years ,50,40 to 65 years old
NCT02031198,"18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 86 Years   (Adult, Older Adult)",Phase 1,25,Interventional,January 2014,December 2016,https://ClinicalTrials.gov/show/NCT02031198,50 Years to 86 Years ,50,40 to 65 years old
NCT02155946,Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment,Recruiting,Mild Cognitive Impairment|Alzheimer's Disease,All,"50 Years to 88 Years   (Adult, Older Adult)",Not Applicable,100,Interventional,"December 1, 2014","December 31, 2020",https://ClinicalTrials.gov/show/NCT02155946,50 Years to 88 Years ,50,40 to 65 years old
NCT00676143,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,Terminated,Alzheimer Disease,All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1100,Interventional,January 2008,November 2012,https://ClinicalTrials.gov/show/NCT00676143,50 Years to 88 Years ,50,40 to 65 years old
NCT00575055,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),Completed,Alzheimer's Disease,All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1121,Interventional,December 2007,April 2012,https://ClinicalTrials.gov/show/NCT00575055,50 Years to 88 Years ,50,40 to 65 years old
NCT00574132,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),Completed,Alzheimer's Disease,All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1331,Interventional,December 2007,June 2012,https://ClinicalTrials.gov/show/NCT00574132,50 Years to 88 Years ,50,40 to 65 years old
NCT01958437,Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"50 Years to 88 Years   (Adult, Older Adult)",Not Applicable,44,Interventional,"October 1, 2013","March 24, 2017",https://ClinicalTrials.gov/show/NCT01958437,50 Years to 88 Years ,50,40 to 65 years old
NCT02262975,A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS),Completed,Alzheimer's Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 4,532,Observational,July 2014,August 2016,https://ClinicalTrials.gov/show/NCT02262975,50 Years to 89 Years ,50,40 to 65 years old
NCT02434666,Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07,Completed,Dementia of the Alzheimer's Type,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,21,Interventional,"January 8, 2015","November 22, 2016",https://ClinicalTrials.gov/show/NCT02434666,50 Years to 89 Years ,50,40 to 65 years old
NCT04032626,MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients,Not yet recruiting,"Cognitive Impairment, Mild|Cognitive Dysfunction|Amyloid Plaque|Neurodegeneration|Inflammation, Brain",All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,30,Interventional,September 2019,September 2024,https://ClinicalTrials.gov/show/NCT04032626,50 Years to 89 Years ,50,40 to 65 years old
NCT00916617,Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab,Terminated,Alzheimer Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,62,Interventional,June 2009,September 2012,https://ClinicalTrials.gov/show/NCT00916617,50 Years to 89 Years ,50,40 to 65 years old
NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Completed,Alzheimer´s Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,390,Interventional,December 2008,December 2012,https://ClinicalTrials.gov/show/NCT00818662,50 Years to 89 Years ,50,40 to 65 years old
NCT02462161,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 1,24,Interventional,"March 20, 2015","April 16, 2019",https://ClinicalTrials.gov/show/NCT02462161,50 Years to 89 Years ,50,40 to 65 years old
NCT01524887,"Phase 3 IGIV, 10% in Alzheimer´s Disease",Terminated,Alzheimer´s Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,508,Interventional,January 2012,July 2013,https://ClinicalTrials.gov/show/NCT01524887,50 Years to 89 Years ,50,40 to 65 years old
NCT03790774,Neurofeedback in Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Not Applicable,6,Interventional,"June 6, 2019",July 2020,https://ClinicalTrials.gov/show/NCT03790774,50 Years to 89 Years ,50,40 to 65 years old
NCT03919162,A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD,Not yet recruiting,Early Alzheimer's Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,462,Interventional,January 2020,April 2023,https://ClinicalTrials.gov/show/NCT03919162,50 Years to 89 Years ,50,40 to 65 years old
NCT02389413,Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,120,Interventional,March 2015,April 2017,https://ClinicalTrials.gov/show/NCT02389413,50 Years to 89 Years ,50,40 to 65 years old
NCT01547169,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,60,Interventional,March 2011,December 2012,https://ClinicalTrials.gov/show/NCT01547169,50 Years to 89 Years ,50,40 to 65 years old
NCT02910102,Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia,Completed,Alzheimer's Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,38,Interventional,October 2016,November 2017,https://ClinicalTrials.gov/show/NCT02910102,50 Years to 89 Years ,50,40 to 65 years old
NCT00667810,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,Terminated,Alzheimer Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,901,Interventional,June 2008,August 2013,https://ClinicalTrials.gov/show/NCT00667810,50 Years to 89 Years ,50,40 to 65 years old
NCT01595646,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,37,Interventional,November 2011,"March 12, 2015",https://ClinicalTrials.gov/show/NCT01595646,50 Years to 89 Years ,50,40 to 65 years old
NCT00880555,"Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)",Completed,Alzheimer Disease|Dementia,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 4,78,Observational,April 2009,May 2014,https://ClinicalTrials.gov/show/NCT00880555,50 Years to 89 Years ,50,40 to 65 years old
NCT02549196,A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type,Completed,Dementia of Alzheimer's Type,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,28,Interventional,"October 7, 2015","September 28, 2017",https://ClinicalTrials.gov/show/NCT02549196,50 Years to 89 Years ,50,40 to 65 years old
NCT01193608,Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 1,88,Interventional,September 2010,October 2013,https://ClinicalTrials.gov/show/NCT01193608,50 Years to 89 Years ,50,40 to 65 years old
NCT01284387,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,126,Interventional,January 2011,February 2014,https://ClinicalTrials.gov/show/NCT01284387,50 Years to 89 Years ,50,40 to 65 years old
NCT01254773,Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,146,Interventional,December 2010,March 2013,https://ClinicalTrials.gov/show/NCT01254773,50 Years to 89 Years ,50,40 to 65 years old
NCT00663026,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,Completed,Alzheimer Disease,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 2,79,Interventional,November 2008,October 2010,https://ClinicalTrials.gov/show/NCT00663026,50 Years to 89 Years ,50,40 to 65 years old
NCT01849042,Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease,Unknown status,Alzheimer's Disease|Dementia,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,188,Interventional,January 2013,August 2015,https://ClinicalTrials.gov/show/NCT01849042,50 Years to 90 Years ,50,40 to 65 years old
NCT00743743,Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease,Withdrawn,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,0,Interventional,September 2008,December 2010,https://ClinicalTrials.gov/show/NCT00743743,50 Years to 90 Years ,50,40 to 65 years old
NCT02502253,BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM),Recruiting,Mild Cognitive Impairment|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,48,Interventional,June 2015,October 2019,https://ClinicalTrials.gov/show/NCT02502253,50 Years to 90 Years ,50,40 to 65 years old
NCT00684281,"Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment",Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,July 2008,December 2011,https://ClinicalTrials.gov/show/NCT00684281,50 Years to 90 Years ,50,40 to 65 years old
NCT03430869,Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK),"Active, not recruiting",Major Depressive Disorder,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,60,Interventional,"March 23, 2018","December 31, 2020",https://ClinicalTrials.gov/show/NCT03430869,50 Years to 90 Years ,50,40 to 65 years old
NCT02359552,Rasagiline Rescue in Alzheimer's Disease Clinical Trial,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,27,Interventional,May 2015,"January 4, 2019",https://ClinicalTrials.gov/show/NCT02359552,50 Years to 90 Years ,50,40 to 65 years old
NCT00672945,A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil,Terminated,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,420,Interventional,April 2008,,https://ClinicalTrials.gov/show/NCT00672945,50 Years to 90 Years ,50,40 to 65 years old
NCT00110552,Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients,Completed,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,111,Interventional,July 2005,October 2014,https://ClinicalTrials.gov/show/NCT00110552,50 Years to 90 Years ,50,40 to 65 years old
NCT01782742,Bexarotene Amyloid Treatment for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,20,Interventional,February 2013,December 2014,https://ClinicalTrials.gov/show/NCT01782742,50 Years to 90 Years ,50,40 to 65 years old
NCT00624026,Memantine - Communication Study,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,107,Interventional,November 2007,December 2008,https://ClinicalTrials.gov/show/NCT00624026,50 Years to 90 Years ,50,40 to 65 years old
NCT02503501,Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease,"Active, not recruiting",Mild Cognitive Impairment|Alzheimer's Disease (AD),All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,49,Interventional,August 2015,November 2019,https://ClinicalTrials.gov/show/NCT02503501,50 Years to 90 Years ,50,40 to 65 years old
NCT00973518,Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG),Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,160,Observational,September 2009,June 2010,https://ClinicalTrials.gov/show/NCT00973518,50 Years to 90 Years ,50,40 to 65 years old
NCT03101085,S-Equol in Alzheimer's Disease 2 Trial,Recruiting,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Interventional,"May 5, 2017","June 30, 2020",https://ClinicalTrials.gov/show/NCT03101085,50 Years to 90 Years ,50,40 to 65 years old
NCT00348140,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,1468,Interventional,"July 12, 2006","March 20, 2009",https://ClinicalTrials.gov/show/NCT00348140,50 Years to 90 Years ,50,40 to 65 years old
NCT01404169,"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",Completed,Alzheimer's Type Dementia,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,260,Interventional,September 2011,September 2014,https://ClinicalTrials.gov/show/NCT01404169,50 Years to 90 Years ,50,40 to 65 years old
NCT01584440,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients",Completed,Agitation|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,220,Interventional,June 2012,September 2014,https://ClinicalTrials.gov/show/NCT01584440,50 Years to 90 Years ,50,40 to 65 years old
NCT01874418,Biomarker Study to Diagnose Alzheimer's Disease,Unknown status,Alzheimer Disease|Mild Cognitive Impairment,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,90,Interventional,March 2012,February 2015,https://ClinicalTrials.gov/show/NCT01874418,50 Years to 90 Years ,50,40 to 65 years old
NCT00481520,"Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease",Completed,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,72,Interventional,June 2007,January 2008,https://ClinicalTrials.gov/show/NCT00481520,50 Years to 90 Years ,50,40 to 65 years old
NCT01940952,Zydena on Cognitive Function of Alzheimer's Disease Patients,Unknown status,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,210,Interventional,September 2013,,https://ClinicalTrials.gov/show/NCT01940952,50 Years to 90 Years ,50,40 to 65 years old
NCT00688207,Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR),Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,14,Interventional,April 2008,September 2008,https://ClinicalTrials.gov/show/NCT00688207,50 Years to 90 Years ,50,40 to 65 years old
NCT01600469,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,86,Interventional,January 2012,May 2013,https://ClinicalTrials.gov/show/NCT01600469,50 Years to 90 Years ,50,40 to 65 years old
NCT03543878,Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials,Recruiting,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,10,Interventional,"November 16, 2018",December 2019,https://ClinicalTrials.gov/show/NCT03543878,50 Years to 90 Years ,50,40 to 65 years old
NCT03393520,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,Agitation in Patients With Dementia of the Alzheimer's Type,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,412,Interventional,"October 13, 2017",June 2021,https://ClinicalTrials.gov/show/NCT03393520,50 Years to 90 Years ,50,40 to 65 years old
NCT01122329,A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,17,Interventional,October 2010,January 2015,https://ClinicalTrials.gov/show/NCT01122329,50 Years to 90 Years ,50,40 to 65 years old
NCT01894620,The Effect of rTMS Treatment on Alzheimer's and Sleep Quality,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,11,Interventional,May 2013,October 2014,https://ClinicalTrials.gov/show/NCT01894620,50 Years to 90 Years ,50,40 to 65 years old
NCT01876823,Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment,Completed,Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Interventional,April 2006,March 2010,https://ClinicalTrials.gov/show/NCT01876823,50 Years to 90 Years ,50,40 to 65 years old
NCT00800709,Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,26,Interventional,July 2008,October 2010,https://ClinicalTrials.gov/show/NCT00800709,50 Years to 90 Years ,50,40 to 65 years old
NCT00678431,Randomized Trial of a Nutritional Supplement in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,27,Interventional,January 2008,June 2011,https://ClinicalTrials.gov/show/NCT00678431,50 Years to 90 Years ,50,40 to 65 years old
NCT02094729,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,26,Interventional,September 2013,May 2015,https://ClinicalTrials.gov/show/NCT02094729,50 Years to 90 Years ,50,40 to 65 years old
NCT02524405,BEAM: Brain-Eye Amyloid Memory Study,Recruiting,Alzheimer's Disease|Mild Cognitive Impairment|Vascular Cognitive Impairment|Parkinson's Disease|Lewy Body Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,345,Observational,February 2016,December 2021,https://ClinicalTrials.gov/show/NCT02524405,50 Years to 90 Years ,50,40 to 65 years old
NCT02051608,A Study of Gantenerumab in Participants With Mild Alzheimer Disease,"Active, not recruiting",Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,389,Interventional,"March 27, 2014","November 20, 2020",https://ClinicalTrials.gov/show/NCT02051608,50 Years to 90 Years ,50,40 to 65 years old
NCT01687153,A Study of Brain Aging in Vietnam War Veterans,Recruiting,Traumatic Brain Injury|Post Traumatic Stress Disorder|Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,420,Observational,October 2012,September 2019,https://ClinicalTrials.gov/show/NCT01687153,50 Years to 90 Years ,50,40 to 65 years old
NCT01436188,A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease,Completed,Healthy|Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,5,Interventional,September 2011,June 2013,https://ClinicalTrials.gov/show/NCT01436188,50 Years to 90 Years ,50,40 to 65 years old
NCT03325556,Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis,"Active, not recruiting",Dementia-related Psychosis,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,356,Interventional,"September 27, 2017",November 2019,https://ClinicalTrials.gov/show/NCT03325556,50 Years to 90 Years ,50,40 to 65 years old
NCT00531804,A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,60,Interventional,December 2006,September 2010,https://ClinicalTrials.gov/show/NCT00531804,50 Years to 90 Years ,50,40 to 65 years old
NCT04065061,"Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations",Completed,Supplement|Cognition Disorders in Old Age|Vision|fMRI,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,68,Interventional,"May 22, 2015","May 10, 2017",https://ClinicalTrials.gov/show/NCT04065061,50 Years to 90 Years ,50,40 to 65 years old
NCT00810147,"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,209,Interventional,February 2009,June 2010,https://ClinicalTrials.gov/show/NCT00810147,50 Years to 90 Years ,50,40 to 65 years old
NCT00348309,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1496,Interventional,"July 6, 2006","January 28, 2009",https://ClinicalTrials.gov/show/NCT00348309,50 Years to 90 Years ,50,40 to 65 years old
NCT02353598,A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease,Completed,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,77,Interventional,"February 26, 2015","March 26, 2019",https://ClinicalTrials.gov/show/NCT02353598,50 Years to 90 Years ,50,40 to 65 years old
NCT01864655,Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,24,Interventional,July 2013,,https://ClinicalTrials.gov/show/NCT01864655,50 Years to 90 Years ,50,40 to 65 years old
NCT03420807,Retinal Metabolic Imaging of Alzheimer Patient,Recruiting,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,50,Interventional,"December 4, 2017","September 26, 2020",https://ClinicalTrials.gov/show/NCT03420807,50 Years to 90 Years ,50,40 to 65 years old
NCT00428090,Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,862,Interventional,"February 27, 2007","September 5, 2008",https://ClinicalTrials.gov/show/NCT00428090,50 Years to 90 Years ,50,40 to 65 years old
NCT02531360,Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies,Completed,Alzheimer's Disease (AD)|Progressive Supranuclear Palsy (PSP)|Cortical Basal Syndrome (CBS)|Frontal Temporal Dementia (FTD),All,"50 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,7,Interventional,May 2015,August 2016,https://ClinicalTrials.gov/show/NCT02531360,50 Years to 90 Years ,50,40 to 65 years old
NCT02814045,Role of Hypoxia Ans Sleep Fragmentation in Alzheimer's Disease. and Sleep Fragmentation.,Recruiting,Alzheimer's Disease|Obstructive Sleep Apnea,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,144,Observational,November 2015,June 2019,https://ClinicalTrials.gov/show/NCT02814045,50 Years to 90 Years ,50,40 to 65 years old
NCT01642420,Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression,Unknown status,Alzheimers Disease|Mild Cognitive Impairment,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,115,Observational,April 2012,February 2017,https://ClinicalTrials.gov/show/NCT01642420,50 Years to 90 Years ,50,40 to 65 years old
NCT02442765,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Completed,Agitation in Patients With Dementia of the Alzheimer's Type,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,410,Interventional,September 2015,"February 27, 2019",https://ClinicalTrials.gov/show/NCT02442765,50 Years to 90 Years ,50,40 to 65 years old
NCT01767311,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","Active, not recruiting",Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,800,Interventional,"December 20, 2012","November 24, 2021",https://ClinicalTrials.gov/show/NCT01767311,50 Years to 90 Years ,50,40 to 65 years old
NCT01677572,"Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,197,Interventional,"October 5, 2012","July 31, 2019",https://ClinicalTrials.gov/show/NCT01677572,50 Years to 90 Years ,50,40 to 65 years old
NCT03503669,Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training,Recruiting,Mild Cognitive Impairment|Alzheimer's Disease,Female,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Interventional,"May 1, 2018",May 2021,https://ClinicalTrials.gov/show/NCT03503669,50 Years to 90 Years ,50,40 to 65 years old
NCT03860792,Therapeutic Diets in Alzheimer's Disease,Not yet recruiting,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,October 2019,November 2023,https://ClinicalTrials.gov/show/NCT03860792,50 Years to 90 Years ,50,40 to 65 years old
NCT01677754,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,542,Interventional,"October 24, 2012","June 12, 2015",https://ClinicalTrials.gov/show/NCT01677754,50 Years to 90 Years ,50,40 to 65 years old
NCT02446132,"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,Agitation in Patients With Dementia of the Alzheimer's Type,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,700,Interventional,December 2015,June 2022,https://ClinicalTrials.gov/show/NCT02446132,50 Years to 90 Years ,50,40 to 65 years old
NCT01811381,Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease,Recruiting,Mild Cognitive Impairment,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,80,Interventional,"January 20, 2014","December 31, 2019",https://ClinicalTrials.gov/show/NCT01811381,50 Years to 90 Years ,50,40 to 65 years old
NCT01094340,Thalidomide for Patients With Mild to Moderate Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Interventional,March 2010,January 2013,https://ClinicalTrials.gov/show/NCT01094340,50 Years to 90 Years ,50,40 to 65 years old
NCT01681602,Effect of Physical Exercise in Alzheimer Patients,Completed,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,200,Interventional,January 2012,June 2014,https://ClinicalTrials.gov/show/NCT01681602,50 Years to 90 Years ,50,40 to 65 years old
NCT00480870,The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients,Completed,"Alzheimer Disease|Sleep Apnea, Obstructive",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,65,Interventional,April 1999,January 2005,https://ClinicalTrials.gov/show/NCT00480870,50 Years to 90 Years ,50,40 to 65 years old
NCT03058965,Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain,Completed,Alzheimer Disease|Healthy Volunteers|Progressive Supranuclear Palsy,All,"50 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,12,Interventional,"November 29, 2016","May 11, 2018",https://ClinicalTrials.gov/show/NCT03058965,50 Years to 90 Years ,50,40 to 65 years old
NCT02560753,Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,36,Interventional,July 2015,"June 30, 2016",https://ClinicalTrials.gov/show/NCT02560753,50 Years to 90 Years ,50,40 to 65 years old
NCT02256306,The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study,Completed,Mild-To-Moderate Alzheimer's Disease|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,18,Interventional,September 2014,February 2017,https://ClinicalTrials.gov/show/NCT02256306,50 Years to 90 Years ,50,40 to 65 years old
NCT03352024,Impact of Hypno-analgesia on Pain During a Lumbar Puncture for Diagnosis of Alzheimer's Disease,Not yet recruiting,Cognitive Impairment|Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Interventional,January 2018,January 2020,https://ClinicalTrials.gov/show/NCT03352024,50 Years to 90 Years ,50,40 to 65 years old
NCT00663936,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,373,Interventional,April 2008,June 2011,https://ClinicalTrials.gov/show/NCT00663936,50 Years to 90 Years ,50,40 to 65 years old
NCT02521558,Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease,Recruiting,Memory Disorders|Mild Cognitive Impairment|Alzheimer's Disease,Female,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Interventional,September 2015,September 2020,https://ClinicalTrials.gov/show/NCT02521558,50 Years to 90 Years ,50,40 to 65 years old
NCT01978548,A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease,Completed,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,45,Interventional,December 2013,April 2015,https://ClinicalTrials.gov/show/NCT01978548,50 Years to 90 Years ,50,40 to 65 years old
NCT00087724,A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,510,Interventional,July 2004,September 2006,https://ClinicalTrials.gov/show/NCT00087724,50 Years to 90 Years ,50,40 to 65 years old
NCT01425957,Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment,Completed,MILD COGNITIVE IMPAIRMENT,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,229,Interventional,December 2011,October 2015,https://ClinicalTrials.gov/show/NCT01425957,50 Years to 90 Years ,50,40 to 65 years old
NCT01492374,"Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,40,Interventional,February 2012,October 2013,https://ClinicalTrials.gov/show/NCT01492374,50 Years to 90 Years ,50,40 to 65 years old
NCT01522404,Effects of Atomoxetine in Mild Cognitive Impairment,Completed,Mild Cognitive Impairment,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,39,Interventional,March 2012,"June 30, 2018",https://ClinicalTrials.gov/show/NCT01522404,50 Years to 90 Years ,50,40 to 65 years old
NCT01746706,Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).,Unknown status,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,October 2011,November 2017,https://ClinicalTrials.gov/show/NCT01746706,50 Years to 90 Years ,50,40 to 65 years old
NCT03443973,Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),Recruiting,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,760,Interventional,"August 22, 2018","March 2, 2023",https://ClinicalTrials.gov/show/NCT03443973,50 Years to 90 Years ,50,40 to 65 years old
NCT03441516,Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia,Enrolling by invitation,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,80,Interventional,"April 19, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03441516,50 Years to 90 Years ,50,40 to 65 years old
NCT02912936,A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease,Recruiting,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,September 2016,December 2019,https://ClinicalTrials.gov/show/NCT02912936,50 Years to 90 Years ,50,40 to 65 years old
NCT00735800,Telephone Support for Dementia Caregivers,Completed,Dementia,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,250,Interventional,February 2008,May 2013,https://ClinicalTrials.gov/show/NCT00735800,50 Years to 90 Years ,50,40 to 65 years old
NCT00151502,To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,600,Interventional,November 2002,July 2007,https://ClinicalTrials.gov/show/NCT00151502,50 Years to 90 Years ,50,40 to 65 years old
NCT01560585,Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Interventional,April 2012,August 2014,https://ClinicalTrials.gov/show/NCT01560585,50 Years to 90 Years ,50,40 to 65 years old
NCT02964611,Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration,Recruiting,Alzheimer's Disease|Parkinson's Disease|Frontotemporal Lobar Degeneration,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,120,Observational,January 2013,December 2019,https://ClinicalTrials.gov/show/NCT02964611,50 Years to 90 Years ,50,40 to 65 years old
NCT00814697,Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease,Completed,Alzheimer's Disease|Aphasia|Dementia,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,12,Interventional,December 2008,August 2012,https://ClinicalTrials.gov/show/NCT00814697,50 Years to 90 Years ,50,40 to 65 years old
NCT01380288,Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,300,Interventional,June 2011,"December 31, 2017",https://ClinicalTrials.gov/show/NCT01380288,50 Years to 90 Years ,50,40 to 65 years old
NCT00921297,Cataract Removal and Alzheimer's Disease,Completed,Cataracts|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,122,Interventional,June 2009,"March 30, 2017",https://ClinicalTrials.gov/show/NCT00921297,50 Years to 90 Years ,50,40 to 65 years old
NCT00766363,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease",Completed,Alzheimer's Disease|Central Nervous System Diseases,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,49,Interventional,October 2008,March 2009,https://ClinicalTrials.gov/show/NCT00766363,50 Years to 90 Years ,50,40 to 65 years old
NCT02686554,Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia,Recruiting,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,200,Observational,January 2016,December 2019,https://ClinicalTrials.gov/show/NCT02686554,50 Years to 90 Years ,50,40 to 65 years old
NCT01025466,Exelon Patch and Combination With Memantine Comparative Trial,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,206,Interventional,December 2008,April 2010,https://ClinicalTrials.gov/show/NCT01025466,50 Years to 90 Years ,50,40 to 65 years old
NCT03887455,A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease,Recruiting,Early Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,1566,Interventional,"March 27, 2019","March 7, 2024",https://ClinicalTrials.gov/show/NCT03887455,50 Years to 90 Years ,50,40 to 65 years old
NCT02356055,Mass Practice of Activities of Daily Living in Dementia (STOMP),Completed,Dementia|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,32,Interventional,October 2014,November 2016,https://ClinicalTrials.gov/show/NCT02356055,50 Years to 90 Years ,50,40 to 65 years old
NCT00693004,Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,236,Interventional,May 2008,,https://ClinicalTrials.gov/show/NCT00693004,50 Years to 90 Years ,50,40 to 65 years old
NCT03444870,Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),Recruiting,Alzheimer Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,760,Interventional,"June 6, 2018","March 2, 2023",https://ClinicalTrials.gov/show/NCT03444870,50 Years to 90 Years ,50,40 to 65 years old
NCT00257673,Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,183,Interventional,November 2005,October 2007,https://ClinicalTrials.gov/show/NCT00257673,50 Years to 90 Years ,50,40 to 65 years old
NCT02442778,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Completed,Agitation in Patients With Dementia of the Alzheimer's Type,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,522,Interventional,September 2015,"September 9, 2019",https://ClinicalTrials.gov/show/NCT02442778,50 Years to 90 Years ,50,40 to 65 years old
NCT04100057,Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia,Not yet recruiting,Alzheimer Disease|Mild Cognitive Impairment|Neuropsychiatric Symptoms|Sleep Disturbance,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,150,Interventional,"October 1, 2019","August 30, 2024",https://ClinicalTrials.gov/show/NCT04100057,50 Years to 90 Years ,50,40 to 65 years old
NCT02750306,Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061),Completed,Insomnia|Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,285,Interventional,"May 23, 2016","September 30, 2018",https://ClinicalTrials.gov/show/NCT02750306,50 Years to 90 Years ,50,40 to 65 years old
NCT01703702,Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,641,Interventional,October 2012,April 2015,https://ClinicalTrials.gov/show/NCT01703702,50 Years to 90 Years ,50,40 to 65 years old
NCT01615666,A Composite MR Neuroimaging Marker for Alzheimer's Disease,Withdrawn,Alzheimer's Disease|Mild Cognitive Impairment|Frontotemporal Dementia,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,0,Observational,March 2009,January 2016,https://ClinicalTrials.gov/show/NCT01615666,50 Years to 90 Years ,50,40 to 65 years old
NCT01369225,Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 1,52,Interventional,July 2011,August 2014,https://ClinicalTrials.gov/show/NCT01369225,50 Years to 90 Years ,50,40 to 65 years old
NCT00083421,Effects of ONO-2506PO in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,647,Interventional,June 2004,July 2007,https://ClinicalTrials.gov/show/NCT00083421,50 Years to 90 Years ,50,40 to 65 years old
NCT00580931,Safety Study of Nicotinamide to Treat Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Interventional,January 2008,July 2014,https://ClinicalTrials.gov/show/NCT00580931,50 Years to 95 Years ,50,40 to 65 years old
NCT03073876,Detecting an Early Response to Donepezil With Measures of Visual Attention,"Active, not recruiting",Alzheimer Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,24,Interventional,"December 1, 2005","July 31, 2019",https://ClinicalTrials.gov/show/NCT03073876,50 Years to 95 Years ,50,40 to 65 years old
NCT00009217,Treatment of Behavioral Symptoms in Alzheimer's Disease,Completed,Alzheimer's Disease|Psychosis|Agitation,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,44,Interventional,January 1999,December 2004,https://ClinicalTrials.gov/show/NCT00009217,50 Years to 95 Years ,50,40 to 65 years old
NCT00417482,Antipsychotic Discontinuation in Alzheimer's Disease,Completed,Alzheimer Disease|Psychotic Disorders|Agitation|Aggression,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,180,Interventional,August 2004,April 2011,https://ClinicalTrials.gov/show/NCT00417482,50 Years to 95 Years ,50,40 to 65 years old
NCT01703117,Riluzole in Mild Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,48,Interventional,November 2013,November 2020,https://ClinicalTrials.gov/show/NCT01703117,50 Years to 95 Years ,50,40 to 65 years old
NCT01636596,Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease,Withdrawn,Alzheimer's Disease|Mild Cognitive Impairment,All,"50 Years to 95 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,September 2013,January 2015,https://ClinicalTrials.gov/show/NCT01636596,50 Years to 95 Years ,50,40 to 65 years old
NCT01273272,Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers,Completed,Alzheimer Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,50,Interventional,February 2011,September 2017,https://ClinicalTrials.gov/show/NCT01273272,50 Years to 95 Years ,50,40 to 65 years old
NCT00768261,Corticolimbic Degeneration and Treatment of Dementia,Completed,Dementia,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,39,Interventional,November 2004,October 2009,https://ClinicalTrials.gov/show/NCT00768261,50 Years to 95 Years ,50,40 to 65 years old
NCT00013650,Effects of an Anti-Inflammatory Drug in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 1,60,Interventional,"March 22, 2001","April 21, 2008",https://ClinicalTrials.gov/show/NCT00013650,50 Years to 95 Years ,50,40 to 65 years old
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Completed,Alzheimer Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 3,17,Interventional,May 2005,February 2010,https://ClinicalTrials.gov/show/NCT00255086,50 Years to 95 Years ,50,40 to 65 years old
NCT01772095,ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE,Completed,Alzheimer Disease|Dementia|Cognitive Disorders,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 4,389,Observational,February 2013,November 2013,https://ClinicalTrials.gov/show/NCT01772095,50 Years to 95 Years ,50,40 to 65 years old
NCT01766336,A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,296,Interventional,January 2013,August 2015,https://ClinicalTrials.gov/show/NCT01766336,50 Years to 95 Years ,50,40 to 65 years old
NCT01735630,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"50 Years to 95 Years   (Adult, Older Adult)",Phase 2,350,Interventional,November 2012,May 2015,https://ClinicalTrials.gov/show/NCT01735630,50 Years to 95 Years ,50,40 to 65 years old
NCT04121208,MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease,Not yet recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"50 Years to 99 Years   (Adult, Older Adult)",Phase 1,54,Interventional,November 2019,November 2021,https://ClinicalTrials.gov/show/NCT04121208,50 Years to 99 Years ,50,40 to 65 years old
NCT00911807,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,Completed,Alzheimer Disease,All,"51 Years and older   (Adult, Older Adult)",Phase 2,217,Interventional,October 2004,April 2008,https://ClinicalTrials.gov/show/NCT00911807,51 Years and older ,51,40 to 65 years old
NCT00996918,A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients,Terminated,Alzheimer Disease,All,"51 Years and older   (Adult, Older Adult)",Phase 3,198,Interventional,December 2009,November 2012,https://ClinicalTrials.gov/show/NCT00996918,51 Years and older ,51,40 to 65 years old
NCT01736579,"Long-Term Study of IGIV, 10% in Alzheimer´s Disease",Terminated,Alzheimer´s Disease,All,"51 Years and older   (Adult, Older Adult)",Phase 3,6,Interventional,November 2012,June 2013,https://ClinicalTrials.gov/show/NCT01736579,51 Years and older ,51,40 to 65 years old
NCT00937352,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"51 Years and older   (Adult, Older Adult)",Phase 3,896,Interventional,July 2009,September 2012,https://ClinicalTrials.gov/show/NCT00937352,51 Years and older ,51,40 to 65 years old
NCT01312363,Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients,Completed,Alzheimer's Disease,All,"51 Years to 85 Years   (Adult, Older Adult)",Phase 4,300,Observational,June 2009,July 2011,https://ClinicalTrials.gov/show/NCT01312363,51 Years to 85 Years ,51,40 to 65 years old
NCT00998764,A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients,Terminated,Alzheimer Disease,All,"51 Years to 90 Years   (Adult, Older Adult)",Phase 3,494,Interventional,December 2009,November 2012,https://ClinicalTrials.gov/show/NCT00998764,51 Years to 90 Years ,51,40 to 65 years old
NCT00490568,Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers,Terminated,Alzheimer's Disease,All,"51 Years to 91 Years   (Adult, Older Adult)",Phase 3,1461,Interventional,"August 8, 2007","June 1, 2009",https://ClinicalTrials.gov/show/NCT00490568,51 Years to 91 Years ,51,40 to 65 years old
NCT00550420,Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers,Terminated,Alzheimer's Disease,All,"51 Years to 91 Years   (Adult, Older Adult)",Phase 3,331,Interventional,"October 1, 2007","February 12, 2009",https://ClinicalTrials.gov/show/NCT00550420,51 Years to 91 Years ,51,40 to 65 years old
NCT01238991,"Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"52 Years to 87 Years   (Adult, Older Adult)",Phase 2,53,Interventional,December 2010,December 2013,https://ClinicalTrials.gov/show/NCT01238991,52 Years to 87 Years ,52,40 to 65 years old
NCT00385684,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,"Alzheimer Disease|Dementia|Dementia, Vascular|Pain",All,"55 Years and older   (Adult, Older Adult)",Phase 4,11,Interventional,October 2007,June 2014,https://ClinicalTrials.gov/show/NCT00385684,55 Years and older ,55,40 to 65 years old
NCT00013182,Effect of Activity on Sleep of Cognitively-Impaired Veterans,Completed,Alzheimer's Disease|Sleep Disorders,Male,"55 Years and older   (Adult, Older Adult)",Not Applicable,90,Interventional,,June 2001,https://ClinicalTrials.gov/show/NCT00013182,55 Years and older ,55,40 to 65 years old
NCT03330353,Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy,Recruiting,PSP - Progressive Supranuclear Palsy|PD - Parkinson's Disease|AD - Alzheimer's Disease|ALS (Amyotrophic Lateral Sclerosis),All,"55 Years and older   (Adult, Older Adult)",Phase 4,56,Observational,"November 1, 2017","October 1, 2019",https://ClinicalTrials.gov/show/NCT03330353,55 Years and older ,55,40 to 65 years old
NCT00012857,Pain Management and Behavioral Outcomes in Patients With Dementia,Completed,"Dementia|Alzheimer Disease, Pain|Behavior, Agitation",All,"55 Years and older   (Adult, Older Adult)",Phase 2,66,Interventional,,March 2001,https://ClinicalTrials.gov/show/NCT00012857,55 Years and older ,55,40 to 65 years old
NCT01733355,"A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807",Terminated,Alzheimers Disease|AD,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,11,Interventional,July 2012,March 2013,https://ClinicalTrials.gov/show/NCT01733355,55 Years and older ,55,40 to 65 years old
NCT02196545,Physical Activity Training Program for Patients With Alzheimer's Dementia,Completed,Dementia,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,August 2011,July 2013,https://ClinicalTrials.gov/show/NCT02196545,55 Years and older ,55,40 to 65 years old
NCT00249158,A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia,Completed,Dementia|Alzheimer Disease|Vascular Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,344,Interventional,March 1998,February 2001,https://ClinicalTrials.gov/show/NCT00249158,55 Years and older ,55,40 to 65 years old
NCT01058941,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,67,Interventional,September 2010,December 2014,https://ClinicalTrials.gov/show/NCT01058941,55 Years and older ,55,40 to 65 years old
NCT00249145,A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia,Completed,"Dementia|Alzheimer Disease|Dementia, Vascular",All,"55 Years and older   (Adult, Older Adult)",Phase 3,349,Interventional,April 1995,December 1996,https://ClinicalTrials.gov/show/NCT00249145,55 Years and older ,55,40 to 65 years old
NCT01264614,Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults,Completed,Cognitive Decline|Dementia|Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,22,Interventional,December 2010,April 2011,https://ClinicalTrials.gov/show/NCT01264614,55 Years and older ,55,40 to 65 years old
NCT00242593,Rosiglitazone Effects on Cognition for Adults in Later Life,Unknown status,Mild Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Phase 2,120,Interventional,June 2006,December 2011,https://ClinicalTrials.gov/show/NCT00242593,55 Years and older ,55,40 to 65 years old
NCT01723488,"A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808",Terminated,Alzheimers Disease,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,12,Interventional,July 2012,March 2013,https://ClinicalTrials.gov/show/NCT01723488,55 Years and older ,55,40 to 65 years old
NCT01068353,Safety and Tolerability of Etanercept in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,41,Interventional,January 2011,,https://ClinicalTrials.gov/show/NCT01068353,55 Years and older ,55,40 to 65 years old
NCT03556280,Multi-Center Study of Sensory Stimulation to Improve Brain Function,Recruiting,"Alzheimer Disease|Cognitive Impairment|Mild Cognitive Impairment|Dementia Alzheimers|Dementia, Mild|Dementia, Alzheimer Type|Dementia of Alzheimer Type|Dementia|Cognitive Impairment, Mild|Cognitive Decline",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"April 24, 2018",October 2019,https://ClinicalTrials.gov/show/NCT03556280,55 Years and older ,55,40 to 65 years old
NCT02908815,Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,November 2016,November 2020,https://ClinicalTrials.gov/show/NCT02908815,55 Years and older ,55,40 to 65 years old
NCT00090402,Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease,Completed,Alzheimer's Disease|Oxidative Stress|Dementia|Hyperlipidemia|Inflammation,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,39,Interventional,April 2004,August 2007,https://ClinicalTrials.gov/show/NCT00090402,55 Years and older ,55,40 to 65 years old
NCT03075241,Z-Drugs for Sleep Disorders in Alzheimer's Disease,Recruiting,Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,60,Interventional,October 2016,December 2020,https://ClinicalTrials.gov/show/NCT03075241,55 Years and older ,55,40 to 65 years old
NCT01142258,Trazodone for Sleep Disorders in Alzheimer's Disease,Completed,Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,40,Interventional,March 2010,August 2012,https://ClinicalTrials.gov/show/NCT01142258,55 Years and older ,55,40 to 65 years old
NCT03070535,APOE Genotype and Diet Influences on Alzheimer's Biomarkers,Recruiting,Alzheimer's Disease; Dementia,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,September 2016,"May 31, 2020",https://ClinicalTrials.gov/show/NCT03070535,55 Years and older ,55,40 to 65 years old
NCT00105547,Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's,Completed,Alzheimer Disease|Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1600,Interventional,February 2005,May 2008,https://ClinicalTrials.gov/show/NCT00105547,55 Years and older ,55,40 to 65 years old
NCT00253123,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia,Completed,"Dementia|Alzheimer Disease|Dementia, Vascular",All,"55 Years and older   (Adult, Older Adult)",Phase 3,626,Interventional,,March 1997,https://ClinicalTrials.gov/show/NCT00253123,55 Years and older ,55,40 to 65 years old
NCT03330587,Living Alone in Old Age With Cognitive Impairment,Recruiting,Living Alone|Alzheimer Disease|Mild Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,"March 1, 2016","September 1, 2020",https://ClinicalTrials.gov/show/NCT03330587,55 Years and older ,55,40 to 65 years old
NCT00621647,Seroquel- Agitation Associated With Dementia,Completed,Alzheimer's Disease|Vascular Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,333,Interventional,September 2002,November 2003,https://ClinicalTrials.gov/show/NCT00621647,55 Years and older ,55,40 to 65 years old
NCT01061489,Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment,Completed,Mild Cognitive Impairment (MCI)|Mild Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,65,Interventional,August 2009,March 2013,https://ClinicalTrials.gov/show/NCT01061489,55 Years and older ,55,40 to 65 years old
NCT01747213,Bisnorcymserine in Healthy Adult Volunteers,Completed,Alzheimer's Disease|Healthy Volunteers,All,"55 Years and older   (Adult, Older Adult)",Phase 1,75,Interventional,"January 1, 2013","January 8, 2019",https://ClinicalTrials.gov/show/NCT01747213,55 Years and older ,55,40 to 65 years old
NCT00762411,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1111,Interventional,September 2008,April 2011,https://ClinicalTrials.gov/show/NCT00762411,55 Years and older ,55,40 to 65 years old
NCT03821857,Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease,Recruiting,Alzheimer Disease,Female,"55 Years and older   (Adult, Older Adult)",Phase 4,200,Interventional,August 2019,May 2023,https://ClinicalTrials.gov/show/NCT03821857,55 Years and older ,55,40 to 65 years old
NCT03991195,Intervention of Intestinal Microorganism in Mild Cognitive Impairment,Recruiting,"Gut Microbiota|Mild Cognitive Impairment|Dementia, Alzheimer Type|Neuroimaging",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,June 2019,December 2021,https://ClinicalTrials.gov/show/NCT03991195,55 Years and older ,55,40 to 65 years old
NCT00357357,European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,40,Interventional,July 2006,August 2008,https://ClinicalTrials.gov/show/NCT00357357,55 Years and older ,55,40 to 65 years old
NCT02018913,Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study,Unknown status,Alzheimer's Disease|Vascular Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 4,140,Observational,April 2014,April 2018,https://ClinicalTrials.gov/show/NCT02018913,55 Years and older ,55,40 to 65 years old
NCT01802554,Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention,Completed,Depressive Symptoms|Inflammation,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,April 2008,February 2013,https://ClinicalTrials.gov/show/NCT01802554,55 Years and older ,55,40 to 65 years old
NCT00438568,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,173,Interventional,June 2006,December 2011,https://ClinicalTrials.gov/show/NCT00438568,55 Years and older ,55,40 to 65 years old
NCT01937221,Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease,Completed,Mild Cognitive Impairment|Mild to Moderate Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,September 2013,July 2017,https://ClinicalTrials.gov/show/NCT01937221,55 Years and older ,55,40 to 65 years old
NCT02317523,Alzheimer's Caregiver Coping: Mental and Physical Health,Completed,Alzheimer Disease|Alzheimer Dementia|Alzheimer's Disease|Dementia,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,151,Interventional,September 2014,"June 30, 2019",https://ClinicalTrials.gov/show/NCT02317523,55 Years and older ,55,40 to 65 years old
NCT00757939,A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED),Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,40,Interventional,September 2008,October 2010,https://ClinicalTrials.gov/show/NCT00757939,55 Years and older ,55,40 to 65 years old
NCT01780974,Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention,Completed,Treated Hypertension,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42,Interventional,April 2013,October 2015,https://ClinicalTrials.gov/show/NCT01780974,55 Years and older ,55,40 to 65 years old
NCT03761381,OCT Angiography and NRAI in Dementia,Recruiting,Alzheimer Disease|Dementia|Mild Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Phase 4,20,Observational,"September 14, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03761381,55 Years and older ,55,40 to 65 years old
NCT01183806,Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients,Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,40,Interventional,July 2010,March 2012,https://ClinicalTrials.gov/show/NCT01183806,55 Years and older ,55,40 to 65 years old
NCT02848404,Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application,Enrolling by invitation,Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,June 2016,March 2020,https://ClinicalTrials.gov/show/NCT02848404,55 Years and older ,55,40 to 65 years old
NCT02541929,Fish Oil Brain Delivery Study,"Active, not recruiting",Brain Health,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,31,Interventional,"June 30, 2016","September 30, 2019",https://ClinicalTrials.gov/show/NCT02541929,55 Years and older ,55,40 to 65 years old
NCT00325728,Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Chronic Insomnia,All,"55 Years and older   (Adult, Older Adult)",Phase 2,74,Interventional,"March 21, 2006","August 20, 2007",https://ClinicalTrials.gov/show/NCT00325728,55 Years and older ,55,40 to 65 years old
NCT02537496,Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,36,Interventional,"January 14, 2016","October 10, 2018",https://ClinicalTrials.gov/show/NCT02537496,55 Years and older ,55,40 to 65 years old
NCT01253122,Comparative Bioavailability in Healthy Elderly Volunteers,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,February 2010,April 2010,https://ClinicalTrials.gov/show/NCT01253122,55 Years and older ,55,40 to 65 years old
NCT02240693,Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,128,Interventional,"January 15, 2015","October 9, 2017",https://ClinicalTrials.gov/show/NCT02240693,55 Years and older ,55,40 to 65 years old
NCT01253499,Multiple Dose Study of TRx0037,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,31,Interventional,March 2010,May 2010,https://ClinicalTrials.gov/show/NCT01253499,55 Years and older ,55,40 to 65 years old
NCT03682874,Identifying Novel Aging Targets for Treatment of Delirium,Recruiting,Delirium|Dementia Alzheimers|Respiratory Failure,All,"55 Years and older   (Adult, Older Adult)",Phase 4,25,Observational,"October 10, 2018",October 2020,https://ClinicalTrials.gov/show/NCT03682874,55 Years and older ,55,40 to 65 years old
NCT03960476,Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults,Not yet recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,700,Interventional,"September 1, 2019","February 29, 2024",https://ClinicalTrials.gov/show/NCT03960476,55 Years and older ,55,40 to 65 years old
NCT02359864,Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,"October 1, 2019",May 2021,https://ClinicalTrials.gov/show/NCT02359864,55 Years and older ,55,40 to 65 years old
NCT02337907,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,329,Interventional,"January 21, 2015","October 10, 2017",https://ClinicalTrials.gov/show/NCT02337907,55 Years and older ,55,40 to 65 years old
NCT01867775,Mirtazapine for Sleep Disorders in Alzheimer's Disease,Unknown status,Alzheimer's Disease|Sleep Disorders,All,"55 Years and older   (Adult, Older Adult)",Phase 3,30,Interventional,May 2012,May 2014,https://ClinicalTrials.gov/show/NCT01867775,55 Years and older ,55,40 to 65 years old
NCT00420420,MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011),Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,144,Interventional,November 2006,August 2008,https://ClinicalTrials.gov/show/NCT00420420,55 Years and older ,55,40 to 65 years old
NCT00322036,Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's,Terminated,Alzheimer Disease|Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,800,Interventional,May 2006,December 2008,https://ClinicalTrials.gov/show/NCT00322036,55 Years and older ,55,40 to 65 years old
NCT03140865,Wake Forest Alzheimer's Disease Clinical Core,Recruiting,Alzheimer's Disease|Mild Cognitive Impairment|Prediabetic State,All,"55 Years and older   (Adult, Older Adult)",Phase 4,850,Observational,January 2014,June 2021,https://ClinicalTrials.gov/show/NCT03140865,55 Years and older ,55,40 to 65 years old
NCT03089827,Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease,Enrolling by invitation,Alzheimer Disease|Mild Cognitive Impairment,All,"55 Years and older   (Adult, Older Adult)",Phase 4,300,Observational,"May 21, 2014",January 2025,https://ClinicalTrials.gov/show/NCT03089827,55 Years and older ,55,40 to 65 years old
NCT00777608,A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED),Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,106,Interventional,December 2008,April 2010,https://ClinicalTrials.gov/show/NCT00777608,55 Years and older ,55,40 to 65 years old
NCT00359944,Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,171,Interventional,February 2006,September 2008,https://ClinicalTrials.gov/show/NCT00359944,55 Years and older ,55,40 to 65 years old
NCT00065689,High Intensity Light Therapy in Alzheimer's Disease,Completed,Alzheimer's Disease|Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,107,Interventional,March 2003,September 2005,https://ClinicalTrials.gov/show/NCT00065689,55 Years and older ,55,40 to 65 years old
NCT01127633,Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1457,Interventional,December 2010,February 2017,https://ClinicalTrials.gov/show/NCT01127633,55 Years and older ,55,40 to 65 years old
NCT01013610,"An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease",Completed,Mild Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,110,Interventional,November 2009,March 2011,https://ClinicalTrials.gov/show/NCT01013610,55 Years and older ,55,40 to 65 years old
NCT03179501,"NP001, Alzheimer's Disease, and Blood Markers of Inflammation",Terminated,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,4,Interventional,"September 1, 2017","July 31, 2018",https://ClinicalTrials.gov/show/NCT03179501,55 Years and older ,55,40 to 65 years old
NCT01658722,Retrieval of Patient Information After Discontinuation,Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 4,169,Observational,December 2011,August 2012,https://ClinicalTrials.gov/show/NCT01658722,55 Years and older ,55,40 to 65 years old
NCT03748303,Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study,Not yet recruiting,Alzheimer Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 1,12,Interventional,"October 15, 2019",October 2020,https://ClinicalTrials.gov/show/NCT03748303,55 Years and older ,55,40 to 65 years old
NCT00056225,VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study),Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,340,Interventional,January 2003,June 2007,https://ClinicalTrials.gov/show/NCT00056225,55 Years and older ,55,40 to 65 years old
NCT00254033,Apathy Associated With Alzheimer's Disease,Completed,Dementia|Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 4,40,Interventional,October 2003,October 2006,https://ClinicalTrials.gov/show/NCT00254033,55 Years and older ,55,40 to 65 years old
NCT02351882,Safety and Efficacy of Nabilone in Alzheimer's Disease,Completed,Alzheimer Disease|Agitation|Weight Loss|Pain|Oxidative Stress,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Interventional,January 2015,March 2019,https://ClinicalTrials.gov/show/NCT02351882,55 Years and older ,55,40 to 65 years old
NCT00594568,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1537,Interventional,March 2008,May 2011,https://ClinicalTrials.gov/show/NCT00594568,55 Years and older ,55,40 to 65 years old
NCT00083590,Huperzine A in Alzheimer's Disease,Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,150,Interventional,April 2004,November 2007,https://ClinicalTrials.gov/show/NCT00083590,55 Years and older ,55,40 to 65 years old
NCT02035982,Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease,Completed,Alzheimer's Disease|Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 3,40,Interventional,July 2010,September 2015,https://ClinicalTrials.gov/show/NCT02035982,55 Years and older ,55,40 to 65 years old
NCT01195389,Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease,Unknown status,Alzheimer's Dementia,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,December 2010,October 2011,https://ClinicalTrials.gov/show/NCT01195389,55 Years and older ,55,40 to 65 years old
NCT00739037,Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease,Terminated,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,10,Interventional,August 2008,December 2008,https://ClinicalTrials.gov/show/NCT00739037,55 Years and older ,55,40 to 65 years old
NCT03933696,"Light, Metabolic Syndrome and Alzheimer's Disease",Recruiting,Mild Cognitive Impairment|Alzheimer Disease|Type2 Diabetes,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,"April 1, 2019","September 1, 2022",https://ClinicalTrials.gov/show/NCT03933696,55 Years and older ,55,40 to 65 years old
NCT00495820,Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study,Completed,Alzheimer's Disease|Apathy|Dementia,All,"55 Years and older   (Adult, Older Adult)",Phase 4,60,Interventional,August 2007,June 2010,https://ClinicalTrials.gov/show/NCT00495820,55 Years and older ,55,40 to 65 years old
NCT01313806,Study of Magnetic Fields to Treat Alzheimer's Disease,Withdrawn,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,September 2011,September 2012,https://ClinicalTrials.gov/show/NCT01313806,55 Years and older ,55,40 to 65 years old
NCT00596024,Lutein and Alzheimer's Disease Study,Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,3,Interventional,December 2007,July 2009,https://ClinicalTrials.gov/show/NCT00596024,55 Years and older ,55,40 to 65 years old
NCT02788513,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"Active, not recruiting",Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,611,Interventional,"August 11, 2016","October 18, 2019",https://ClinicalTrials.gov/show/NCT02788513,55 Years and older ,55,40 to 65 years old
NCT03777722,Light and the Effect on Metabolic Syndrome and Alzheimer's Disease,Recruiting,"Alzheimer Disease|Diabetes Mellitus, Type 2",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,"November 1, 2018","October 31, 2023",https://ClinicalTrials.gov/show/NCT03777722,55 Years and older ,55,40 to 65 years old
NCT00034762,Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease,Completed,Dementia|Alzheimer Disease|Mental Disorders,All,"55 Years and older   (Adult, Older Adult)",Phase 3,473,Interventional,December 2000,January 2003,https://ClinicalTrials.gov/show/NCT00034762,55 Years and older ,55,40 to 65 years old
NCT01459016,A Non-drug Methods Study in Participants With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,56,Interventional,December 2011,December 2014,https://ClinicalTrials.gov/show/NCT01459016,55 Years and older ,55,40 to 65 years old
NCT03347084,Deep Brain Stimulation With LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease,Recruiting,Brain Imaging|Mild Cognitive Impairment|Alzheimer Disease|Deep Brain Stimulation,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,8,Interventional,"November 10, 2018","March 1, 2020",https://ClinicalTrials.gov/show/NCT03347084,55 Years and older ,55,40 to 65 years old
NCT01266525,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,Completed,Dementia Alzheimer's Type,All,"55 Years and older   (Adult, Older Adult)",Phase 2,291,Interventional,February 2011,January 2013,https://ClinicalTrials.gov/show/NCT01266525,55 Years and older ,55,40 to 65 years old
NCT01000870,Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513,Terminated,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,6,Interventional,October 2009,September 2010,https://ClinicalTrials.gov/show/NCT01000870,55 Years and older ,55,40 to 65 years old
NCT00905372,Effect of LY2062430 on the Progression of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1000,Interventional,May 2009,April 2012,https://ClinicalTrials.gov/show/NCT00905372,55 Years and older ,55,40 to 65 years old
NCT03082755,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 4,136,Interventional,"July 1, 2017","March 31, 2022",https://ClinicalTrials.gov/show/NCT03082755,55 Years and older ,55,40 to 65 years old
NCT00392912,Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone,Completed,Alzheimer's Disease|Hypogonadism,Male,"55 Years and older   (Adult, Older Adult)",Not Applicable,10,Interventional,April 2007,July 2010,https://ClinicalTrials.gov/show/NCT00392912,55 Years and older ,55,40 to 65 years old
NCT01561430,Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70,Interventional,March 2012,August 2013,https://ClinicalTrials.gov/show/NCT01561430,55 Years and older ,55,40 to 65 years old
NCT00362024,MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED),Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,24,Interventional,November 2006,November 2007,https://ClinicalTrials.gov/show/NCT00362024,55 Years and older ,55,40 to 65 years old
NCT02817906,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",Terminated,"Agitation in Dementia, Including Alzheimer's Disease",All,"55 Years and older   (Adult, Older Adult)",Phase 3,177,Interventional,June 2016,December 2018,https://ClinicalTrials.gov/show/NCT02817906,55 Years and older ,55,40 to 65 years old
NCT00183378,Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease,Completed,Alzheimer Disease|Sleep Initiation and Maintenance Disorders,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,132,Interventional,September 2005,March 2011,https://ClinicalTrials.gov/show/NCT00183378,55 Years and older ,55,40 to 65 years old
NCT02221622,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Completed,Mild Cognitive Impairment|Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,24,Interventional,August 2014,February 2018,https://ClinicalTrials.gov/show/NCT02221622,55 Years and older ,55,40 to 65 years old
NCT02769000,Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's,Recruiting,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,May 2016,April 2020,https://ClinicalTrials.gov/show/NCT02769000,55 Years and older ,55,40 to 65 years old
NCT00464334,A Study of V950 in People With Alzheimer Disease (V950-001 AM7),Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,86,Interventional,March 2007,January 2012,https://ClinicalTrials.gov/show/NCT00464334,55 Years and older ,55,40 to 65 years old
NCT00904683,Effect of LY2062430 on the Progression of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1040,Interventional,May 2009,June 2012,https://ClinicalTrials.gov/show/NCT00904683,55 Years and older ,55,40 to 65 years old
NCT00954369,Exploratory and Safety Study of [F-18]W372,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,24,Interventional,August 2009,February 2010,https://ClinicalTrials.gov/show/NCT00954369,55 Years and older ,55,40 to 65 years old
NCT01388478,Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,20,Interventional,July 2011,April 2014,https://ClinicalTrials.gov/show/NCT01388478,55 Years and older ,55,40 to 65 years old
NCT01617577,Efficacy and Safety of Filgrastim in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,8,Interventional,June 2009,February 2012,https://ClinicalTrials.gov/show/NCT01617577,55 Years and older ,55,40 to 65 years old
NCT00205179,Alzheimer's Disease: Potential Benefit of Isoflavones,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,60,Interventional,January 2005,December 2009,https://ClinicalTrials.gov/show/NCT00205179,55 Years and older ,55,40 to 65 years old
NCT02702817,Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia,Completed,Alzheimer Disease|Cognitive Decline Due to Alzheimer Disease|Mild Cognitive Impairment Due to Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2,200,Interventional,"August 1, 2012","July 15, 2017",https://ClinicalTrials.gov/show/NCT02702817,55 Years and older ,55,40 to 65 years old
NCT01035138,A Study of Semagacestat for Alzheimer's Patients,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,180,Interventional,December 2009,April 2011,https://ClinicalTrials.gov/show/NCT01035138,55 Years and older ,55,40 to 65 years old
NCT00750282,Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers,Completed,Alzheimer Disease|Amyloid Beta-Protein,All,"55 Years and older   (Adult, Older Adult)",Phase 2,422,Interventional,August 2008,November 2010,https://ClinicalTrials.gov/show/NCT00750282,55 Years and older ,55,40 to 65 years old
NCT01217021,Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558,Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Early Phase 1,10,Interventional,September 2010,March 2011,https://ClinicalTrials.gov/show/NCT01217021,55 Years and older ,55,40 to 65 years old
NCT02972658,A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia,Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,421,Interventional,"March 15, 2017","October 2, 2018",https://ClinicalTrials.gov/show/NCT02972658,55 Years and older ,55,40 to 65 years old
NCT02800395,Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease,Recruiting,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,350,Interventional,December 2014,December 2024,https://ClinicalTrials.gov/show/NCT02800395,55 Years and older ,55,40 to 65 years old
NCT00191009,Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,124,Interventional,October 2003,January 2006,https://ClinicalTrials.gov/show/NCT00191009,55 Years and older ,55,40 to 65 years old
NCT00380276,Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol,Terminated,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1000,Interventional,September 2006,December 2008,https://ClinicalTrials.gov/show/NCT00380276,55 Years and older ,55,40 to 65 years old
NCT01128361,Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD),Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,76,Interventional,May 2010,April 2015,https://ClinicalTrials.gov/show/NCT01128361,55 Years and older ,55,40 to 65 years old
NCT01329601,Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI,Unknown status,Dementia of the Alzheimer Type,All,"55 Years and older   (Adult, Older Adult)",Phase 4,24,Interventional,January 2011,December 2011,https://ClinicalTrials.gov/show/NCT01329601,55 Years and older ,55,40 to 65 years old
NCT02127476,A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years and older   (Adult, Older Adult)",Phase 1,57,Interventional,July 2014,May 2017,https://ClinicalTrials.gov/show/NCT02127476,55 Years and older ,55,40 to 65 years old
NCT00946530,Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease,Completed,Sleep Initiation and Maintenance Disorders,All,"55 Years to 100 Years   (Adult, Older Adult)",Not Applicable,118,Interventional,September 2004,December 2010,https://ClinicalTrials.gov/show/NCT00946530,55 Years to 100 Years ,55,40 to 65 years old
NCT03852901,Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production,Recruiting,Aging|Cognitive|Ketones|Blood Sugar,All,"55 Years to 100 Years   (Adult, Older Adult)",Phase 1,100,Interventional,"March 28, 2019","December 31, 2021",https://ClinicalTrials.gov/show/NCT03852901,55 Years to 100 Years ,55,40 to 65 years old
NCT00478166,Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease,Completed,Magnetic Resonance Imaging|Alzheimer's Disease|Dementia|Adult Children|Risk,All,"55 Years to 65 Years   (Adult, Older Adult)",Phase 4,206,Observational,July 2005,October 2007,https://ClinicalTrials.gov/show/NCT00478166,55 Years to 65 Years ,55,40 to 65 years old
NCT02460783,"Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function",Recruiting,Alzheimer's Disease|Obesity|Diabetes Mellitus,All,"55 Years to 70 Years   (Adult, Older Adult)",Phase 2,150,Interventional,"June 22, 2015","July 1, 2020",https://ClinicalTrials.gov/show/NCT02460783,55 Years to 70 Years ,55,40 to 65 years old
NCT02010476,Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men,Completed,Alzheimer's Disease,Male,"55 Years to 70 Years   (Adult, Older Adult)",Phase 4,58,Observational,November 2013,April 2016,https://ClinicalTrials.gov/show/NCT02010476,55 Years to 70 Years ,55,40 to 65 years old
NCT03673722,"Mediterranean Diet, Exercise and Dementia Risk in UK Adults",Recruiting,Dementia,All,"55 Years to 74 Years   (Adult, Older Adult)",Not Applicable,108,Interventional,"May 1, 2019","June 30, 2020",https://ClinicalTrials.gov/show/NCT03673722,55 Years to 74 Years ,55,40 to 65 years old
NCT03577262,A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density,Completed,Healthy|Alzheimer Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,19,Interventional,"July 23, 2018","August 2, 2019",https://ClinicalTrials.gov/show/NCT03577262,55 Years to 75 Years ,55,40 to 65 years old
NCT03625622,Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease,Recruiting,Mild to Moderate Alzheimer's Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,210,Interventional,"January 15, 2019","August 1, 2020",https://ClinicalTrials.gov/show/NCT03625622,55 Years to 75 Years ,55,40 to 65 years old
NCT03024944,TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind,Withdrawn,Diabetes Mellitus|Alzheimer Dementia,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,0,Interventional,December 2017,January 2020,https://ClinicalTrials.gov/show/NCT03024944,55 Years to 75 Years ,55,40 to 65 years old
NCT03706261,Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults,Recruiting,Alzheimer Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,150,Interventional,"March 22, 2019",June 2023,https://ClinicalTrials.gov/show/NCT03706261,55 Years to 75 Years ,55,40 to 65 years old
NCT02180269,"A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants",Completed,Healthy,Male,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,24,Interventional,June 2014,August 2014,https://ClinicalTrials.gov/show/NCT02180269,55 Years to 75 Years ,55,40 to 65 years old
NCT02353884,Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 4,150,Observational,January 2010,December 2012,https://ClinicalTrials.gov/show/NCT02353884,55 Years to 75 Years ,55,40 to 65 years old
NCT03278119,Sleep Aging and Risk for Alzheimer's 2.0,Recruiting,Alzheimer Disease|Sleep Apnea,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 4,124,Observational,"May 1, 2018","May 30, 2023",https://ClinicalTrials.gov/show/NCT03278119,55 Years to 75 Years ,55,40 to 65 years old
NCT03053908,Orexin and Tau Pathology in Cognitively Normal Elderly,Recruiting,Elderly|Alzheimer Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Not Applicable,19,Interventional,"March 27, 2018",November 2019,https://ClinicalTrials.gov/show/NCT03053908,55 Years to 75 Years ,55,40 to 65 years old
NCT02260700,"A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants",Completed,Healthy,Male,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,12,Interventional,September 2013,November 2013,https://ClinicalTrials.gov/show/NCT02260700,55 Years to 75 Years ,55,40 to 65 years old
NCT03824197,Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD),Recruiting,Alzheimer Disease|Cerebral Amyloid Angiopathy,All,"55 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"May 7, 2019","December 31, 2020",https://ClinicalTrials.gov/show/NCT03824197,55 Years to 75 Years ,55,40 to 65 years old
NCT01887535,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants",Completed,Healthy,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,70,Interventional,May 2013,December 2013,https://ClinicalTrials.gov/show/NCT01887535,55 Years to 75 Years ,55,40 to 65 years old
NCT00412048,Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease,Withdrawn,Alzheimer's Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Not Applicable,0,Interventional,April 2012,February 2018,https://ClinicalTrials.gov/show/NCT00412048,55 Years to 75 Years ,55,40 to 65 years old
NCT03375697,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease","Active, not recruiting",Alzheimer Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,72,Interventional,"December 22, 2017","December 21, 2019",https://ClinicalTrials.gov/show/NCT03375697,55 Years to 75 Years ,55,40 to 65 years old
NCT03417986,Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers,"Active, not recruiting",Alzheimer Disease,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Interventional,"November 24, 2017",July 2021,https://ClinicalTrials.gov/show/NCT03417986,55 Years to 75 Years ,55,40 to 65 years old
NCT03461861,Network-Level Mechanisms for Preclinical Alzheimer's Disease Development,Recruiting,APOE 4,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,50,Interventional,"April 11, 2019","March 31, 2020",https://ClinicalTrials.gov/show/NCT03461861,55 Years to 75 Years ,55,40 to 65 years old
NCT03354143,"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)",Recruiting,Hypertension,All,"55 Years to 79 Years   (Adult, Older Adult)",Phase 2,120,Interventional,"April 10, 2018","October 31, 2022",https://ClinicalTrials.gov/show/NCT03354143,55 Years to 79 Years ,55,40 to 65 years old
NCT02547818,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"55 Years to 79 Years   (Adult, Older Adult)",Phase 3,620,Interventional,September 2015,December 2020,https://ClinicalTrials.gov/show/NCT02547818,55 Years to 79 Years ,55,40 to 65 years old
NCT02864303,Use of Saliva for Alzheimer's Disease Diagnosis,Unknown status,Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years to 80 Years   (Adult, Older Adult)",Not Applicable,250,Interventional,June 2012,December 2018,https://ClinicalTrials.gov/show/NCT02864303,55 Years to 80 Years ,55,40 to 65 years old
NCT03823404,GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,573,Interventional,"March 28, 2019","December 31, 2022",https://ClinicalTrials.gov/show/NCT03823404,55 Years to 80 Years ,55,40 to 65 years old
NCT00876863,"Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,49,Interventional,November 2008,December 2017,https://ClinicalTrials.gov/show/NCT00876863,55 Years to 80 Years ,55,40 to 65 years old
NCT01120002,Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,50,Interventional,May 2010,December 2012,https://ClinicalTrials.gov/show/NCT01120002,55 Years to 80 Years ,55,40 to 65 years old
NCT01702480,Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects,Completed,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,116,Interventional,"November 5, 2012","July 3, 2015",https://ClinicalTrials.gov/show/NCT01702480,55 Years to 80 Years ,55,40 to 65 years old
NCT00459550,A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,50,Interventional,"March 12, 2007","May 30, 2011",https://ClinicalTrials.gov/show/NCT00459550,55 Years to 80 Years ,55,40 to 65 years old
NCT03418688,A Multiple Ascending Dose Study of COR388,Completed,Alzheimer Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,33,Interventional,"March 6, 2018","October 15, 2018",https://ClinicalTrials.gov/show/NCT03418688,55 Years to 80 Years ,55,40 to 65 years old
NCT03862222,Atlas of Retinal Imaging in Alzheimer's Study,Not yet recruiting,Alzheimer Disease|Mild Cognitive Impairment|Mild Dementia|Aging|Cognitive Change,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 4,330,Observational,December 2019,November 2024,https://ClinicalTrials.gov/show/NCT03862222,55 Years to 80 Years ,55,40 to 65 years old
NCT01965756,Effect of Insulin Sensitizer Metformin on AD Biomarkers,Completed,Alzheimer's Disease|Vascular Dementia|Dementia|Memory Impairment,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,20,Interventional,January 2013,April 2017,https://ClinicalTrials.gov/show/NCT01965756,55 Years to 80 Years ,55,40 to 65 years old
NCT02833792,Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease,Recruiting,Alzheimer Dementia,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,40,Interventional,June 2016,June 2020,https://ClinicalTrials.gov/show/NCT02833792,55 Years to 80 Years ,55,40 to 65 years old
NCT02844855,Memory for Action in Neurological Patients,Recruiting,Alzheimer Disease|Parkinson Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Not Applicable,99,Interventional,"December 26, 2016","August 31, 2021",https://ClinicalTrials.gov/show/NCT02844855,55 Years to 80 Years ,55,40 to 65 years old
NCT01254448,Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,38,Interventional,September 2010,May 2011,https://ClinicalTrials.gov/show/NCT01254448,55 Years to 80 Years ,55,40 to 65 years old
NCT02707458,Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration,Completed,Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,23,Interventional,April 2016,March 2017,https://ClinicalTrials.gov/show/NCT02707458,55 Years to 80 Years ,55,40 to 65 years old
NCT03151382,A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease,Unknown status,Alzheimer Disease|Cognitive Function,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 4,30,Interventional,"May 20, 2017","June 30, 2018",https://ClinicalTrials.gov/show/NCT03151382,55 Years to 80 Years ,55,40 to 65 years old
NCT01795339,A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients,Completed,Healthy Elderly Volunteers|Mild-to-moderate Alzheimer's Disease Patients,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,47,Interventional,March 2013,March 2014,https://ClinicalTrials.gov/show/NCT01795339,55 Years to 80 Years ,55,40 to 65 years old
NCT01072812,Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment,Terminated,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 1,5,Interventional,February 2010,July 2010,https://ClinicalTrials.gov/show/NCT01072812,55 Years to 80 Years ,55,40 to 65 years old
NCT01841905,Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 4,60,Observational,July 2013,December 2016,https://ClinicalTrials.gov/show/NCT01841905,55 Years to 80 Years ,55,40 to 65 years old
NCT03461276,Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD,Recruiting,Mild Cognitive Impairment|Alzheimer Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,120,Interventional,"February 8, 2018",February 2022,https://ClinicalTrials.gov/show/NCT03461276,55 Years to 80 Years ,55,40 to 65 years old
NCT02063269,Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles,Unknown status,Alzheimer's Disease,All,"55 Years to 80 Years   (Adult, Older Adult)",Not Applicable,70,Interventional,February 2014,June 2017,https://ClinicalTrials.gov/show/NCT02063269,55 Years to 80 Years ,55,40 to 65 years old
NCT03093519,A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"55 Years to 84 Years   (Adult, Older Adult)",Phase 1,21,Interventional,"March 3, 2017","December 6, 2017",https://ClinicalTrials.gov/show/NCT03093519,55 Years to 84 Years ,55,40 to 65 years old
NCT02377713,A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.,Completed,Alzheimer's Disease,All,"55 Years to 84 Years   (Adult, Older Adult)",Phase 1,20,Interventional,March 2015,September 2016,https://ClinicalTrials.gov/show/NCT02377713,55 Years to 84 Years ,55,40 to 65 years old
NCT01730430,Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias,Completed,Alzheimer's Disease|Dementias,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,40,Observational,July 2012,December 2013,https://ClinicalTrials.gov/show/NCT01730430,55 Years to 85 Years ,55,40 to 65 years old
NCT01397539,Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,53,Interventional,June 2011,August 2013,https://ClinicalTrials.gov/show/NCT01397539,55 Years to 85 Years ,55,40 to 65 years old
NCT02973971,ADDIA Chronobiological Study,Completed,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,24,Observational,November 2016,"March 29, 2018",https://ClinicalTrials.gov/show/NCT02973971,55 Years to 85 Years ,55,40 to 65 years old
NCT01429623,A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment,Completed,Mild Cognitive Impairment|Dementia,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,210,Interventional,February 2012,September 2016,https://ClinicalTrials.gov/show/NCT01429623,55 Years to 85 Years ,55,40 to 65 years old
NCT04049643,Hearing Aid and Individuals With Cognitive Disorders,Not yet recruiting,"Presbycusis, Bilateral|Alzheimer Disease 2 Due to Apoe4 Isoform",All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"December 1, 2019","December 31, 2020",https://ClinicalTrials.gov/show/NCT04049643,55 Years to 85 Years ,55,40 to 65 years old
NCT02263235,In Vivo Alzheimer Proteomics,Unknown status,Probable Alzheimer Disease|Parkinson Disease|Neurological Disease Without Cognitive Degradation|Brain Trauma|Acute Hydrocephaly,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Interventional,June 2013,June 2017,https://ClinicalTrials.gov/show/NCT02263235,55 Years to 85 Years ,55,40 to 65 years old
NCT03721705,Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type,Recruiting,"Alzheimer Disease|Cognitive Dysfunction|Mild Cognitive Impairment|Mild Dementia|Cognitive Decline|Dementia, Alzheimer Type",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,250,Interventional,"November 12, 2018","January 31, 2020",https://ClinicalTrials.gov/show/NCT03721705,55 Years to 85 Years ,55,40 to 65 years old
NCT03672474,REGEnLIFE RGn530 - Feasibility Pilot,Recruiting,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,64,Interventional,"September 7, 2018","October 19, 2019",https://ClinicalTrials.gov/show/NCT03672474,55 Years to 85 Years ,55,40 to 65 years old
NCT03486938,Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease,Recruiting,Mild Cognitive Impairment|Prodromal Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,830,Interventional,"January 15, 2019",November 2022,https://ClinicalTrials.gov/show/NCT03486938,55 Years to 85 Years ,55,40 to 65 years old
NCT01852110,Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,240,Interventional,"October 22, 2013","April 11, 2016",https://ClinicalTrials.gov/show/NCT01852110,55 Years to 85 Years ,55,40 to 65 years old
NCT00375557,Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients,Withdrawn,Alzheimer's Disease|Dementia|Behavioral Symptoms,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,0,Interventional,October 2006,September 2007,https://ClinicalTrials.gov/show/NCT00375557,55 Years to 85 Years ,55,40 to 65 years old
NCT02431468,A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,147,Interventional,November 2015,February 2017,https://ClinicalTrials.gov/show/NCT02431468,55 Years to 85 Years ,55,40 to 65 years old
NCT02386306,"Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,39,Interventional,February 2015,October 2015,https://ClinicalTrials.gov/show/NCT02386306,55 Years to 85 Years ,55,40 to 65 years old
NCT02434718,Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,21,Interventional,"June 30, 2015","December 9, 2016",https://ClinicalTrials.gov/show/NCT02434718,55 Years to 85 Years ,55,40 to 65 years old
NCT02079909,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,482,Interventional,March 2014,"May 5, 2017",https://ClinicalTrials.gov/show/NCT02079909,55 Years to 85 Years ,55,40 to 65 years old
NCT01211782,AC-1204 Long-term Efficacy Response Trial (ALERT Protocol),Withdrawn,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,0,Interventional,,,https://ClinicalTrials.gov/show/NCT01211782,55 Years to 85 Years ,55,40 to 65 years old
NCT00909285,Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients,Completed,"Alzheimer Disease, Early Onset",All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,20,Interventional,July 2009,July 2010,https://ClinicalTrials.gov/show/NCT00909285,55 Years to 85 Years ,55,40 to 65 years old
NCT02004392,Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025,Terminated,Alzheimer's Disease|Dementia,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,348,Interventional,June 2014,August 2017,https://ClinicalTrials.gov/show/NCT02004392,55 Years to 85 Years ,55,40 to 65 years old
NCT00744978,"Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,66,Interventional,July 2009,November 2010,https://ClinicalTrials.gov/show/NCT00744978,55 Years to 85 Years ,55,40 to 65 years old
NCT01249196,A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,256,Interventional,May 2010,,https://ClinicalTrials.gov/show/NCT01249196,55 Years to 85 Years ,55,40 to 65 years old
NCT02756858,An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,32,Interventional,March 2016,November 2020,https://ClinicalTrials.gov/show/NCT02756858,55 Years to 85 Years ,55,40 to 65 years old
NCT04070378,Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease,Not yet recruiting,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,15,Interventional,"October 1, 2019","June 1, 2022",https://ClinicalTrials.gov/show/NCT04070378,55 Years to 85 Years ,55,40 to 65 years old
NCT00988598,"A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,15,Interventional,October 2009,July 2010,https://ClinicalTrials.gov/show/NCT00988598,55 Years to 85 Years ,55,40 to 65 years old
NCT01969123,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,Terminated,Alzheimer's Disease|Dementia,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,474,Interventional,October 2013,January 2017,https://ClinicalTrials.gov/show/NCT01969123,55 Years to 85 Years ,55,40 to 65 years old
NCT01168245,TMS Stimulation and Cognitive Training in Alzheimer Patients,Completed,Alzheimer Disease|Mild to Moderate,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,15,Interventional,January 2010,September 2011,https://ClinicalTrials.gov/show/NCT01168245,55 Years to 85 Years ,55,40 to 65 years old
NCT03081546,Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease,Enrolling by invitation,Mild Cognitive Impairment|Healthy Controls,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,80,Observational,"May 4, 2017",October 2019,https://ClinicalTrials.gov/show/NCT03081546,55 Years to 85 Years ,55,40 to 65 years old
NCT03901105,Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease,Completed,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,205,Interventional,"March 28, 2019","April 28, 2019",https://ClinicalTrials.gov/show/NCT03901105,55 Years to 85 Years ,55,40 to 65 years old
NCT03817684,Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects,Recruiting,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,255,Interventional,"April 30, 2019",June 2020,https://ClinicalTrials.gov/show/NCT03817684,55 Years to 85 Years ,55,40 to 65 years old
NCT02064920,Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318),Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,36,Interventional,"April 22, 2014","July 13, 2016",https://ClinicalTrials.gov/show/NCT02064920,55 Years to 85 Years ,55,40 to 65 years old
NCT00930059,A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,198,Interventional,September 2009,September 2010,https://ClinicalTrials.gov/show/NCT00930059,55 Years to 85 Years ,55,40 to 65 years old
NCT03531684,Efficacy and Safety of MMFS in Early AD,Recruiting,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,12,Interventional,"March 20, 2018","March 30, 2020",https://ClinicalTrials.gov/show/NCT03531684,55 Years to 85 Years ,55,40 to 65 years old
NCT02195596,Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.,Unknown status,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,April 2013,December 2015,https://ClinicalTrials.gov/show/NCT02195596,55 Years to 85 Years ,55,40 to 65 years old
NCT03757325,Study to Evaluate DNL747 in Subjects With Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,16,Interventional,"February 13, 2019",August 2019,https://ClinicalTrials.gov/show/NCT03757325,55 Years to 85 Years ,55,40 to 65 years old
NCT02244541,"Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,32,Interventional,December 2014,November 2016,https://ClinicalTrials.gov/show/NCT02244541,55 Years to 85 Years ,55,40 to 65 years old
NCT02925650,"Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease",Recruiting,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,24,Interventional,"March 2, 2017","December 31, 2019",https://ClinicalTrials.gov/show/NCT02925650,55 Years to 85 Years ,55,40 to 65 years old
NCT03560245,A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine,Completed,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,108,Interventional,"June 20, 2018","July 25, 2019",https://ClinicalTrials.gov/show/NCT03560245,55 Years to 85 Years ,55,40 to 65 years old
NCT02573740,"Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment",Terminated,Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,8,Interventional,December 2015,June 2016,https://ClinicalTrials.gov/show/NCT02573740,55 Years to 85 Years ,55,40 to 65 years old
NCT00627848,"Rivastigmine in Mild Alzheimer's Disease, FMRI Study",Completed,Alzheimer' Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,20,Interventional,March 2007,December 2008,https://ClinicalTrials.gov/show/NCT00627848,55 Years to 85 Years ,55,40 to 65 years old
NCT02912169,Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease,Withdrawn,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,0,Interventional,"November 1, 2015","November 15, 2017",https://ClinicalTrials.gov/show/NCT02912169,55 Years to 85 Years ,55,40 to 65 years old
NCT01969136,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,Terminated,Alzheimer's Disease|Dementia,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,403,Interventional,October 2013,January 2017,https://ClinicalTrials.gov/show/NCT01969136,55 Years to 85 Years ,55,40 to 65 years old
NCT03740178,Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005),Not yet recruiting,Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Interventional,"September 27, 2019","February 28, 2020",https://ClinicalTrials.gov/show/NCT03740178,55 Years to 85 Years ,55,40 to 65 years old
NCT01561053,A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,347,Interventional,"April 19, 2012","March 6, 2018",https://ClinicalTrials.gov/show/NCT01561053,55 Years to 85 Years ,55,40 to 65 years old
NCT02327182,Safety Study of MT-4666 in Subjects With Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,117,Interventional,December 2014,October 2015,https://ClinicalTrials.gov/show/NCT02327182,55 Years to 85 Years ,55,40 to 65 years old
NCT03472664,Brain Energy for Amyloid Transformation in Alzheimer's Disease Study,Recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,120,Interventional,"July 16, 2018",April 2023,https://ClinicalTrials.gov/show/NCT03472664,55 Years to 85 Years ,55,40 to 65 years old
NCT01439555,Endothelial Facilitation in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,11,Interventional,November 2011,November 2017,https://ClinicalTrials.gov/show/NCT01439555,55 Years to 85 Years ,55,40 to 65 years old
NCT03706885,Efavirenz for Patients With Mild Cognitive Impairment,Recruiting,"Alzheimer Disease, Early Onset",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,36,Interventional,"December 21, 2018",May 2020,https://ClinicalTrials.gov/show/NCT03706885,55 Years to 85 Years ,55,40 to 65 years old
NCT01028911,"A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,9,Interventional,December 2009,May 2010,https://ClinicalTrials.gov/show/NCT01028911,55 Years to 85 Years ,55,40 to 65 years old
NCT03055741,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),Completed,Mild-moderate Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,180,Interventional,"December 28, 2016",August 2019,https://ClinicalTrials.gov/show/NCT03055741,55 Years to 85 Years ,55,40 to 65 years old
NCT03538522,"A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831",Not yet recruiting,"Mild Cognitive Impairment|Alzheimer Disease|Alzheimer Dementia|Dementia, Vascular|Dementia With Lewy Bodies|Cognitive Impairment|Tauopathies|Neurodegenerative Diseases|Neurocognitive Disorders|Cognitive Disorder",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,156,Interventional,"September 15, 2018","April 15, 2019",https://ClinicalTrials.gov/show/NCT03538522,55 Years to 85 Years ,55,40 to 65 years old
NCT03959553,GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD),Not yet recruiting,Moderate Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,90,Interventional,"September 1, 2019","February 28, 2022",https://ClinicalTrials.gov/show/NCT03959553,55 Years to 85 Years ,55,40 to 65 years old
NCT03363269,Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease,Completed,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,116,Interventional,"April 12, 2016","April 17, 2019",https://ClinicalTrials.gov/show/NCT03363269,55 Years to 85 Years ,55,40 to 65 years old
NCT02760602,A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,26,Interventional,June 2016,May 2017,https://ClinicalTrials.gov/show/NCT02760602,55 Years to 85 Years ,55,40 to 65 years old
NCT02783573,A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia,Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 3,1722,Interventional,"July 1, 2016","September 28, 2018",https://ClinicalTrials.gov/show/NCT02783573,55 Years to 85 Years ,55,40 to 65 years old
NCT00040443,Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.,Completed,Mild Cognitive Impairment,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,175,Interventional,April 2002,June 2004,https://ClinicalTrials.gov/show/NCT00040443,55 Years to 85 Years ,55,40 to 65 years old
NCT03184467,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,Unknown status,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,90,Interventional,June 2017,June 2019,https://ClinicalTrials.gov/show/NCT03184467,55 Years to 85 Years ,55,40 to 65 years old
NCT02986932,Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease,Completed,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,6,Interventional,December 2016,December 2017,https://ClinicalTrials.gov/show/NCT02986932,55 Years to 85 Years ,55,40 to 65 years old
NCT03456349,Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,60,Interventional,"November 10, 2017","July 16, 2018",https://ClinicalTrials.gov/show/NCT03456349,55 Years to 85 Years ,55,40 to 65 years old
NCT00582855,Effect of AQW051 in Patients With Memory Impairment,Terminated,Mild Alzheimer's Disease|Amnestic Mild Cognitive Impairment,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,54,Interventional,December 2007,,https://ClinicalTrials.gov/show/NCT00582855,55 Years to 85 Years ,55,40 to 65 years old
NCT02246075,Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine,Withdrawn,Alzheimer's Disease|Dementia|Cognition,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,0,Interventional,July 2015,,https://ClinicalTrials.gov/show/NCT02246075,55 Years to 85 Years ,55,40 to 65 years old
NCT02951598,A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD),"Active, not recruiting",Alzheimer Disease|Mild Cognitive Impairment,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,1400,Interventional,"October 29, 2016","October 28, 2020",https://ClinicalTrials.gov/show/NCT02951598,55 Years to 85 Years ,55,40 to 65 years old
NCT02626572,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,500,Interventional,February 2015,September 2017,https://ClinicalTrials.gov/show/NCT02626572,55 Years to 85 Years ,55,40 to 65 years old
NCT03132272,Immunoadsorption for Treatment of Alzheimer's Disease,Recruiting,Alzheimer Dementia,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,15,Interventional,July 2016,"December 31, 2019",https://ClinicalTrials.gov/show/NCT03132272,55 Years to 85 Years ,55,40 to 65 years old
NCT00742417,Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,42,Interventional,July 2007,March 2011,https://ClinicalTrials.gov/show/NCT00742417,55 Years to 85 Years ,55,40 to 65 years old
NCT01374438,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,29,Interventional,July 2011,May 2013,https://ClinicalTrials.gov/show/NCT01374438,55 Years to 85 Years ,55,40 to 65 years old
NCT03316898,A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease,Withdrawn,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,0,Interventional,"September 30, 2018","November 4, 2018",https://ClinicalTrials.gov/show/NCT03316898,55 Years to 85 Years ,55,40 to 65 years old
NCT03402659,"Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease",Completed,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,161,Interventional,"December 29, 2017","July 31, 2019",https://ClinicalTrials.gov/show/NCT03402659,55 Years to 85 Years ,55,40 to 65 years old
NCT02931136,Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging,Not yet recruiting,Mild Cognitive Impairment|Biomarker|Diagnosis|Treatment,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,300,Interventional,November 2019,December 2025,https://ClinicalTrials.gov/show/NCT02931136,55 Years to 85 Years ,55,40 to 65 years old
NCT03929302,Brain Energy Metabolism and Sleep in Adults,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Cognitive Change|Energy Metabolism|Sleep Disturbance,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"November 30, 2018","July 31, 2021",https://ClinicalTrials.gov/show/NCT03929302,55 Years to 85 Years ,55,40 to 65 years old
NCT02245737,An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease,Terminated,Alzheimer´s Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,2218,Interventional,"September 30, 2014","October 4, 2018",https://ClinicalTrials.gov/show/NCT02245737,55 Years to 85 Years ,55,40 to 65 years old
NCT02623764,EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors,"Active, not recruiting",Alzheimer´s Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,218,Observational,December 2015,November 2019,https://ClinicalTrials.gov/show/NCT02623764,55 Years to 85 Years ,55,40 to 65 years old
NCT00660088,Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,60,Observational,April 2008,August 2008,https://ClinicalTrials.gov/show/NCT00660088,55 Years to 85 Years ,55,40 to 65 years old
NCT01125683,"To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease",Terminated,Alzheimer´s Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Interventional,June 2010,March 2011,https://ClinicalTrials.gov/show/NCT01125683,55 Years to 85 Years ,55,40 to 65 years old
NCT02880956,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,453,Interventional,"October 17, 2016","July 28, 2021",https://ClinicalTrials.gov/show/NCT02880956,55 Years to 85 Years ,55,40 to 65 years old
NCT01767909,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),Completed,Amnestic Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,239,Interventional,"January 8, 2014","December 11, 2018",https://ClinicalTrials.gov/show/NCT01767909,55 Years to 85 Years ,55,40 to 65 years old
NCT01739348,An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,2211,Interventional,"November 30, 2012","April 14, 2017",https://ClinicalTrials.gov/show/NCT01739348,55 Years to 85 Years ,55,40 to 65 years old
NCT01409915,Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Interventional,March 2011,"May 30, 2020",https://ClinicalTrials.gov/show/NCT01409915,55 Years to 85 Years ,55,40 to 65 years old
NCT04104373,The Ontario Neurodegenerative Disease Research Initiative,Completed,Alzheimer Disease|Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Parkinson Disease|Stroke,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,522,Observational,"July 7, 2014","April 30, 2018",https://ClinicalTrials.gov/show/NCT04104373,55 Years to 85 Years ,55,40 to 65 years old
NCT01970150,The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease,Terminated,Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,5,Interventional,February 2014,April 2015,https://ClinicalTrials.gov/show/NCT01970150,55 Years to 85 Years ,55,40 to 65 years old
NCT02279511,ATP in Alzheimer Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,20,Interventional,December 2014,February 2016,https://ClinicalTrials.gov/show/NCT02279511,55 Years to 85 Years ,55,40 to 65 years old
NCT02778581,Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment,Unknown status,Cognitive Impairments|Alzheimer Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Interventional,March 2016,July 2017,https://ClinicalTrials.gov/show/NCT02778581,55 Years to 85 Years ,55,40 to 65 years old
NCT02791191,A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia,Terminated,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,316,Interventional,"June 16, 2016","July 2, 2018",https://ClinicalTrials.gov/show/NCT02791191,55 Years to 85 Years ,55,40 to 65 years old
NCT03617497,Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease,Not yet recruiting,Alzheimer Disease|Alzheimer Dementia|Epilepsy|Sleep Wake Disorders,All,"55 Years to 85 Years   (Adult, Older Adult)",Not Applicable,130,Interventional,"October 1, 2018","September 30, 2022",https://ClinicalTrials.gov/show/NCT03617497,55 Years to 85 Years ,55,40 to 65 years old
NCT02036645,"SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",Completed,Mild-Moderate Alzheimer's Disease|Healthy Elderly,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,77,Interventional,"February 4, 2014","September 15, 2016",https://ClinicalTrials.gov/show/NCT02036645,55 Years to 85 Years ,55,40 to 65 years old
NCT01024660,The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Early Phase 1,155,Interventional,December 2009,January 2011,https://ClinicalTrials.gov/show/NCT01024660,55 Years to 85 Years ,55,40 to 65 years old
NCT03856359,Trial of Rifaximin in Probable Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,10,Interventional,"April 9, 2019",February 2021,https://ClinicalTrials.gov/show/NCT03856359,55 Years to 85 Years ,55,40 to 65 years old
NCT00243451,Early Detection of Mild Cognitive Impairment in Individual Patients,Completed,Mild Cognitive Impairment|Mild Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 4,34,Observational,September 2003,July 2011,https://ClinicalTrials.gov/show/NCT00243451,55 Years to 85 Years ,55,40 to 65 years old
NCT00443417,A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,188,Interventional,April 2007,January 2009,https://ClinicalTrials.gov/show/NCT00443417,55 Years to 85 Years ,55,40 to 65 years old
NCT01424436,Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient,Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 1,19,Interventional,"May 19, 2010","December 8, 2011",https://ClinicalTrials.gov/show/NCT01424436,55 Years to 85 Years ,55,40 to 65 years old
NCT02167256,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,159,Interventional,December 2014,"February 27, 2018",https://ClinicalTrials.gov/show/NCT02167256,55 Years to 85 Years ,55,40 to 65 years old
NCT01727622,Arterial Spin Labeling (ASL) MRI for Cognitive Decline,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 4,102,Observational,August 2012,"May 31, 2018",https://ClinicalTrials.gov/show/NCT01727622,55 Years to 89 Years ,55,40 to 65 years old
NCT01482351,Mild Cognitive Impairment and Obstructive Sleep Apnea,Completed,Obstructive Sleep Apnea|Mild Cognitive Impairment,All,"55 Years to 89 Years   (Adult, Older Adult)",Not Applicable,54,Interventional,September 2012,December 2014,https://ClinicalTrials.gov/show/NCT01482351,55 Years to 89 Years ,55,40 to 65 years old
NCT03533257,Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 2,100,Interventional,"August 27, 2018","September 1, 2020",https://ClinicalTrials.gov/show/NCT03533257,55 Years to 89 Years ,55,40 to 65 years old
NCT03620981,Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,Recruiting,Agitation Associated With Dementia of the Alzheimer's Type,All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,407,Interventional,"August 20, 2018",November 2021,https://ClinicalTrials.gov/show/NCT03620981,55 Years to 89 Years ,55,40 to 65 years old
NCT03926520,Electroconvulsive Therapy (ECT) for Agitation in Alzheimer's Dementia (AD),Not yet recruiting,"Alzheimer Dementia|Agitation,Psychomotor",All,"55 Years to 89 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,"September 30, 2019",March 2023,https://ClinicalTrials.gov/show/NCT03926520,55 Years to 89 Years ,55,40 to 65 years old
NCT03448445,A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting,"Active, not recruiting",Mild Cognitive Impairment,All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 4,201,Observational,"June 22, 2018",March 2021,https://ClinicalTrials.gov/show/NCT03448445,55 Years to 89 Years ,55,40 to 65 years old
NCT03724942,Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,Recruiting,Agitation Associated With Dementia of the Alzheimer's Type,All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 3,157,Interventional,"November 9, 2018",May 2021,https://ClinicalTrials.gov/show/NCT03724942,55 Years to 89 Years ,55,40 to 65 years old
NCT02168920,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,Terminated,Agitation Associated With Dementia of the Alzheimer's Type,All,"55 Years to 89 Years   (Adult, Older Adult)",Phase 3,150,Interventional,"June 11, 2014","March 18, 2016",https://ClinicalTrials.gov/show/NCT02168920,55 Years to 89 Years ,55,40 to 65 years old
NCT01922258,Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,Completed,Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,270,Interventional,September 2013,March 2017,https://ClinicalTrials.gov/show/NCT01922258,55 Years to 90 Years ,55,40 to 65 years old
NCT01883648,Study to Evaluate Coconut Oil for Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,21,Interventional,June 2013,"February 1, 2017",https://ClinicalTrials.gov/show/NCT01883648,55 Years to 90 Years ,55,40 to 65 years old
NCT01862640,Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,Completed,Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,433,Interventional,July 2013,March 2017,https://ClinicalTrials.gov/show/NCT01862640,55 Years to 90 Years ,55,40 to 65 years old
NCT01908010,"Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,20,Interventional,July 2013,November 2013,https://ClinicalTrials.gov/show/NCT01908010,55 Years to 90 Years ,55,40 to 65 years old
NCT00902499,Evolution of Memory Related Activity,Unknown status,Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,160,Observational,May 2006,May 2011,https://ClinicalTrials.gov/show/NCT00902499,55 Years to 90 Years ,55,40 to 65 years old
NCT00066157,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,Alzheimer Disease,Female,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,42,Interventional,September 2001,December 2007,https://ClinicalTrials.gov/show/NCT00066157,55 Years to 90 Years ,55,40 to 65 years old
NCT03702816,"The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)",Enrolling by invitation,Alzheimer Disease|Parkinson Disease|Inflammation,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,70,Interventional,"December 13, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03702816,55 Years to 90 Years ,55,40 to 65 years old
NCT04098666,Metformin in Alzheimer's Dementia Prevention,Not yet recruiting,Amnestic Mild Cognitive Impairment (aMCI),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,370,Interventional,"April 1, 2020","May 31, 2024",https://ClinicalTrials.gov/show/NCT04098666,55 Years to 90 Years ,55,40 to 65 years old
NCT01482845,"A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease",Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,20,Interventional,November 2011,March 2012,https://ClinicalTrials.gov/show/NCT01482845,55 Years to 90 Years ,55,40 to 65 years old
NCT00809510,A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,63,Interventional,January 2009,,https://ClinicalTrials.gov/show/NCT00809510,55 Years to 90 Years ,55,40 to 65 years old
NCT01549834,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,434,Interventional,March 2012,October 2013,https://ClinicalTrials.gov/show/NCT01549834,55 Years to 90 Years ,55,40 to 65 years old
NCT00232570,Quetiapine for the Treatment of Insomnia in Alzheimer's Disease,Unknown status,Alzheimer's Disease|Insomnia,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,18,Interventional,November 2005,January 2010,https://ClinicalTrials.gov/show/NCT00232570,55 Years to 90 Years ,55,40 to 65 years old
NCT02220738,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,19,Interventional,September 2014,March 2016,https://ClinicalTrials.gov/show/NCT02220738,55 Years to 90 Years ,55,40 to 65 years old
NCT01137526,Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,267,Interventional,May 2010,July 2011,https://ClinicalTrials.gov/show/NCT01137526,55 Years to 90 Years ,55,40 to 65 years old
NCT00602680,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,1,Interventional,January 2008,July 2008,https://ClinicalTrials.gov/show/NCT00602680,55 Years to 90 Years ,55,40 to 65 years old
NCT00071721,Valproate in Dementia (VALID),Completed,Alzheimer Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,313,Interventional,October 2003,December 2009,https://ClinicalTrials.gov/show/NCT00071721,55 Years to 90 Years ,55,40 to 65 years old
NCT00413621,MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,40,Observational,"December 14, 2006",,https://ClinicalTrials.gov/show/NCT00413621,55 Years to 90 Years ,55,40 to 65 years old
NCT03912571,Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment,Recruiting,Sleep Disorder,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,95,Interventional,"November 13, 2011",September 2019,https://ClinicalTrials.gov/show/NCT03912571,55 Years to 90 Years ,55,40 to 65 years old
NCT01047254,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,Completed,Apathy in Dementia,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,110,Interventional,January 2010,July 2014,https://ClinicalTrials.gov/show/NCT01047254,55 Years to 90 Years ,55,40 to 65 years old
NCT01504958,Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,22,Interventional,December 2010,May 2015,https://ClinicalTrials.gov/show/NCT01504958,55 Years to 90 Years ,55,40 to 65 years old
NCT03896698,Feasibility Study of Transcranial Ultrasound Stimulation on Alzheimer's Disease Patients,Not yet recruiting,Alzheimer Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,10,Interventional,"May 1, 2019","November 30, 2020",https://ClinicalTrials.gov/show/NCT03896698,55 Years to 90 Years ,55,40 to 65 years old
NCT00620191,Metformin in Amnestic Mild Cognitive Impairment,Completed,Amnestic Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,80,Interventional,February 2008,February 2012,https://ClinicalTrials.gov/show/NCT00620191,55 Years to 90 Years ,55,40 to 65 years old
NCT01078636,Alzheimer's Disease Neuroimaging Initiative Grand Opportunity,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,342,Observational,April 2010,October 2012,https://ClinicalTrials.gov/show/NCT01078636,55 Years to 90 Years ,55,40 to 65 years old
NCT00555204,Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,337,Interventional,November 2007,,https://ClinicalTrials.gov/show/NCT00555204,55 Years to 90 Years ,55,40 to 65 years old
NCT00209456,Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia,Completed,Lewy Body Dementia|Non-DLB Dementia|Alzheimer’s|Vascular Dementia,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,326,Interventional,November 2003,,https://ClinicalTrials.gov/show/NCT00209456,55 Years to 90 Years ,55,40 to 65 years old
NCT01688128,Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART),Completed,Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,50,Interventional,August 2012,December 2015,https://ClinicalTrials.gov/show/NCT01688128,55 Years to 90 Years ,55,40 to 65 years old
NCT01628653,Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training,Completed,Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,10,Interventional,June 2011,February 2012,https://ClinicalTrials.gov/show/NCT01628653,55 Years to 90 Years ,55,40 to 65 years old
NCT03630419,Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients,Completed,Mild Cognitive Impairment|Alzheimer Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,5,Interventional,"February 10, 2018","July 28, 2018",https://ClinicalTrials.gov/show/NCT03630419,55 Years to 90 Years ,55,40 to 65 years old
NCT00093951,SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD),Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,280,Interventional,April 2004,September 2007,https://ClinicalTrials.gov/show/NCT00093951,55 Years to 90 Years ,55,40 to 65 years old
NCT00106899,ADNI: Alzheimer's Disease Neuroimaging Initiative,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,818,Observational,July 2005,June 2011,https://ClinicalTrials.gov/show/NCT00106899,55 Years to 90 Years ,55,40 to 65 years old
NCT03548584,"A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,Agitaton Associated With Alzheimer's Dementia|Alzheimer Dementia,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,225,Interventional,"May 16, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03548584,55 Years to 90 Years ,55,40 to 65 years old
NCT00483028,"A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI",Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,38,Interventional,June 2004,January 2007,https://ClinicalTrials.gov/show/NCT00483028,55 Years to 90 Years ,55,40 to 65 years old
NCT00628017,Preliminary Study of Fish Oil and Dementia,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,46,Interventional,January 2003,March 2005,https://ClinicalTrials.gov/show/NCT00628017,55 Years to 90 Years ,55,40 to 65 years old
NCT03954613,Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease,Not yet recruiting,Alzheimer Disease|Cognitive Change,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,198,Interventional,"July 1, 2019","March 1, 2021",https://ClinicalTrials.gov/show/NCT03954613,55 Years to 90 Years ,55,40 to 65 years old
NCT01676935,This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,349,Interventional,August 2012,March 2014,https://ClinicalTrials.gov/show/NCT01676935,55 Years to 90 Years ,55,40 to 65 years old
NCT01463384,Minocycline in Patients With Alzheimer's Disease,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,13,Interventional,September 2011,October 2012,https://ClinicalTrials.gov/show/NCT01463384,55 Years to 90 Years ,55,40 to 65 years old
NCT02843529,Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI),Enrolling by invitation,Alzheimer Disease|Mild Cognitive Impairment|Memory Disorders|Cognitive Impairment|Dementia|Presymptomatic Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,900,Interventional,"May 11, 2015","December 3, 2020",https://ClinicalTrials.gov/show/NCT02843529,55 Years to 90 Years ,55,40 to 65 years old
NCT02854033,Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol,Recruiting,Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,2000,Observational,October 2016,October 2021,https://ClinicalTrials.gov/show/NCT02854033,55 Years to 90 Years ,55,40 to 65 years old
NCT01832350,Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease,Unknown status,Alzheimer's Disease|Pseudobulbar Affect (PBA),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,60,Interventional,December 2012,December 2017,https://ClinicalTrials.gov/show/NCT01832350,55 Years to 90 Years ,55,40 to 65 years old
NCT02471196,Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,308,Interventional,"August 14, 2015","December 4, 2017",https://ClinicalTrials.gov/show/NCT02471196,55 Years to 90 Years ,55,40 to 65 years old
NCT00065767,Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease,Completed,Alzheimer Disease,Female,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Interventional,September 2001,March 2005,https://ClinicalTrials.gov/show/NCT00065767,55 Years to 90 Years ,55,40 to 65 years old
NCT02720445,Memory Improvement Through Nicotine Dosing (MIND) Study,Recruiting,Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,300,Interventional,"January 13, 2017",December 2020,https://ClinicalTrials.gov/show/NCT02720445,55 Years to 90 Years ,55,40 to 65 years old
NCT01900665,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,2129,Interventional,July 2013,February 2017,https://ClinicalTrials.gov/show/NCT01900665,55 Years to 90 Years ,55,40 to 65 years old
NCT00257712,"SMART: Somatotrophics, Memory, and Aging Research Trial",Completed,Aging|Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,151,Interventional,February 2006,December 2011,https://ClinicalTrials.gov/show/NCT00257712,55 Years to 90 Years ,55,40 to 65 years old
NCT00855868,Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,28,Interventional,March 2009,January 2011,https://ClinicalTrials.gov/show/NCT00855868,55 Years to 90 Years ,55,40 to 65 years old
NCT01324518,Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,100,Interventional,April 2011,October 2012,https://ClinicalTrials.gov/show/NCT01324518,55 Years to 90 Years ,55,40 to 65 years old
NCT01690195,Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,343,Interventional,September 2012,February 2014,https://ClinicalTrials.gov/show/NCT01690195,55 Years to 90 Years ,55,40 to 65 years old
NCT01099332,Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease,Unknown status,Alzheimer's Disease|Mild Cognitive Impairment,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Interventional,November 2009,January 2011,https://ClinicalTrials.gov/show/NCT01099332,55 Years to 90 Years ,55,40 to 65 years old
NCT01231971,Alzheimer's Disease Neuroimaging Initiative 2,Completed,Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)|Significant Memory Concern (SMC)|Early Mild Cognitive Impairment (EMCI)|Late Mild Cognitive Impairment (LMCI),All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,1185,Observational,January 2011,"November 29, 2017",https://ClinicalTrials.gov/show/NCT01231971,55 Years to 90 Years ,55,40 to 65 years old
NCT01018875,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,242,Interventional,December 2009,February 2011,https://ClinicalTrials.gov/show/NCT01018875,55 Years to 90 Years ,55,40 to 65 years old
NCT04057807,Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,16,Interventional,"March 29, 2017",September 2021,https://ClinicalTrials.gov/show/NCT04057807,55 Years to 90 Years ,55,40 to 65 years old
NCT01624389,Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study,Unknown status,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,January 2012,January 2015,https://ClinicalTrials.gov/show/NCT01624389,55 Years to 90 Years ,55,40 to 65 years old
NCT00933608,Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 4,17,Interventional,July 2009,September 2011,https://ClinicalTrials.gov/show/NCT00933608,55 Years to 90 Years ,55,40 to 65 years old
NCT03056495,Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease,Recruiting,Alzheimer Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 1,44,Interventional,"September 28, 2017",March 2022,https://ClinicalTrials.gov/show/NCT03056495,55 Years to 90 Years ,55,40 to 65 years old
NCT01527916,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,438,Interventional,February 2012,November 2013,https://ClinicalTrials.gov/show/NCT01527916,55 Years to 90 Years ,55,40 to 65 years old
NCT00948909,Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 2,274,Interventional,October 2009,November 2010,https://ClinicalTrials.gov/show/NCT00948909,55 Years to 90 Years ,55,40 to 65 years old
NCT02190084,Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia,Completed,Apathy|Alzheimer's Dementia,All,"55 Years to 91 Years   (Adult, Older Adult)",Phase 4,20,Interventional,May 2014,July 2019,https://ClinicalTrials.gov/show/NCT02190084,55 Years to 91 Years ,55,40 to 65 years old
NCT03594123,A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,Recruiting,Alzheimer's Disease,All,"55 Years to 91 Years   (Adult, Older Adult)",Phase 3,250,Interventional,"October 12, 2018",August 2021,https://ClinicalTrials.gov/show/NCT03594123,55 Years to 91 Years ,55,40 to 65 years old
NCT03811847,A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.,Recruiting,Alzheimer Dementia,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,8,Interventional,"October 30, 2019","January 30, 2021",https://ClinicalTrials.gov/show/NCT03811847,55 Years to 95 Years ,55,40 to 65 years old
NCT01951118,Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly,Completed,"Alzheimer Disease|Mild Cognitive Impairment|Delirium, Dementia, Amnestic, Cognitive Disorders",All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,121,Interventional,October 2013,May 2019,https://ClinicalTrials.gov/show/NCT01951118,55 Years to 95 Years ,55,40 to 65 years old
NCT03814382,Acupuncture to Reduce Anxiety in Alzheimer's Disease (AD) and AD Related Dementias,Recruiting,Alzheimer's Dementia With Behavioral Disturbance,All,"55 Years to 95 Years   (Adult, Older Adult)",Not Applicable,20,Interventional,"March 11, 2019","June 30, 2020",https://ClinicalTrials.gov/show/NCT03814382,55 Years to 95 Years ,55,40 to 65 years old
NCT00095719,Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia,Completed,Dementia|Alzheimer's Disease,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 3,125,Interventional,December 2003,March 2005,https://ClinicalTrials.gov/show/NCT00095719,55 Years to 95 Years ,55,40 to 65 years old
NCT00523666,Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®),Unknown status,Alzheimer's Disease,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,20,Interventional,September 2006,September 2008,https://ClinicalTrials.gov/show/NCT00523666,55 Years to 95 Years ,55,40 to 65 years old
NCT00172900,MRS and DTI of White Matter in Alzheimer's Disease,Unknown status,Alzheimer's Disease|Vascular Dementia,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,40,Observational,June 2005,,https://ClinicalTrials.gov/show/NCT00172900,55 Years to 95 Years ,55,40 to 65 years old
NCT04094129,Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients,Not yet recruiting,Alzheimer Disease,All,"55 Years to 95 Years   (Adult, Older Adult)",Not Applicable,80,Interventional,"September 12, 2019","May 22, 2022",https://ClinicalTrials.gov/show/NCT04094129,55 Years to 95 Years ,55,40 to 65 years old
NCT01845636,Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil,Completed,Mild Cognitive Impairment,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,41,Interventional,August 2012,March 2016,https://ClinicalTrials.gov/show/NCT01845636,55 Years to 95 Years ,55,40 to 65 years old
NCT01438060,Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type,Completed,"Dementia, Alzheimer Type",All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 3,232,Interventional,August 2000,July 2010,https://ClinicalTrials.gov/show/NCT01438060,55 Years to 95 Years ,55,40 to 65 years old
NCT00192816,Pain Perception in Alzheimer's Disease,Unknown status,Dementia Alzheimer Type,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,60,Observational,June 2005,,https://ClinicalTrials.gov/show/NCT00192816,55 Years to 95 Years ,55,40 to 65 years old
NCT01119638,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,Completed,Agitation|Psychosis|Alzheimer's Disease,All,"55 Years to 95 Years   (Adult, Older Adult)",Phase 4,40,Interventional,April 2008,May 2010,https://ClinicalTrials.gov/show/NCT01119638,55 Years to 95 Years ,55,40 to 65 years old
NCT00544856,Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease,Completed,Alzheimer's Disease|Cognitive Impairment,All,"55 Years to 95 Years   (Adult, Older Adult)",Not Applicable,39,Interventional,October 2007,October 2008,https://ClinicalTrials.gov/show/NCT00544856,55 Years to 95 Years ,55,40 to 65 years old
NCT01812213,Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI),Unknown status,Mild Cognitive Impairment,All,"55 Years to 99 Years   (Adult, Older Adult)",Phase 2,120,Interventional,March 2013,August 2018,https://ClinicalTrials.gov/show/NCT01812213,55 Years to 99 Years ,55,40 to 65 years old
NCT00471211,"Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease",Completed,Alzheimer's Disease,All,"56 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,December 2006,December 2007,https://ClinicalTrials.gov/show/NCT00471211,56 Years and older ,56,40 to 65 years old
NCT02648906,A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients,Unknown status,Alzheimer Disease,All,"56 Years to 90 Years   (Adult, Older Adult)",Phase 4,128,Interventional,July 2015,,https://ClinicalTrials.gov/show/NCT02648906,56 Years to 90 Years ,56,40 to 65 years old
NCT03712787,An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD),Enrolling by invitation,Alzheimer's Disease,All,"57 Years to 87 Years   (Adult, Older Adult)",Phase 2,360,Interventional,"March 22, 2019","October 8, 2026",https://ClinicalTrials.gov/show/NCT03712787,57 Years to 87 Years ,57,40 to 65 years old
NCT03016702,The Cognitive Resilience Study,Completed,Alzheimer Disease,All,"58 Years to 70 Years   (Adult, Older Adult)",Not Applicable,29,Interventional,"February 27, 2017","August 9, 2017",https://ClinicalTrials.gov/show/NCT03016702,58 Years to 70 Years ,58,40 to 65 years old
NCT00239746,BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories,Unknown status,Alzheimer's Disease,All,"59 Years and older   (Adult, Older Adult)",Phase 1,40,Interventional,October 2005,August 2009,https://ClinicalTrials.gov/show/NCT00239746,59 Years and older ,59,40 to 65 years old
NCT02187276,The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia,Completed,"Alzheimer Disease, Late Onset",All,"59 Years to 92 Years   (Adult, Older Adult)",Phase 4,129,Observational,June 2009,March 2013,https://ClinicalTrials.gov/show/NCT02187276,59 Years to 92 Years ,59,40 to 65 years old
NCT02978768,Tai Chi 6-Form Sports Apparatus With Alzheimer's Disease,Completed,Alzheimer Disease,All,"59 Years to 92 Years   (Adult, Older Adult)",Not Applicable,67,Interventional,August 2011,June 2015,https://ClinicalTrials.gov/show/NCT02978768,59 Years to 92 Years ,59,40 to 65 years old
NCT02007291,Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment,Completed,Late Onset Alzheimer,All,"59 Years to 93 Years   (Adult, Older Adult)",Phase 4,71,Observational,June 2009,March 2013,https://ClinicalTrials.gov/show/NCT02007291,59 Years to 93 Years ,59,40 to 65 years old
NCT00448318,Evaluating the Effects of Music Interventions on Hospitalised People With Dementia,Unknown status,"Dementia|Alzheimer's Disease|Dementia, Vascular|Lewy Body Disease",All,"60 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,180,Interventional,March 2007,October 2008,https://ClinicalTrials.gov/show/NCT00448318,60 Years and older ,60,40 to 65 years old
NCT03672448,The China Longitudinal Aging Study of Cognitive Impairment,Recruiting,"Mild Cognitive Impairment|Alzheimer Disease|Dementia, Vascular|Dementia With Lewy Bodies|Dementia Frontal|Depression|Anxiety",All,"60 Years and older   (Adult, Older Adult)",Phase 4,10000,Observational,"September 1, 2018","November 30, 2023",https://ClinicalTrials.gov/show/NCT03672448,60 Years and older ,60,40 to 65 years old
NCT03357328,Therapy Light Rooms for Improved Sleep in Dementia Patients,Completed,Sleep Fragmentation|Behavioural and Psychiatric Symptoms of Dementia|Dementia,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,70,Interventional,"September 25, 2017","April 24, 2018",https://ClinicalTrials.gov/show/NCT03357328,60 Years and older ,60,40 to 65 years old
NCT01315717,Gait and Alzheimer Interaction Tracking (GAIT) Study,Completed,Gait Apraxia|Alzheimer Disease|Impaired Cognition|Cerebral Atrophy,All,"60 Years and older   (Adult, Older Adult)",Phase 4,912,Observational,November 2009,May 2016,https://ClinicalTrials.gov/show/NCT01315717,60 Years and older ,60,40 to 65 years old
NCT02330510,Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease,Recruiting,Alzheimer's Disease|Small Vessel Disease White Matter Hyperintensities Subtype|Vascular Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Phase 4,80,Observational,August 2014,February 2020,https://ClinicalTrials.gov/show/NCT02330510,60 Years and older ,60,40 to 65 years old
NCT02626377,Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté,Recruiting,Breast Cancer|Colorectal Cancer|Prostate Cancer|Alzheimer Disease|Age-related Macular Degeneration|Parkinson Disease|Cardiac Disease|Ischemic Stroke|Hemorrhagic Stroke,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,7604,Interventional,October 2015,October 2025,https://ClinicalTrials.gov/show/NCT02626377,60 Years and older ,60,40 to 65 years old
NCT01839422,Imaging of New Learning in Severe Alzheimer's Disease Patients,Unknown status,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,January 2012,,https://ClinicalTrials.gov/show/NCT01839422,60 Years and older ,60,40 to 65 years old
NCT03698760,Computerized Olfactory Test - Alzheimer Disease Mild Stage,Recruiting,Alzheimer Disease|Olfaction Disorders,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,"June 25, 2019",July 2020,https://ClinicalTrials.gov/show/NCT03698760,60 Years and older ,60,40 to 65 years old
NCT02959502,Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression,Recruiting,Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Dementia|Transcranial Direct Current Stimulation|tDCS,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,40,Interventional,"October 31, 2016",December 2019,https://ClinicalTrials.gov/show/NCT02959502,60 Years and older ,60,40 to 65 years old
NCT00693888,"Lighthouse Project on Dementia, Ulm, Germany",Unknown status,Dementia,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,June 2008,September 2010,https://ClinicalTrials.gov/show/NCT00693888,60 Years and older ,60,40 to 65 years old
NCT00646074,Self- Care TALK Study - Promoting Alzheimer's Disease (AD) Spousal Caregiver Health,Completed,Caregiving,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,46,Interventional,July 2006,August 2008,https://ClinicalTrials.gov/show/NCT00646074,60 Years and older ,60,40 to 65 years old
NCT03121950,Movement and Music Intervention for Individuals With Dementia,Completed,Dementia With Lewy Bodies|Dementia,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,21,Interventional,"April 1, 2017","December 30, 2017",https://ClinicalTrials.gov/show/NCT03121950,60 Years and older ,60,40 to 65 years old
NCT00997425,Home Evaluation of Exit Barriers in Wandering,Completed,"Dementia, Alzheimer Type|Problem Behavior",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,19,Interventional,October 2009,December 2012,https://ClinicalTrials.gov/show/NCT00997425,60 Years and older ,60,40 to 65 years old
NCT02933177,Effectiveness of Flash Mediation Therapy,Completed,Dementia,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,241,Interventional,May 2016,March 2017,https://ClinicalTrials.gov/show/NCT02933177,60 Years and older ,60,40 to 65 years old
NCT02361424,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,47,Interventional,February 2013,June 2015,https://ClinicalTrials.gov/show/NCT02361424,60 Years and older ,60,40 to 65 years old
NCT02176629,Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease,Completed,MCI|Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,August 2014,February 2015,https://ClinicalTrials.gov/show/NCT02176629,60 Years and older ,60,40 to 65 years old
NCT02248636,Cholinesterase Inhibitor Discontinuation,Completed,Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,72,Interventional,"January 22, 2015","October 1, 2019",https://ClinicalTrials.gov/show/NCT02248636,60 Years and older ,60,40 to 65 years old
NCT01630525,""" The Eyes Have it "" : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease",Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,83,Observational,December 2012,December 2015,https://ClinicalTrials.gov/show/NCT01630525,60 Years and older ,60,40 to 65 years old
NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 3,365,Interventional,December 2009,January 2014,https://ClinicalTrials.gov/show/NCT01028053,60 Years and older ,60,40 to 65 years old
NCT01798199,Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,21,Interventional,May 2013,September 2014,https://ClinicalTrials.gov/show/NCT01798199,60 Years and older ,60,40 to 65 years old
NCT00549601,"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease",Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,142,Interventional,September 2007,April 2009,https://ClinicalTrials.gov/show/NCT00549601,60 Years and older ,60,40 to 65 years old
NCT02292238,Benfotiamine in Alzheimer's Disease: A Pilot Study,"Active, not recruiting",Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,76,Interventional,November 2014,November 2019,https://ClinicalTrials.gov/show/NCT02292238,60 Years and older ,60,40 to 65 years old
NCT02294513,Hearing Instruments in Alzheimer's Disease,Completed,Alzheimer Disease|Hearing Loss,All,"60 Years and older   (Adult, Older Adult)",Phase 4,25,Observational,October 2014,February 2017,https://ClinicalTrials.gov/show/NCT02294513,60 Years and older ,60,40 to 65 years old
NCT04121858,Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease,Recruiting,Alzheimer Disease|Dementia,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,700,Interventional,"October 9, 2019","October 1, 2023",https://ClinicalTrials.gov/show/NCT04121858,60 Years and older ,60,40 to 65 years old
NCT02664584,"The Trinity, Ulster and Department of Agriculture Cohort Study",Unknown status,Cardiovascular Disease|Osteoporosis|Alzheimer's Disease|Hypertension,All,"60 Years and older   (Adult, Older Adult)",Phase 4,5186,Observational,December 2008,December 2018,https://ClinicalTrials.gov/show/NCT02664584,60 Years and older ,60,40 to 65 years old
NCT01095718,Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease,Unknown status,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,300,Interventional,March 2010,,https://ClinicalTrials.gov/show/NCT01095718,60 Years and older ,60,40 to 65 years old
NCT03548883,Examining Neuroinflammation in AlzHeimer's,Enrolling by invitation,"Alzheimer Disease, Early-Onset",All,"60 Years and older   (Adult, Older Adult)",Phase 4,18,Observational,June 2016,December 2018,https://ClinicalTrials.gov/show/NCT03548883,60 Years and older ,60,40 to 65 years old
NCT00843518,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,132,Interventional,February 2009,June 2011,https://ClinicalTrials.gov/show/NCT00843518,60 Years and older ,60,40 to 65 years old
NCT03185208,Lithium As a Treatment to Prevent Impairment of Cognition in Elders,Recruiting,Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Phase 4,80,Interventional,"September 1, 2017","March 31, 2022",https://ClinicalTrials.gov/show/NCT03185208,60 Years and older ,60,40 to 65 years old
NCT03799991,Vestibular Therapy in Alzheimer's Disease,Not yet recruiting,Vestibular Diseases|Vestibular Disorder|Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,70,Interventional,"July 1, 2020","June 30, 2024",https://ClinicalTrials.gov/show/NCT03799991,60 Years and older ,60,40 to 65 years old
NCT01478204,A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,925,Observational,June 2008,July 2009,https://ClinicalTrials.gov/show/NCT01478204,60 Years and older ,60,40 to 65 years old
NCT02386670,Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD),Recruiting,"Mild Cognitive Impairment|Major Depressive Disorder, Recurrent, In Remission|Major Depressive Disorder, Single Episode, in Full Remission",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,375,Interventional,January 2015,February 2021,https://ClinicalTrials.gov/show/NCT02386670,60 Years and older ,60,40 to 65 years old
NCT02205710,Adaptive Cognitive Training in Healthy Older Adults,Completed,Mild Cognitive Impairment|Mild to Moderate Dementia|Alzheimer`s Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,99,Interventional,August 2016,August 2018,https://ClinicalTrials.gov/show/NCT02205710,60 Years and older ,60,40 to 65 years old
NCT02518243,Safe & Easy for Alzheimer's Disease and Related Pathologies,Unknown status,Cognitive Deterioration,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,14,Interventional,June 2015,,https://ClinicalTrials.gov/show/NCT02518243,60 Years and older ,60,40 to 65 years old
NCT03991624,Lack of Decision-making in Patients With Alzheimer's Disease : Functions Involved and the Daily Consequences,Recruiting,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,180,Interventional,"September 27, 2019",April 2021,https://ClinicalTrials.gov/show/NCT03991624,60 Years and older ,60,40 to 65 years old
NCT00190372,AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) Patients,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,240,Interventional,October 2004,May 2008,https://ClinicalTrials.gov/show/NCT00190372,60 Years and older ,60,40 to 65 years old
NCT03075007,Brain Vascular Disease in Aging and Dementia,Completed,Alzheimer Disease|White Matter Hyperintensities|Dementia|Aging,All,"60 Years and older   (Adult, Older Adult)",Phase 4,48,Observational,"May 23, 2017","August 31, 2019",https://ClinicalTrials.gov/show/NCT03075007,60 Years and older ,60,40 to 65 years old
NCT00581867,Memory and Insulin in Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,31,Interventional,October 2007,May 2012,https://ClinicalTrials.gov/show/NCT00581867,60 Years and older ,60,40 to 65 years old
NCT00229333,"Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia",Unknown status,Depressive Syndrome,All,"60 Years and older   (Adult, Older Adult)",Phase 4,40,Interventional,December 2004,,https://ClinicalTrials.gov/show/NCT00229333,60 Years and older ,60,40 to 65 years old
NCT00368459,Raloxifene for Women With Alzheimer's Disease,Completed,Alzheimer Disease,Female,"60 Years and older   (Adult, Older Adult)",Phase 2,42,Interventional,August 2006,January 2012,https://ClinicalTrials.gov/show/NCT00368459,60 Years and older ,60,40 to 65 years old
NCT01325259,FluoroAv45 Imaging Research-in Alzheimer's Disease,Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Phase 2,54,Interventional,April 2009,December 2013,https://ClinicalTrials.gov/show/NCT01325259,60 Years and older ,60,40 to 65 years old
NCT01515982,Physical Exercise as an Additional Treatment for Alzheimer Disease,Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,February 2010,December 2013,https://ClinicalTrials.gov/show/NCT01515982,60 Years and older ,60,40 to 65 years old
NCT00231946,ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301),Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 3,555,Interventional,September 2005,,https://ClinicalTrials.gov/show/NCT00231946,60 Years and older ,60,40 to 65 years old
NCT00035204,"A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease",Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,63,Interventional,,May 2003,https://ClinicalTrials.gov/show/NCT00035204,60 Years and older ,60,40 to 65 years old
NCT00611312,Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,25,Interventional,February 2008,September 2012,https://ClinicalTrials.gov/show/NCT00611312,60 Years and older ,60,40 to 65 years old
NCT02702102,Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies,Completed,Diffuse Lewy Body Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 2,5,Interventional,December 2015,"September 4, 2019",https://ClinicalTrials.gov/show/NCT02702102,60 Years and older ,60,40 to 65 years old
NCT00146263,Cognitive Training in the Elderly,Unknown status,Dementia,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,300,Interventional,September 2005,June 2007,https://ClinicalTrials.gov/show/NCT00146263,60 Years and older ,60,40 to 65 years old
NCT02664571,Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis,Not yet recruiting,Amyloid Cerebral Angiopathy|Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,32,Interventional,January 2020,January 2021,https://ClinicalTrials.gov/show/NCT02664571,60 Years and older ,60,40 to 65 years old
NCT00792662,"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",Withdrawn,Diabetes Mellitus|Alzheimer's Disease|Apathy|Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 4,0,Interventional,November 2008,December 2011,https://ClinicalTrials.gov/show/NCT00792662,60 Years and older ,60,40 to 65 years old
NCT01867346,Early Markers of Cognitive Change and Alzheimer s Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2850,Observational,"March 19, 2003","January 2, 2015",https://ClinicalTrials.gov/show/NCT01867346,60 Years and older ,60,40 to 65 years old
NCT02521818,Dietary Treatments for Cognitive Impairment in Older Adults,Completed,Mild Cognitive Impairment|Probable Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,38,Interventional,August 2015,"July 1, 2019",https://ClinicalTrials.gov/show/NCT02521818,60 Years and older ,60,40 to 65 years old
NCT00597376,Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints,Completed,Subjective Memory Loss in Older Persons,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,104,Interventional,November 2007,May 2011,https://ClinicalTrials.gov/show/NCT00597376,60 Years and older ,60,40 to 65 years old
NCT00062569,Bathing Persons With Alzheimer's Disease aT Home (The BATH Study),Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,90,Interventional,September 2002,June 2006,https://ClinicalTrials.gov/show/NCT00062569,60 Years and older ,60,40 to 65 years old
NCT01569997,Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units,Completed,Dementia in Nursing Home,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,1428,Interventional,May 2010,September 2013,https://ClinicalTrials.gov/show/NCT01569997,60 Years and older ,60,40 to 65 years old
NCT02472899,Biomarker Study for Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,150,Observational,February 2007,June 2016,https://ClinicalTrials.gov/show/NCT02472899,60 Years and older ,60,40 to 65 years old
NCT01409694,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 3,90,Interventional,September 2011,January 2016,https://ClinicalTrials.gov/show/NCT01409694,60 Years and older ,60,40 to 65 years old
NCT00384423,Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,80,Interventional,October 2006,,https://ClinicalTrials.gov/show/NCT00384423,60 Years and older ,60,40 to 65 years old
NCT03981380,11C-PIB PET Study in MESA at Columbia University,Enrolling by invitation,Cognitive Impairment|Vascular Diseases|Alzheimer Disease|Atherosclerosis,All,"60 Years and older   (Adult, Older Adult)",Phase 2,250,Interventional,September 2019,June 2023,https://ClinicalTrials.gov/show/NCT03981380,60 Years and older ,60,40 to 65 years old
NCT03665831,Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults,Recruiting,Major Depressive Disorder|Alzheimer Disease|Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,28,Interventional,"October 23, 2018",April 2020,https://ClinicalTrials.gov/show/NCT03665831,60 Years and older ,60,40 to 65 years old
NCT03846232,Detection of Cerebral Proteinopathy in Alzheimer's Disease Through Magnetic Resonance Imaging,Recruiting,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,"February 12, 2019","December 31, 2020",https://ClinicalTrials.gov/show/NCT03846232,60 Years and older ,60,40 to 65 years old
NCT03691428,Stress Reduction Study for Partners of Early Stage Dementia,Recruiting,Dementia Caregiving,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,100,Interventional,"January 5, 2019","May 30, 2020",https://ClinicalTrials.gov/show/NCT03691428,60 Years and older ,60,40 to 65 years old
NCT02361242,24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion,Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,45,Interventional,June 2013,December 2015,https://ClinicalTrials.gov/show/NCT02361242,60 Years and older ,60,40 to 65 years old
NCT02694445,Monetary Cost of Alzheimer's Disease in China,Unknown status,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2500,Observational,January 2016,August 2016,https://ClinicalTrials.gov/show/NCT02694445,60 Years and older ,60,40 to 65 years old
NCT01423396,Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease,Recruiting,Alzheimer's Disease|Cardiovascular Risk Factors,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,406,Interventional,"March 15, 2010",March 2021,https://ClinicalTrials.gov/show/NCT01423396,60 Years and older ,60,40 to 65 years old
NCT02051244,Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?,Unknown status,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,February 2014,February 2015,https://ClinicalTrials.gov/show/NCT02051244,60 Years and older ,60,40 to 65 years old
NCT03899844,Study to Evaluate Amyloid in Blood and Imaging Related to Dementia,Recruiting,Alzheimer Disease|Alzheimer Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 4,1120,Observational,"April 9, 2019",August 2023,https://ClinicalTrials.gov/show/NCT03899844,60 Years and older ,60,40 to 65 years old
NCT00182988,Alzheimer's Caregiver Communication Study,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,140,Observational,October 2004,December 2007,https://ClinicalTrials.gov/show/NCT00182988,60 Years and older ,60,40 to 65 years old
NCT03455569,A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers,Recruiting,Sleep|Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,80,Interventional,"September 11, 2018","April 30, 2022",https://ClinicalTrials.gov/show/NCT03455569,60 Years and older ,60,40 to 65 years old
NCT03554226,Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study,"Active, not recruiting",Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,330,Interventional,"November 1, 2014","December 31, 2018",https://ClinicalTrials.gov/show/NCT03554226,60 Years and older ,60,40 to 65 years old
NCT01712074,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,Terminated,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,186,Interventional,November 2012,September 2015,https://ClinicalTrials.gov/show/NCT01712074,60 Years and older ,60,40 to 65 years old
NCT02838563,Validation of a Scale of Well-Being Assessment (SIWA) in Patients With Alzheimer's Disease or a Related Disease.,Terminated,Well-Being,All,"60 Years and older   (Adult, Older Adult)",Phase 4,135,Observational,"January 13, 2016","April 27, 2017",https://ClinicalTrials.gov/show/NCT02838563,60 Years and older ,60,40 to 65 years old
NCT04019665,Self-screening of Cognitive Impairment in Primary Care,Not yet recruiting,Cognition Disorder|Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,200,Interventional,July 2019,January 2020,https://ClinicalTrials.gov/show/NCT04019665,60 Years and older ,60,40 to 65 years old
NCT01138111,Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients,Completed,Alzheimer Disease|Amyloid Beta-Protein,All,"60 Years and older   (Adult, Older Adult)",Phase 1,45,Interventional,June 2008,December 2011,https://ClinicalTrials.gov/show/NCT01138111,60 Years and older ,60,40 to 65 years old
NCT01314131,Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home,Unknown status,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,48,Interventional,March 2011,June 2012,https://ClinicalTrials.gov/show/NCT01314131,60 Years and older ,60,40 to 65 years old
NCT01548053,The Primary Care - Dementia Assessment and Treatment Algorithm,Completed,Dementia|Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,55,Interventional,March 2012,May 2016,https://ClinicalTrials.gov/show/NCT01548053,60 Years and older ,60,40 to 65 years old
NCT03866018,Contribution of Physical Activity to Self-esteem and Motivation in Older Adults With Minor to Major Cognitive Disorders Such as Alzheimer's Disease or Related Disorders,Not yet recruiting,Cognitive Disorders,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"March 1, 2019","August 31, 2019",https://ClinicalTrials.gov/show/NCT03866018,60 Years and older ,60,40 to 65 years old
NCT02222181,Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,55,Interventional,April 2014,March 2016,https://ClinicalTrials.gov/show/NCT02222181,60 Years and older ,60,40 to 65 years old
NCT02670993,Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,59,Interventional,January 2016,June 2016,https://ClinicalTrials.gov/show/NCT02670993,60 Years and older ,60,40 to 65 years old
NCT01021644,"Genes, Exercise, Memory and Neurodegeneration",Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,73,Interventional,October 2009,December 2013,https://ClinicalTrials.gov/show/NCT01021644,60 Years and older ,60,40 to 65 years old
NCT03313518,Therapeutic Role of Transcranial DCS in Alzheimer,Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,"August 12, 2016","October 10, 2017",https://ClinicalTrials.gov/show/NCT03313518,60 Years and older ,60,40 to 65 years old
NCT03887923,Vestibular Physical Therapy for People With Alzheimer Disease,Recruiting,Vestibular Diseases|Alzheimer Disease|Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,10,Interventional,"May 10, 2019","December 31, 2019",https://ClinicalTrials.gov/show/NCT03887923,60 Years and older ,60,40 to 65 years old
NCT03786510,A Study on the Effectiveness of Multidomain Intervention Program for Reducing Risks of Dementia,Completed,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,32,Interventional,"November 1, 2016","July 31, 2017",https://ClinicalTrials.gov/show/NCT03786510,60 Years and older ,60,40 to 65 years old
NCT02831283,Imaging Inflammation in Alzheimer's Disease,Enrolling by invitation,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2,100,Interventional,June 2016,June 2021,https://ClinicalTrials.gov/show/NCT02831283,60 Years and older ,60,40 to 65 years old
NCT04012346,Modulation of Cognition and Brain Connectivity by Noninvasive Brain Stimulation in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Recruiting,Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"April 30, 2018",December 2019,https://ClinicalTrials.gov/show/NCT04012346,60 Years and older ,60,40 to 65 years old
NCT01000038,"Wii-fit for Activity, Balance and Gait in Assisted Living",Completed,Falls|Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,22,Interventional,March 2009,July 2011,https://ClinicalTrials.gov/show/NCT01000038,60 Years and older ,60,40 to 65 years old
NCT01978353,Memory Training in Patients With Amnestic Mild Cognitive Impairment,Completed,Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,November 2012,October 2015,https://ClinicalTrials.gov/show/NCT01978353,60 Years and older ,60,40 to 65 years old
NCT01409564,Cilostazol Augmentation Study in Dementia,Completed,Alzheimer's Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 4,46,Interventional,May 2010,July 2013,https://ClinicalTrials.gov/show/NCT01409564,60 Years and older ,60,40 to 65 years old
NCT01416012,Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations,Unknown status,Disease Alzheimer,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,180,Interventional,October 2011,September 2013,https://ClinicalTrials.gov/show/NCT01416012,60 Years and older ,60,40 to 65 years old
NCT03757910,Brain Imaging in the Diabetes Prevention Program Outcomes Study,Enrolling by invitation,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Early Phase 1,20,Interventional,"October 1, 2019","January 31, 2020",https://ClinicalTrials.gov/show/NCT03757910,60 Years and older ,60,40 to 65 years old
NCT03638284,Non-invasive Brain Stimulation Using Transcranial Direct Current Stimulation for Neuropsychiatric Symptoms of Dementia,Recruiting,"Dementia; Alzheimer, Mixed Type (Etiology)",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,"July 5, 2018","May 1, 2020",https://ClinicalTrials.gov/show/NCT03638284,60 Years and older ,60,40 to 65 years old
NCT01993836,Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care,Completed,Alzheimers Disease|Postoperative Delirium|Post Operative Cognitive Dysfunction,All,"60 Years and older   (Adult, Older Adult)",Phase 4,191,Interventional,November 2013,"January 10, 2019",https://ClinicalTrials.gov/show/NCT01993836,60 Years and older ,60,40 to 65 years old
NCT01002586,"Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia",Completed,Alzheimer's Dementia|Falls|Gait Impairment|Balance Impairment,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,22,Interventional,November 2009,October 2012,https://ClinicalTrials.gov/show/NCT01002586,60 Years and older ,60,40 to 65 years old
NCT00743418,Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease,Unknown status,Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,300,Interventional,June 2007,,https://ClinicalTrials.gov/show/NCT00743418,60 Years and older ,60,40 to 65 years old
NCT02208193,"Alzheimer's Disease, Art and Garden",Unknown status,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Interventional,July 2014,September 2017,https://ClinicalTrials.gov/show/NCT02208193,60 Years and older ,60,40 to 65 years old
NCT04096261,The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease,Recruiting,Blood Brain Barrier Defect|Sleep Deprivation|Sleep Apnea|Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,132,Observational,"September 12, 2019","December 31, 2019",https://ClinicalTrials.gov/show/NCT04096261,60 Years and older ,60,40 to 65 years old
NCT00165750,Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients,Terminated,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,40,Interventional,March 2005,November 2008,https://ClinicalTrials.gov/show/NCT00165750,60 Years and older ,60,40 to 65 years old
NCT01255163,A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,Terminated,Alzheimer's Disease|Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Phase 2,57,Interventional,"November 21, 2010","November 18, 2016",https://ClinicalTrials.gov/show/NCT01255163,60 Years and older ,60,40 to 65 years old
NCT02210286,Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia,Completed,Dementia|Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,20,Interventional,July 2014,July 2016,https://ClinicalTrials.gov/show/NCT02210286,60 Years and older ,60,40 to 65 years old
NCT03644043,Evidence Amyloid Scan EEG Study,Recruiting,Alzheimer Disease|Dementia Frontal|Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2000,Observational,"July 20, 2018","November 30, 2020",https://ClinicalTrials.gov/show/NCT03644043,60 Years and older ,60,40 to 65 years old
NCT02267057,Efficacy of Pain Treatment on Depression in Patients With Dementia,Completed,Depression|Pain|Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 4,163,Interventional,August 2014,"December 21, 2016",https://ClinicalTrials.gov/show/NCT02267057,60 Years and older ,60,40 to 65 years old
NCT03208491,AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders,Unknown status,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,136,Interventional,"September 30, 2017","December 30, 2018",https://ClinicalTrials.gov/show/NCT03208491,60 Years and older ,60,40 to 65 years old
NCT03676881,Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease,Recruiting,Alzheimer Disease|Dementia|Neuropathology|Mild Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Phase 4,120,Observational,"September 4, 2018",December 2021,https://ClinicalTrials.gov/show/NCT03676881,60 Years and older ,60,40 to 65 years old
NCT02557464,Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.,Unknown status,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,48,Interventional,"November 10, 2015",November 2017,https://ClinicalTrials.gov/show/NCT02557464,60 Years and older ,60,40 to 65 years old
NCT02021682,CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,58,Observational,December 2013,July 2017,https://ClinicalTrials.gov/show/NCT02021682,60 Years and older ,60,40 to 65 years old
NCT02005380,Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,20,Observational,November 2013,November 2013,https://ClinicalTrials.gov/show/NCT02005380,60 Years and older ,60,40 to 65 years old
NCT00476008,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,60,Interventional,July 2007,October 2012,https://ClinicalTrials.gov/show/NCT00476008,60 Years and older ,60,40 to 65 years old
NCT02873546,tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia,Unknown status,Alzheimer's Disease|Progressive Primary Aphasia|Early or Mild State,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,52,Interventional,"July 19, 2013","July 31, 2018",https://ClinicalTrials.gov/show/NCT02873546,60 Years and older ,60,40 to 65 years old
NCT04093882,The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease,Recruiting,Blood Brain Barrier|Alzheimer Disease|Cognitive Dysfunction|Dementia,All,"60 Years and older   (Adult, Older Adult)",Phase 4,132,Observational,"September 12, 2019","December 31, 2019",https://ClinicalTrials.gov/show/NCT04093882,60 Years and older ,60,40 to 65 years old
NCT00499200,"Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy",Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 1,42,Interventional,October 2007,June 2008,https://ClinicalTrials.gov/show/NCT00499200,60 Years and older ,60,40 to 65 years old
NCT02686190,Effects of Light-therapy in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,91,Interventional,July 2012,December 2014,https://ClinicalTrials.gov/show/NCT02686190,60 Years and older ,60,40 to 65 years old
NCT00082602,Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 3,83,Interventional,May 2004,April 2005,https://ClinicalTrials.gov/show/NCT00082602,60 Years and older ,60,40 to 65 years old
NCT01329484,Computerized Personal Interventions for Alzheimer's Patients,Unknown status,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,159,Interventional,March 2011,September 2012,https://ClinicalTrials.gov/show/NCT01329484,60 Years and older ,60,40 to 65 years old
NCT00951834,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Completed,Alzheimer's Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,21,Interventional,October 2009,February 2015,https://ClinicalTrials.gov/show/NCT00951834,60 Years and older ,60,40 to 65 years old
NCT03962439,Impact of Challenging Engagement on Cognition in Older Adults,Recruiting,Cognitive Change,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,90,Interventional,"June 1, 2019",February 2020,https://ClinicalTrials.gov/show/NCT03962439,60 Years and older ,60,40 to 65 years old
NCT03827733,Gut Microbiota and Alzheimer's Diseases,Recruiting,Alzheimer Disease,All,"60 Years and older   (Adult, Older Adult)",Phase 4,200,Observational,"February 1, 2018","December 31, 2020",https://ClinicalTrials.gov/show/NCT03827733,60 Years and older ,60,40 to 65 years old
NCT00000177,Estrogen Hormone Protocol,Completed,Alzheimer Disease,Female,"60 Years and older   (Adult, Older Adult)",Phase 3,120,Interventional,October 1995,January 1999,https://ClinicalTrials.gov/show/NCT00000177,60 Years and older ,60,40 to 65 years old
NCT02861846,Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy,Recruiting,Epilepsy,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,90,Interventional,"March 1, 2017","March 1, 2022",https://ClinicalTrials.gov/show/NCT02861846,60 Years and older ,60,40 to 65 years old
NCT02840045,Development of a New Neuroimaging Method Aimed to Differentiate Mnesic Abilities of Alzheimer and Depressed Patients,Unknown status,Alzheimer Disease|Depression,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30,Interventional,"February 20, 2015","August 20, 2018",https://ClinicalTrials.gov/show/NCT02840045,60 Years and older ,60,40 to 65 years old
NCT01434940,Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression,Unknown status,Alzheimer Disease|Depression,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,288,Interventional,April 2010,July 2018,https://ClinicalTrials.gov/show/NCT01434940,60 Years and older ,60,40 to 65 years old
NCT00178568,Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia,Completed,Sleep Disorders,All,"60 Years and older   (Adult, Older Adult)",Phase 4,60,Observational,February 2003,November 2009,https://ClinicalTrials.gov/show/NCT00178568,60 Years and older ,60,40 to 65 years old
NCT03585907,Feasibility and Efficacy of Dietary Interventions for Older Adults With Subjective Cognitive Decline,Withdrawn,Alzheimer Disease|Cognitive Impairment,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,0,Interventional,"September 2, 2019","September 1, 2021",https://ClinicalTrials.gov/show/NCT03585907,60 Years and older ,60,40 to 65 years old
NCT01920672,"Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD",Completed,Alzheimer's Disease,All,"60 Years to 100 Years   (Adult, Older Adult)",Not Applicable,82,Interventional,September 2013,June 2015,https://ClinicalTrials.gov/show/NCT01920672,60 Years to 100 Years ,60,40 to 65 years old
NCT01661894,Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly,Completed,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia,All,"60 Years to 70 Years   (Adult, Older Adult)",Phase 1,82,Interventional,April 2012,April 2014,https://ClinicalTrials.gov/show/NCT01661894,60 Years to 70 Years ,60,40 to 65 years old
NCT03131453,A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,1145,Interventional,"August 3, 2017","March 31, 2025",https://ClinicalTrials.gov/show/NCT03131453,60 Years to 75 Years ,60,40 to 65 years old
NCT02978729,Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial,Enrolling by invitation,Alzheimer Disease|Genetic Predisposition to Disease,All,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,3000,Interventional,August 2016,August 2021,https://ClinicalTrials.gov/show/NCT02978729,60 Years to 75 Years ,60,40 to 65 years old
NCT04113967,Efficacy of a Biodanza Program in People With Alzheimer's Disease.,Completed,Alzheimer Dementia (AD)|Mental Disorder|Mood Disorders|Physically Disabled,All,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Interventional,"March 1, 2018","October 1, 2018",https://ClinicalTrials.gov/show/NCT04113967,60 Years to 75 Years ,60,40 to 65 years old
NCT03121066,Transcranial Magnetic Stimulation for Alzheimer's Disease Treatment,Not yet recruiting,Alzheimer Disease,All,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,45,Interventional,October 2018,October 2020,https://ClinicalTrials.gov/show/NCT03121066,60 Years to 75 Years ,60,40 to 65 years old
NCT03224988,Bilateral Brain Dynamics in Cognition and Aging,Recruiting,Alzheimer Disease|Aging|MCI,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Observational,"March 20, 2018",August 2020,https://ClinicalTrials.gov/show/NCT03224988,60 Years to 75 Years ,60,40 to 65 years old
NCT03959124,Deep Brain Stimulation for Alzheimer's Disease,Recruiting,"Alzheimer Disease|Dementia, Alzheimer Type|Deep Brain Stimulation",All,"60 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"July 15, 2019","September 30, 2021",https://ClinicalTrials.gov/show/NCT03959124,60 Years to 75 Years ,60,40 to 65 years old
NCT03814603,"The Sleep Amyloid, Slow WAve Race and Ethnicity Study",Recruiting,Alzheimer Disease,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 4,210,Observational,"November 21, 2018",June 2023,https://ClinicalTrials.gov/show/NCT03814603,60 Years to 75 Years ,60,40 to 65 years old
NCT02087865,Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease,Recruiting,Genetic Risk for Alzheimer's Disease,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 4,90,Interventional,May 2014,"February 27, 2020",https://ClinicalTrials.gov/show/NCT02087865,60 Years to 75 Years ,60,40 to 65 years old
NCT02565511,A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"Active, not recruiting",Alzheimer's Disease,All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,481,Interventional,"November 30, 2015","March 31, 2025",https://ClinicalTrials.gov/show/NCT02565511,60 Years to 75 Years ,60,40 to 65 years old
NCT03688126,U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk,Recruiting,Alzheimer Disease,All,"60 Years to 79 Years   (Adult, Older Adult)",Not Applicable,2000,Interventional,"January 8, 2019",November 2023,https://ClinicalTrials.gov/show/NCT03688126,60 Years to 79 Years ,60,40 to 65 years old
NCT01696019,Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders,Completed,Cognitive Impairment|Dementia|Mild Cognitive Impairment|Alzheimer Disease,All,"60 Years to 79 Years   (Adult, Older Adult)",Not Applicable,120,Interventional,July 2008,September 2009,https://ClinicalTrials.gov/show/NCT01696019,60 Years to 79 Years ,60,40 to 65 years old
NCT03613844,DHA Brain Delivery Trial,Recruiting,Brain DHA Delivery and Alzheimer's Disease Risk,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,320,Interventional,"July 1, 2018","September 30, 2024",https://ClinicalTrials.gov/show/NCT03613844,60 Years to 80 Years ,60,40 to 65 years old
NCT02843906,"Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?",Unknown status,Senile Plaques|Tau Proteins|Alzheimer Disease|Bipolar Disorders|Mild Cognitive Impairment,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,180,Interventional,July 2015,July 2018,https://ClinicalTrials.gov/show/NCT02843906,60 Years to 80 Years ,60,40 to 65 years old
NCT02520232,"Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition",Completed,Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,139,Interventional,June 2015,"May 11, 2018",https://ClinicalTrials.gov/show/NCT02520232,60 Years to 80 Years ,60,40 to 65 years old
NCT03978052,Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention,Not yet recruiting,Alzheimer Disease|Nutritional Intervention|Cognitive Function,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,September 2019,September 2021,https://ClinicalTrials.gov/show/NCT03978052,60 Years to 80 Years ,60,40 to 65 years old
NCT00205621,Positron Emission Tomography of Amyloid in Alzheimer's Disease,Suspended,Alzheimer's Disease,Male,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,50,Interventional,October 2005,December 2009,https://ClinicalTrials.gov/show/NCT00205621,60 Years to 80 Years ,60,40 to 65 years old
NCT02228187,Brain-Computer Interface System for Training Memory and Attention in Elderly,Completed,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,240,Interventional,July 2015,June 2017,https://ClinicalTrials.gov/show/NCT02228187,60 Years to 80 Years ,60,40 to 65 years old
NCT03382353,EMuNI Project: Multiple Nonpharmacological Interventions,"Active, not recruiting",Lifestyle Risk Reduction,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120,Interventional,January 2016,June 2018,https://ClinicalTrials.gov/show/NCT03382353,60 Years to 80 Years ,60,40 to 65 years old
NCT01208675,The Swedish BioFINDER Study,"Active, not recruiting",Mild Cognitive Impairment|Alzheimer's Disease|Dementia With Lewy Bodies|Vascular Dementia,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 4,900,Observational,September 2010,December 2022,https://ClinicalTrials.gov/show/NCT01208675,60 Years to 80 Years ,60,40 to 65 years old
NCT03727360,Exercise for Brain Health in the Fight Against Alzheimer's Disease,Recruiting,Healthy Cognition,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,152,Interventional,"October 8, 2018",April 2023,https://ClinicalTrials.gov/show/NCT03727360,60 Years to 80 Years ,60,40 to 65 years old
NCT03274817,A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol,Recruiting,Alzheimer Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,31,Interventional,"July 11, 2017",January 2020,https://ClinicalTrials.gov/show/NCT03274817,60 Years to 80 Years ,60,40 to 65 years old
NCT02062099,PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO),Unknown status,Memory Complaint|Mild Cognitive Impairment|Alzheimer Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,36,Interventional,January 2014,January 2018,https://ClinicalTrials.gov/show/NCT02062099,60 Years to 80 Years ,60,40 to 65 years old
NCT00094939,Predictors of Cognitive Decline in Normal Aging,Unknown status,Alzheimer Disease|Dementia,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 4,170,Observational,September 2003,August 2008,https://ClinicalTrials.gov/show/NCT00094939,60 Years to 80 Years ,60,40 to 65 years old
NCT00979446,Passport to Brain Wellness in Sedentary Adults,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,63,Interventional,June 2008,August 2009,https://ClinicalTrials.gov/show/NCT00979446,60 Years to 80 Years ,60,40 to 65 years old
NCT03255720,Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes,Not yet recruiting,Alzheimer Dementia,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 4,40,Observational,"September 29, 2017","December 31, 2022",https://ClinicalTrials.gov/show/NCT03255720,60 Years to 80 Years ,60,40 to 65 years old
NCT03954899,Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging,Recruiting,Mild Cognitive Impairment|Cognitive Decline|Healthy Aging,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,230,Interventional,"September 30, 2019",October 2024,https://ClinicalTrials.gov/show/NCT03954899,60 Years to 80 Years ,60,40 to 65 years old
NCT03370744,Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD,Recruiting,Subjective Cognitive Decline|Preclinical Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 4,300,Observational,"March 15, 2017",December 2021,https://ClinicalTrials.gov/show/NCT03370744,60 Years to 80 Years ,60,40 to 65 years old
NCT02273895,"The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study",Completed,AD,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,29,Interventional,April 2004,January 2010,https://ClinicalTrials.gov/show/NCT02273895,60 Years to 80 Years ,60,40 to 65 years old
NCT00687141,"Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects",Completed,Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 1,112,Interventional,November 2007,June 2008,https://ClinicalTrials.gov/show/NCT00687141,60 Years to 80 Years ,60,40 to 65 years old
NCT01094145,Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease,Completed,Alzheimer Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,6,Interventional,January 2010,January 2013,https://ClinicalTrials.gov/show/NCT01094145,60 Years to 80 Years ,60,40 to 65 years old
NCT04064021,Acupuncture Treatment for Improving Alzheimer's Dementia,Not yet recruiting,Cognitive Deficits|Alzheimer Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,"June 30, 2020","March 31, 2021",https://ClinicalTrials.gov/show/NCT04064021,60 Years to 80 Years ,60,40 to 65 years old
NCT03847038,BarcelonaBeta Dementia Prevention Research Clinic: a Study on Risk Factors Disclosure,Recruiting,Alzheimer Disease|Dementia|Mild Cognitive Impairment|Subjective Cognitive Decline,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,425,Interventional,"July 16, 2018","December 31, 2022",https://ClinicalTrials.gov/show/NCT03847038,60 Years to 80 Years ,60,40 to 65 years old
NCT00094952,Biomarkers and Early Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 4,80,Observational,April 2003,March 2008,https://ClinicalTrials.gov/show/NCT00094952,60 Years to 80 Years ,60,40 to 65 years old
NCT01055392,Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease,Unknown status,Cognitive Impairment|Alzheimer Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Interventional,March 2007,,https://ClinicalTrials.gov/show/NCT01055392,60 Years to 80 Years ,60,40 to 65 years old
NCT02726906,Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study,Recruiting,"Aging|Cognitive Ability, General",All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Interventional,July 2016,April 2020,https://ClinicalTrials.gov/show/NCT02726906,60 Years to 80 Years ,60,40 to 65 years old
NCT02836054,Study of Degenerescence CSF Hallmarks in Older Bipolar Patients,Recruiting,Bipolar Disorder|Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,November 2013,December 2019,https://ClinicalTrials.gov/show/NCT02836054,60 Years to 80 Years ,60,40 to 65 years old
NCT02576639,Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age,Completed,Alzheimer's Disease,All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 2,124,Interventional,"August 10, 2015","March 11, 2016",https://ClinicalTrials.gov/show/NCT02576639,60 Years to 80 Years ,60,40 to 65 years old
NCT03475446,The Effect of tES on a Cognitive Training,Recruiting,Memory Impairment,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,180,Interventional,"January 15, 2018","December 30, 2020",https://ClinicalTrials.gov/show/NCT03475446,60 Years to 85 Years ,60,40 to 65 years old
NCT02377206,Neuroinflammation and Cognitive Decline in Alzheimer Disease,Unknown status,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,45,Interventional,March 2015,March 2017,https://ClinicalTrials.gov/show/NCT02377206,60 Years to 85 Years ,60,40 to 65 years old
NCT02114372,"Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study","Active, not recruiting","Alzheimer's Disease|Plaque, Amyloid",All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,1146,Observational,"February 5, 2014","April 3, 2023",https://ClinicalTrials.gov/show/NCT02114372,60 Years to 85 Years ,60,40 to 65 years old
NCT03351452,tES Effects on Associative Memory Performance,Enrolling by invitation,Healthy|Mild Cognitive Impairment|Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,74,Interventional,"April 9, 2018","September 1, 2020",https://ClinicalTrials.gov/show/NCT03351452,60 Years to 85 Years ,60,40 to 65 years old
NCT03900273,Development of Novel Measures for Alzheimer's Disease Prevention Trials,Recruiting,Healthy Participants,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,320,Interventional,"February 25, 2019","March 31, 2023",https://ClinicalTrials.gov/show/NCT03900273,60 Years to 85 Years ,60,40 to 65 years old
NCT01354691,Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease,Completed,Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,201,Interventional,February 2011,March 2013,https://ClinicalTrials.gov/show/NCT01354691,60 Years to 85 Years ,60,40 to 65 years old
NCT00551772,A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.,Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Interventional,August 2007,,https://ClinicalTrials.gov/show/NCT00551772,60 Years to 85 Years ,60,40 to 65 years old
NCT01885806,Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease,Unknown status,Alzheimer's Disease|Apathy,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,40,Interventional,June 2013,December 2015,https://ClinicalTrials.gov/show/NCT01885806,60 Years to 85 Years ,60,40 to 65 years old
NCT02423200,"Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD",Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Interventional,April 2015,November 2016,https://ClinicalTrials.gov/show/NCT02423200,60 Years to 85 Years ,60,40 to 65 years old
NCT01466088,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)",Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,386,Interventional,October 2011,May 2014,https://ClinicalTrials.gov/show/NCT01466088,60 Years to 85 Years ,60,40 to 65 years old
NCT02089555,African American Alzheimer's Progression Markers - CSF and Neuro-Imaging,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,135,Observational,September 2013,June 2016,https://ClinicalTrials.gov/show/NCT02089555,60 Years to 85 Years ,60,40 to 65 years old
NCT03249688,Multimodal Preventive Trial for Alzheimer's Disease,Recruiting,Alzheimer Disease; Prodromal,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,150,Interventional,"October 16, 2017","September 1, 2019",https://ClinicalTrials.gov/show/NCT03249688,60 Years to 85 Years ,60,40 to 65 years old
NCT03790709,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,450,Interventional,"July 3, 2018","March 31, 2021",https://ClinicalTrials.gov/show/NCT03790709,60 Years to 85 Years ,60,40 to 65 years old
NCT01055561,A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia,Completed,Alzheimer's Disease|Dementia,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,30,Interventional,January 2010,March 2011,https://ClinicalTrials.gov/show/NCT01055561,60 Years to 85 Years ,60,40 to 65 years old
NCT02363504,The Locus Coeruleus and Memory,Recruiting,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,70,Observational,"February 1, 2017",August 2019,https://ClinicalTrials.gov/show/NCT02363504,60 Years to 85 Years ,60,40 to 65 years old
NCT00948259,Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease,Completed,Alzheimer´s Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Interventional,December 2008,November 2009,https://ClinicalTrials.gov/show/NCT00948259,60 Years to 85 Years ,60,40 to 65 years old
NCT02991235,Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease,"Active, not recruiting",Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,December 2016,December 2018,https://ClinicalTrials.gov/show/NCT02991235,60 Years to 85 Years ,60,40 to 65 years old
NCT02253732,Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs,Completed,Mild Cognitive Impairment|Alzheimer Disease|Parkinson Disease|Healthy Volunteers,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Interventional,September 2015,March 2018,https://ClinicalTrials.gov/show/NCT02253732,60 Years to 85 Years ,60,40 to 65 years old
NCT03668405,A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD),Terminated,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,18,Interventional,"June 26, 2018","May 27, 2019",https://ClinicalTrials.gov/show/NCT03668405,60 Years to 85 Years ,60,40 to 65 years old
NCT02569398,An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia,Completed,Asymptomatic Amyloid-positive,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,596,Interventional,"October 29, 2015","December 20, 2018",https://ClinicalTrials.gov/show/NCT02569398,60 Years to 85 Years ,60,40 to 65 years old
NCT01039701,"4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease",Completed,Mild to Moderate Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,99,Interventional,December 2009,July 2010,https://ClinicalTrials.gov/show/NCT01039701,60 Years to 85 Years ,60,40 to 65 years old
NCT02608021,Neurotrack Test Validation Protocol,Recruiting,Mild Cognitive Impairment,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,80,Observational,"October 1, 2015",September 2019,https://ClinicalTrials.gov/show/NCT02608021,60 Years to 85 Years ,60,40 to 65 years old
NCT02615002,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),"Active, not recruiting",Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,500,Interventional,November 2015,"November 30, 2019",https://ClinicalTrials.gov/show/NCT02615002,60 Years to 85 Years ,60,40 to 65 years old
NCT03954210,SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid,Recruiting,Insomnia,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,200,Interventional,"August 27, 2019",September 2020,https://ClinicalTrials.gov/show/NCT03954210,60 Years to 85 Years ,60,40 to 65 years old
NCT00582127,Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.,Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,50,Observational,January 2008,November 2010,https://ClinicalTrials.gov/show/NCT00582127,60 Years to 85 Years ,60,40 to 65 years old
NCT02423122,"A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)",Completed,Alzheimer's Disease|Mild Cognitive Impairment,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,16,Interventional,April 2015,September 2016,https://ClinicalTrials.gov/show/NCT02423122,60 Years to 85 Years ,60,40 to 65 years old
NCT02839187,Neuro Imaging and Multimodal Alzheimer's Disease,Completed,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,59,Interventional,June 2010,May 2012,https://ClinicalTrials.gov/show/NCT02839187,60 Years to 85 Years ,60,40 to 65 years old
NCT01481961,Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease,Completed,Alzheimer's Disease|Cognition Disorders,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,15,Interventional,November 2010,May 2012,https://ClinicalTrials.gov/show/NCT01481961,60 Years to 85 Years ,60,40 to 65 years old
NCT03784183,Neuropsychological and Neurophysiological Effects of Cognitive Stimulation in Patients With Alzheimer's Disease and Mild Cognitive Impairment,Recruiting,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,126,Interventional,"September 27, 2018","October 1, 2020",https://ClinicalTrials.gov/show/NCT03784183,60 Years to 85 Years ,60,40 to 65 years old
NCT02913664,Risk Reduction for Alzheimer's Disease,Recruiting,Cognitively Normal Older Adults|Hypertension|Subjective Cognitive Decline|Family History of Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,640,Interventional,September 2016,September 2022,https://ClinicalTrials.gov/show/NCT02913664,60 Years to 85 Years ,60,40 to 65 years old
NCT02388152,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,Terminated,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,50,Interventional,March 2015,"July 4, 2019",https://ClinicalTrials.gov/show/NCT02388152,60 Years to 85 Years ,60,40 to 65 years old
NCT03367403,A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ),"Active, not recruiting",Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,266,Interventional,"December 18, 2017","November 12, 2021",https://ClinicalTrials.gov/show/NCT03367403,60 Years to 85 Years ,60,40 to 65 years old
NCT01428362,VI-1121 for the Treatment Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,61,Interventional,August 2011,August 2013,https://ClinicalTrials.gov/show/NCT01428362,60 Years to 85 Years ,60,40 to 65 years old
NCT00117403,Anti-Oxidant Treatment of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,75,Interventional,January 2006,September 2007,https://ClinicalTrials.gov/show/NCT00117403,60 Years to 85 Years ,60,40 to 65 years old
NCT03860857,MRI and PET Biomarkers for Cognitive Decline in Older Adults,Recruiting,Alzheimer Disease|Cognitive Impairment|Cognitive Decline,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 3,200,Interventional,"May 1, 2018","December 22, 2024",https://ClinicalTrials.gov/show/NCT03860857,60 Years to 85 Years ,60,40 to 65 years old
NCT01716637,Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 1,12,Interventional,February 2010,May 2016,https://ClinicalTrials.gov/show/NCT01716637,60 Years to 85 Years ,60,40 to 65 years old
NCT03020381,Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study,Recruiting,Gait Apraxia|Mild Cognitive Impairment|Subjective Cognitive Impairment|Cerebral Atrophy|Alzheimer Disease|Dementia,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 4,400,Observational,December 2007,December 2020,https://ClinicalTrials.gov/show/NCT03020381,60 Years to 85 Years ,60,40 to 65 years old
NCT02305836,Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease,Recruiting,Cognitive Impairment,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,334,Interventional,June 2017,December 2019,https://ClinicalTrials.gov/show/NCT02305836,60 Years to 85 Years ,60,40 to 65 years old
NCT00501111,Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,659,Interventional,July 2007,August 2008,https://ClinicalTrials.gov/show/NCT00501111,60 Years to 85 Years ,60,40 to 65 years old
NCT03467477,Tau Screening Study in Subjects With Early Symptomatic AD,Completed,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,161,Interventional,"March 8, 2018","November 15, 2018",https://ClinicalTrials.gov/show/NCT03467477,60 Years to 85 Years ,60,40 to 65 years old
NCT03322462,Tau Screening Study in Patients With Early Symptomatic AD,Completed,Alzheimer Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,153,Interventional,"October 26, 2017","August 31, 2018",https://ClinicalTrials.gov/show/NCT03322462,60 Years to 85 Years ,60,40 to 65 years old
NCT03518073,A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease,"Active, not recruiting",Alzheimer Disease (AD),All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,285,Interventional,"April 30, 2018","October 22, 2021",https://ClinicalTrials.gov/show/NCT03518073,60 Years to 85 Years ,60,40 to 65 years old
NCT03333837,Improvisational Movement for People With Memory Loss and Their Caregivers,Recruiting,Alzheimer's Disease (Incl Subtypes)|Dementia|Mild Cognitive Impairment,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,240,Interventional,"February 6, 2018",April 2020,https://ClinicalTrials.gov/show/NCT03333837,60 Years to 85 Years ,60,40 to 65 years old
NCT03270137,Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer Disease,Unknown status,Alzheimer Disease|Transcranial Magnetic Stimulation,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,19,Interventional,"March 10, 2016","August 31, 2017",https://ClinicalTrials.gov/show/NCT03270137,60 Years to 85 Years ,60,40 to 65 years old
NCT01038726,Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults,Completed,Aging|Alzheimer's Disease,All,"60 Years to 85 Years   (Adult, Older Adult)",Not Applicable,108,Interventional,December 2009,September 2012,https://ClinicalTrials.gov/show/NCT01038726,60 Years to 85 Years ,60,40 to 65 years old
NCT02350634,18F-AV-1451 High Resolution Autopsy Study,Completed,Alzheimer's Disease,All,"60 Years to 89 Years   (Adult, Older Adult)",Phase 1,3,Interventional,June 2015,"May 18, 2018",https://ClinicalTrials.gov/show/NCT02350634,60 Years to 89 Years ,60,40 to 65 years old
NCT03359902,Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation,Recruiting,Mild Cognitive Impairment,All,"60 Years to 89 Years   (Adult, Older Adult)",Not Applicable,250,Interventional,"January 1, 2018","June 30, 2020",https://ClinicalTrials.gov/show/NCT03359902,60 Years to 89 Years ,60,40 to 65 years old
NCT02792257,Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Recruiting,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,160,Interventional,"March 1, 2017",December 2020,https://ClinicalTrials.gov/show/NCT02792257,60 Years to 90 Years ,60,40 to 65 years old
NCT04075435,Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia,Not yet recruiting,"Alzheimer Disease|Anxiety|Agitation,Psychomotor",All,"60 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,12,Interventional,"November 1, 2019","November 1, 2021",https://ClinicalTrials.gov/show/NCT04075435,60 Years to 90 Years ,60,40 to 65 years old
NCT02263287,"LESCOD: ""Lewy Body Screening in Cognitive Disorders""",Terminated,Alzheimer Disease|Lewy Body Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,133,Interventional,October 2014,August 2017,https://ClinicalTrials.gov/show/NCT02263287,60 Years to 90 Years ,60,40 to 65 years old
NCT04010175,Digital Cognitive Remote Training in Alzheimer's Disease (MA-EIAD),Not yet recruiting,Alzheimer Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,165,Interventional,September 2019,May 2022,https://ClinicalTrials.gov/show/NCT04010175,60 Years to 90 Years ,60,40 to 65 years old
NCT03001557,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"Active, not recruiting",Irregular Sleep-Wake Rhythm Disorder,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,62,Interventional,"December 20, 2016","April 9, 2020",https://ClinicalTrials.gov/show/NCT03001557,60 Years to 90 Years ,60,40 to 65 years old
NCT01825317,Effect of NeuroAD on Alzheimer Patients,Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,32,Interventional,March 2013,December 2013,https://ClinicalTrials.gov/show/NCT01825317,60 Years to 90 Years ,60,40 to 65 years old
NCT01825330,Effect of NeuroAD on the Cognitive Function of Alzheimer Patients,Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,131,Interventional,October 2013,March 2016,https://ClinicalTrials.gov/show/NCT01825330,60 Years to 90 Years ,60,40 to 65 years old
NCT01605448,Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment,Completed,Mild Cognitive Impairment,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,14,Interventional,January 2010,January 2012,https://ClinicalTrials.gov/show/NCT01605448,60 Years to 90 Years ,60,40 to 65 years old
NCT00040378,Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE),Completed,Alzheimer Disease,Male,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,4246,Observational,May 2002,August 2016,https://ClinicalTrials.gov/show/NCT00040378,60 Years to 90 Years ,60,40 to 65 years old
NCT00908999,Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD),Completed,Anosognosia|Alzheimer's Disease|Mild Cognitive Impairment,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,60,Observational,April 2008,September 2011,https://ClinicalTrials.gov/show/NCT00908999,60 Years to 90 Years ,60,40 to 65 years old
NCT00900770,Implications of Amyloid Pathology,Unknown status,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,100,Observational,November 2008,March 2014,https://ClinicalTrials.gov/show/NCT00900770,60 Years to 90 Years ,60,40 to 65 years old
NCT00539305,Hormone and Information Processing Study,Completed,Mild Cognitive Impairment|Alzheimer's Disease,Male,"60 Years to 90 Years   (Adult, Older Adult)",Phase 3,22,Interventional,July 2009,May 2012,https://ClinicalTrials.gov/show/NCT00539305,60 Years to 90 Years ,60,40 to 65 years old
NCT00381381,The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,199,Interventional,May 2006,December 2008,https://ClinicalTrials.gov/show/NCT00381381,60 Years to 90 Years ,60,40 to 65 years old
NCT00938665,Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.,Completed,Memory Disorders|Alzheimer Disease|Dementia|Cognitive Impairment|Frontotemporal Dementia,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,204,Observational,December 2010,February 2014,https://ClinicalTrials.gov/show/NCT00938665,60 Years to 90 Years ,60,40 to 65 years old
NCT02772185,Neurostimulation and Cognitive Intervention in Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Interventional,May 2016,May 2019,https://ClinicalTrials.gov/show/NCT02772185,60 Years to 90 Years ,60,40 to 65 years old
NCT02074215,Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,19,Interventional,March 2011,December 2013,https://ClinicalTrials.gov/show/NCT02074215,60 Years to 90 Years ,60,40 to 65 years old
NCT03531710,"An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311","Active, not recruiting",Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,34,Interventional,"August 10, 2018",April 2020,https://ClinicalTrials.gov/show/NCT03531710,60 Years to 90 Years ,60,40 to 65 years old
NCT03094546,Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline,Recruiting,Subjective Cognitive Decline (SCD),All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,100,Interventional,January 2017,June 2020,https://ClinicalTrials.gov/show/NCT03094546,60 Years to 90 Years ,60,40 to 65 years old
NCT03560960,Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease,Not yet recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,"60 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,240,Interventional,October 2019,July 2023,https://ClinicalTrials.gov/show/NCT03560960,60 Years to 90 Years ,60,40 to 65 years old
NCT03520998,A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer Disease|Mild to Moderate Alzheimer Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,40,Interventional,"April 16, 2018","May 24, 2019",https://ClinicalTrials.gov/show/NCT03520998,60 Years to 90 Years ,60,40 to 65 years old
NCT01819545,The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,300,Observational,January 2012,December 2015,https://ClinicalTrials.gov/show/NCT01819545,60 Years to 90 Years ,60,40 to 65 years old
NCT02142777,S-Equol in Alzheimer's Disease (SEAD) Trial,Completed,Alzheimer's Disease,Female,"60 Years to 90 Years   (Adult, Older Adult)",Phase 1,15,Interventional,July 2014,April 2016,https://ClinicalTrials.gov/show/NCT02142777,60 Years to 90 Years ,60,40 to 65 years old
NCT02166827,"Effects of a NeuroAD System, for the Treatment of Alzheimer Disease",Terminated,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1,Interventional,November 2014,November 2015,https://ClinicalTrials.gov/show/NCT02166827,60 Years to 90 Years ,60,40 to 65 years old
NCT00880412,A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,197,Interventional,April 2008,August 2009,https://ClinicalTrials.gov/show/NCT00880412,60 Years to 90 Years ,60,40 to 65 years old
NCT00911690,Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders,Completed,Dementia|Alzheimers Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 4,102,Observational,July 2009,March 2016,https://ClinicalTrials.gov/show/NCT00911690,60 Years to 90 Years ,60,40 to 65 years old
NCT00319891,Computer-Based Training for Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 1,6,Interventional,September 2004,October 2006,https://ClinicalTrials.gov/show/NCT00319891,60 Years to 90 Years ,60,40 to 65 years old
NCT02551809,"Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients",Completed,Alzheimer's Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Phase 2,43,Interventional,October 2015,August 2018,https://ClinicalTrials.gov/show/NCT02551809,60 Years to 90 Years ,60,40 to 65 years old
NCT02147652,Personalized Music Therapy and Agitation in Dementia,Enrolling by invitation,Alzheimer's Disease|Vascular Dementia,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"October 14, 2014",June 2020,https://ClinicalTrials.gov/show/NCT02147652,60 Years to 90 Years ,60,40 to 65 years old
NCT00824967,Non Pharmacological Management of Behavioural Symptoms in Nursing Home,Terminated,ALZHEIMER Disease,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,306,Interventional,October 2007,October 2009,https://ClinicalTrials.gov/show/NCT00824967,60 Years to 90 Years ,60,40 to 65 years old
NCT02769234,EEG/ERP Longitudinal Study in Alzheimer's Disease (AD),Unknown status,Alzheimer's Disease,All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 4,75,Observational,May 2016,July 2017,https://ClinicalTrials.gov/show/NCT02769234,60 Years to 95 Years ,60,40 to 65 years old
NCT03765762,A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease,Recruiting,Severe Alzheimer Disease,All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 2,20,Interventional,"January 15, 2019",March 2020,https://ClinicalTrials.gov/show/NCT03765762,60 Years to 95 Years ,60,40 to 65 years old
NCT03300726,Synaptic Injury and Functional Connectivity in Alzheimer's Disease,"Active, not recruiting","Alzheimer Disease, Late Onset",All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 4,30,Observational,"February 12, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03300726,60 Years to 95 Years ,60,40 to 65 years old
NCT01935024,Benefits of Exercise in Alzheimer's Disease,Recruiting,Alzheimer's Disease,All,"60 Years to 95 Years   (Adult, Older Adult)",Not Applicable,60,Interventional,"August 1, 2013",April 2020,https://ClinicalTrials.gov/show/NCT01935024,60 Years to 95 Years ,60,40 to 65 years old
NCT01454453,Optimisation of Antipsychotic Drug Use in Older People,Terminated,Alzheimer's Disease|Schizophrenia,All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 4,64,Interventional,May 2012,July 2015,https://ClinicalTrials.gov/show/NCT01454453,60 Years to 95 Years ,60,40 to 65 years old
NCT02833870,Non-pharmacological Care of Alzheimer's Disease: Benefice of Musical Interventions,Completed,Alzheimer's Disease (AD) and Related Disorders,All,"60 Years to 99 Years   (Adult, Older Adult)",Not Applicable,150,Interventional,September 2013,June 2015,https://ClinicalTrials.gov/show/NCT02833870,60 Years to 99 Years ,60,40 to 65 years old
NCT00814502,Zolpidem CR and Hospitalized Patients With Dementia,Completed,"Dementia|Alzheimer Disease|Dementia, Vascular|Sleep Disorders|Circadian Dysregulation",All,"60 Years to 99 Years   (Adult, Older Adult)",Not Applicable,20,Interventional,December 2008,December 2013,https://ClinicalTrials.gov/show/NCT00814502,60 Years to 99 Years ,60,40 to 65 years old
NCT00260624,Escitalopram Treatment of Patients With Agitated Dementia,Completed,Alzheimer's Disease|Psychomotor Agitation,All,"61 Years and older   (Adult, Older Adult)",Phase 4,20,Interventional,February 2003,December 2006,https://ClinicalTrials.gov/show/NCT00260624,61 Years and older ,61,40 to 65 years old
NCT03537729,Effects of Visual Cues and Education for People Who Live Within Long Term Care Communities to Assist in Wayfinding,Recruiting,Alzheimer Disease|Alzheimer Dementia|Age-Related Memory Disorders|Dementia,All,"62 Years and older   (Adult, Older Adult)",Not Applicable,137,Interventional,"April 1, 2019","April 30, 2023",https://ClinicalTrials.gov/show/NCT03537729,62 Years and older ,62,40 to 65 years old
NCT00056628,COGNIShunt® System for Alzheimer's Disease,Completed,Alzheimer Disease,All,"62 Years to 85 Years   (Adult, Older Adult)",Phase 3,250,Interventional,January 2001,October 2004,https://ClinicalTrials.gov/show/NCT00056628,62 Years to 85 Years ,62,40 to 65 years old
NCT02958930,Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease,Completed,"Alzheimer Disease|Alzheimer Disease, Late Onset",All,"63 Years and older   (Adult, Older Adult)",Not Applicable,8,Interventional,"October 1, 2017","January 11, 2019",https://ClinicalTrials.gov/show/NCT02958930,63 Years and older ,63,40 to 65 years old
NCT03927040,Transcranial Electromagnetic Treatment Against Alzheimer's Disease,"Active, not recruiting","Alzheimer Disease|Alzheimer Disease, Late Onset",All,"63 Years to 84 Years   (Adult, Older Adult)",Not Applicable,7,Interventional,"April 15, 2019",October 2019,https://ClinicalTrials.gov/show/NCT03927040,63 Years to 84 Years ,63,40 to 65 years old
NCT03313895,The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI,Recruiting,Mild Cognitive Impairment,All,65 Years and older   (Older Adult),Not Applicable,128,Interventional,"July 5, 2018","May 31, 2022",https://ClinicalTrials.gov/show/NCT03313895,65 Years and older ,65,40 to 65 years old
NCT01847586,Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,49,Interventional,April 2013,October 2017,https://ClinicalTrials.gov/show/NCT01847586,65 Years and older ,65,40 to 65 years old
NCT03333096,Assessing Neurovisual Function in Patients With Cognitive Impairment,Recruiting,Glaucoma|Mild Cognitive Impairment|Glaucoma and Mild Cognitive Impairment|Healthy,All,65 Years and older   (Older Adult),Not Applicable,60,Interventional,"December 1, 2017","January 1, 2019",https://ClinicalTrials.gov/show/NCT03333096,65 Years and older ,65,40 to 65 years old
NCT00831298,Assessment of Sleep Disturbance in Alzheimer Disease,Completed,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,70,Interventional,July 2010,November 2011,https://ClinicalTrials.gov/show/NCT00831298,65 Years and older ,65,40 to 65 years old
NCT03672279,Validation of a Novel Self-Administered Cognitive Assessment Tool (CogCheck) in Patients With Mild and Major Neurocognitive Disorder,Not yet recruiting,"Dementia Alzheimers|Dementia|Mild Cognitive Impairment|Dementia, Vascular|Dementia With Lewy Bodies|Cognition Disorders|Neurocognitive Disorders",All,65 Years and older   (Older Adult),Phase 4,150,Observational,"July 1, 2020","December 31, 2024",https://ClinicalTrials.gov/show/NCT03672279,65 Years and older ,65,40 to 65 years old
NCT03462121,A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease,Recruiting,Mild to Moderate Dementia Due to Alzheimer's Disease|With or Without Coexisting Cerebrovascular Disease,All,65 Years and older   (Older Adult),Phase 2,81,Interventional,"March 1, 2018","July 30, 2020",https://ClinicalTrials.gov/show/NCT03462121,65 Years and older ,65,40 to 65 years old
NCT00814346,Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions,Completed,Alzheimer's Disease|Cognitive Impairment,All,65 Years and older   (Older Adult),Phase 2,49,Interventional,October 2008,July 2012,https://ClinicalTrials.gov/show/NCT00814346,65 Years and older ,65,40 to 65 years old
NCT00177671,Antidepressant Medication Plus Donepezil for Treating Late-life Depression,Completed,Depression|Dementia,All,65 Years and older   (Older Adult),Phase 4,220,Interventional,December 2003,September 2009,https://ClinicalTrials.gov/show/NCT00177671,65 Years and older ,65,40 to 65 years old
NCT03287765,Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans,Recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Phase 2,80,Interventional,May 2016,November 2021,https://ClinicalTrials.gov/show/NCT03287765,65 Years and older ,65,40 to 65 years old
NCT03941119,Evaluating the Impact of VR-therapy on BPSD and QoL of Individuals With Dementia Admitted to Hospital,Recruiting,Dementia|Delirium Superimposed on Dementia,All,65 Years and older   (Older Adult),Not Applicable,200,Interventional,"May 6, 2019","June 15, 2021",https://ClinicalTrials.gov/show/NCT03941119,65 Years and older ,65,40 to 65 years old
NCT03403257,Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive),Enrolling by invitation,"Dementia|Dementia Alzheimers|Dementia, Vascular|Dementia, Mixed",All,65 Years and older   (Older Adult),Phase 4,776,Observational,"April 11, 2018","September 30, 2022",https://ClinicalTrials.gov/show/NCT03403257,65 Years and older ,65,40 to 65 years old
NCT02172612,A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly,Completed,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,50,Interventional,September 2014,"November 20, 2015",https://ClinicalTrials.gov/show/NCT02172612,65 Years and older ,65,40 to 65 years old
NCT00063310,ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation,Completed,Alzheimer Disease,Female,65 Years and older   (Older Adult),Phase 2,90,Interventional,March 2003,February 2006,https://ClinicalTrials.gov/show/NCT00063310,65 Years and older ,65,40 to 65 years old
NCT03246269,Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA),Completed,"Cognitive Impairment|Cognitive Decline|Cognition Disorders|Cognitive Symptom|Cognitive Change|Cognitive Deterioration|Cognitive Abnormality|Cognitive Impairment, Mild|Cognition Disorders in Old Age|Dementia|Dementia Alzheimers|Dementia, Alzheimer Type|Dementia, Mild|Dementia of Alzheimer Type",All,65 Years and older   (Older Adult),Phase 4,334,Observational,December 2016,April 2017,https://ClinicalTrials.gov/show/NCT03246269,65 Years and older ,65,40 to 65 years old
NCT01577394,Oculomotor Testing in the Differential Diagnosis of Dementia,Completed,Lewy Body Disease|Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 3,65,Interventional,June 2011,April 2016,https://ClinicalTrials.gov/show/NCT01577394,65 Years and older ,65,40 to 65 years old
NCT03175874,Autophagy and Pathological Aging,Recruiting,Osteoporosis,Female,65 Years and older   (Older Adult),Not Applicable,60,Interventional,"December 20, 2017",February 2020,https://ClinicalTrials.gov/show/NCT03175874,65 Years and older ,65,40 to 65 years old
NCT01773915,New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study,Unknown status,"Alzheimer Disease, Late Onset",All,65 Years and older   (Older Adult),Phase 4,20,Observational,December 2012,June 2014,https://ClinicalTrials.gov/show/NCT01773915,65 Years and older ,65,40 to 65 years old
NCT03643003,Music Therapy for Persons With Dementia,Completed,Quality of Life|Social Interaction|Emotions|Mood|Feelings|Alzheimer Disease|Dementia,All,65 Years and older   (Older Adult),Not Applicable,32,Interventional,"May 25, 2018","September 30, 2018",https://ClinicalTrials.gov/show/NCT03643003,65 Years and older ,65,40 to 65 years old
NCT00488007,"Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids",Completed,Alzheimer Disease|Presbycusis,All,65 Years and older   (Older Adult),Not Applicable,51,Interventional,May 2007,September 2013,https://ClinicalTrials.gov/show/NCT00488007,65 Years and older ,65,40 to 65 years old
NCT03152630,Research on the Early and Prognosis Diagnosis of Vascular Dementia,Recruiting,Dementia,All,65 Years and older   (Older Adult),Phase 4,600,Observational,"March 30, 2016",January 2036,https://ClinicalTrials.gov/show/NCT03152630,65 Years and older ,65,40 to 65 years old
NCT03038282,Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients,Not yet recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,100,Interventional,"February 20, 2017","October 20, 2019",https://ClinicalTrials.gov/show/NCT03038282,65 Years and older ,65,40 to 65 years old
NCT02434393,Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project,"Active, not recruiting",Major Depression|Late Life Depression (LLD),All,65 Years and older   (Older Adult),Phase 4,133,Observational,"March 4, 2015",January 2021,https://ClinicalTrials.gov/show/NCT02434393,65 Years and older ,65,40 to 65 years old
NCT02284906,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,Terminated,Mild Cognitive Impairment Due to Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 3,40,Interventional,"February 12, 2015","May 8, 2018",https://ClinicalTrials.gov/show/NCT02284906,65 Years and older ,65,40 to 65 years old
NCT02351453,"Patients With Alzheimer Disease, Spouse Carers and Risk of Institutionalization: a Prospective Observational Cohort Study of Dyads (AID Study)",Completed,Alzheimer Disease,All,65 Years and older   (Older Adult),Phase 4,207,Observational,August 2011,February 2013,https://ClinicalTrials.gov/show/NCT02351453,65 Years and older ,65,40 to 65 years old
NCT01329536,The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease,Completed,Alzheimer's Disease|Agitation,All,65 Years and older   (Older Adult),Phase 4,50,Observational,December 2010,October 2011,https://ClinicalTrials.gov/show/NCT01329536,65 Years and older ,65,40 to 65 years old
NCT00548951,Alzheimer Patients and the Snoezelen Program,Completed,Dementia,All,65 Years and older   (Older Adult),Phase 1,18,Interventional,September 2005,December 2006,https://ClinicalTrials.gov/show/NCT00548951,65 Years and older ,65,40 to 65 years old
NCT02829801,Evaluation of the Animal Intervention Used as Therapy,Unknown status,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,40,Interventional,"March 2, 2016","May 2, 2019",https://ClinicalTrials.gov/show/NCT02829801,65 Years and older ,65,40 to 65 years old
NCT03622905,ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease,Recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,210,Interventional,"August 1, 2019","October 1, 2024",https://ClinicalTrials.gov/show/NCT03622905,65 Years and older ,65,40 to 65 years old
NCT04063124,Senolytic Therapy to Modulate Progression of Alzheimer's Disease,Not yet recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Phase 1|Phase 2,5,Interventional,December 2019,"December 31, 2020",https://ClinicalTrials.gov/show/NCT04063124,65 Years and older ,65,40 to 65 years old
NCT04102514,A Dyadic Approach for a Remote Physical Activity Intervention in Adults With AD and Their Caregivers,Not yet recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,100,Interventional,April 2020,April 2024,https://ClinicalTrials.gov/show/NCT04102514,65 Years and older ,65,40 to 65 years old
NCT01362686,Comparative Research of Alzheimer's Disease Drugs,Terminated,Dementia|Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,200,Interventional,April 2011,October 2015,https://ClinicalTrials.gov/show/NCT01362686,65 Years and older ,65,40 to 65 years old
NCT03256539,"Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease",Not yet recruiting,Sleep|Alzheimer Disease|Cognitive Impairment|Aging|CBT,All,65 Years and older   (Older Adult),Not Applicable,40,Interventional,September 2019,May 2022,https://ClinicalTrials.gov/show/NCT03256539,65 Years and older ,65,40 to 65 years old
NCT03841539,Nutrition Interventions for Cognitive Enhancement,Recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,200,Interventional,"March 7, 2019",February 2023,https://ClinicalTrials.gov/show/NCT03841539,65 Years and older ,65,40 to 65 years old
NCT00388544,Enhancing Quality of Life for Nursing Home Residents,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 2,128,Interventional,May 2005,February 2010,https://ClinicalTrials.gov/show/NCT00388544,65 Years and older ,65,40 to 65 years old
NCT00294307,Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers,Completed,"Dementia|Dementia, Vascular|Alzheimer Disease|Delirium, Dementia, Amnestic, Cognitive Disorders|Lewy Body Disease|Mild Cognitive Impairment",All,65 Years and older   (Older Adult),Phase 4,814,Observational,February 2006,August 2012,https://ClinicalTrials.gov/show/NCT00294307,65 Years and older ,65,40 to 65 years old
NCT00867399,A Safety and Tolerability Study of ABT-126 in Elderly,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 1,30,Interventional,March 2009,,https://ClinicalTrials.gov/show/NCT00867399,65 Years and older ,65,40 to 65 years old
NCT02196116,Amyloïd Load in Elderly Population: Effect of Cognitive Reserve,Unknown status,"Plaque, Amyloid|Cognitive Deficits",All,65 Years and older   (Older Adult),Not Applicable,120,Interventional,July 2014,July 2016,https://ClinicalTrials.gov/show/NCT02196116,65 Years and older ,65,40 to 65 years old
NCT00295152,Effects of Community Occupational Therapy in Older Patients With Dementia and Their Caregivers.,Unknown status,Community Occupational Therapy|Dementia Patients|Primary Caregivers of Dementia Patients,All,65 Years and older   (Older Adult),Not Applicable,135,Interventional,April 2001,February 2005,https://ClinicalTrials.gov/show/NCT00295152,65 Years and older ,65,40 to 65 years old
NCT03300180,Caregiver Outcomes of Alzheimer's Disease Screening,Recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,3600,Interventional,"October 15, 2018","September 30, 2023",https://ClinicalTrials.gov/show/NCT03300180,65 Years and older ,65,40 to 65 years old
NCT00874939,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),Terminated,Alzheimer's Disease|Dementia,All,65 Years and older   (Older Adult),Phase 1,4,Interventional,"April 6, 2009","April 20, 2009",https://ClinicalTrials.gov/show/NCT00874939,65 Years and older ,65,40 to 65 years old
NCT03717597,Nonrandomized Evaluation of a Multidimensional Behavioral Intervention,Recruiting,Subjective Cognitive Concerns (SCC),All,65 Years and older   (Older Adult),Not Applicable,60,Interventional,"April 26, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03717597,65 Years and older ,65,40 to 65 years old
NCT00076440,Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study,Completed,Alzheimer Disease,Male,65 Years and older   (Older Adult),Phase 2,90,Interventional,December 2003,March 2007,https://ClinicalTrials.gov/show/NCT00076440,65 Years and older ,65,40 to 65 years old
NCT01311492,Exercise Trial for Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,10,Interventional,March 2011,April 2013,https://ClinicalTrials.gov/show/NCT01311492,65 Years and older ,65,40 to 65 years old
NCT00267124,Brain Aging Project--Kansas University,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 4,172,Observational,November 2004,August 2009,https://ClinicalTrials.gov/show/NCT00267124,65 Years and older ,65,40 to 65 years old
NCT03275363,The University of Hong Kong Neurocognitive Disorder Cohort,Recruiting,Neurocognitive Disorder|Mild Cognitive Impairment|Alzheimer Dementia|Vascular Dementia|Age-related Cognitive Decline,All,65 Years and older   (Older Adult),Phase 4,500,Observational,"September 1, 2014","January 4, 2022",https://ClinicalTrials.gov/show/NCT03275363,65 Years and older ,65,40 to 65 years old
NCT04036955,"Evaluation of an Innovative Information, Training and Social Support Intervention ""INFOSADEM"" to Principal Caregivers of Dementia Patients Living at Home",Completed,Dementia,All,65 Years and older   (Older Adult),Not Applicable,160,Interventional,"March 1, 2016","December 31, 2018",https://ClinicalTrials.gov/show/NCT04036955,65 Years and older ,65,40 to 65 years old
NCT01202994,Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET,"Active, not recruiting",Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 2,27,Interventional,May 2011,December 2018,https://ClinicalTrials.gov/show/NCT01202994,65 Years and older ,65,40 to 65 years old
NCT01129115,Dose Response Study of Aerobic Exercise in Older Adults,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Early Phase 1,101,Interventional,May 2010,April 2014,https://ClinicalTrials.gov/show/NCT01129115,65 Years and older ,65,40 to 65 years old
NCT00547560,Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population,Completed,Healthy,All,65 Years and older   (Older Adult),Phase 1,49,Interventional,August 2007,October 2009,https://ClinicalTrials.gov/show/NCT00547560,65 Years and older ,65,40 to 65 years old
NCT00246896,Care Management for Patients With Alzheimer Disease and Their Family Caregivers,Completed,Alzheimer's Disease|Dementia,All,65 Years and older   (Older Adult),Not Applicable,220,Interventional,August 2001,August 2005,https://ClinicalTrials.gov/show/NCT00246896,65 Years and older ,65,40 to 65 years old
NCT02000583,Alzheimer's Prevention Through Exercise,"Active, not recruiting",Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,100,Interventional,November 2013,December 2019,https://ClinicalTrials.gov/show/NCT02000583,65 Years and older ,65,40 to 65 years old
NCT03001232,The Effect of Movement-oriented Dementia Care on ADL and QoL of Dementia Patients in Nursing Homes,Completed,Dementia,All,65 Years and older   (Older Adult),Not Applicable,66,Interventional,March 2014,March 2015,https://ClinicalTrials.gov/show/NCT03001232,65 Years and older ,65,40 to 65 years old
NCT01222351,Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172,"Active, not recruiting",Late Onset Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,161,Interventional,December 2010,January 2029,https://ClinicalTrials.gov/show/NCT01222351,65 Years and older ,65,40 to 65 years old
NCT04044495,"Sleep, Rhythms and Risk of Alzheimer's Disease",Recruiting,Alzheimer Disease|Sleep,All,65 Years and older   (Older Adult),Not Applicable,100,Interventional,"September 9, 2019","September 1, 2020",https://ClinicalTrials.gov/show/NCT04044495,65 Years and older ,65,40 to 65 years old
NCT03324711,"Psychometric Validation of the ""Antillanisée"" Version of the Mini Mental State Examination (MMSEa)",Recruiting,Elderly Patients|Cognitive Disorder|Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,300,Interventional,November 2016,May 2020,https://ClinicalTrials.gov/show/NCT03324711,65 Years and older ,65,40 to 65 years old
NCT01708304,Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs),Completed,Alzheimer's Disease|Dementia|Memory Impairment|Cognitive Impairment,All,65 Years and older   (Older Adult),Not Applicable,510,Interventional,November 2012,June 2017,https://ClinicalTrials.gov/show/NCT01708304,65 Years and older ,65,40 to 65 years old
NCT04021888,The Effects of Exercise Program in Alzheimer's Patients With Mild to Moderate Stage Alzheimer's Disease,"Active, not recruiting",Alzheimer Disease|Aerobic Exercise|Breathing Exercise|Resistance Training,All,65 Years and older   (Older Adult),Not Applicable,60,Interventional,"July 16, 2018","July 30, 2020",https://ClinicalTrials.gov/show/NCT04021888,65 Years and older ,65,40 to 65 years old
NCT03286608,Polyphenols and Risk of Dementia,Completed,"Diet, Polyphenols, Flavonoids, Stilbenes, Aged, Dementia, Alzheimer's Disease, Epidemiology",All,65 Years and older   (Older Adult),Phase 4,1329,Observational,"January 1, 1999","December 31, 2015",https://ClinicalTrials.gov/show/NCT03286608,65 Years and older ,65,40 to 65 years old
NCT04095962,Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia,Recruiting,Dementia|Alzheimer Disease|Vascular Dementia,All,65 Years and older   (Older Adult),Not Applicable,100,Interventional,"September 1, 2018",July 2020,https://ClinicalTrials.gov/show/NCT04095962,65 Years and older ,65,40 to 65 years old
NCT03002142,Auditory Rehabilitation and Cognition in Alzheimer Patients,Recruiting,Alzheimer's Disease|Hearing Loss,All,65 Years and older   (Older Adult),Not Applicable,184,Interventional,"March 31, 2017",February 2020,https://ClinicalTrials.gov/show/NCT03002142,65 Years and older ,65,40 to 65 years old
NCT03741543,Learning and Coping With Early Stage Dementia,"Active, not recruiting",Dementia|Alzheimer Disease|Vascular Dementia,All,65 Years and older   (Older Adult),Not Applicable,100,Interventional,"March 3, 2014","December 31, 2021",https://ClinicalTrials.gov/show/NCT03741543,65 Years and older ,65,40 to 65 years old
NCT02420756,Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study,Completed,Alzheimer's Disease|Dementia|Mild Cognitive Impairment,All,65 Years and older   (Older Adult),Phase 4,18488,Observational,February 2016,December 2017,https://ClinicalTrials.gov/show/NCT02420756,65 Years and older ,65,40 to 65 years old
NCT03360552,Evaluating the Effectiveness of a New Way of Organizing Primary Health Care to Improve the Management of Alzheimer's Disease,Not yet recruiting,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,320,Interventional,"January 2, 2018","January 1, 2021",https://ClinicalTrials.gov/show/NCT03360552,65 Years and older ,65,40 to 65 years old
NCT03723707,Enhanced Quality in Primary Care for Elders With Diabetes and Dementia,Recruiting,Diabetes|Dementia|Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,1000,Interventional,"December 3, 2018",March 2022,https://ClinicalTrials.gov/show/NCT03723707,65 Years and older ,65,40 to 65 years old
NCT01400542,Sleep Apnea in Early to Mid-Stage Alzheimer's Disease,Terminated,Early Onset Alzheimer Disease|Alzheimer Disease|Obstructive Sleep Apnea Syndromes,All,65 Years and older   (Older Adult),Phase 4,22,Observational,December 2010,June 2014,https://ClinicalTrials.gov/show/NCT01400542,65 Years and older ,65,40 to 65 years old
NCT03234686,Deferiprone to Delay Dementia (The 3D Study),Recruiting,Mild Cognitive Impairment|Prodromal Alzheimer's Disease|Mild Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 2,171,Interventional,"January 19, 2018",December 2021,https://ClinicalTrials.gov/show/NCT03234686,65 Years and older ,65,40 to 65 years old
NCT03581643,Validation of the Montreal Cognitive Assessment in Patients With Mild and Major Neurocognitive Disorder,Completed,Alzheimer Disease|Mild Cognitive Impairment,All,65 Years and older   (Older Adult),Phase 4,430,Observational,"March 6, 2017","May 8, 2018",https://ClinicalTrials.gov/show/NCT03581643,65 Years and older ,65,40 to 65 years old
NCT01699503,Indiana University Dementia Screening Trial,Completed,Dementia|Alzheimer's Disease|Mild Cognitive Impairment,All,65 Years and older   (Older Adult),Not Applicable,4005,Interventional,October 2012,"November 22, 2017",https://ClinicalTrials.gov/show/NCT01699503,65 Years and older ,65,40 to 65 years old
NCT00042172,Treatment for Early Memory Loss,Completed,Cognition Disorders|Alzheimer Disease,All,65 Years and older   (Older Adult),Phase 4,40,Interventional,June 2002,September 2004,https://ClinicalTrials.gov/show/NCT00042172,65 Years and older ,65,40 to 65 years old
NCT02781220,Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial,"Active, not recruiting",Mild Cognitive Impairment|Dementia|Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 4,69,Observational,July 2016,July 2019,https://ClinicalTrials.gov/show/NCT02781220,65 Years and older ,65,40 to 65 years old
NCT03840759,Short-term Effects of an Inpatient Geriatric Consultation Team on Geriatric Syndrome Patients,Completed,Depression|Senile Dementia,All,65 Years and older   (Older Adult),Not Applicable,59,Interventional,"January 1, 2017","December 31, 2017",https://ClinicalTrials.gov/show/NCT03840759,65 Years and older ,65,40 to 65 years old
NCT03549078,A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia,Recruiting,Functional Aging|Subjective Cognitive Concerns|Compensation Strategies|Brain Health Activities,All,65 Years and older   (Older Adult),Not Applicable,120,Interventional,"January 1, 2017",November 2019,https://ClinicalTrials.gov/show/NCT03549078,65 Years and older ,65,40 to 65 years old
NCT02444078,Effects of Exercise on Functional Ability in People With Dementia in Nursing Homes:a Cluster Randomised Controlled Trial,Completed,Alzheimer Disease|Dementia,All,65 Years and older   (Older Adult),Not Applicable,140,Interventional,August 2015,September 2017,https://ClinicalTrials.gov/show/NCT02444078,65 Years and older ,65,40 to 65 years old
NCT03638323,Age-related Hearing Loss and Lexical Disorders,Completed,Alzheimer Disease|Presbycusis|Lexical Syntactic Disorder,All,65 Years and older   (Older Adult),Phase 4,46,Observational,"August 27, 2018","January 31, 2019",https://ClinicalTrials.gov/show/NCT03638323,65 Years and older ,65,40 to 65 years old
NCT03035201,COcoa Supplement and Multivitamin Outcomes Study for the Mind,"Active, not recruiting",Cognitive Impairment|Dementia|Aging,All,65 Years and older   (Older Adult),Phase 4,2262,Observational,September 2016,October 2020,https://ClinicalTrials.gov/show/NCT03035201,65 Years and older ,65,40 to 65 years old
NCT01143350,Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders,Terminated,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,300,Interventional,March 2010,March 2011,https://ClinicalTrials.gov/show/NCT01143350,65 Years and older ,65,40 to 65 years old
NCT01646723,Volunteers Adding Life in Dementia,Completed,Dementia|Alzheimer Disease|Behavior,All,65 Years and older   (Older Adult),Not Applicable,75,Interventional,June 2012,March 2016,https://ClinicalTrials.gov/show/NCT01646723,65 Years and older ,65,40 to 65 years old
NCT00480220,Specific Care and Assistance Plan for Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,1200,Interventional,August 2003,August 2007,https://ClinicalTrials.gov/show/NCT00480220,65 Years and older ,65,40 to 65 years old
NCT02719834,Behavioral Expressions in Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 4,4,Observational,April 2016,February 2018,https://ClinicalTrials.gov/show/NCT02719834,65 Years and older ,65,40 to 65 years old
NCT01049555,Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,42,Interventional,September 2011,December 2012,https://ClinicalTrials.gov/show/NCT01049555,65 Years and older ,65,40 to 65 years old
NCT01834716,Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study,Completed,Alzheimer's Disease Prevention,All,65 Years and older   (Older Adult),Not Applicable,16,Interventional,April 2013,December 2014,https://ClinicalTrials.gov/show/NCT01834716,65 Years and older ,65,40 to 65 years old
NCT02502045,"Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's",Completed,Alzheimer's Disease,Female,65 Years and older   (Older Adult),Not Applicable,18,Interventional,May 2012,January 2016,https://ClinicalTrials.gov/show/NCT02502045,65 Years and older ,65,40 to 65 years old
NCT02814422,Triglyceride-rich Lipoprotein and Development of Dementia,Unknown status,Dementia,All,65 Years and older   (Older Adult),Phase 4,1000,Observational,July 2014,July 2017,https://ClinicalTrials.gov/show/NCT02814422,65 Years and older ,65,40 to 65 years old
NCT02438202,Electroconvulsive Therapy for Treatment of Alzheimer´s Disease,Not yet recruiting,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,15,Interventional,December 2019,January 2021,https://ClinicalTrials.gov/show/NCT02438202,65 Years and older ,65,40 to 65 years old
NCT02365051,Translation of COPE for Publicly-Funded Home Care Clients and Their Families,"Active, not recruiting",Dementia|Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,582,Interventional,May 2015,"March 31, 2020",https://ClinicalTrials.gov/show/NCT02365051,65 Years and older ,65,40 to 65 years old
NCT03475316,Movement Intervention for Memory Enhancement,Recruiting,"Alzheimer Disease|Dementia|Cognitive Decline|Cognitive Impairment|Dementia, Alzheimer Type",All,65 Years and older   (Older Adult),Not Applicable,32,Interventional,"March 28, 2019","August 31, 2020",https://ClinicalTrials.gov/show/NCT03475316,65 Years and older ,65,40 to 65 years old
NCT01316562,Predictive Value of Cognitive Tests Performed for the Diagnosis of Alzheimer's Disease and Related Disorders,Unknown status,Alzheimer's Disease|Impaired Cognition|Memory Disorders,All,65 Years and older   (Older Adult),Phase 4,500,Observational,July 2009,July 2012,https://ClinicalTrials.gov/show/NCT01316562,65 Years and older ,65,40 to 65 years old
NCT01903421,Inhalational Anesthesia and Precipitation of Dementia: is There a Link?,"Active, not recruiting",Alzheimer's Disease|Dementia,All,65 Years and older   (Older Adult),Not Applicable,500,Interventional,March 2014,December 2019,https://ClinicalTrials.gov/show/NCT01903421,65 Years and older ,65,40 to 65 years old
NCT02302482,Predictive Factors and Autonomy Level Change,Recruiting,Memory Impairment,All,65 Years and older   (Older Adult),Not Applicable,6780,Interventional,November 2014,November 2023,https://ClinicalTrials.gov/show/NCT02302482,65 Years and older ,65,40 to 65 years old
NCT00401167,Memantine for Agitation and Aggression in Severe Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 4,32,Interventional,November 2006,January 2010,https://ClinicalTrials.gov/show/NCT00401167,65 Years and older ,65,40 to 65 years old
NCT00329706,Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID),Completed,Dementia,All,65 Years and older   (Older Adult),Not Applicable,710,Interventional,June 2006,January 2017,https://ClinicalTrials.gov/show/NCT00329706,65 Years and older ,65,40 to 65 years old
NCT03593941,Ageing Gut Brain Interactions,Recruiting,Dementia Alzheimers,All,65 Years and older   (Older Adult),Phase 4,60,Observational,"August 1, 2018","October 1, 2018",https://ClinicalTrials.gov/show/NCT03593941,65 Years and older ,65,40 to 65 years old
NCT00443014,The Dementia Study in Northern Norway,Completed,Alzheimer Disease,All,65 Years and older   (Older Adult),Phase 4,187,Interventional,June 2003,June 2009,https://ClinicalTrials.gov/show/NCT00443014,65 Years and older ,65,40 to 65 years old
NCT02360527,Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease,Completed,Retinal Neurodegeneration|Alzheimer´s Disease|Type 2 Diabetes,All,65 Years and older   (Older Adult),Phase 4,126,Observational,September 2014,December 2015,https://ClinicalTrials.gov/show/NCT02360527,65 Years and older ,65,40 to 65 years old
NCT00647478,System-IGF-1 Pathway and Alzheimer's Disease,Completed,"Alzheimer's Disease|Mild Cognitive Impairment|Cognitive Function 1, Social|Control With Normal Activities of Daily Living",All,65 Years and older   (Older Adult),Phase 4,693,Observational,October 2007,July 2012,https://ClinicalTrials.gov/show/NCT00647478,65 Years and older ,65,40 to 65 years old
NCT02462291,New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders),Completed,Alzheimer Disease|Behavioral Disorders|Cognitive Impairment,All,65 Years and older   (Older Adult),Not Applicable,163,Interventional,June 2015,December 2015,https://ClinicalTrials.gov/show/NCT02462291,65 Years and older ,65,40 to 65 years old
NCT01689948,Alzheimer Disease : Rehabilitation's Intervention at Home,Terminated,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,17,Interventional,October 2012,September 2014,https://ClinicalTrials.gov/show/NCT01689948,65 Years and older ,65,40 to 65 years old
NCT03838952,The Efficacy of Traditional Chinese Herbal Medicine for Dementia,Not yet recruiting,Dementia|Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,20,Interventional,"February 11, 2019","December 31, 2020",https://ClinicalTrials.gov/show/NCT03838952,65 Years and older ,65,40 to 65 years old
NCT02317250,Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II,Withdrawn,Mild Cognitive Impairment,All,65 Years and older   (Older Adult),Phase 3,0,Interventional,June 2018,December 2022,https://ClinicalTrials.gov/show/NCT02317250,65 Years and older ,65,40 to 65 years old
NCT04073628,The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment,Not yet recruiting,Mild Cognitive Impairment|Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,240,Interventional,"October 1, 2019","October 31, 2024",https://ClinicalTrials.gov/show/NCT04073628,65 Years and older ,65,40 to 65 years old
NCT03848312,Preventing Alzheimer's Disease With Cognitive Training,Recruiting,Age-related Cognitive Decline,All,65 Years and older   (Older Adult),Not Applicable,1600,Interventional,"February 19, 2019","June 30, 2020",https://ClinicalTrials.gov/show/NCT03848312,65 Years and older ,65,40 to 65 years old
NCT02921672,Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline,Completed,Alzheimer's Disease|Cognitive Impairment,All,65 Years and older   (Older Adult),Not Applicable,30,Interventional,March 2016,December 2018,https://ClinicalTrials.gov/show/NCT02921672,65 Years and older ,65,40 to 65 years old
NCT00951197,Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects,Completed,Dementia|Alzheimer Disease,All,65 Years and older   (Older Adult),Phase 4,318,Observational,April 2009,March 2011,https://ClinicalTrials.gov/show/NCT00951197,65 Years and older ,65,40 to 65 years old
NCT02709356,Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,20,Interventional,October 2015,February 2018,https://ClinicalTrials.gov/show/NCT02709356,65 Years and older ,65,40 to 65 years old
NCT01582919,Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study,Completed,Dementia|Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,304,Interventional,September 2012,June 2015,https://ClinicalTrials.gov/show/NCT01582919,65 Years and older ,65,40 to 65 years old
NCT01384344,Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy,Completed,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,82,Interventional,June 2011,June 2012,https://ClinicalTrials.gov/show/NCT01384344,65 Years and older ,65,40 to 65 years old
NCT02719938,Triggered Palliative Care for Advanced Dementia,Completed,Alzheimer Disease|Dementia,All,65 Years and older   (Older Adult),Not Applicable,62,Interventional,March 2016,"October 31, 2017",https://ClinicalTrials.gov/show/NCT02719938,65 Years and older ,65,40 to 65 years old
NCT03466736,Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects,Recruiting,Alzheimer Disease|Mild Cognitive Impairment,All,65 Years and older   (Older Adult),Phase 4,210,Observational,"September 1, 2018","April 30, 2022",https://ClinicalTrials.gov/show/NCT03466736,65 Years and older ,65,40 to 65 years old
NCT02802371,Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program,Recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,240,Interventional,August 2016,February 2020,https://ClinicalTrials.gov/show/NCT02802371,65 Years and older ,65,40 to 65 years old
NCT00750529,Alzheimer and Sleep,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 1,15,Interventional,November 2008,September 2013,https://ClinicalTrials.gov/show/NCT00750529,65 Years and older ,65,40 to 65 years old
NCT03984396,Optimal Medication Management in Alzheimer's Disease and Dementia,Recruiting,Dementia,All,65 Years and older   (Older Adult),Not Applicable,3671,Interventional,"March 6, 2019",August 2022,https://ClinicalTrials.gov/show/NCT03984396,65 Years and older ,65,40 to 65 years old
NCT03221296,Fall Prevention - Vestibular Rehabilitation,Completed,Alzheimer Dementia (AD)|Vascular Dementia,All,65 Years and older   (Older Adult),Not Applicable,29,Interventional,"June 27, 2017","August 23, 2018",https://ClinicalTrials.gov/show/NCT03221296,65 Years and older ,65,40 to 65 years old
NCT02432222,Effects of Visual Arts Training on Dementia,Completed,Dementia|Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,23,Interventional,April 2015,December 2015,https://ClinicalTrials.gov/show/NCT02432222,65 Years and older ,65,40 to 65 years old
NCT02846415,Play Intervention for Dementia for Promoting Cognitive Function: A Feasibility Study,Completed,Dementia|Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,30,Interventional,"August 1, 2016","December 31, 2017",https://ClinicalTrials.gov/show/NCT02846415,65 Years and older ,65,40 to 65 years old
NCT02078310,Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia,Completed,Alzheimer's Disease,All,65 Years and older   (Older Adult),Phase 1|Phase 2,35,Interventional,February 2014,November 2014,https://ClinicalTrials.gov/show/NCT02078310,65 Years and older ,65,40 to 65 years old
NCT01606488,Effects of Brain Beta-Amyloid on Postoperative Cognition,Recruiting,Postoperative Cognitive Dysfunction,All,65 Years and older   (Older Adult),Phase 4,100,Interventional,May 2012,June 2019,https://ClinicalTrials.gov/show/NCT01606488,65 Years and older ,65,40 to 65 years old
NCT00208819,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,Completed,"Senile Dementia, Alzheimer Type|Dementia, Alzheimer Type|Alzheimer Disease|Dementia",All,65 Years and older   (Older Adult),Phase 4,50,Interventional,September 2003,July 2007,https://ClinicalTrials.gov/show/NCT00208819,65 Years and older ,65,40 to 65 years old
NCT01815112,Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging,Terminated,Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia,All,65 Years and older   (Older Adult),Not Applicable,60,Interventional,February 2008,April 2014,https://ClinicalTrials.gov/show/NCT01815112,65 Years and older ,65,40 to 65 years old
NCT02997982,Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease,Recruiting,Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex,All,65 Years and older   (Older Adult),Phase 2,36,Interventional,December 2016,April 2019,https://ClinicalTrials.gov/show/NCT02997982,65 Years and older ,65,40 to 65 years old
NCT03046121,A Family-centered Intervention for Acutely-ill Persons With Dementia,Recruiting,Alzheimer Disease,All,65 Years and older   (Older Adult),Not Applicable,438,Interventional,"November 6, 2017","February 28, 2022",https://ClinicalTrials.gov/show/NCT03046121,65 Years and older ,65,40 to 65 years old
NCT01314638,Study of Adherence and Effects of Balance Exercices (SIEL BLEU Associatio),Unknown status,Gait Apraxia|Alzheimer Disease|Impaired Cognition,All,65 Years and older   (Older Adult),Phase 4,100,Observational,May 2010,June 2011,https://ClinicalTrials.gov/show/NCT01314638,65 Years and older ,65,40 to 65 years old
NCT01715181,Volunteers Adding Life in Dementia: VALID,Completed,Dementia|Alzheimer's Disease,All,65 Years and older   (Older Adult),Not Applicable,75,Interventional,January 2013,March 2016,https://ClinicalTrials.gov/show/NCT01715181,65 Years and older ,65,40 to 65 years old
NCT02020356,Music Therapy in Alzheimer's Disease,Terminated,Alzheimer's Type Dementia,All,65 Years to 100 Years   (Older Adult),Not Applicable,35,Interventional,April 2013,June 2015,https://ClinicalTrials.gov/show/NCT02020356,65 Years to 100 Years ,65,40 to 65 years old
NCT03615027,Dementia-specific Intervention of Advance Care Planning,Recruiting,Alzheimer Disease,All,65 Years to 100 Years   (Older Adult),Not Applicable,60,Interventional,"August 3, 2018","December 31, 2019",https://ClinicalTrials.gov/show/NCT03615027,65 Years to 100 Years ,65,40 to 65 years old
NCT02849639,The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression,Recruiting,Alzheimer's Disease|Dementia,All,65 Years to 101 Years   (Older Adult),Early Phase 1,90,Interventional,"April 4, 2017",March 2021,https://ClinicalTrials.gov/show/NCT02849639,65 Years to 101 Years ,65,40 to 65 years old
NCT02941289,"Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease",Unknown status,Alzheimer's Disease,All,65 Years to 75 Years   (Older Adult),Not Applicable,64,Interventional,November 2016,May 2019,https://ClinicalTrials.gov/show/NCT02941289,65 Years to 75 Years ,65,40 to 65 years old
NCT03923712,"PhysIcal Exercise ,Cerebral, COgnitive and Metabolome in People at Risk of Mild Cognitive Impairment",Recruiting,Mild Cognitive Impairment|Alzheimer Dementia,All,65 Years to 75 Years   (Older Adult),Not Applicable,100,Interventional,"January 15, 2018",December 2019,https://ClinicalTrials.gov/show/NCT03923712,65 Years to 75 Years ,65,40 to 65 years old
NCT00833274,Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases,Completed,Alzheimer Disease,All,65 Years to 75 Years   (Older Adult),Not Applicable,70,Interventional,February 2009,October 2011,https://ClinicalTrials.gov/show/NCT00833274,65 Years to 75 Years ,65,40 to 65 years old
NCT02331784,Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease,Completed,"Older Adults, Aging Brain",All,65 Years to 79 Years   (Older Adult),Not Applicable,68,Interventional,April 2015,"April 20, 2017",https://ClinicalTrials.gov/show/NCT02331784,65 Years to 79 Years ,65,40 to 65 years old
NCT02959489,Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN),Recruiting,Alzheimer Disease|Amyloid Beta-Peptides|Risk Assessment|Education|Neuropsychological Tests|Neuroimaging,All,65 Years to 80 Years   (Older Adult),Not Applicable,270,Interventional,November 2016,December 2019,https://ClinicalTrials.gov/show/NCT02959489,65 Years to 80 Years ,65,40 to 65 years old
NCT02546310,Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects,Completed,Alzheimer's Disease,All,65 Years to 80 Years   (Older Adult),Phase 1,54,Interventional,October 2015,February 2017,https://ClinicalTrials.gov/show/NCT02546310,65 Years to 80 Years ,65,40 to 65 years old
NCT03928405,Effect of Virtual Reality on Balance and Gait Speed With Alzheimer's Dementia,Completed,Alzheimer's Dementia,All,65 Years to 80 Years   (Older Adult),Not Applicable,32,Interventional,"January 1, 2018","June 6, 2018",https://ClinicalTrials.gov/show/NCT03928405,65 Years to 80 Years ,65,40 to 65 years old
NCT01931566,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,Terminated,Mild Cognitive Impairment Due to Alzheimer's Disease,All,65 Years to 83 Years   (Older Adult),Phase 3,3494,Interventional,"August 1, 2013","September 6, 2018",https://ClinicalTrials.gov/show/NCT01931566,65 Years to 83 Years ,65,40 to 65 years old
NCT02817074,MIND Diet Intervention and Cognitive Decline,"Active, not recruiting",Cognitive Decline|Dementia|Alzheimer Disease|Vascular Dementia,All,65 Years to 84 Years   (Older Adult),Phase 3,604,Interventional,January 2017,April 2021,https://ClinicalTrials.gov/show/NCT02817074,65 Years to 84 Years ,65,40 to 65 years old
NCT02349191,Omental Transposition Surgery for Mild Alzheimer's Disease,Unknown status,Alzheimer's Disease,All,65 Years to 85 Years   (Older Adult),Not Applicable,25,Interventional,March 2016,May 2019,https://ClinicalTrials.gov/show/NCT02349191,65 Years to 85 Years ,65,40 to 65 years old
NCT03578991,Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease,Recruiting,Patients Aged 65-85 (Both Included)|Diagnosed of Mild Cognitive Impairment|Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years,All,65 Years to 85 Years   (Older Adult),Not Applicable,174,Interventional,"July 1, 2019",May 2020,https://ClinicalTrials.gov/show/NCT03578991,65 Years to 85 Years ,65,40 to 65 years old
NCT02360657,Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia,Completed,Alzheimer's Disease,All,65 Years to 85 Years   (Older Adult),Phase 1,18,Interventional,"February 16, 2015","September 8, 2015",https://ClinicalTrials.gov/show/NCT02360657,65 Years to 85 Years ,65,40 to 65 years old
NCT04009629,Dementia Risk and Dynamic Response to Exercise,Enrolling by invitation,Alzheimer Disease 2 Due to Apoe4 Isoform|Healthy Aging,All,65 Years to 85 Years   (Older Adult),Not Applicable,60,Interventional,"October 1, 2019","July 1, 2021",https://ClinicalTrials.gov/show/NCT04009629,65 Years to 85 Years ,65,40 to 65 years old
NCT01467726,"Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects",Completed,Alzheimer's Disease,All,65 Years to 85 Years   (Older Adult),Phase 1,40,Interventional,November 2011,January 2012,https://ClinicalTrials.gov/show/NCT01467726,65 Years to 85 Years ,65,40 to 65 years old
NCT02746484,ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program,Completed,Cognitive Impairments|Dementia|Alzheimer Disease,All,65 Years to 85 Years   (Older Adult),Not Applicable,30,Interventional,April 2015,October 2016,https://ClinicalTrials.gov/show/NCT02746484,65 Years to 85 Years ,65,40 to 65 years old
NCT01893398,Multistimulation Group Therapy for Alzheimer's Disease,Completed,Alzheimer's Disease,All,65 Years to 85 Years   (Older Adult),Not Applicable,60,Interventional,January 2010,,https://ClinicalTrials.gov/show/NCT01893398,65 Years to 85 Years ,65,40 to 65 years old
NCT01436045,Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.,Completed,Alzheimer's Disease,All,65 Years to 85 Years   (Older Adult),Phase 2,12,Interventional,September 2011,June 2013,https://ClinicalTrials.gov/show/NCT01436045,65 Years to 85 Years ,65,40 to 65 years old
NCT03361410,Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year,Recruiting,Mild Cognitive Impairment,All,65 Years to 85 Years   (Older Adult),Phase 2,32,Interventional,"November 18, 2017",January 2021,https://ClinicalTrials.gov/show/NCT03361410,65 Years to 85 Years ,65,40 to 65 years old
NCT02488720,Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study,"Active, not recruiting",Cognition Disorders,All,65 Years to 85 Years   (Older Adult),Phase 4,500,Observational,"September 8, 2015",June 2020,https://ClinicalTrials.gov/show/NCT02488720,65 Years to 85 Years ,65,40 to 65 years old
NCT03890861,"Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)""",Not yet recruiting,"Dementia, Alzheimer Type",All,65 Years to 85 Years   (Older Adult),Not Applicable,200,Interventional,August 2019,"November 30, 2023",https://ClinicalTrials.gov/show/NCT03890861,65 Years to 85 Years ,65,40 to 65 years old
NCT02008357,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,"Active, not recruiting",Cognition Disorders,All,65 Years to 85 Years   (Older Adult),Phase 3,1150,Interventional,"February 28, 2014","July 22, 2022",https://ClinicalTrials.gov/show/NCT02008357,65 Years to 85 Years ,65,40 to 65 years old
NCT03378453,Narcolepsy Protect Against Alzheimer's Disease?,Completed,Narcolepsy|Amyloid Pathology,All,65 Years to 85 Years   (Older Adult),Not Applicable,38,Interventional,"April 7, 2016",November 2017,https://ClinicalTrials.gov/show/NCT03378453,65 Years to 85 Years ,65,40 to 65 years old
NCT01295957,Alzheimer's Disease Reminiscence Quality of Life,Completed,Alzheimer's Disease,All,65 Years to 87 Years   (Older Adult),Phase 4,135,Interventional,January 2010,November 2010,https://ClinicalTrials.gov/show/NCT01295957,65 Years to 87 Years ,65,40 to 65 years old
NCT03944603,Longitudinal Innate Immunity and Aging Study,Recruiting,Healthy Older Adults Ages 65-89,All,65 Years to 89 Years   (Older Adult),Phase 4,300,Observational,"April 30, 2019","May 31, 2024",https://ClinicalTrials.gov/show/NCT03944603,65 Years to 89 Years ,65,40 to 65 years old
NCT04018092,The Revitalize Study,Not yet recruiting,"Cognitive Aging|Alzheimer Disease, Protection Against",All,65 Years to 89 Years   (Older Adult),Phase 2,168,Interventional,January 2020,January 2025,https://ClinicalTrials.gov/show/NCT04018092,65 Years to 89 Years ,65,40 to 65 years old
NCT01713816,Human Brain Antioxidants During Oxidative Stress,Completed,Oxidative Stress|Alzheimer's Disease|Aging,All,65 Years to 89 Years   (Older Adult),Phase 4,52,Observational,June 2013,"July 24, 2018",https://ClinicalTrials.gov/show/NCT01713816,65 Years to 89 Years ,65,40 to 65 years old
NCT00403507,Exercise Treatment of Mild-Stage Probable Alzheimer's Disease,Completed,Alzheimer Disease|Memory Disorders|Dementia,All,65 Years to 89 Years   (Older Adult),Phase 2,79,Interventional,October 2006,October 2009,https://ClinicalTrials.gov/show/NCT00403507,65 Years to 89 Years ,65,40 to 65 years old
NCT03946930,IGF Binding Protein-2 Associated With Cognitive Decline,Recruiting,Alzheimer Disease,All,65 Years to 90 Years   (Older Adult),Phase 4,500,Observational,"December 13, 2018","December 31, 2021",https://ClinicalTrials.gov/show/NCT03946930,65 Years to 90 Years ,65,40 to 65 years old
NCT00160147,Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,Terminated,Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,All,65 Years to 90 Years   (Older Adult),Phase 3,60,Interventional,December 2005,January 2008,https://ClinicalTrials.gov/show/NCT00160147,65 Years to 90 Years ,65,40 to 65 years old
NCT01692977,What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate?,Completed,Alzheimer Disease,All,65 Years to 90 Years   (Older Adult),Not Applicable,77,Interventional,August 2012,October 2014,https://ClinicalTrials.gov/show/NCT01692977,65 Years to 90 Years ,65,40 to 65 years old
NCT01669876,Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease,Terminated,Alzheimer Disease,All,65 Years to 90 Years   (Older Adult),Phase 2,85,Interventional,August 2012,February 2015,https://ClinicalTrials.gov/show/NCT01669876,65 Years to 90 Years ,65,40 to 65 years old
NCT00820937,Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI),Completed,Lewy Body Dementia,All,65 Years to 90 Years   (Older Adult),Not Applicable,20,Interventional,March 2006,March 2008,https://ClinicalTrials.gov/show/NCT00820937,65 Years to 90 Years ,65,40 to 65 years old
NCT02351388,Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research,Unknown status,Alzheimer Disease|Depression,All,65 Years to 90 Years   (Older Adult),Phase 1|Phase 2,20,Interventional,December 2014,,https://ClinicalTrials.gov/show/NCT02351388,65 Years to 90 Years ,65,40 to 65 years old
NCT03226522,Addressing Dementia Via Agitation-Centered Evaluation,Recruiting,"Agitation in Patients With Dementia of the Alzheimer's Type|Alzheimer Disease|Agitation,Psychomotor",All,65 Years to 90 Years   (Older Adult),Phase 2|Phase 3,435,Interventional,"July 13, 2017",September 2019,https://ClinicalTrials.gov/show/NCT03226522,65 Years to 90 Years ,65,40 to 65 years old
NCT03034746,Impact of Physical Activity on Successful Aging,Completed,Alzheimer Disease|Cognitive Impairment|Physical Activity,All,65 Years to 90 Years   (Older Adult),Not Applicable,90,Interventional,September 2013,October 2016,https://ClinicalTrials.gov/show/NCT03034746,65 Years to 90 Years ,65,40 to 65 years old
NCT02501876,Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease,Completed,Alzheimer´s Disease|Diabetes Mellitus Type 2,All,65 Years to 90 Years   (Older Adult),Phase 4,202,Observational,May 2015,May 2016,https://ClinicalTrials.gov/show/NCT02501876,65 Years to 90 Years ,65,40 to 65 years old
NCT00190021,Donepezil Treatment of Psychotic Symptoms in Dementia Patients,Unknown status,Dementia of Alzheimer Type,All,65 Years to 90 Years   (Older Adult),Phase 3,80,Interventional,,,https://ClinicalTrials.gov/show/NCT00190021,65 Years to 90 Years ,65,40 to 65 years old
NCT03649724,The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's,Not yet recruiting,Alzheimer Disease,All,65 Years to 90 Years   (Older Adult),Phase 2,50,Interventional,February 2020,February 2026,https://ClinicalTrials.gov/show/NCT03649724,65 Years to 90 Years ,65,40 to 65 years old
NCT01729598,Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study,Completed,Alzheimer's Disease,All,65 Years to 90 Years   (Older Adult),Early Phase 1,14,Interventional,April 2012,October 2014,https://ClinicalTrials.gov/show/NCT01729598,65 Years to 90 Years ,65,40 to 65 years old
NCT02045056,Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease,Completed,Preclinical Alzheimer's Disease,All,65 Years to 90 Years   (Older Adult),Early Phase 1,72,Interventional,May 2014,June 2019,https://ClinicalTrials.gov/show/NCT02045056,65 Years to 90 Years ,65,40 to 65 years old
NCT01825577,Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.,Terminated,Dementia|Accidental Falls|Apathy,All,65 Years to 95 Years   (Older Adult),Phase 4,14,Interventional,November 2012,February 2015,https://ClinicalTrials.gov/show/NCT01825577,65 Years to 95 Years ,65,40 to 65 years old
NCT01172145,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,Apathy|Alzheimer's Disease,All,65 Years to 95 Years   (Older Adult),Phase 3,22,Interventional,July 2005,September 2007,https://ClinicalTrials.gov/show/NCT01172145,65 Years to 95 Years ,65,40 to 65 years old
NCT03977025,Alzheimer Biomarkers on CSF of Elderly Patients Undergoing Surgery,Recruiting,Alzheimer Disease,All,65 Years to 99 Years   (Older Adult),Phase 4,30,Observational,"June 11, 2019",March 2020,https://ClinicalTrials.gov/show/NCT03977025,65 Years to 99 Years ,65,40 to 65 years old
NCT02963415,Concurrent Aerobic Exercise and Virtual Reality Cognitive Training,Not yet recruiting,Preclinical Alzheimer's Disease,All,65 Years to 99 Years   (Older Adult),Not Applicable,12,Interventional,"September 30, 2019",March 2021,https://ClinicalTrials.gov/show/NCT02963415,65 Years to 99 Years ,65,40 to 65 years old
NCT01954550,Effects of Aerobic Exercise for Treating Alzheimer's Disease,"Active, not recruiting","Alzheimer's Disease, Late Onset",All,66 Years and older   (Older Adult),Not Applicable,96,Interventional,March 2014,December 2020,https://ClinicalTrials.gov/show/NCT01954550,66 Years and older ,66,65 and older
NCT01741194,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,Completed,Alzheimer's Disease,All,66 Years to 90 Years   (Older Adult),Phase 2|Phase 3,418,Interventional,March 2013,"April 14, 2017",https://ClinicalTrials.gov/show/NCT01741194,66 Years to 90 Years ,66,65 and older
NCT01571427,Conversations as a Means to Delay the Onset of Alzheimer's Disease,Completed,Mild Cognitive Impairment|Cognitive Change,All,70 Years and older   (Older Adult),Early Phase 1,83,Interventional,February 2012,September 2013,https://ClinicalTrials.gov/show/NCT01571427,70 Years and older ,70,65 and older
NCT02052947,Co-LEsions in Alzheimer Disease and Related Disorders,Recruiting,Alzheimer's Disease|Cerebrovascular Disease|Lewy Body Disease,All,70 Years and older   (Older Adult),Not Applicable,214,Interventional,January 2014,October 2020,https://ClinicalTrials.gov/show/NCT02052947,70 Years and older ,70,65 and older
NCT00007189,Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT),Completed,Alzheimer Disease,All,70 Years and older   (Older Adult),Phase 3,2625,Interventional,January 2001,,https://ClinicalTrials.gov/show/NCT00007189,70 Years and older ,70,65 and older
NCT00912886,Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease,Completed,Alzheimer Disease,All,70 Years and older   (Older Adult),Phase 4,90,Observational,September 2009,September 2011,https://ClinicalTrials.gov/show/NCT00912886,70 Years and older ,70,65 and older
NCT01566071,Ability to Drive of Early Stage Alzheimer Disease,Completed,Alzheimer Disease,All,70 Years and older   (Older Adult),Not Applicable,60,Interventional,July 2012,July 2015,https://ClinicalTrials.gov/show/NCT01566071,70 Years and older ,70,65 and older
NCT02529436,Overuse of Antidepressant in Patients With Alzheimer Disease,Completed,Alzheimer Disease,All,70 Years and older   (Older Adult),Phase 4,54,Observational,April 2015,December 2015,https://ClinicalTrials.gov/show/NCT02529436,70 Years and older ,70,65 and older
NCT01231295,Isotopic Imaging for Prodromal Alzheimer's Disease,Completed,Alzheimer Disease,All,70 Years and older   (Older Adult),Phase 4,143,Observational,February 2011,September 2016,https://ClinicalTrials.gov/show/NCT01231295,70 Years and older ,70,65 and older
NCT00276510,A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints,Completed,"Memory Disorders, Age-Related|Retention Disorders, Cognitive",All,70 Years and older   (Older Adult),Phase 4,2878,Interventional,February 2002,November 2009,https://ClinicalTrials.gov/show/NCT00276510,70 Years and older ,70,65 and older
NCT03691519,Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells,Recruiting,Alzheimer Disease,All,70 Years and older   (Older Adult),Phase 3,400,Interventional,"April 17, 2018",April 2022,https://ClinicalTrials.gov/show/NCT03691519,70 Years and older ,70,65 and older
NCT03129269,Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults,Recruiting,Frail Elderly,All,70 Years and older   (Older Adult),Not Applicable,345,Interventional,"January 2, 2017","December 31, 2021",https://ClinicalTrials.gov/show/NCT03129269,70 Years and older ,70,65 and older
NCT01192529,Evaluation of a Diet in Patients With Senile Dementia,Unknown status,Alzheimer's Disease|Parkinson's Disease|Senile Dementia,All,70 Years and older   (Older Adult),Not Applicable,184,Interventional,October 2010,December 2012,https://ClinicalTrials.gov/show/NCT01192529,70 Years and older ,70,65 and older
NCT01345110,A Longitudinal Multidimensional Population Study on Brain Aging,Completed,Dementia|Alzheimer Disease|Vascular Dementia,All,70 Years to 75 Years   (Older Adult),Phase 4,1321,Observational,November 2009,December 2015,https://ClinicalTrials.gov/show/NCT01345110,70 Years to 75 Years ,70,65 and older
NCT02224326,Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia,"Active, not recruiting",Alzheimer´s Disease,All,70 Years to 78 Years   (Older Adult),Phase 4,604,Observational,June 2011,December 2021,https://ClinicalTrials.gov/show/NCT02224326,70 Years to 78 Years ,70,65 and older
NCT00099567,"Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline",Completed,Cognitive Decline,All,70 Years to 79 Years   (Older Adult),Phase 4,2632,Observational,January 1997,December 2002,https://ClinicalTrials.gov/show/NCT00099567,70 Years to 79 Years ,70,65 and older
NCT03999879,"PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION",Recruiting,Alzheimer Disease,All,70 Years to 85 Years   (Older Adult),Phase 4,45,Observational,"May 1, 2019","December 1, 2020",https://ClinicalTrials.gov/show/NCT03999879,70 Years to 85 Years ,70,65 and older
NCT01880151,Neuroelectrical Biomarkers for Alzheimer's Disease Stages,Unknown status,Alzheimer Disease,All,70 Years to 85 Years   (Older Adult),Not Applicable,90,Interventional,June 2013,July 2017,https://ClinicalTrials.gov/show/NCT01880151,70 Years to 85 Years ,70,65 and older
NCT01780896,Relationship Between Vestibular Function and Topographic Memory,Unknown status,Normal Elderly Population,All,70 Years to 85 Years   (Older Adult),Phase 4,50,Observational,February 2013,June 2013,https://ClinicalTrials.gov/show/NCT01780896,70 Years to 85 Years ,70,65 and older
NCT03683394,Systematic Multi-domain Alzheimer's Risk Reduction Trial,Enrolling by invitation,Dementia|Alzheimer Disease,All,70 Years to 89 Years   (Older Adult),Not Applicable,200,Interventional,"August 30, 2018","January 31, 2021",https://ClinicalTrials.gov/show/NCT03683394,70 Years to 89 Years ,70,65 and older
NCT03597360,Low Dose Ionizing Radiation Using CT Scans as a Potential Therapy for Alzheimer's Dementia: A Pilot Study,Recruiting,Dementia Alzheimers,All,70 Years to 90 Years   (Older Adult),Not Applicable,3,Interventional,January 2019,June 2019,https://ClinicalTrials.gov/show/NCT03597360,70 Years to 90 Years ,70,65 and older
NCT03487380,Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease,Recruiting,Alzheimer Disease|Intestinal Microbiota,All,70 Years to 90 Years   (Older Adult),Not Applicable,300,Interventional,"September 4, 2017",September 2020,https://ClinicalTrials.gov/show/NCT03487380,70 Years to 90 Years ,70,65 and older
NCT00546767,Home-Based Assessment for Alzheimer Disease Prevention,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,75 Years and older   (Older Adult),Not Applicable,640,Interventional,September 2007,June 2013,https://ClinicalTrials.gov/show/NCT00546767,75 Years and older ,75,65 and older
NCT02041728,The Detection of Early Dementia With the Digital Game Memory,Completed,Alzheimer's Disease,All,75 Years and older   (Older Adult),Phase 4,20,Observational,January 2013,April 2013,https://ClinicalTrials.gov/show/NCT02041728,75 Years and older ,75,65 and older
NCT03282097,Decisions About Cancer Screening in Alzheimer's Disease,Recruiting,"Cancer, Breast",Female,75 Years and older   (Older Adult),Not Applicable,426,Interventional,"November 17, 2017",October 2022,https://ClinicalTrials.gov/show/NCT03282097,75 Years and older ,75,65 and older
NCT00954616,Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly,Completed,Alzheimer's Disease,All,75 Years and older   (Older Adult),Phase 4,636,Observational,January 2009,January 2012,https://ClinicalTrials.gov/show/NCT00954616,75 Years and older ,75,65 and older
NCT02138682,Validation of DaTscan for Detection of Parkinson Disease Related Disorders,Unknown status,Parkinson Disease|Movement Disorders,All,75 Years and older   (Older Adult),Phase 4,20,Observational,July 2014,,https://ClinicalTrials.gov/show/NCT02138682,75 Years and older ,75,65 and older
NCT01743534,Conservation of Praxis in the Food and Alzheimer Disease,Completed,Alzheimer Disease,All,75 Years and older   (Older Adult),Phase 4,32,Observational,July 2011,July 2016,https://ClinicalTrials.gov/show/NCT01743534,75 Years and older ,75,65 and older
NCT00010803,Ginkgo Biloba Prevention Trial in Older Individuals,Completed,Dementia|Alzheimer's Disease,All,75 Years and older   (Older Adult),Phase 3,3069,Interventional,October 2000,July 2011,https://ClinicalTrials.gov/show/NCT00010803,75 Years and older ,75,65 and older
NCT01953705,n-3 PUFA for Vascular Cognitive Aging,"Active, not recruiting",Age Related Cognitive Decline|Alzheimer's Disease|Vascular Dementia|Endothelial Dysfunction|Executive Dysfunction,All,75 Years and older   (Older Adult),Phase 2,102,Interventional,May 2014,August 2019,https://ClinicalTrials.gov/show/NCT01953705,75 Years and older ,75,65 and older
NCT00034567,Healthy Aging and Memory Study,Completed,Alzheimer Disease,All,75 Years and older   (Older Adult),Phase 4,650,Observational,,,https://ClinicalTrials.gov/show/NCT00034567,75 Years and older ,75,65 and older
NCT01417130,Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial,Unknown status,Alzheimer Disease|Dementia,All,75 Years and older   (Older Adult),Phase 4,1650,Observational,August 2009,August 2012,https://ClinicalTrials.gov/show/NCT01417130,75 Years and older ,75,65 and older
NCT01570322,Determinants of Quality of Life Related to Health in Alzheimer Disease,Unknown status,Alzheimer Disease,All,75 Years and older   (Older Adult),Phase 4,400,Observational,,,https://ClinicalTrials.gov/show/NCT01570322,75 Years and older ,75,65 and older
NCT02578303,Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations,Recruiting,Alzheimer Disease,All,75 Years to 120 Years   (Older Adult),Not Applicable,139,Interventional,May 2015,"January 1, 2020",https://ClinicalTrials.gov/show/NCT02578303,75 Years to 120 Years ,75,65 and older
NCT03981159,Effect of Exercise Training in Alzheimer's Patients,Completed,Alzheimer Disease,All,80 Years to 90 Years   (Older Adult),Not Applicable,20,Interventional,"March 1, 2017","November 15, 2017",https://ClinicalTrials.gov/show/NCT03981159,80 Years to 90 Years ,80,65 and older
NCT03284112,Old SCHOOL Hip-Hop: Improve Alzheimer's Disease Knowledge,Recruiting,Dementia,All,"9 Years and older   (Child, Adult, Older Adult)",Not Applicable,6000,Interventional,"September 18, 2018",July 2022,https://ClinicalTrials.gov/show/NCT03284112,9 Years and older ,9,up to 18 years old
NCT00039702,Brain Imaging in Alzheimer's Disease,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,40,Observational,June 2002,September 2004,https://ClinicalTrials.gov/show/NCT00039702,"Child, Adult, Older Adult",0,Age not specified
NCT04041895,Detecting Probable Alzheimer's Disease From Speech Using Linguistical Analysis,Recruiting,Alzheimer Disease|Dementia,All,"Child, Adult, Older Adult",Phase 4,20,Observational,"August 13, 2018",August 2020,https://ClinicalTrials.gov/show/NCT04041895,"Child, Adult, Older Adult",0,Age not specified
NCT02878486,Intervention to Reduce Sedentary Time,Completed,Mild Cognitive Impairment,All,"Child, Adult, Older Adult",Not Applicable,6,Interventional,August 2016,January 2018,https://ClinicalTrials.gov/show/NCT02878486,"Child, Adult, Older Adult",0,Age not specified
NCT01525368,Outcome Predictors of a Cognitive Intervention in aMCI,Completed,Amnestic Mild Cognitive Impairment,All,"Child, Adult, Older Adult",Phase 4,110,Observational,September 2010,July 2014,https://ClinicalTrials.gov/show/NCT01525368,"Child, Adult, Older Adult",0,Age not specified
NCT02158910,A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,2231,Observational,March 2015,June 2016,https://ClinicalTrials.gov/show/NCT02158910,"Child, Adult, Older Adult",0,Age not specified
NCT00606476,"AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease",Terminated,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2,194,Interventional,December 2006,September 2012,https://ClinicalTrials.gov/show/NCT00606476,"Child, Adult, Older Adult",0,Age not specified
NCT03938727,"Cardiovascular Risk Factors, Aging and Dementia",Recruiting,Dementia,All,"Child, Adult, Older Adult",Phase 4,500,Observational,"June 14, 2019",December 2020,https://ClinicalTrials.gov/show/NCT03938727,"Child, Adult, Older Adult",0,Age not specified
NCT03408041,Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,129,Observational,"May 1, 2016","October 1, 2017",https://ClinicalTrials.gov/show/NCT03408041,"Child, Adult, Older Adult",0,Age not specified
NCT00297414,An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine,Completed,Mild Cognitive Impairment,All,"Child, Adult, Older Adult",Phase 4,1083,Observational,June 2004,January 2005,https://ClinicalTrials.gov/show/NCT00297414,"Child, Adult, Older Adult",0,Age not specified
NCT00202124,Double Blind Study of Trp01 in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,12,Interventional,April 2001,March 2002,https://ClinicalTrials.gov/show/NCT00202124,"Child, Adult, Older Adult",0,Age not specified
NCT03485898,Study of Patients Hospitalized in Specialized Cognitive-behavioral Unit (UCC),Terminated,Behavior Disorders,All,"Child, Adult, Older Adult",Phase 4,58,Observational,"April 12, 2018","July 31, 2019",https://ClinicalTrials.gov/show/NCT03485898,"Child, Adult, Older Adult",0,Age not specified
NCT00393627,Behavioral Sleep Intervention in Adult Family Homes,Completed,Dementia,All,"Child, Adult, Older Adult",Phase 2,47,Interventional,June 2006,August 2009,https://ClinicalTrials.gov/show/NCT00393627,"Child, Adult, Older Adult",0,Age not specified
NCT03690193,Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Not Applicable,15,Interventional,"December 3, 2013","January 6, 2017",https://ClinicalTrials.gov/show/NCT03690193,"Child, Adult, Older Adult",0,Age not specified
NCT00105105,Mifepristone as Adjunctive Therapy in Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2,160,Interventional,April 2003,November 2005,https://ClinicalTrials.gov/show/NCT00105105,"Child, Adult, Older Adult",0,Age not specified
NCT01946243,The Feasibility of Florbetapir Quantitation,Completed,Alzheimers Disease,All,"Child, Adult, Older Adult",Phase 4,96,Interventional,August 2013,April 2014,https://ClinicalTrials.gov/show/NCT01946243,"Child, Adult, Older Adult",0,Age not specified
NCT00630500,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),Completed,Dementia Associated With Parkinson's Disease|Dementia With Lewy Bodies,All,"Child, Adult, Older Adult",Phase 2,75,Interventional,February 2006,March 2009,https://ClinicalTrials.gov/show/NCT00630500,"Child, Adult, Older Adult",0,Age not specified
NCT01023425,Clinical Trial of Donepezil Between the Naive Group and the Switching Group,Completed,Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Not Applicable,72,Interventional,February 2008,April 2009,https://ClinicalTrials.gov/show/NCT01023425,"Child, Adult, Older Adult",0,Age not specified
NCT01998711,Impact of a Memory Group for Older Adults Reporting Memory Difficulties,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,62,Interventional,October 2004,November 2007,https://ClinicalTrials.gov/show/NCT01998711,"Child, Adult, Older Adult",0,Age not specified
NCT01126099,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,20,Interventional,March 2010,March 2014,https://ClinicalTrials.gov/show/NCT01126099,"Child, Adult, Older Adult",0,Age not specified
NCT02667665,Verification Study and Reactivity Study for the Validity of QuQu Scale,Completed,Alzheimer's Disease Dementia|Cognitive Concern Without Dementia,All,"Child, Adult, Older Adult",Phase 4,240,Observational,"February 19, 2016","November 15, 2016",https://ClinicalTrials.gov/show/NCT02667665,"Child, Adult, Older Adult",0,Age not specified
NCT02033941,Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD),Recruiting,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2,20,Interventional,November 2014,September 2020,https://ClinicalTrials.gov/show/NCT02033941,"Child, Adult, Older Adult",0,Age not specified
NCT03124550,Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias,Recruiting,"Sedentary Lifestyle|Stress, Psychological",All,"Child, Adult, Older Adult",Not Applicable,20,Interventional,"May 11, 2017",July 2020,https://ClinicalTrials.gov/show/NCT03124550,"Child, Adult, Older Adult",0,Age not specified
NCT01357629,Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease,Terminated,Alzheimer´s Disease,All,"Child, Adult, Older Adult",Phase 4,11,Observational,July 2011,November 2013,https://ClinicalTrials.gov/show/NCT01357629,"Child, Adult, Older Adult",0,Age not specified
NCT03384043,Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease,Recruiting,"Alzheimer Disease|Cognitive Impairment, Mild|Dementia, Mild",All,"Child, Adult, Older Adult",Not Applicable,52,Interventional,"January 8, 2018",December 2019,https://ClinicalTrials.gov/show/NCT03384043,"Child, Adult, Older Adult",0,Age not specified
NCT00287742,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease,Terminated,Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Phase 3,33,Interventional,March 2002,March 2003,https://ClinicalTrials.gov/show/NCT00287742,"Child, Adult, Older Adult",0,Age not specified
NCT02245568,Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),Terminated,Alzheimer's Disease|Behavioral Variant Frontotemporal Dementia,All,"Child, Adult, Older Adult",Phase 3,913,Interventional,August 2014,May 2017,https://ClinicalTrials.gov/show/NCT02245568,"Child, Adult, Older Adult",0,Age not specified
NCT02162251,Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease,Completed,Alzheimer's Desease,All,"Child, Adult, Older Adult",Phase 4,3482,Observational,"June 1, 2013","April 15, 2016",https://ClinicalTrials.gov/show/NCT02162251,"Child, Adult, Older Adult",0,Age not specified
NCT02260167,"Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol",Unknown status,Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Phase 2,46,Interventional,September 2014,,https://ClinicalTrials.gov/show/NCT02260167,"Child, Adult, Older Adult",0,Age not specified
NCT02192554,Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo,Completed,Agitation Associated With Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,All,"Child, Adult, Older Adult",Phase 4,450,Observational,June 2014,May 2017,https://ClinicalTrials.gov/show/NCT02192554,"Child, Adult, Older Adult",0,Age not specified
NCT02350127,Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia,Completed,Dementia|Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2|Phase 3,88,Interventional,"May 4, 2015","December 31, 2018",https://ClinicalTrials.gov/show/NCT02350127,"Child, Adult, Older Adult",0,Age not specified
NCT02346201,Apathy in Dementia Methylphenidate Trial 2,Recruiting,Apathy|Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 3,200,Interventional,January 2016,June 2020,https://ClinicalTrials.gov/show/NCT02346201,"Child, Adult, Older Adult",0,Age not specified
NCT01225809,AD01 Follow up Extension Visit,Completed,Alzheimer´s Disease,All,"Child, Adult, Older Adult",Phase 4,17,Observational,September 2010,January 2011,https://ClinicalTrials.gov/show/NCT01225809,"Child, Adult, Older Adult",0,Age not specified
NCT00934050,ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2,103,Interventional,June 2009,June 2011,https://ClinicalTrials.gov/show/NCT00934050,"Child, Adult, Older Adult",0,Age not specified
NCT02770482,Amyloid Beta-peptide 1-40 and Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"Child, Adult, Older Adult",Not Applicable,200,Interventional,June 2014,,https://ClinicalTrials.gov/show/NCT02770482,"Child, Adult, Older Adult",0,Age not specified
NCT00515333,TRx0014 in Patients With Mild or Moderate Alzheimer's Disease,Completed,"Dementia, Alzheimer Type",All,"Child, Adult, Older Adult",Phase 2,323,Interventional,August 2004,December 2007,https://ClinicalTrials.gov/show/NCT00515333,"Child, Adult, Older Adult",0,Age not specified
NCT00161473,Alzheimer's in Long-Term Care--Treatment for Agitation,Completed,Alzheimer Disease|Psychomotor Agitation,All,"Child, Adult, Older Adult",Not Applicable,24,Interventional,January 2001,September 2009,https://ClinicalTrials.gov/show/NCT00161473,"Child, Adult, Older Adult",0,Age not specified
NCT00046358,"The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease",Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,50,Interventional,September 2002,August 2005,https://ClinicalTrials.gov/show/NCT00046358,"Child, Adult, Older Adult",0,Age not specified
NCT00203320,TNF-Alpha Inhibition for Treatment of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 1,30,Interventional,April 2005,January 2006,https://ClinicalTrials.gov/show/NCT00203320,"Child, Adult, Older Adult",0,Age not specified
NCT00203359,TNF-Alpha Inhibition for Treatment of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 1,15,Interventional,September 2004,April 2006,https://ClinicalTrials.gov/show/NCT00203359,"Child, Adult, Older Adult",0,Age not specified
NCT00105638,Telehealth Education Program for Caregivers of Veterans With Dementia,Completed,Dementia|Alzheimer Disease,All,"Child, Adult, Older Adult",Not Applicable,160,Interventional,September 2005,April 2007,https://ClinicalTrials.gov/show/NCT00105638,"Child, Adult, Older Adult",0,Age not specified
NCT00866060,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Moderate to Severe Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,800,Interventional,February 2008,June 2013,https://ClinicalTrials.gov/show/NCT00866060,"Child, Adult, Older Adult",0,Age not specified
NCT02353845,Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology,Completed,Mild Cognitive Impairment|Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,297,Observational,November 2013,August 2016,https://ClinicalTrials.gov/show/NCT02353845,"Child, Adult, Older Adult",0,Age not specified
NCT00297362,A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,344,Observational,June 2004,October 2005,https://ClinicalTrials.gov/show/NCT00297362,"Child, Adult, Older Adult",0,Age not specified
NCT00001977,The Effect of Acetylcholine on Memory and Attention,Completed,Alzheimer's Disease|Healthy,All,"Child, Adult, Older Adult",Phase 4,70,Observational,January 2000,April 2001,https://ClinicalTrials.gov/show/NCT00001977,"Child, Adult, Older Adult",0,Age not specified
NCT01315704,Alzheimer's Disease and Related Disorders,Unknown status,Alzheimer's Disease|Gait Apraxia|Impaired Cognition,All,"Child, Adult, Older Adult",Phase 4,700,Observational,November 2009,November 2017,https://ClinicalTrials.gov/show/NCT01315704,"Child, Adult, Older Adult",0,Age not specified
NCT02029547,Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians,Withdrawn,Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,0,Interventional,October 2014,May 2015,https://ClinicalTrials.gov/show/NCT02029547,"Child, Adult, Older Adult",0,Age not specified
NCT02107599,The Feasibility of Florbetapir Quantitation in Europe,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,96,Interventional,March 2014,May 2014,https://ClinicalTrials.gov/show/NCT02107599,"Child, Adult, Older Adult",0,Age not specified
NCT02336360,Augmenting 18F-AV-1451 Dosimetry Estimates,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 1,6,Interventional,January 2015,June 2015,https://ClinicalTrials.gov/show/NCT02336360,"Child, Adult, Older Adult",0,Age not specified
NCT00599469,Far Infrared Treatment for Alzheimer's Disease,Unknown status,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 1,4,Interventional,February 2008,April 2009,https://ClinicalTrials.gov/show/NCT00599469,"Child, Adult, Older Adult",0,Age not specified
NCT04004702,Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE),Not yet recruiting,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 2,65,Interventional,January 2020,June 2025,https://ClinicalTrials.gov/show/NCT04004702,"Child, Adult, Older Adult",0,Age not specified
NCT02013518,Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia,Unknown status,Alzheimers' Disease,All,"Child, Adult, Older Adult",Not Applicable,200,Interventional,September 2013,December 2016,https://ClinicalTrials.gov/show/NCT02013518,"Child, Adult, Older Adult",0,Age not specified
NCT01198093,Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD),Unknown status,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,800,Observational,November 2005,August 2015,https://ClinicalTrials.gov/show/NCT01198093,"Child, Adult, Older Adult",0,Age not specified
NCT03901092,A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 3,262,Interventional,"March 26, 2019","April 26, 2019",https://ClinicalTrials.gov/show/NCT03901092,"Child, Adult, Older Adult",0,Age not specified
NCT01972204,Intensive Instruction on the Use of Aricept,Completed,Alzheimer's Type Dementia,All,"Child, Adult, Older Adult",Not Applicable,125,Interventional,September 2013,August 2017,https://ClinicalTrials.gov/show/NCT01972204,"Child, Adult, Older Adult",0,Age not specified
NCT02267486,Exploratory Study for the Validity of QuQu Scale,Completed,Alzheimer Dementia,All,"Child, Adult, Older Adult",Phase 4,972,Observational,October 2014,,https://ClinicalTrials.gov/show/NCT02267486,"Child, Adult, Older Adult",0,Age not specified
NCT03611439,Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients,Completed,Alzheimer Disease|Alzheimer Dementia,All,"Child, Adult, Older Adult",Not Applicable,50,Interventional,"October 1, 2013","December 25, 2015",https://ClinicalTrials.gov/show/NCT03611439,"Child, Adult, Older Adult",0,Age not specified
NCT00105612,Memory Aid for Informed Consent in Alzheimer's Research,Completed,Alzheimer's Disease|Aging,All,"Child, Adult, Older Adult",Not Applicable,110,Interventional,September 2004,March 2007,https://ClinicalTrials.gov/show/NCT00105612,"Child, Adult, Older Adult",0,Age not specified
NCT03508024,Patients With Alzheimer's Disease or Related Youth Disease,Recruiting,"Alzheimer Disease, Early Onset|Lewy Body Disease|Frontotemporal Lobar Degeneration",All,"Child, Adult, Older Adult",Phase 4,220,Observational,"January 5, 2018",January 2019,https://ClinicalTrials.gov/show/NCT03508024,"Child, Adult, Older Adult",0,Age not specified
NCT00283725,Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease,Completed,Dementia|Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,573,Observational,June 2003,December 2006,https://ClinicalTrials.gov/show/NCT00283725,"Child, Adult, Older Adult",0,Age not specified
NCT03349320,"Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms",Completed,Late Onset Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,37,Observational,June 2009,March 2013,https://ClinicalTrials.gov/show/NCT03349320,"Child, Adult, Older Adult",0,Age not specified
NCT03435705,Maintenance of Occupational Therapy for Patients With Alzheimer,Recruiting,Alzheimer's Disease or Related Disorder,All,"Child, Adult, Older Adult",Not Applicable,240,Interventional,"January 17, 2018","November 17, 2020",https://ClinicalTrials.gov/show/NCT03435705,"Child, Adult, Older Adult",0,Age not specified
NCT03718494,The Kronos Early Estrogen Prevention Study (KEEPS),Enrolling by invitation,Alzheimer Dementia,Female,"Child, Adult, Older Adult",Phase 4,688,Interventional,"May 22, 2019",June 2022,https://ClinicalTrials.gov/show/NCT03718494,"Child, Adult, Older Adult",0,Age not specified
NCT00059410,Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,210,Observational,January 2003,September 2005,https://ClinicalTrials.gov/show/NCT00059410,"Child, Adult, Older Adult",0,Age not specified
NCT00505167,Memantine Versus Donepezil in Early Stages of Alzheimer's Disease,Completed,"Dementia, Alzheimer Type",All,"Child, Adult, Older Adult",Phase 4,64,Interventional,July 2007,December 2008,https://ClinicalTrials.gov/show/NCT00505167,"Child, Adult, Older Adult",0,Age not specified
NCT03821844,Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease,Not yet recruiting,Dementia,All,"Child, Adult, Older Adult",Not Applicable,1620,Interventional,"May 1, 2019","December 31, 2021",https://ClinicalTrials.gov/show/NCT03821844,"Child, Adult, Older Adult",0,Age not specified
NCT03900936,Detecting Dementia Earlier,Recruiting,Alzheimer Disease|MCI|Aging,All,"Child, Adult, Older Adult",Phase 4,20,Observational,"January 19, 2017","August 30, 2021",https://ClinicalTrials.gov/show/NCT03900936,"Child, Adult, Older Adult",0,Age not specified
NCT02409082,Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures,Completed,Alzheimers Disease|Inflammation|Hip Fracture,All,"Child, Adult, Older Adult",Phase 4,400,Observational,"September 11, 2013","December 20, 2016",https://ClinicalTrials.gov/show/NCT02409082,"Child, Adult, Older Adult",0,Age not specified
NCT00211159,OmegAD (Omega-3 and Alzheimer's Disease),Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,204,Interventional,December 2000,,https://ClinicalTrials.gov/show/NCT00211159,"Child, Adult, Older Adult",0,Age not specified
NCT02129348,Treatment of Psychosis and Agitation in Alzheimer's Disease,Recruiting,Alzheimer's Disease|Psychosis|Agitation,All,"Child, Adult, Older Adult",Phase 2,80,Interventional,June 2014,January 2020,https://ClinicalTrials.gov/show/NCT02129348,"Child, Adult, Older Adult",0,Age not specified
NCT01479855,Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type,Unknown status,Mild Cognitive Impairment|Alzheimers Disease,All,"Child, Adult, Older Adult",Phase 4,180,Observational,January 2012,December 2013,https://ClinicalTrials.gov/show/NCT01479855,"Child, Adult, Older Adult",0,Age not specified
NCT03289377,NRC:Improving Healthcare for Cognitively Impaired Elders and Their Caregivers,Recruiting,Alzheimer Disease|Nurse Training,All,"Child, Adult, Older Adult",Not Applicable,50,Interventional,"February 1, 2018",October 2018,https://ClinicalTrials.gov/show/NCT03289377,"Child, Adult, Older Adult",0,Age not specified
NCT03442322,Optimizing Care for Patients With Dementia,Recruiting,Alzheimer Disease,All,"Child, Adult, Older Adult",Not Applicable,80,Interventional,"March 15, 2018",December 2021,https://ClinicalTrials.gov/show/NCT03442322,"Child, Adult, Older Adult",0,Age not specified
NCT02247180,Cognitive Rehabilitation in Alzheimer`s Disease,Unknown status,Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,14,Interventional,September 2014,December 2015,https://ClinicalTrials.gov/show/NCT02247180,"Child, Adult, Older Adult",0,Age not specified
NCT00299676,An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period,Completed,Alzheimer Disease|Dementia|Galantamine,All,"Child, Adult, Older Adult",Phase 4,61,Observational,May 2005,March 2008,https://ClinicalTrials.gov/show/NCT00299676,"Child, Adult, Older Adult",0,Age not specified
NCT02051790,Evaluation of Reader Training Processes,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,241,Interventional,March 2014,August 2014,https://ClinicalTrials.gov/show/NCT02051790,"Child, Adult, Older Adult",0,Age not specified
NCT01505504,Mirtazapine in Alzheimer-associated Weight Loss,Completed,Alzheimer's Disease|Weight Loss|Mixed Dementia|Dementia,All,"Child, Adult, Older Adult",Phase 4,22,Observational,January 2004,December 2011,https://ClinicalTrials.gov/show/NCT01505504,"Child, Adult, Older Adult",0,Age not specified
NCT00396825,Video-Based Coping Skills Training for Caregivers,Completed,Caregivers,All,"Child, Adult, Older Adult",Phase 2,116,Interventional,January 2007,May 2009,https://ClinicalTrials.gov/show/NCT00396825,"Child, Adult, Older Adult",0,Age not specified
NCT01081743,Effectiveness of Care Management in Alzheimer Patients,Completed,Alzheimer Disease or Associated Disorder|Mild to Moderately Severe Dementia,All,"Child, Adult, Older Adult",Not Applicable,270,Interventional,"November 24, 2009","October 2, 2013",https://ClinicalTrials.gov/show/NCT01081743,"Child, Adult, Older Adult",0,Age not specified
NCT00064870,Alzheimer's Disease Genetics Study,Recruiting,Alzheimer Disease|Late Onset Alzheimer Disease|Dementia,All,"Child, Adult, Older Adult",Phase 4,3000,Observational,June 2002,July 2021,https://ClinicalTrials.gov/show/NCT00064870,"Child, Adult, Older Adult",0,Age not specified
NCT02248116,Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type,Terminated,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 2|Phase 3,198,Interventional,May 1999,,https://ClinicalTrials.gov/show/NCT02248116,"Child, Adult, Older Adult",0,Age not specified
NCT01129596,Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,10238,Observational,"June 10, 2010","June 23, 2016",https://ClinicalTrials.gov/show/NCT01129596,"Child, Adult, Older Adult",0,Age not specified
NCT00001933,Nefiracetam in the Treatment of Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2,50,Interventional,July 1999,January 2002,https://ClinicalTrials.gov/show/NCT00001933,"Child, Adult, Older Adult",0,Age not specified
NCT00470418,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Completed,Alzheimer Disease|Dementia,All,"Child, Adult, Older Adult",Phase 2,15,Interventional,January 2007,March 2010,https://ClinicalTrials.gov/show/NCT00470418,"Child, Adult, Older Adult",0,Age not specified
NCT01029132,Characteristics of Treatment Responders to Galantamine,Completed,Dementia,All,"Child, Adult, Older Adult",Not Applicable,66,Interventional,April 2007,October 2009,https://ClinicalTrials.gov/show/NCT01029132,"Child, Adult, Older Adult",0,Age not specified
NCT00015548,CATIE-Alzheimer's Disease Trial,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,450,Interventional,March 2001,October 2004,https://ClinicalTrials.gov/show/NCT00015548,"Child, Adult, Older Adult",0,Age not specified
NCT00147693,Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?,Completed,"Dementia, Vascular|Dementia|Alzheimer Disease|Lewy Body Disease",All,"Child, Adult, Older Adult",Not Applicable,304,Interventional,June 2005,February 2006,https://ClinicalTrials.gov/show/NCT00147693,"Child, Adult, Older Adult",0,Age not specified
NCT00088387,Effect of Lithium and Divalproex in Alzheimer's Disease,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 2,35,Interventional,July 2004,March 2005,https://ClinicalTrials.gov/show/NCT00088387,"Child, Adult, Older Adult",0,Age not specified
NCT01371214,Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot,Completed,Dementia,All,"Child, Adult, Older Adult",Phase 1,12,Interventional,June 2011,September 2012,https://ClinicalTrials.gov/show/NCT01371214,"Child, Adult, Older Adult",0,Age not specified
NCT03472482,Optical Coherence Tomography in Cerebral Amyloidosis,Recruiting,"Alzheimer Disease|Dementia Alzheimers|Dementia|Lewy Body Disease|Dementia, Lewy Body|Mild Cognitive Impairment",All,"Child, Adult, Older Adult",Phase 4,85,Observational,"March 25, 2016","December 31, 2019",https://ClinicalTrials.gov/show/NCT03472482,"Child, Adult, Older Adult",0,Age not specified
NCT02989402,"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.",Recruiting,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,102,Interventional,"December 31, 2018","February 3, 2020",https://ClinicalTrials.gov/show/NCT02989402,"Child, Adult, Older Adult",0,Age not specified
NCT02380703,Aggression Prevention Training for Caregivers of Persons With Dementia (APT),Completed,Dementia|Pain|Alzheimer's Disease|Aggression|Depression|Interpersonal Relations,All,"Child, Adult, Older Adult",Not Applicable,228,Interventional,"February 5, 2015","October 23, 2018",https://ClinicalTrials.gov/show/NCT02380703,"Child, Adult, Older Adult",0,Age not specified
NCT01870453,Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease,Withdrawn,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 4,0,Observational,October 2013,December 2018,https://ClinicalTrials.gov/show/NCT01870453,"Child, Adult, Older Adult",0,Age not specified
NCT04064164,Speeko for Elderspeak,Not yet recruiting,Dementia|Staff Attitude,All,"Child, Adult, Older Adult",Not Applicable,80,Interventional,"November 15, 2019","April 30, 2021",https://ClinicalTrials.gov/show/NCT04064164,"Child, Adult, Older Adult",0,Age not specified
NCT03884023,Effect of REST in the Alzheimer Disease Continuum,Not yet recruiting,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,300,Observational,"June 28, 2019","February 12, 2020",https://ClinicalTrials.gov/show/NCT03884023,"Child, Adult, Older Adult",0,Age not specified
NCT00001549,Diagnosis and Natural History Study of Patients With Neurological Conditions,Completed,Alzheimer's Disease|Dementia|Movement Disorder|Multiple System Atrophy|Parkinson's Disease,All,"Child, Adult, Older Adult",Phase 4,600,Observational,October 1995,January 2006,https://ClinicalTrials.gov/show/NCT00001549,"Child, Adult, Older Adult",0,Age not specified
NCT03773016,Touchscreen Technology and Art for People With Dementia in Care Homes,Enrolling by invitation,Mild Dementia|Moderate Dementia,All,"Child, Adult, Older Adult",Not Applicable,12,Interventional,"February 20, 2019","April 12, 2019",https://ClinicalTrials.gov/show/NCT03773016,"Child, Adult, Older Adult",0,Age not specified
NCT01695889,Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?,Unknown status,Alzheimer´s Disease|General Anesthesia,All,"Child, Adult, Older Adult",Phase 4,877,Observational,May 2012,July 2016,https://ClinicalTrials.gov/show/NCT01695889,"Child, Adult, Older Adult",0,Age not specified
NCT01023867,Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia,Completed,Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Not Applicable,88,Interventional,March 2007,June 2010,https://ClinicalTrials.gov/show/NCT01023867,"Child, Adult, Older Adult",0,Age not specified
NCT00001917,Brain Imaging in Elderly People and Individuals With Alzheimer's Disease,Completed,Alzheimer's Disease|Healthy,All,"Child, Adult, Older Adult",Phase 4,150,Observational,April 1999,April 2005,https://ClinicalTrials.gov/show/NCT00001917,"Child, Adult, Older Adult",0,Age not specified
NCT01217541,Collaboration Between Department of Old Age Psychiatry and Nursing Homes,Completed,Dementia|Alzheimer's Disease|Behavioral Symptoms|Agitation,All,"Child, Adult, Older Adult",Not Applicable,700,Interventional,September 2010,March 2012,https://ClinicalTrials.gov/show/NCT01217541,"Child, Adult, Older Adult",0,Age not specified
NCT03710642,Prazosin for Agitation in Alzheimer's Disease,Recruiting,Alzheimer's Disease|Disruptive Behavior,All,"Child, Adult, Older Adult",Phase 2,186,Interventional,"July 30, 2019","December 31, 2022",https://ClinicalTrials.gov/show/NCT03710642,"Child, Adult, Older Adult",0,Age not specified
NCT01023685,To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients,Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 2,24,Interventional,December 2009,February 2012,https://ClinicalTrials.gov/show/NCT01023685,"Child, Adult, Older Adult",0,Age not specified
NCT03062449,Phase IIa L-serine Trial for eAD,Recruiting,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 2,40,Interventional,"March 1, 2017","December 31, 2020",https://ClinicalTrials.gov/show/NCT03062449,"Child, Adult, Older Adult",0,Age not specified
NCT02162264,Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,8662,Observational,"June 1, 2013","July 22, 2016",https://ClinicalTrials.gov/show/NCT02162264,"Child, Adult, Older Adult",0,Age not specified
NCT00627029,Evaluation of Programs of Coordinated Care and Disease Management,Unknown status,Congestive Heart Failure|Diabetes|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Cancer|Cerebrovascular Disease|Alzheimer's Disease|Psychotic Disorder|Major Depression,All,"Child, Adult, Older Adult",Not Applicable,18277,Interventional,September 2000,December 2016,https://ClinicalTrials.gov/show/NCT00627029,"Child, Adult, Older Adult",0,Age not specified
NCT03378245,"Telemedicine-based, Multidisciplinary-team, Intervention to Reduce Unnecessary Hospitalizations",Suspended,Dementia Alzheimers|Disruptive Behavior,All,"Child, Adult, Older Adult",Not Applicable,40,Interventional,September 2013,August 2022,https://ClinicalTrials.gov/show/NCT03378245,"Child, Adult, Older Adult",0,Age not specified
NCT00291421,A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease,Completed,Alzheimer Disease|Dementia|Nervous System Diseases|Mental Disorders|Brain Diseases,All,"Child, Adult, Older Adult",Phase 4,2360,Observational,July 2002,May 2006,https://ClinicalTrials.gov/show/NCT00291421,"Child, Adult, Older Adult",0,Age not specified
NCT02353949,Investigating the Clinical Consequences of Flutemetamol-PET-scanning,Recruiting,Mild Cognitive Impairment|Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Phase 3,110,Interventional,May 2015,"December 31, 2020",https://ClinicalTrials.gov/show/NCT02353949,"Child, Adult, Older Adult",0,Age not specified
NCT03491150,An Open-Label Crenezumab Study in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 3,149,Interventional,"April 11, 2018","May 31, 2019",https://ClinicalTrials.gov/show/NCT03491150,"Child, Adult, Older Adult",0,Age not specified
NCT00309725,A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 3,139,Interventional,,October 1999,https://ClinicalTrials.gov/show/NCT00309725,"Child, Adult, Older Adult",0,Age not specified
NCT01351142,Cytokines and Cognitive Decline in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Not Applicable,133,Interventional,November 2009,,https://ClinicalTrials.gov/show/NCT01351142,"Child, Adult, Older Adult",0,Age not specified
NCT00391794,Efficacy of Early Stage Alzheimer's Support Groups,Completed,Memory Loss|Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Not Applicable,154,Interventional,September 2006,May 2011,https://ClinicalTrials.gov/show/NCT00391794,"Child, Adult, Older Adult",0,Age not specified
NCT00012831,Nurse Managed Clinic for Dementia Patients and Family Caregivers,Completed,Alzheimer's Disease|Caregivers|Dementia,Male,"Child, Adult, Older Adult",Phase 4,120,Observational,,June 2001,https://ClinicalTrials.gov/show/NCT00012831,"Child, Adult, Older Adult",0,Age not specified
NCT00001235,Genetic Studies in Alzheimer's Disease,Completed,Alzheimer's Disease|Nervous System Disease,All,"Child, Adult, Older Adult",Phase 4,1500,Observational,February 1988,February 2004,https://ClinicalTrials.gov/show/NCT00001235,"Child, Adult, Older Adult",0,Age not specified
NCT03656159,Evaluation of a New CBT for People With Alzheimer's Disease and Their Caregivers,Recruiting,Alzheimer Disease,All,"Child, Adult, Older Adult",Not Applicable,30,Interventional,January 2017,June 2020,https://ClinicalTrials.gov/show/NCT03656159,"Child, Adult, Older Adult",0,Age not specified
NCT00001662,Treatment of Alzheimer's Disease With CX516 (Ampalex),Completed,Alzheimer's Disease|Dementia,All,"Child, Adult, Older Adult",Phase 2,40,Interventional,December 1996,November 2005,https://ClinicalTrials.gov/show/NCT00001662,"Child, Adult, Older Adult",0,Age not specified
NCT01574456,Blood-brain Barrier Permeability in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,39,Observational,March 2012,December 2013,https://ClinicalTrials.gov/show/NCT01574456,"Child, Adult, Older Adult",0,Age not specified
NCT00898807,Citalopram for Agitation in Alzheimer's Disease,Completed,Alzheimer's Disease|Agitation,All,"Child, Adult, Older Adult",Phase 3,186,Interventional,July 2009,September 2013,https://ClinicalTrials.gov/show/NCT00898807,"Child, Adult, Older Adult",0,Age not specified
NCT00698165,Observational Study on Costs and Caregiver Burden in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,2400,Observational,June 2007,January 2009,https://ClinicalTrials.gov/show/NCT00698165,"Child, Adult, Older Adult",0,Age not specified
NCT04103580,Caregiver Speaks: A Technologically Mediated Storytelling Intervention,Not yet recruiting,Alzheimer Disease,All,"Child, Adult, Older Adult",Not Applicable,468,Interventional,"November 1, 2019","December 31, 2025",https://ClinicalTrials.gov/show/NCT04103580,"Child, Adult, Older Adult",0,Age not specified
NCT01609348,Venlafaxine for Depression in Alzheimer's Disease (DIADs-3),Completed,Alzheimer's Disease|Depression,All,"Child, Adult, Older Adult",Not Applicable,5,Interventional,April 2012,January 2017,https://ClinicalTrials.gov/show/NCT01609348,"Child, Adult, Older Adult",0,Age not specified
NCT00001972,PET Scan of Brain Metabolism in Relation to Age and Disease,Completed,Alzheimer's Disease|Brain Neoplasm|Niemann Pick Disease,All,"Child, Adult, Older Adult",Phase 4,123,Observational,September 1994,August 2002,https://ClinicalTrials.gov/show/NCT00001972,"Child, Adult, Older Adult",0,Age not specified
NCT00684944,Open Label Study of TRx0014 in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 2,111,Interventional,"September 13, 2007","December 2, 2010",https://ClinicalTrials.gov/show/NCT00684944,"Child, Adult, Older Adult",0,Age not specified
NCT03672266,Studies of Brain and Body Interaction,Recruiting,"Autistic Disorders Spectrum|Adhd|Asperger Syndrome|Alzheimer Disease|Parkinson|Tremor Essential|Dementia, Alzheimer Type|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia With Lewy Bodies|Dementia Frontal",All,"Child, Adult, Older Adult",Phase 4,100,Observational,"August 1, 2018","July 1, 2019",https://ClinicalTrials.gov/show/NCT03672266,"Child, Adult, Older Adult",0,Age not specified
NCT01251718,Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease,Completed,Alzheimer's Disease,All,"Child, Adult, Older Adult",Phase 4,894,Observational,"December 1, 2010","February 18, 2016",https://ClinicalTrials.gov/show/NCT01251718,"Child, Adult, Older Adult",0,Age not specified
NCT00955409,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",Completed,Alzheimer Disease,All,"Child, Adult, Older Adult",Phase 2,50,Interventional,November 2009,December 2013,https://ClinicalTrials.gov/show/NCT00955409,"Child, Adult, Older Adult",0,Age not specified
NCT01354444,Trial of Carvedilol in Alzheimer's Disease,Completed,Alzheimer's Disease,All,"up to 100 Years   (Child, Adult, Older Adult)",Phase 4,29,Interventional,June 2011,January 2017,https://ClinicalTrials.gov/show/NCT01354444,up to 100 Years ,0,Age not specified
NCT02055092,Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family,Unknown status,Frontotemporal Dementia|Alzheimer's Disease.,All,"up to 69 Years   (Child, Adult, Older Adult)",Phase 4,250,Observational,February 2014,December 2016,https://ClinicalTrials.gov/show/NCT02055092,up to 69 Years ,0,Age not specified
NCT01097096,"Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",Completed,Alzheimer's Disease,All,"up to 85 Years   (Child, Adult, Older Adult)",Phase 2,177,Interventional,March 2010,December 2012,https://ClinicalTrials.gov/show/NCT01097096,up to 85 Years ,0,Age not specified
NCT01689233,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,Completed,Alzheimer's Disease,All,"up to 89 Years   (Child, Adult, Older Adult)",Phase 3,800,Interventional,October 2012,May 2016,https://ClinicalTrials.gov/show/NCT01689233,up to 89 Years ,0,Age not specified
NCT01689246,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,Completed,Alzheimer's Disease,All,"up to 89 Years   (Child, Adult, Older Adult)",Phase 3,891,Interventional,January 2013,November 2015,https://ClinicalTrials.gov/show/NCT01689246,up to 89 Years ,0,Age not specified
NCT01552265,Shanghai Mild Cognitive Impairment Cohort Study,Completed,Mild Cognitive Impairment,All,"up to 90 Years   (Child, Adult, Older Adult)",Phase 4,400,Observational,February 2012,"July 31, 2017",https://ClinicalTrials.gov/show/NCT01552265,up to 90 Years ,0,Age not specified
NCT03863041,Study of Phosphorylated Metabolism Profile as Predictive Biomarker of Cognitive Decline in Memory Complaint.,Recruiting,Memory Complaint|Alzheimer Disease|Phosphorylated Metabolism Profile|Magnetic Resonance Spectroscopy,All,"up to 90 Years   (Child, Adult, Older Adult)",Not Applicable,60,Interventional,"April 8, 2019",November 2021,https://ClinicalTrials.gov/show/NCT03863041,up to 90 Years ,0,Age not specified
NCT01626391,Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease,Terminated,Alzheimer's Disease,All,"up to 90 Years   (Child, Adult, Older Adult)",Phase 2,9,Interventional,September 2012,March 2013,https://ClinicalTrials.gov/show/NCT01626391,up to 90 Years ,0,Age not specified
NCT03446001,Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease,Recruiting,Alzheimer Disease,All,"up to 90 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,375,Interventional,"January 10, 2018",December 2020,https://ClinicalTrials.gov/show/NCT03446001,up to 90 Years ,0,Age not specified
